

## May 2017

### Volume 5 Number 2

**Editor:**

Kaye Wilson & Doris Chong  
 email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)  
 Telephone +64 4 460 4990  
 Facsimile +64 4 460 4995  
 Level 9, 40 Mercer Street  
 PO Box 10 254 Wellington 6143

**Freephone Information Line**

**0800 66 00 50 (9am – 5pm weekdays)**

**Circulation**

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website [www.schedule.co.nz](http://www.schedule.co.nz).

**Production**

Typeset automatically from XML and T<sub>E</sub>X.  
 XML version of the Schedule available from [www.pharmac.govt.nz/pub/HML/archive/](http://www.pharmac.govt.nz/pub/HML/archive/)

**Programmers**

Anrik Drenth & John Geering

email: [texschedule@pharmac.govt.nz](mailto:texschedule@pharmac.govt.nz)

©Pharmaceutical Management Agency



ISSN 1179-3708 pdf

ISSN 1172-9694 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

[creativecommons.org/licenses/by/3.0/nz/](http://creativecommons.org/licenses/by/3.0/nz/).

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

## Part I General Rules **5**

## Part II Alimentary Tract and Metabolism **13**

### Blood and Blood Forming Organs **29**

### Cardiovascular System **42**

### Dermatologicals **54**

### Genito-Urinary System **60**

### Hormone Preparations **65**

### Infections **75**

### Musculoskeletal System **99**

### Nervous System **109**

### Oncology Agents and Immunosuppressants **136**

### Respiratory System and Allergies **186**

### Sensory Organs **194**

### Various **200**

### Extemporaneous Compounds (ECPs) **208**

### Special Foods **211**

### Vaccines **226**

## Part III Optional Pharmaceuticals **234**

### Index **236**

# Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

## PHARMAC's role:

***"Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided."***

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at <http://www.pharmac.health.nz/about>.

## Named Patient Pharmaceutical Assessment policy

Named Patient Pharmaceutical Assessment (NPPA) provides a mechanism for individual patients to receive funding for medicines not listed in the Pharmaceutical Schedule (either at all or for their clinical circumstances). PHARMAC will assess applications that meet the prerequisites according to its Factors for Consideration before deciding whether to approve applications for funding. The Factors for Consideration will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions.

For more information on NPPA, or to apply, visit the PHARMAC website at <http://www.pharmac.health.nz/link/nppa> or call the Panel Coordinators at 0800 660 050 Option 2.

## The Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The Schedule does not show the final cost to Government of subsidising each community pharmaceutical, nor to DHB hospitals in purchasing each hospital pharmaceutical or other pharmaceuticals, including medical devices. The final cost will depend on any rebate and other arrangements PHARMAC has with the supplier or on any logistics arrangements put in place.

## Finding Information in Section H

This book contains Section H of the Pharmaceutical Schedule and lists pharmaceuticals that can be used in DHB hospitals:

- Part I lists the rules in relation to use of Pharmaceuticals by DHB hospitals.
- Part II lists hospital pharmaceuticals that are funded for use in DHB hospitals. These are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. It also provides information on any national contracts that exist, and indicates which products have Hospital Supply Status (HSS).
- Part III lists optional pharmaceuticals for which national contracts exist, and DHB hospitals may choose to fund. In addition to the products listed in this book, a number of additional Optional Pharmaceuticals are listed in an addendum to Part III available at <http://www.pharmac.govt.nz>.

The listings are displayed alphabetically under each heading. The index lists both chemical entities and product brand names.

# Glossary

## Units of Measure

gram .....	g	microgram.....	mcg	millimole.....	mmol
kilogram .....	kg	milligram .....	mg	unit.....	u
international unit .....	iu	millilitre.....	ml		

## Abbreviations

application .....	app	enteric coated .....	EC	solution .....	soln
capsule .....	cap	granules.....	grans	suppository .....	suppos
cream.....	crm	injection .....	inj	tablet.....	tab
dispersible .....	disp	liquid .....	liq	tincture.....	tinc
effervescent .....	eff	lotion .....	lotn		
emulsion .....	emul	ointment.....	oint		

HSS    Hospital Supply Status (Refer to Rule 20)

Guide to Section H listings

Example

ANATOMICAL HEADING			
	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
THERAPEUTIC HEADING			
Generic name listed by therapeutic group and subgroup	CHEMICAL A - <b>Restricted</b> see terms below ⚡ Presentation A.....10.00	100	Brand A
	➡ <b>Restricted</b> Only for use in children under 12 years of age		Brand or manufacturer's name
Indicates only presentation B1 is Restricted	CHEMICAL B - <b>Some items restricted</b> see terms below ⚡ Presentation B1.....1,589.00 Presentation B2 ➡ <b>Restricted</b> Oncologist or haematologist	1	Brand B1 e.g. Brand B2
From 1 January 2012 to 30 June 2014, at least 99% of the total volume of this item purchased must be Brand C	CHEMICAL C Presentation C - <b>-1% DV Limit Jan-12 to 2014</b> .....15.00	28	Brand C
	CHEMICAL D - <b>Restricted</b> see terms below ⚡ Presentation D - <b>-1% DV Limit Mar-13 to 2014</b> .....38.65	500	Brand D
Standard national price excluding GST	➡ <b>Restricted</b> <i>Limited to five weeks' treatment</i> Either: 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or 2 For the prophylaxis of venous thromboembolism following a total knee replacement.		Quantity the Price applies to
Form and strength	CHEMICAL E Presentation E.....		e.g. Brand E
			Not a contracted product
⚡ Item restricted (see above); ⚡ Item restricted (see below) Products with Hospital Supply Status (HSS) are in <b>bold</b>			

## INTRODUCTION

Section H contains general rules that apply, and other information relating, to Hospital Pharmaceuticals and Optional Pharmaceuticals.

Where relevant, Section H shows the Price at which a Pharmaceutical can be purchased directly from the Pharmaceutical supplier by DHBs, providers of logistics services, wholesalers or other such distributors, or Contract Manufacturers.

The Price is determined via contractual arrangements between PHARMAC and the relevant Pharmaceutical supplier. Where a Pharmaceutical is listed in Part II of Section H, but no Price and/or brand of Pharmaceutical is indicated, each DHB may purchase any brand and/or pay the price that the DHB negotiates with the relevant Pharmaceutical supplier.

As required by section 23(7) of the Act, in performing any of its functions in relation to the supply of Pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule.

## INTERPRETATION AND DEFINITIONS

### 1 Interpretation and Definitions

1.1 In this Schedule, unless the context otherwise requires:

“**Act**”, means the New Zealand Public Health and Disability Act 2000.

“**Combined Pharmaceutical Budget**”, means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

“**Community**”, means any setting outside of a DHB Hospital.

“**Community Pharmaceutical**”, means a Pharmaceutical listed in Sections A to G or I of the Pharmaceutical Schedule that is subsidised by the Funder from the Combined Pharmaceutical Budget and, for the purposes of this Section H, includes Pharmaceutical Cancer Treatments (PCTs).

“**Contract Manufacturer**”, means a manufacturer or a supplier that is a party to a contract with the relevant DHB Hospital to compound Pharmaceuticals, on request from that DHB Hospital.

“**Designated Delivery Point**”, means at a DHB Hospital's discretion:

- a delivery point agreed between a Pharmaceutical supplier and the relevant DHB Hospital, to which delivery point that Pharmaceutical supplier must supply a National Contract Pharmaceutical directly at the Price; and/or
- any delivery point designated by the relevant DHB Hospital or PHARMAC, such delivery point being within 30 km of the relevant Pharmaceutical supplier's national distribution centre.

“**DHB**”, means an organisation established as a District Health Board by or under Section 19 of the Act.

“**DHB Hospital**”, means a hospital (including community trust hospitals) and/or an associated health service that is funded by a DHB including (but not limited to) district nursing services and child dental services.

“**DV Limit**”, means, for a particular National Contract Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

“**DV Pharmaceutical**”, means a discretionary variance Pharmaceutical that does not have HSS but is used in place of one that does. Usually this means it is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant National Contract Pharmaceutical with HSS. Where this is not the case, a note will be included with the listing of the relevant Pharmaceutical.

“**Extemporaneously Compounded Product**”, means a Pharmaceutical that is compounded from two or more Pharmaceuticals, for the purposes of reconstitution, dilution or otherwise.

“**First Transition Period**”, means the period of time after notification that a Pharmaceutical has been awarded HSS and before HSS is implemented.

“**Funder**”, means the body or bodies responsible, pursuant to the Act, for the funding of Pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

“**Give**”, means to administer, provide or dispense (or, in the case of a Medical Device, use) a Pharmaceutical, or to arrange for the administration, provision or dispensing (or, in the case of a Medical Device, use) of a Pharmaceutical, and “**Given**” has a corresponding meaning.

“**Hospital Pharmaceuticals**”, means the list of Pharmaceuticals set out in Section H Part II of the Schedule which includes some National Contract Pharmaceuticals.

“**HSS**”, stands for hospital supply status, which means the status of being the brand of the relevant National Contract Pharmaceutical that DHBs are obliged to purchase, subject to any DV Limit, for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant Pharmaceutical supplier. Pharmaceuticals with HSS are listed in Section H in bold text.

**“Indication Restriction”**, means a limitation placed by PHARMAC on the funding of a Hospital Pharmaceutical which restricts funding to treatment of particular clinical circumstances.

**“Individual DV Limit”**, means, for a particular National Contract Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

**“Local Restriction”**, means a restriction on the use of a Pharmaceutical in specific DHB Hospitals on the basis of prescriber type that is implemented by the relevant DHB in accordance with rule 7.

**“Medical Device”**, has the meaning set out in the Medicines Act 1981.

**“Named Patient Pharmaceutical Assessment Advisory Panel”**, means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising PHARMAC, in accordance with its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and any Exceptional Circumstances renewal applications submitted after 1 March 2012.

**“National Contract”**, means a contractual arrangement between PHARMAC and a Pharmaceutical supplier which sets out the basis on which any Pharmaceutical may be purchased for use in a DHB Hospital, including an agreement as to a national price.

**“National Contract Pharmaceutical”**, means a brand of Pharmaceutical listed in Section H, where PHARMAC has entered into contractual arrangements with the relevant Pharmaceutical supplier that specify the terms and conditions of listing, including the Price. Such Pharmaceuticals are recognisable in Section H because the relevant listing identifies the brand and Price.

**“National DV Limit”**, means, for a particular National Contract Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

**“Optional Pharmaceuticals”**, means the list of National Contract Pharmaceuticals set out in Section H Part III of the Schedule.

**“PHARMAC”**, means the Pharmaceutical Management Agency established by Section 46 of the Act.

**“Pharmacode”**, means the six or seven digit identifier assigned to a Pharmaceutical by the Pharmacy Guild following application from a Pharmaceutical supplier.

**“Pharmaceutical”**, means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I of the Schedule.

**“Pharmaceutical Cancer Treatment”**, means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a “PCT” or “PCT only” Pharmaceutical that DHBs must fund for use in their DHB hospitals, and/or in association with outpatient services provided by their DHB Hospitals, in relation to the treatment of cancers.

**“Prescriber Restriction”**, means a restriction placed by PHARMAC on the funding of a Pharmaceutical on the basis of prescriber type (and where relevant in these rules, includes a Local Restriction).

**“Price”**, means the standard national price for a National Contract Pharmaceutical, and, unless agreed otherwise between PHARMAC and the Pharmaceutical supplier, includes any costs associated with the supply of the National Contract Pharmaceutical to, at a DHB Hospital's discretion, any Designated Delivery Point, or to a Contract Manufacturer (expressly for the purpose of compounding), but does not include the effect of any rebates which may have been negotiated between PHARMAC and the Pharmaceutical supplier.

**“Restriction”**, means a limitation, put in place by PHARMAC or a DHB, restricting the funding of a Pharmaceutical and includes Indication Restrictions, Local Restrictions and Prescriber Restrictions (as defined in this Part I of Section H).

**“Schedule”**, means this Pharmaceutical Schedule and all its sections and appendices.

**“Special Authority Approval”**, means an approval for funding of a Community Pharmaceutical that is marked in Sections B-G of the Schedule as being subject to a Special Authority restriction.

**“Total Market Volume”**, means, for a particular Pharmaceutical with HSS in any given period, in accordance with the data available to PHARMAC, the sum of:

- a) the total number of Units of the relevant Pharmaceutical with HSS purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit; and
- b) the total number of Units of all the relevant DV Pharmaceuticals purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit.

**“Unapproved Indication”**, means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Clinicians prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in rule 23.

**“Unit”**, means an individual unit of a Pharmaceutical (e.g. a tablet, 1 ml of an oral liquid, an ampoule or a syringe).

**“Unlisted Pharmaceutical”**, means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical, but is not listed in Section H Part II.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
- a) the singular includes the plural; and
  - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under, that legislation.

## HOSPITAL SUPPLY OF PHARMACEUTICALS

### 2 Hospital Pharmaceuticals

2.1 Section H Part II contains the list of Hospital Pharmaceuticals that must be funded by DHB Hospitals. Section H Part II does not currently encompass the following categories of pharmaceuticals except for any items specifically listed in this Section H Part II:

- a) Medical Devices;
- b) whole or fractionated blood products;
- c) diagnostic products which have an ex vivo use, such as pregnancy tests and reagents;
- d) disinfectants and sterilising products, except those that are to be used in or on a patient;
- e) foods and probiotics;
- f) radioactive materials;
- g) medical gases;
- h) parenteral nutrition; and
- i) pharmaceutical products for in-vivo investigation of allergy.

Subject to rule 2.2, the funding of pharmaceuticals identified in a-i above is a decision for individual DHB Hospitals.

2.2 Section H Part III lists Optional Pharmaceuticals that PHARMAC and the relevant Pharmaceutical supplier have entered into contractual arrangements for the purchase of, including an agreement on a national price and other obligations such as HSS. DHB Hospitals may choose whether or not to fund the Optional Pharmaceuticals listed in Part III of Section H, but if they do, they must comply with any National Contract requirements.

2.3 Section H Part II does not encompass the provision of pharmaceutical treatments for DHB Hospital staff as part of an occupational health and safety programme. DHB Hospitals may choose whether or not to fund pharmaceutical treatments for such use, but if they do, they must comply with any National Contract requirements.

### 3 DHB Supply Obligations

- 3.1 In accordance with section 23(7) of the Act, in performing any of its functions in relation to the supply of pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule, which includes these General Rules.
- 3.2 DHB Hospitals are not required to hold stock of every Hospital Pharmaceutical listed in Section H Part II, but they must Give it within a reasonable time if it is prescribed.
- 3.3 DHB Hospitals are able to hold stock of an Unlisted Pharmaceutical if doing so is considered necessary for the DHB Hospital to be able to Give the Unlisted Pharmaceutical in a timely manner under rules 11–17 inclusive.
- 3.4 Except where permitted in accordance with rule 11, DHBs must not Give:
  - a) an Unlisted Pharmaceutical; or
  - b) a Hospital Pharmaceutical outside of any relevant Restrictions.

### 4 Funding

- 4.1 The purchase costs of Hospital Pharmaceuticals or Optional Pharmaceuticals administered, provided or dispensed by DHB Hospitals must be funded by the relevant DHB Hospital from its own budget, with the exception of:
  - a) Pharmaceutical Cancer Treatments;
  - b) Community Pharmaceuticals that have been brought to the DHB hospital by the patient who is being treated by outpatient Services or who is admitted as an inpatient;
  - c) Community Pharmaceuticals that have been dispensed to a mental health day clinic under a Practitioner's Supply Order; and
  - d) Unlisted Pharmaceutical that have been brought to the DHB Hospital by the patient who is admitted as an inpatient.
- 4.2 For the avoidance of doubt, Pharmaceutical Cancer Treatments and Community Pharmaceuticals are funded through the Combined Pharmaceutical Budget, and Unlisted Pharmaceuticals are funded by the patient.

### LIMITS ON SUPPLY

#### 5 Prescriber Restrictions

- 5.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has a Prescriber Restriction if it is prescribed:
- by a clinician of the type specified in the restriction for that Pharmaceutical or, subject to rule 5.2, pursuant to a recommendation from such a clinician;
  - in accordance with a protocol or guideline that has been endorsed by the DHB Hospital; or
  - in an emergency situation, provided that the prescriber has made reasonable attempts to comply with rule 5.1(a) above. If on-going treatment is required (i.e. beyond 24 hours) subsequent prescribing must comply with rule 5.1(a).
- 5.2 Where a Hospital Pharmaceutical is prescribed pursuant to a recommendation from a clinician of the type specified in the restriction for that Pharmaceutical:
- the prescriber must consult with a clinician of the type specified in the restriction for that Pharmaceutical; and
  - the consultation must relate to the patient for whom the prescription is written; and
  - the consultation may be in person, by telephone, letter, facsimile or email; and
  - appropriate records are kept of the consultation, including recording the name of the advising clinician on the prescription/chart.
- 5.3 Where a clinician is working under supervision of a consultant who is of the type specified in the restriction for that Pharmaceutical, the requirements of rule 5.2 can be deemed to have been met.

#### 6 Indication Restrictions

- 6.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has an Indication Restriction, if it is prescribed for treatment of a patient with the particular clinical circumstances set out in the Indication Restriction.
- 6.2 If a patient has a current Special Authority Approval for the Hospital Pharmaceutical that the DHB Hospital wishes to Give, then the Indication Restriction is deemed to have been met.
- 6.3 If a Hospital Pharmaceutical has an Indication Restriction that is “for continuation only” then the DHB Hospital should only Give the Hospital Pharmaceutical where:
- the patient has been treated with the Pharmaceutical in the Community; or
  - the patient is unable to be treated with an alternative Hospital Pharmaceutical, and the prescriber has explained to the patient that the Pharmaceutical is not fully subsidised in the Community.

#### 7 Local Restrictions

- 7.1 A DHB Hospital may implement a Local Restriction, provided that:
- in doing so, it ensures that the Local Restriction does not unreasonably limit funded access to the Hospital Pharmaceutical or undermine PHARMAC's decision that the Hospital Pharmaceutical must be funded;
  - it provides PHARMAC with details of each Local Restriction that it implements; and
- 7.2 PHARMAC may, when it considers that a Local Restriction does not conform to rule 7.1 above, require a DHB to amend or remove that Local Restriction.

#### 8 Community use of Hospital Pharmaceuticals

- 8.1 Except where otherwise specified in Section H, DHB Hospitals can Give any Hospital Pharmaceutical to a patient for use in the Community, provided that:
- the quantity does not exceed that sufficient for up to 30 days' treatment, unless:
    - it would be inappropriate to provide less than the amount in an original pack; or
    - the relevant DHB Hospital has a Dispensing for Discharge Policy and the quantity dispensed is in accordance with that policy; and
  - the Hospital Pharmaceutical is supplied consistent with any applicable Restrictions.

#### 9 Community use of Medical Devices

- 9.1 Subject to rules 9.2 and 9.3, DHB Hospitals may Give a Medical Device for patients for use in the Community.
- 9.2 Where a Medical Device (or a similar Medical Device) is a Community Pharmaceutical, the DHB Hospital must supply:
- the brand of Medical Device that is listed in Sections A-G of the Schedule; and
  - only to patients who meet the funding eligibility criteria set out in Sections A-G of the Schedule.
- 9.3 Where a DHB Hospital has supplied a Medical Device to a patient; and
- that Medical Device (or a similar Medical Device) is subsequently listed in Sections A-G of the Schedule; and
  - the patient would not meet any funding eligibility criteria for the Medical Device set out in Sections A-G of the Schedule; and



c) the Medical Device has consumable components that need to be replaced throughout its usable life; then DHB Hospitals may continue to fund consumable products for that patient until the end of the usable life of the Medical Device. At the end of the usable life of the device, funding for a replacement device must be consistent with the Pharmaceutical Schedule and/or in accordance with the Named Patient Pharmaceutical Assessment policy.

9.4 DHB Hospitals may also continue to fund consumable products, as in rule 9.3 above, in situations where the DHB has been funding consumable products but where the Medical Device was funded by the patient.

#### 10 Extemporaneous Compounding

10.1 A DHB Hospital may Give any Extemporaneously Compounded Product for a patient in its care, provided that:

- a) all of the component Pharmaceuticals of the Extemporaneously Compounded Product are Hospital Pharmaceuticals; and
- b) the Extemporaneously Compounded Product is supplied consistent with any applicable rules or Restrictions for its component Hospital Pharmaceuticals.

10.2 For the avoidance of doubt, this rule 10.1 applies to any Extemporaneously Compounded Product, whether it is manufactured by the DHB Hospital or by a Contract Manufacturer.

### EXCEPTIONS

#### 11 Named Patient Pharmaceutical Assessment

11.1 A DHB Hospitals may only Give:

- a) an Unlisted Pharmaceutical; or
- b) a Hospital Pharmaceutical outside of any relevant Restrictions,

in accordance with the Named Patient Pharmaceutical Assessment Policy or rules 12–17 inclusive.

#### 12 Continuation

12.1 Where a patient's clinical circumstances have been stabilised via treatment in the Community with a pharmaceutical that has not been funded by the Funder, and that patient is admitted to hospital as an inpatient, a DHB Hospital may fund that pharmaceutical for the duration of the patient's stay, where:

- a) the patient has not brought (or cannot arrange to bring) the pharmaceuticals to the DHB Hospital, or pharmacy staff consider that the pharmaceuticals brought to the DHB Hospital by the patient cannot be used; and
- b) interrupted or delayed treatment would have significant adverse clinical consequences; and
- c) it is not considered appropriate to switch treatment to a Hospital Pharmaceutical.

#### 13 Pre-Existing Use

13.1 Subject to 13.2, where a DHB Hospital has Given a pharmaceutical for a patient prior to 1 July 2013, and the pharmaceutical:

- a) is an Unlisted Pharmaceutical; or
- b) treatment of the patient would not comply with any relevant Restrictions;

the DHB Hospital may continue to Give that pharmaceutical if it is considered that there would be significant adverse clinical consequences from ceasing or switching treatment.

13.2 Each DHB Hospital must, by no later than 1 October 2013, provide PHARMAC with a report on pharmaceuticals it has Given in accordance with this rule 13 where treatment has continued beyond 1 August 2013.

#### 14 Clinical Trials and Free Stock

14.1 DHB Hospitals may Give any pharmaceutical that is funded by a third party and is being used:

- 14.1.1 as part of a clinical trial that has Ethics Committee approval; or
- 14.1.2 for on-going treatment of patients following the end of such a clinical trial.

14.2 DHB Hospitals may Give any pharmaceutical that is provided free of charge by a supplier, provided that the pharmaceutical is provided as part of a programme of which the DHB, or supplier, has notified PHARMAC.

#### 15 Pharmaceutical Cancer Treatments in Paediatrics

DHB Hospitals may Give any pharmaceutical for use within a paediatric oncology/haematology service for the treatment of cancer.

#### 16 Other Government Funding

DHB Hospitals may Give any pharmaceutical where funding for that pharmaceutical has been specifically provided by a Government entity other than PHARMAC or a DHB.

### 17 Other Exceptions

- 17.1 PHARMAC may also approve the funding of a pharmaceutical within a single DHB Hospital for information gathering purposes or otherwise related to PHARMAC's decision-making process for considering additions to or amendments to the Pharmaceutical Schedule.
- 17.2 Funding approvals granted under rule [17.1](#) will be subject to specific limitations on use as determined appropriate by PHARMAC in each circumstance, in consultation with the relevant DHB Hospital and/or DHB.

## NATIONAL CONTRACTING

### 18 Hospital Pharmaceutical Contracts

- 18.1 A DHB Hospital may enter into a contract for the purchase of any Pharmaceutical, including any Medical Device, that it is entitled to fund in accordance with this Schedule H and that is not a National Contract Pharmaceutical, provided that such a contract:
  - a) does not oblige the relevant DHB Hospital to purchase a volume of that Pharmaceutical, if that Pharmaceutical is a DV Pharmaceutical, that is greater than the relevant DV Limit;
  - b) enables PHARMAC to access and use future price and volume data in respect of that Pharmaceutical; and
  - c) enables the relevant DHB Hospital to terminate the contract or relevant parts of the contract in order to give full effect to the National Contract on no more than 3 months' written notice to the Pharmaceutical supplier.
- 18.2 From 1 July 2013, where a DHB Hospital has a pre-existing supply contract for a particular brand of chemical entity for which there is a National Contract Pharmaceutical, the DHB may continue purchasing the chemical entity in accordance with its pre-existing supply contract however:
  - a) from the day its pre-existing supply contract expires, that DHB Hospital is to purchase the relevant National Contract Pharmaceutical listed in Section H at the Price, and is to comply with any DV Limits for the National Contract Pharmaceutical where it has HSS;
  - b) if purchase of the relevant National Contract Pharmaceutical listed in Section H at the Price, where it has HSS, would not cause the relevant DHB Hospital to be in breach of its pre-existing supply contract for a particular brand of chemical entity; the DHB Hospital must purchase the National Contract Pharmaceutical.
- 18.3 Following written notification from PHARMAC that a Pharmaceutical is a National Contract Pharmaceutical, either through Section H updates or otherwise, DHB Hospitals must, unless PHARMAC expressly notifies otherwise:
  - a) take any steps available to them to terminate pre-existing contracts or relevant parts of such a contract, and
  - b) not enter any new contracts or extend the period of any current contracts, for the supply of that National Contract Pharmaceutical or the relevant chemical entity or Medical Device.

### 19 National Contract Pharmaceuticals

- 19.1 DHB Hospitals must take all necessary steps to enable any contracts between PHARMAC and a Pharmaceutical supplier in relation to National Contract Pharmaceuticals to be given full effect.
- 19.2 The contractual arrangement between PHARMAC and the relevant supplier of a National Contract Pharmaceutical requires it to be made available for purchase at the relevant Price by any or all of the following:
  - a) DHB Hospitals at Designated Delivery Points; and/or
  - b) Contract Manufacturers (expressly for the purpose of compounding).

In the case of Medical Devices, a National Contract may require the Medical Device to be purchased by, and/or supplied to, a third party logistics provider.

### 20 Hospital Supply Status (HSS)

- 20.1 The DV Limit for any National Contract Pharmaceutical which has HSS is set out in the listing of the relevant National Contract Pharmaceutical in Section H, and may be amended from time to time.
- 20.2 If a National Contract Pharmaceutical is listed in Section H as having HSS, DHB Hospitals:
  - a) are expected to use up any existing stocks of DV Pharmaceuticals during the First Transition Period;
  - b) must not purchase DV Pharmaceuticals in volumes exceeding their usual requirements, or in volumes exceeding those which they reasonably expect to use, within the First Transition Period;
  - c) must ensure that Contract Manufacturers, when manufacturing an Extemporaneously Compounded Product on their behalf, use the National Contract Pharmaceutical with HSS; and
  - d) must purchase the National Contract Pharmaceutical with HSS except:
    - i) to the extent that the DHB Hospital may use its discretion to purchase a DV Pharmaceutical within the DV Limit, provided that (subject to rule [20.2\(d\)\(iii\)](#) below) the DV Limit has not been exceeded nationally;

- ii) if the Pharmaceutical supplier fails to supply that National Contract Pharmaceutical, in which case the relevant DHB Hospital does not have to comply with the DV Limit for that National Contract Pharmaceutical during that period of non-supply (and any such month(s) included in a period of non-supply will be excluded in any review of the DV Limit in accordance with rule 20.3 below);
- iii) that where the DV Limit has been exceeded nationally, the DHB Hospital may negotiate with the Pharmaceutical supplier that supplies the National Contract Pharmaceutical with HSS for written permission to vary the application of that DHB Hospital's Individual DV Limit for any patient whose exceptional needs require a DV Pharmaceutical.

20.3 PHARMAC may, in its discretion, for any period or part period:

- a) review usage by DHB Hospitals of the National Contract Pharmaceutical and DV Pharmaceuticals to determine whether the DV Limit has been exceeded; and
- b) audit compliance by DHB Hospitals with the DV Limits and related requirements.

20.4 PHARMAC will address any issues of non-compliance by any individual DHB or DHB Hospital with a DV Limit by:

- a) obtaining the relevant DHB or DHB Hospital's assurance that it will comply with the DV Limit for that National Contract Pharmaceutical with HSS in the remainder of the applicable period and any subsequent periods; and
- b) informing the relevant supplier of the HSS Pharmaceutical of any individual DHB or DHB Hospital's non-compliance with the DV Limit for that HSS Pharmaceutical.

20.5 In addition to the steps taken by PHARMAC under rule 20.4 above to address any issues of non-compliance by any individual DHB or DHB Hospital with a DV Limit, the relevant Pharmaceutical supplier may require, in its discretion, financial compensation from the relevant DHB or DHB Hospital:

- a) an amount representing that DHB or DHB Hospital's contribution towards exceeding the DV Limit (where PHARMAC is able to quantify this based on the information available to it); or
- b) the sum of \$1,000 or \$5,000 (depending on the terms of the applicable national contract applying to the HSS Pharmaceutical),

whichever is the greater as between sub-paragraphs (a) and (b) within the number of business days specified in the notice from the Pharmaceutical supplier requiring such payment to be made.

20.6 The terms and conditions of a National Contract shall apply for a National Contract Pharmaceutical which has HSS for a Medical Device. In the event there is any inconsistency between such a National Contract and these General Rules, for example but not limited to a DV Pharmaceutical or DV Limit, the National Contract shall prevail.

## 21 Collection of rebates and payment of financial compensation

21.1 Following the receipt of any rebates from a Pharmaceutical supplier in respect of a particular National Contract Pharmaceutical, PHARMAC will notify each relevant DHB and DHB Hospital of the amount of the rebate owing to it, being a portion of the total rebate determined by PHARMAC on the basis of that DHB Hospital's usage of that National Contract Pharmaceutical, where this is able to be determined. Where data to determine individual DHB Hospitals' usage is not available, PHARMAC will apportion rebates on the basis of an alternative method agreed between the relevant DHBs and PHARMAC.

21.2 PHARMAC will pay each DHB Hospital the rebate amounts (if any) owing to it, no less frequently than once each calendar quarter in respect of rebates received quarterly (or more often).

## 22 Price and Volume Data

22.1 DHB Hospitals must provide to PHARMAC, on a monthly basis in accordance with PHARMAC's requirements, any volume data and, unless it would result in a breach of a pre-existing contract, price data held by those DHB Hospitals in respect of any Pharmaceutical (including any Medical Device) listed in Section H.

22.2 All price and volume data provided to PHARMAC under rule 22.1 above should identify the relevant Hospital Pharmaceutical by using a Pharmacode or some other unique numerical identifier, and the date (month and year) on which the DHB Hospital incurred a cost for the purchase of that Hospital Pharmaceutical. Volume is to be measured in units (that being the smallest possible whole Unit – e.g. a capsule, a vial, a millilitre etc).

## MISCELLANEOUS PROVISIONS

### 23 Unapproved Pharmaceuticals

Prescribers should, where possible, prescribe Hospital Pharmaceuticals that are approved under the Medicines Act 1981. However, the funding criteria (including Restrictions) under which a Hospital Pharmaceutical is listed in Section H of the Schedule may:

- 23.1 in some cases, explicitly permit a DHB to fund a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or

23.2 not explicitly prohibit a DHB from funding a Pharmaceutical for use for an Unapproved Indication; Accordingly, if clinicians are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, they should:

- 23.1 be aware of and comply with their obligations under sections 25 and/or 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- 23.2 be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that clinicians obtain written consent); and
- 23.3 exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Clinicians should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule, PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Antacids and Antiflatulents</b>			
<b>Antacids and Reflux Barrier Agents</b>			
ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE			
Tab 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg			<i>e.g. Mylanta</i>
Oral liq 400 mg with magnesium hydroxide 400 mg and simethicone 30 mg per 5 ml			<i>e.g. Mylanta Double Strength</i>
SIMETHICONE			
Oral drops 100 mg per ml			
SODIUM ALGINATE WITH MAGNESIUM ALGINATE			
Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet			<i>e.g. Gaviscon Infant</i>
SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE			
Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg			<i>e.g. Gaviscon Double Strength</i>
Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml.....	4.95	500 ml	Acidex
SODIUM CITRATE			
Oral liq 8.8% (300 mmol/l)			
<b>Phosphate Binding Agents</b>			
ALUMINIUM HYDROXIDE			
Tab 600 mg			
CALCIUM CARBONATE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Oral liq 250 mg per ml (100 mg elemental per ml) .....	39.00	500 ml	Roxane
➔ <b>Restricted</b>			
<b>Initiation</b>			
Only for use in children under 12 years of age for use as a phosphate binding agent.			
<b>Antidiarrhoeals and Intestinal Anti-Inflammatory Agents</b>			
<b>Antipropulsives</b>			
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE			
Tab 2.5 mg with atropine sulphate 25 mcg			
LOPERAMIDE HYDROCHLORIDE			
Tab 2 mg – 1% DV Oct-16 to 2019.....	10.75	400	Nodia
Cap 2 mg – 1% DV Sep-16 to 2019.....	7.05	400	Diamide Relief
<b>Rectal and Colonic Anti-Inflammatories</b>			
BUDESONIDE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Cap 3 mg			
➔ <b>Restricted</b>			
<b>Initiation – Crohn's disease</b>			
Both:			

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
- 2 Any of the following:
  - 2.1 Diabetes; or
  - 2.2 Cushingoid habitus; or
  - 2.3 Osteoporosis where there is significant risk of fracture; or
  - 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
  - 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
  - 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
  - 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

## Initiation – Collagenous and lymphocytic colitis (microscopic colitis)

Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

## Initiation – Gut Graft versus Host disease

Patient has gut Graft versus Host disease following allogenic bone marrow transplantation.

## HYDROCORTISONE ACETATE

Rectal foam 10%, CFC free (14 applications) – 1% DV Oct-15 to 2018 .....26.55      21.1 g      **Colifoam**

## MESALAZINE

Tab EC 400 mg .....	49.50	100	Asacol
Tab EC 500 mg .....	49.50	100	Asamax
Tab long-acting 500 mg .....	59.05	100	Pentasa
Tab 800 mg .....	85.50	90	Asacol
Modified release granules 1 g .....	141.72	120 g	Pentasa
Suppos 500 mg .....	22.80	20	Asacol
Suppos 1 g – 1% DV Jun-15 to 2018 .....	54.60	30	<b>Pentasa</b>
Enema 1 g per 100 ml – 1% DV Sep-15 to 2018 .....	41.30	7	<b>Pentasa</b>

## OLSALAZINE

Tab 500 mg  
Cap 250 mg

## SODIUM CROMOGLYCATE

Cap 100 mg

## SULPHASALAZINE

Tab 500 mg – 1% DV Oct-16 to 2019 .....	14.00	100	<b>Salazopyrin</b>
Tab EC 500 mg – 1% DV Oct-16 to 2019 .....	13.50	100	<b>Salazopyrin EN</b>

## Local Preparations for Anal and Rectal Disorders

### Antihæmorrhoidal Preparations

#### CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE

Oint 5 mg with hydrocortisone 5 mg per g .....	15.00	30 g	Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g .....	9.90	12	Proctosedyl

#### FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE

Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mg per g .....	6.35	30 g	Ultraproct
Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mg .....	2.66	12	Ultraproct

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Management of Anal Fissures</b>			
GLYCERYL TRINITRATE			
Oint 0.2%.....	22.00	30 g	Rectogesic
<b>Rectal Sclerosants</b>			
OILY PHENOL [PHENOL OILY]			
Inj 5%, 5 ml vial			
<b>Antispasmodics and Other Agents Altering Gut Motility</b>			
GLYCOPYRRONIUM BROMIDE			
Inj 200 mcg per ml, 1 ml ampoule – 1% DV Jul-16 to 2019 .....	17.14	10	Max Health
HYOSCINE BUTYLBROMIDE			
Tab 10 mg .....	2.18	20	Gastrosoothe
Inj 20 mg, 1 ml ampoule .....	9.57	5	Buscopan
MEBEVERINE HYDROCHLORIDE			
Tab 135 mg – 1% DV Sep-14 to 2017 .....	18.00	90	Colofac
<b>Antiulcerants</b>			
<b>Antisecretory and Cytoprotective</b>			
MISOPROSTOL			
Tab 200 mcg – 1% DV Jun-16 to 2019 .....	41.50	120	Cytotec
<b>H2 Antagonists</b>			
CIMETIDINE			
Tab 200 mg			
Tab 400 mg			
RANITIDINE			
Tab 150 mg – 1% DV Nov-14 to 2017 .....	10.30	500	Ranitidine Relief
Tab 300 mg – 1% DV Nov-14 to 2017 .....	14.73	500	Ranitidine Relief
Oral liq 150 mg per 10 ml – 1% DV Sep-14 to 2017 .....	4.92	300 ml	Peptisoothe
Inj 25 mg per ml, 2 ml ampoule .....	8.75	5	Zantac
<b>Proton Pump Inhibitors</b>			
LANSOPRAZOLE			
Cap 15 mg – 1% DV Jan-16 to 2018 .....	5.08	100	Lanzol Relief
Cap 30 mg – 1% DV Jan-16 to 2018 .....	5.93	100	Lanzol Relief

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>OMEPRAZOLE</b>			
↓ Tab dispersible 20 mg			
➔ <b>Restricted</b>			
<b>Initiation</b>			
Only for use in tube-fed patients.			
Cap 10 mg – 1% DV Jan-15 to 2017	2.23	90	Omezol Relief
Cap 20 mg – 1% DV Jan-15 to 2017	2.91	90	Omezol Relief
Cap 40 mg – 1% DV Jan-15 to 2017	4.42	90	Omezol Relief
Powder for oral liq	42.50	5 g	Midwest
Inj 40 mg ampoule with diluent – 1% DV Sep-16 to 2019	33.98	5	Dr Reddy's Omeprazole
Inj 40 mg vial – 1% DV Jan-17 to 2019	13.00	5	Omezol IV
<b>PANTOPRAZOLE</b>			
Tab EC 20 mg – 1% DV Dec-16 to 2019	2.41	100	Panzop Relief
Tab EC 40 mg – 1% DV Dec-16 to 2019	3.35	100	Panzop Relief
Inj 40 mg vial			

## Site Protective Agents

<b>COLLOIDAL BISMUTH SUBCITRATE</b>			
Tab 120 mg	14.51	50	Gastrodenol
<b>SUCRALFATE</b>			
Tab 1 g			

## Bile and Liver Therapy

L-ORNITHINE L-ASPARTATE – **Restricted** see terms [below](#)

↓ Grans for oral liquid 3 g

➔ **Restricted**

**Initiation**

For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated.

RIFAXIMIN – **Restricted** see terms [below](#)

↓ Tab 550 mg – 1% DV Oct-14 to 2017 625.00 56 Xifaxan

➔ **Restricted**

**Initiation**

For patients with hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

## Diabetes

### Alpha Glucosidase Inhibitors

<b>ACARBOSE</b>			
Tab 50 mg – 1% DV Oct-15 to 2018	4.28	90	Glucobay
Tab 100 mg – 1% DV Oct-15 to 2018	7.78	90	Glucobay

### Hyperglycaemic Agents

DIAZOXIDE – **Restricted** see terms [on the next page](#)

↓ Cap 25 mg	110.00	100	Proglicem
↓ Cap 100 mg	280.00	100	Proglicem
↓ Oral liq 50 mg per ml	620.00	30 ml	Proglycem



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted</b>			
<b>Initiation</b>			
For patients with confirmed hypoglycaemia caused by hyperinsulinism.			
<b>GLUCAGON HYDROCHLORIDE</b>			
Inj 1 mg syringe kit.....	32.00	1	Glucagen Hypokit
<b>GLUCOSE [DEXTROSE]</b>			
Tab 1.5 g			
Tab 3.1 g			
Tab 4 g			
Gel 40%			
<b>GLUCOSE WITH SUCROSE AND FRUCTOSE</b>			
Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet			

### Insulin - Intermediate-Acting Preparations

<b>INSULIN ASPART WITH INSULIN ASPART PROTAMINE</b>			
Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen .....	52.15	5	NovoMix 30 FlexPen
<b>INSULIN ISOPHANE</b>			
Inj insulin human 100 u per ml, 10 ml vial			
Inj insulin human 100 u per ml, 3 ml cartridge			
<b>INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE</b>			
Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge.....	42.66	5	Humalog Mix 25
Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge.....	42.66	5	Humalog Mix 50
<b>INSULIN NEUTRAL WITH INSULIN ISOPHANE</b>			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge			

### Insulin - Long-Acting Preparations

<b>INSULIN GLARGINE</b>			
Inj 100 u per ml, 3 ml disposable pen.....	94.50	5	Lantus SoloStar
Inj 100 u per ml, 3 ml cartridge.....	94.50	5	Lantus
Inj 100 u per ml, 10 ml vial.....	63.00	1	Lantus

### Insulin - Rapid-Acting Preparations

<b>INSULIN ASPART</b>			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
Inj 100 u per ml, 3 ml syringe .....	51.19	5	NovoRapid FlexPen

## ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>INSULIN GLULISINE</b>			
Inj 100 u per ml, 10 ml vial.....	27.03	1	Apidra
Inj 100 u per ml, 3 ml cartridge.....	46.07	5	Apidra
Inj 100 u per ml, 3 ml disposable pen.....	46.07	5	Apidra Solostar

<b>INSULIN LISPRO</b>			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			

### Insulin - Short-Acting Preparations

<b>INSULIN NEUTRAL</b>			
Inj human 100 u per ml, 10 ml vial			
Inj human 100 u per ml, 3 ml cartridge			

### Oral Hypoglycaemic Agents

<b>GLIBENCLAMIDE</b>			
Tab 5 mg			
<b>GLICLAZIDE</b>			
Tab 80 mg – 1% DV Nov-14 to 2017.....	11.50	500	Glizide
<b>GLIPIZIDE</b>			
Tab 5 mg – 1% DV Sep-15 to 2018.....	2.85	100	Minidiab
<b>METFORMIN HYDROCHLORIDE</b>			
Tab immediate-release 500 mg – 1% DV Nov-15 to 2018.....	9.59	1,000	Metckek
Tab immediate-release 850 mg.....	7.82	500	Apotex Metformin Mylan
<b>PIOGLITAZONE</b>			
Tab 15 mg – 1% DV Dec-15 to 2018.....	3.47	90	Vexazone
Tab 30 mg – 1% DV Dec-15 to 2018.....	5.06	90	Vexazone
Tab 45 mg – 1% DV Dec-15 to 2018.....	7.10	90	Vexazone

### Digestives Including Enzymes

<b>PANCREATIC ENZYME</b>			
Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,250 U protease))			
Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) – 1% DV Oct-15 to 2018.....	34.93	100	Creon 10000
Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) – 1% DV Oct-15 to 2018.....	94.38	100	Creon 25000
Powder pancreatin 60.12 mg (3,600 Ph. Eur. u/amylase, 5,000 Ph. Eur. u/lipase and 200 Ph. Eur. u/protease)			
<b>URSODEOXYCHOLIC ACID – Restricted see terms below</b>			
↓ Cap 250 mg – 1% DV Sep-14 to 2017.....	53.40	100	Ursosan

➔ **Restricted**

**Initiation – Alagille syndrome or progressive familial intrahepatic cholestasis**

Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

continued...

	Price	Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

### Initiation – Chronic severe drug induced cholestatic liver injury

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

### Initiation – Cirrhosis

Both:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 µmol/l; decompensated cirrhosis).

### Initiation – Pregnancy

Patient diagnosed with cholestasis of pregnancy.

### Initiation – Haematological transplant

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogeneic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

### Initiation – Total parenteral nutrition induced cholestasis

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
- 2 Liver function has not improved with modifying the TPN composition.

## Laxatives

### Bowel-Cleansing Preparations

#### CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE

Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet

*e.g. PicoPrep*

#### MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet

*e.g. Glycoprep-C*

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet

*e.g. Glycoprep-C*

#### MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE

Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet..... 14.31

4

Klean Prep

### Bulk-Forming Agents

#### ISPAGHULA (PSYLLIUM) HUSK

Powder for oral soln..... 5.51

500 g

Konsyl-D

#### STERCULIA WITH FRANGULA – **Restricted:** For continuation only

➡ Powder for oral soln

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Faecal Softeners</b>			
DOCUSATE SODIUM			
Tab 50 mg – 1% DV Jan-15 to 2017 .....	2.31	100	<b>Coloxyl</b>
Tab 120 mg – 1% DV Jan-15 to 2017 .....	3.13	100	<b>Coloxyl</b>
DOCUSATE SODIUM WITH SENNOSIDES			
Tab 50 mg with sennosides 8 mg.....	4.40	200	Laxsol
PARAFFIN			
Oral liquid 1 mg per ml			
Enema 133 ml			
POLOXAMER			
Oral drops 10% – 1% DV Sep-14 to 2017 .....	3.78	30 ml	<b>Coloxyl</b>
<b>Osmotic Laxatives</b>			
GLYCEROL			
Suppos 1.27 g			
Suppos 2.55 g			
Suppos 3.6 g – 1% DV Sep-15 to 2018 .....	6.50	20	<b>PSM</b>
LACTULOSE			
Oral liq 10 g per 15 ml – 1% DV Sep-16 to 2019 .....	3.18	500 ml	<b>Laevolac</b>
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg			
↓ Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV Oct-14 to 2017 .....	7.65	30	<b>Lax-Sachets</b>
➔ <b>Restricted</b>			
<b>Initiation</b>			
Either:			
1 Both:			
1.1 The patient has problematic constipation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated; and			
1.2 The patient would otherwise require a per rectal preparation; or			
2 For short-term use for faecal disimpaction.			
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE			
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml .....	19.95	50	Micolette
SODIUM PHOSPHATE WITH PHOSPHORIC ACID			
Oral liq 16.4% with phosphoric acid 25.14%			
Enema 10% with phosphoric acid 6.58% .....	2.50	1	Fleet Phosphate Enema
<b>Stimulant Laxatives</b>			
BISACODYL			
Tab 5 mg – 1% DV Oct-15 to 2018 .....	5.99	200	<b>Lax-Tabs</b>
Suppos 10 mg – 1% DV Jan-16 to 2018 .....	3.78	10	<b>Lax-Suppositories</b>
SENNOSIDES			
Tab 7.5 mg			

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

## Metabolic Disorder Agents

ALGLUCOSIDASE ALFA – **Restricted** see terms [below](#)

↓ Inj 50 mg vial ..... 1,142.60 1 Myozyme

→ **Restricted**

### Initiation

Metabolic physician

*Re-assessment required after 12 months*

All of the following:

- 1 The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and
- 2 Any of the following:
  - 2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
  - 2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
  - 2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
  - 2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
- 3 Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
- 4 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
- 5 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

### Continuation

Metabolic physician

*Re-assessment required after 12 months*

All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
- 3 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 4 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
- 5 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6 There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
- 7 There is no evidence of new or progressive cardiomyopathy.

### ARGININE

Powder

Inj 600 mg per ml, 25 ml vial

BETAINE – **Restricted** see terms [below](#)

↓ Powder

→ **Restricted**

Metabolic physician or metabolic disorders dietitian

BIOTIN – **Restricted** see terms [on the next page](#)

↓ Cap 50 mg

↓ Cap 100 mg

↓ Inj 10 mg per ml, 5 ml vial

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted</b>			
Metabolic physician or metabolic disorders dietitian			
GALSULFASE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 1 mg per ml, 5 ml vial – 1% DV May-16 to 2018.....	2,234.00	1	Naglazyme
<b>➔ Restricted</b>			
<b>Initiation</b>			
Metabolic physician			
<i>Re-assessment required after 12 months</i>			
Both:			
1 The patient has been diagnosed with mucopolysaccharidosis VI; and			
2 Either:			
2.1 Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency confirmed by either enzyme activity assay in leukocytes or skin fibroblasts; or			
2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.			
<b>Continuation</b>			
Metabolic physician			
<i>Re-assessment required after 12 months</i>			
All of the following:			
1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and			
2 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and			
3 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and			
4 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.			
HAEM ARGINATE			
Inj 25 mg per ml, 10 ml ampoule			
IDURSULFASE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 2 mg per ml, 3 ml vial.....	4,608.30	1	Elaprase
<b>➔ Restricted</b>			
<b>Initiation</b>			
Metabolic physician			
<i>Limited to 24 weeks treatment</i>			
All of the following:			
1 The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and			
2 Either:			
2.1 Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or			
2.2 Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and			
3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and			
4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and			
5 Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.			
IMIGLUCERASE – <b>Restricted</b> see terms <a href="#">on the next page</a>			
⚡ Inj 40 iu per ml, 5 ml vial			
⚡ Inj 40 iu per ml, 10 ml vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted****Initiation**

Only for use in patients with approval by the Gaucher's Treatment Panel.

LEVOCARNITINE – **Restricted** see terms [below](#)

↓ Cap 500 mg

↓ Oral soln 1,100 mg per 15 ml

↓ Inj 200 mg per ml, 5 ml vial

➔ **Restricted**

Neurologist, metabolic physician or metabolic disorders dietitian

PYRIDOXAL-5-PHOSPHATE – **Restricted** see terms [below](#)

↓ Tab 50 mg

➔ **Restricted**

Neurologist, metabolic physician or metabolic disorders dietitian

SODIUM BENZOATE

Cap 500 mg

Powder

Soln 100 mg per ml

Inj 20%, 10 ml ampoule

SODIUM PHENYLBUTYRATE – **Some items restricted** see terms [below](#)

Tab 500 mg

↓ Grans 483 mg per g.....1,920.00      174 g      Pheburane

Oral liq 250 mg per ml

Inj 200 mg per ml, 10 ml ampoule

➔ **Restricted****Initiation**

Metabolic physician

*Re-assessment required after 12 months*

For the chronic management of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.

**Continuation**

Metabolic physician

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient is benefiting from treatment.

TRIENTINE DIHYDROCHLORIDE

Cap 300 mg

## Minerals

### Calcium

CALCIUM CARBONATE

Tab 1.25 g (500 mg elemental) – **1% DV Sep-14 to 2017** .....5.38      250      **Arrow-Calcium**

Tab eff 1.75 g (1 g elemental) .....2.07      10      Calsource

### Fluoride

SODIUM FLUORIDE

Tab 1.1 mg (0.5 mg elemental)

# ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Iodine</b>			
POTASSIUM IODATE			
Tab 253 mcg (150 mcg elemental iodine) – 1% DV Dec-14 to 2017 .....	3.65	90	NeuroTabs
POTASSIUM IODATE WITH IODINE			
Oral liq 10% with iodine 5%			
<b>Iron</b>			
FERRIC CARBOXYMALTOSE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 50 mg per ml, 10 ml vial.....	150.00	1	Ferinject
➡ <b>Restricted</b>			
<b>Initiation</b>			
Treatment with oral iron has proven ineffective or is clinically inappropriate.			
FERROUS FUMARATE			
Tab 200 mg (65 mg elemental) – 1% DV Jun-15 to 2018 .....	2.89	100	Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID			
Tab 310 mg (100 mg elemental) with folic acid 350 mcg .....	4.75	60	Ferro-F-Tabs
FERROUS GLUCONATE WITH ASCORBIC ACID			
Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg			
FERROUS SULPHATE			
Tab long-acting 325 mg (105 mg elemental).....	2.06	30	Ferrograd
Oral liq 30 mg (6 mg elemental) per ml – 1% DV Oct-16 to 2019 .....	10.80	500 ml	Ferodan
FERROUS SULPHATE WITH ASCORBIC ACID			
Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg			
FERROUS SULPHATE WITH FOLIC ACID			
Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg			
IRON POLYMALTOSE			
Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017 .....	15.22	5	Ferrum H
IRON SUCROSE			
Inj 20 mg per ml, 5 ml ampoule .....	100.00	5	Venofer
<b>Magnesium</b>			
MAGNESIUM HYDROXIDE			
Tab 311 mg (130 mg elemental)			
MAGNESIUM OXIDE			
Cap 663 mg (400 mg elemental)			
MAGNESIUM SULPHATE			
Inj 0.4 mmol per ml, 250 ml bag			
Inj 2 mmol per ml, 5 ml ampoule – 1% DV Oct-14 to 2017.....	12.65	10	DBL
<b>Zinc</b>			
ZINC			
Oral liq 5 mg per 5 drops			
ZINC CHLORIDE			
Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule			



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ZINC SULPHATE			
Cap 137.4 mg (50 mg elemental) – <b>1% DV Mar-15 to 2017</b> .....	11.00	100	<b>Zincaps</b>

## Mouth and Throat

### Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE			
Soln 0.15%			
Spray 0.15%			
Spray 0.3%			
BENZYDAMINE HYDROCHLORIDE WITH CETYLPYRIDINIUM CHLORIDE			
Lozenge 3 mg with cetylpyridinium chloride			
CARBOXYMETHYLCELLULOSE			
Oral spray			
CARMELLOSE SODIUM WITH PECTIN AND GELATINE			
Paste			
Powder			
CHLORHEXIDINE GLUCONATE			
Mouthwash 0.2% – <b>1% DV Sep-15 to 2018</b> .....	2.57	200 ml	<b>healthE</b>
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE			
Adhesive gel 8.7% with cetalkonium chloride 0.01%			
DICHLOROBENZYL ALCOHOL WITH AMYLMETACRESOL			
Lozenge 1.2 mg with amylmetacresol 0.6 mg			
TRIAMCINOLONE ACETONIDE			
Paste 0.1% – <b>1% DV Apr-15 to 2017</b> .....	5.33	5 g	<b>Kenalog in Orabase</b>

### Oropharyngeal Anti-Infectives

AMPHOTERICIN B			
Lozenge 10 mg .....	5.86	20	Fungilin
MICONAZOLE			
Oral gel 20 mg per g – <b>1% DV Sep-15 to 2018</b> .....	4.79	40 g	<b>Decozol</b>
NYSTATIN			
Oral liquid 100,000 u per ml – <b>1% DV Feb-16 to 2017</b> .....	2.55	24 ml	<b>m-Nystatin</b>

### Other Oral Agents

SODIUM HYALURONATE [HYALURONIC ACID] – **Restricted** see terms [below](#)

↓ Inj 20 mg per ml, 1 ml syringe

➔ **Restricted**

Otolaryngologist

THYMOL GLYCERIN			
Compound, BPC – <b>1% DV Aug-16 to 2019</b> .....	9.15	500 ml	<b>PSM</b>

## Vitamins

### Multivitamin Preparations

MULTIVITAMIN AND MINERAL SUPPLEMENT – **Restricted** see terms [on the next page](#)

↓ Cap .....	23.35	180	Clinicians Multivit & Mineral Boost
-------------	-------	-----	--

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted</b>			
<b>Initiation</b>			
<i>Limited to 3 months treatment</i>			
Both:			
1 Patient was admitted to hospital with burns; and			
2 Any of the following:			
2.1 Burn size is greater than 15% of total body surface area (BSA) for all types of burns; or			
2.2 Burn size is greater than 10% of BSA for mid-dermal or deep dermal burns; or			
2.3 Nutritional status prior to admission or dietary intake is poor.			
MULTIVITAMIN RENAL – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Cap.....	8.39	30	Clinicians Renal Vit
<b>➔ Restricted</b>			
<b>Initiation</b>			
Either:			
1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or			
2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73m <sup>2</sup> body surface area (BSA).			
MULTIVITAMINS			
Tab (BPC cap strength) – <b>1% DV Jan-17 to 2019</b> .....	10.50	1,000	<b>Mvite</b>
⚡ Cap vitamin A 2500 u, betacarotene 3 mg, colecalciferol 11 mcg, alpha tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg, rib			<i>e.g. Vitabdeck</i>
<b>➔ Restricted</b>			
<b>Initiation</b>			
Either:			
1 Patient has cystic fibrosis with pancreatic insufficiency; or			
2 Patient is an infant or child with liver disease or short gut syndrome.			
⚡ Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg thiamine 3.2 mg, riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic acid 17 mg, choline 350 mg and inositol 700 mg			<i>e.g. Paediatric Seravit</i>
<b>➔ Restricted</b>			
<b>Initiation</b>			
Patient has inborn errors of metabolism.			
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1)			<i>e.g. Pabrinex IV</i>
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1)			<i>e.g. Pabrinex IM</i>
Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1)			<i>e.g. Pabrinex IV</i>
VITAMIN A WITH VITAMINS D AND C			
Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops			<i>e.g. Vitadol C</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Vitamin A</b>			
RETINOL			
Tab 10,000 iu			
Cap 25,000 iu			
Oral liq 150,000 iu per ml			
<b>Vitamin B</b>			
HYDROXOCOBALAMIN			
Inj 1 mg per ml, 1 ml ampoule – <b>1% DV Sep-15 to 2018</b>	2.31	3	Neo-B12
PYRIDOXINE HYDROCHLORIDE			
Tab 25 mg – <b>1% DV Apr-15 to 2017</b>	2.15	90	Vitamin B6 25
Tab 50 mg – <b>1% DV Oct-14 to 2017</b>	11.55	500	Apo-Pyridoxine
Inj 100 mg per ml, 1 ml ampoule			
THIAMINE HYDROCHLORIDE			
Tab 50 mg			
Tab 100 mg			
Inj 100 mg per ml, 1 ml vial			e.g. Benerva
Inj 100 mg per ml, 2 ml vial			
VITAMIN B COMPLEX			
Tab strong, BPC – <b>1% DV Jan-17 to 2019</b>	7.15	500	Bplex
<b>Vitamin C</b>			
ASCORBIC ACID			
Tab 100 mg – <b>1% DV Jan-17 to 2019</b>	8.10	500	Cvite
Tab chewable 250 mg			
<b>Vitamin D</b>			
ALFACALCIDOL			
Cap 0.25 mcg	26.32	100	One-Alpha
Cap 1 mcg	87.98	100	One-Alpha
Oral drops 2 mcg per ml			
CALCITRIOL			
Cap 0.25 mcg – <b>1% DV Aug-16 to 2019</b>	9.95	100	Calcitriol-AFT
Cap 0.5 mcg – <b>1% DV Aug-16 to 2019</b>	18.39	100	Calcitriol-AFT
Oral liq 1 mcg per ml			
Inj 1 mcg per ml, 1 ml ampoule			
COLECALCIFEROL			
Cap 1.25 mg (50,000 iu)	3.85	12	Vit.D3
<b>Vitamin E</b>			
ALPHA TOCOPHERYL ACETATE – <b>Restricted</b> see terms <a href="#">on the next page</a>			
⚡ Cap 100 u			
⚡ Cap 500 u			
⚡ Oral liq 156 u per ml			

(ex man.	Price		Per	Brand or Generic Manufacturer
	excl. GST)	\$		

➡ Restricted

Initiation – Cystic fibrosis

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:
  - 2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
  - 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Initiation – Osteoradionecrosis

For the treatment of osteoradionecrosis.

Initiation – Other indications

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:
  - 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
  - 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

## Antianaemics

### Hypoplastic and Haemolytic

EPOETIN ALFA [ERYTHROPOIETIN ALFA] – **Restricted** see terms [below](#)

↓ Inj 1,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018 .....	48.68	6	<b>Eprex</b>
↓ Inj 2,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018 .....	120.18	6	<b>Eprex</b>
↓ Inj 3,000 iu in 0.3 ml syringe – 5% DV Mar-15 to 28 Feb 2018 .....	166.87	6	<b>Eprex</b>
↓ Inj 4,000 iu in 0.4 ml syringe – 5% DV Mar-15 to 28 Feb 2018 .....	193.13	6	<b>Eprex</b>
↓ Inj 5,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018 .....	243.26	6	<b>Eprex</b>
↓ Inj 6,000 iu in 0.6 ml syringe – 5% DV Mar-15 to 28 Feb 2018 .....	291.92	6	<b>Eprex</b>
↓ Inj 8,000 iu in 0.8 ml syringe – 5% DV May-15 to 28 Feb 2018 .....	352.69	6	<b>Eprex</b>
↓ Inj 10,000 iu in 1 ml syringe – 5% DV Mar-15 to 28 Feb 2018 .....	395.18	6	<b>Eprex</b>
↓ Inj 40,000 iu in 1 ml syringe – 5% DV May-15 to 28 Feb 2018 .....	263.45	1	<b>Eprex</b>

#### → Restricted

#### Initiation – chronic renal failure

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin  $\leq$  100g/L; and
- 3 Either:
  - 3.1 Both:
    - 3.1.1 Patient does not have diabetes mellitus; and
    - 3.1.2 Glomerular filtration rate  $\leq$  30ml/min; or
  - 3.2 Both:
    - 3.2.1 Patient has diabetes mellitus; and
    - 3.2.2 Glomerular filtration rate  $\leq$  45ml/min; and
- 4 Patient is on haemodialysis or peritoneal dialysis.

#### Initiation – myelodysplasia\*

*Re-assessment required after 2 months*

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
- 2 Has had symptomatic anaemia with haemoglobin  $<$  100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum erythropoietin level of  $<$  500 IU/L; and
- 6 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

#### Continuation – myelodysplasia\*

*Re-assessment required after 12 months*

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

#### Initiation – all other indications

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

Note: Indications marked with \* are Unapproved Indications

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## EPOETIN BETA [ERYTHROPOIETIN BETA] – **Restricted** see terms [below](#)

Note: Epoetin beta is considered a Discretionary Variance Pharmaceutical for epoetin alfa.

- ⚡ Inj 2,000 iu in 0.3 ml syringe
- ⚡ Inj 3,000 iu in 0.3 ml syringe
- ⚡ Inj 4,000 iu in 0.3 ml syringe
- ⚡ Inj 5,000 iu in 0.3 ml syringe
- ⚡ Inj 6,000 iu in 0.3 ml syringe
- ⚡ Inj 10,000 iu in 0.6 ml syringe

### ➔ **Restricted**

#### **Initiation – chronic renal failure**

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin  $\leq$  100g/L; and
- 3 Either:
  - 3.1 Both:
    - 3.1.1 Patient does not have diabetes mellitus; and
    - 3.1.2 Glomerular filtration rate  $\leq$  30ml/min; or
  - 3.2 Both:
    - 3.2.1 Patient has diabetes mellitus; and
    - 3.2.2 Glomerular filtration rate  $\leq$  45ml/min; and
- 4 Patient is on haemodialysis or peritoneal dialysis.

#### **Initiation – myelodysplasia\***

*Re-assessment required after 12 months*

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum erythropoietin level of < 500 IU/L; and
- 6 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

#### **Continuation – myelodysplasia\***

*Re-assessment required after 2 months*

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

#### **Initiation – all other indications**

Haematologist.

For use in patients where blood transfusion is not a viable treatment alternative.

\*Note: Indications marked with \* are Unapproved Indications.

## Megaloblastic

### FOLIC ACID

Tab 0.8 mg – 1% DV Oct-15 to 2018.....	20.60	1,000	<b>Apo-Folic Acid</b>
Tab 5 mg – 1% DV Oct-15 to 2018.....	10.92	500	<b>Apo-Folic Acid</b>
Oral liq 50 mcg per ml .....	24.00	25 ml	<b>Biomed</b>
Inj 5 mg per ml, 10 ml vial			

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

## Antifibrinolytics, Haemostatics and Local Sclerosants

ALUMINIUM CHLORIDE – **Restricted** see terms [below](#)

↓ Topical soln 20% w/v

e.g. Driclor

→ **Restricted**

### Initiation

For use as a haemostatis agent.

APROTININ – **Restricted** see terms [below](#)

↓ Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial

→ **Restricted**

### Initiation

Cardiac anaesthetist

Either:

- 1 Paediatric patient undergoing cardiopulmonary bypass procedure; or
- 2 Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.

ELTROMBOPAG – **Restricted** see terms [below](#)

↓ Tab 25 mg ..... 1,771.00 28 Revolade

↓ Tab 50 mg ..... 3,542.00 28 Revolade

→ **Restricted**

### Initiation – idiopathic thrombocytopenic purpura - post-splenectomy

Haematologist

Limited to 6 weeks treatment

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialed and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
  - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
  - 3.2 Patient has a platelet count of  $\leq 20,000$  platelets per microlitre and has evidence of active bleeding; or
  - 3.3 Patient has a platelet count of  $\leq 10,000$  platelets per microlitre.

### Initiation – (idiopathic thrombocytopenic purpura - preparation for splenectomy)

Haematologist

Limited to 6 weeks treatment

The patient requires eltrombopag treatment as preparation for splenectomy.

### Continuation – (idiopathic thrombocytopenic purpura - post-splenectomy)

Haematologist

Re-assessment required after 12 months

The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of  $> 30,000$  platelets per microlitre

### FERRIC SUBSULFATE

Gel 25.9%

Soln 500 ml

### POLIDOCANOL

Inj 0.5%, 30 ml vial

### SODIUM TETRADECYL SULPHATE

Inj 3%, 2 ml ampoule

## BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
THROMBIN Powder			
TRANEXAMIC ACID			
Tab 500 mg – 1% DV Sep-16 to 2019 .....	20.67	100	Cyklokapron
Inj 100 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018 .....	55.00	10	Cyklokapron

### Anticoagulant Reversal Agents

IDARUCIZUMAB – **Restricted** see terms [below](#)

⚡ Inj 50 mg per ml, 50 ml vial..... 4,250.00 2 Praxbind

➡ **Restricted**

#### Initiation

For the reversal of the anticoagulant effects of dabigatran when required in situations of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures.

### Blood Factors

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – **Restricted** see terms [below](#)

⚡ Inj 1 mg syringe ..... 1,178.30 1 NovoSeven RT  
 ⚡ Inj 2 mg syringe ..... 2,356.60 1 NovoSeven RT  
 ⚡ Inj 5 mg syringe ..... 5,891.50 1 NovoSeven RT  
 ⚡ Inj 8 mg syringe ..... 9,426.40 1 NovoSeven RT

➡ **Restricted**

#### Initiation

When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

FACTOR EIGHT INHIBITOR BYPASSING FRACTION – **Restricted** see terms [below](#)

⚡ Inj 500 U ..... 1,450.00 1 FEIBA NF  
 ⚡ Inj 1,000 U ..... 2,900.00 1 FEIBA NF  
 ⚡ Inj 2,500 U ..... 7,250.00 1 FEIBA NF

➡ **Restricted**

#### Initiation

When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – **Restricted** see terms [below](#)

⚡ Inj 250 iu prefilled syringe ..... 210.00 1 Xyntha  
 ⚡ Inj 500 iu prefilled syringe ..... 420.00 1 Xyntha  
 ⚡ Inj 1,000 iu prefilled syringe ..... 840.00 1 Xyntha  
 ⚡ Inj 2,000 iu prefilled syringe ..... 1,680.00 1 Xyntha  
 ⚡ Inj 3,000 iu prefilled syringe ..... 2,520.00 1 Xyntha

➡ **Restricted**

#### Initiation

Note: Preferred Brand of recombinant factor VIII from 1 March 2016 until 28 February 2019. When used in the treatment of haemophilia, funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

NONACOG ALFA [RECOMBINANT FACTOR IX] – **Restricted** see terms [on the next page](#)

⚡ Inj 250 iu vial ..... 310.00 1 BeneFIX  
 ⚡ Inj 500 iu vial ..... 620.00 1 BeneFIX  
 ⚡ Inj 1,000 iu vial ..... 1,240.00 1 BeneFIX  
 ⚡ Inj 2,000 iu vial ..... 2,480.00 1 BeneFIX  
 ⚡ Inj 3,000 iu vial ..... 3,720.00 1 BeneFIX



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## ➔ Restricted

### Initiation

When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

NONACOG GAMMA, [RECOMBINANT FACTOR IX] – **Restricted** see terms [below](#)

⬇ Inj 250 iu vial.....	287.50	1	RIXUBIS
⬇ Inj 500 iu vial.....	575.00	1	RIXUBIS
⬇ Inj 1,000 iu vial.....	1,150.00	1	RIXUBIS
⬇ Inj 2,000 iu vial.....	2,300.00	1	RIXUBIS
⬇ Inj 3,000 iu vial.....	3,450.00	1	RIXUBIS

## ➔ Restricted

### Initiation

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – **Restricted** see terms [below](#)

⬇ Inj 250 iu vial.....	287.50	1	Advate
⬇ Inj 500 iu vial.....	575.00	1	Advate
⬇ Inj 1,000 iu vial.....	1,150.00	1	Advate
⬇ Inj 1,500 iu vial.....	1,725.00	1	Advate
⬇ Inj 2,000 iu vial.....	2,300.00	1	Advate
⬇ Inj 3,000 iu vial.....	3,450.00	1	Advate

## ➔ Restricted

### Initiation

Notes: Rare Clinical Circumstances Brand of recombinant factor VIII from 1 March 2016 until 28 February 2019. When used in the treatment of haemophilia, access to funded treatment by application to the Haemophilia Treatments Panel. Application details may be obtained from PHARMAC.s website <http://www.pharmac.govt.nz> or:

The Co-ordinator, Haemophilia Treatments Panel Phone: 0800 023 588 Option 2

PHARMAC PO Box 10 254

Facsimile: (04) 974 4881

Wellington

Email: [haemophilia@pharmac.govt.nz](mailto:haemophilia@pharmac.govt.nz)

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) – **Restricted** see terms [below](#)

⬇ Inj 250 iu vial.....	237.50	1	Kogenate FS
⬇ Inj 500 iu vial.....	475.00	1	Kogenate FS
⬇ Inj 1,000 iu vial.....	950.00	1	Kogenate FS
⬇ Inj 2,000 iu vial.....	1,900.00	1	Kogenate FS
⬇ Inj 3,000 iu vial.....	2,850.00	1	Kogenate FS

## ➔ Restricted

### Initiation

Notes: Second Brand of recombinant factor VIII from 1 March 2016 until 28 February 2019. When used in the treatment of haemophilia, access to funded treatment by application to the Haemophilia Treatments Panel. Application details may be obtained from PHARMAC.s website <http://www.pharmac.govt.nz> or:

The Co-ordinator, Haemophilia Treatments Panel Phone: 0800 023 588 Option 2

PHARMAC PO Box 10 254

Facsimile: (04) 974 4881

Wellington

Email: [haemophilia@pharmac.govt.nz](mailto:haemophilia@pharmac.govt.nz)

## Vitamin K

### PHYTOMENADIONE

Inj 2 mg in 0.2 ml ampoule .....	8.00	5	Konakion MM
Inj 10 mg per ml, 1 ml ampoule .....	9.21	5	Konakion MM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Antithrombotics</b>			
<b>Anticoagulants</b>			
<b>BIVALIRUDIN – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 250 mg vial			
➡ <b>Restricted</b>			
<b>Initiation</b>			
Either:			
1 For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance; or			
2 For use in patients undergoing endovascular procedures.			
<b>DABIGATRAN</b>			
Cap 75 mg .....	76.36	60	Pradaxa
Cap 110 mg .....	76.36	60	Pradaxa
Cap 150 mg .....	76.36	60	Pradaxa
<b>DALTEPARIN</b>			
Inj 2,500 iu in 0.2 ml syringe .....	19.97	10	Fragmin
Inj 5,000 iu in 0.2 ml syringe .....	39.94	10	Fragmin
Inj 7,500 iu in 0.75 ml syringe .....	60.03	10	Fragmin
Inj 10,000 iu in 1 ml syringe .....	77.55	10	Fragmin
Inj 12,500 iu in 0.5 ml syringe .....	99.96	10	Fragmin
Inj 15,000 iu in 0.6 ml syringe .....	120.05	10	Fragmin
Inj 18,000 iu in 0.72 ml syringe .....	158.47	10	Fragmin
<b>DANAPAROID – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 750 u in 0.6 ml ampoule			
➡ <b>Restricted</b>			
<b>Initiation</b>			
For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance.			
<b>DEFIBROTIDE – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 80 mg per ml, 2.5 ml ampoule			
➡ <b>Restricted</b>			
<b>Initiation</b>			
Haematologist			
Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities.			
<b>DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]</b>			
Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag			
<b>ENOXAPARIN SODIUM</b>			
Inj 20 mg in 0.2 ml syringe .....	30.91	10	Clexane
Inj 40 mg in 0.4 ml ampoule			
Inj 40 mg in 0.4 ml syringe .....	41.24	10	Clexane
Inj 60 mg in 0.6 ml syringe .....	62.18	10	Clexane
Inj 80 mg in 0.8 ml syringe .....	82.88	10	Clexane
Inj 100 mg in 1 ml syringe .....	103.80	10	Clexane
Inj 120 mg in 0.8 ml syringe .....	128.98	10	Clexane
Inj 150 mg in 1 ml syringe .....	147.41	10	Clexane
<b>FONDAPARINUX SODIUM – Restricted</b> see terms <a href="#">on the next page</a>			
⚡ Inj 2.5 mg in 0.5 ml syringe			
⚡ Inj 7.5 mg in 0.6 ml syringe			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted</b>			
<b>Initiation</b>			
For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance.			
<b>HEPARIN SODIUM</b>			
Inj 100 iu per ml, 250 ml bag			
Inj 1,000 iu per ml, 1 ml ampoule .....	66.80	50	Hospira
Inj 1,000 iu per ml, 35 ml vial			
Inj 1,000 iu per ml, 5 ml ampoule .....	61.04	50	Pfizer
Inj 5,000 iu in 0.2 ml ampoule			
Inj 5,000 iu per ml, 1 ml ampoule .....	14.20	5	Hospira
Inj 5,000 iu per ml, 5 ml ampoule .....	236.60	50	Pfizer
<b>HEPARINISED SALINE</b>			
Inj 10 iu per ml, 5 ml ampoule .....	39.00	50	Pfizer
Inj 100 iu per ml, 2 ml ampoule			
Inj 100 iu per ml, 5 ml ampoule			
<b>PHENINDIONE</b>			
Tab 10 mg			
Tab 25 mg			
Tab 50 mg			
<b>PROTAMINE SULPHATE</b>			
Inj 10 mg per ml, 5 ml ampoule			
<b>RIVAROXABAN – Restricted see terms <a href="#">below</a></b>			
↓ Tab 10 mg .....	153.00	15	Xarelto
<b>➔ Restricted</b>			
<b>Initiation – total hip replacement</b>			
<i>Limited to 5 weeks treatment</i>			
For the prophylaxis of venous thromboembolism.			
<b>Initiation – total knee replacement</b>			
<i>Limited to 2 weeks treatment</i>			
For the prophylaxis of venous thromboembolism.			
<b>SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHLORIDE</b>			
Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 mcg per ml, 5,000 ml bag			
<b>TRISODIUM CITRATE</b>			
Inj 4%, 5 ml ampoule			
Inj 46.7%, 3 ml syringe			
Inj 46.7%, 5 ml ampoule			
<b>WARFARIN SODIUM</b>			
Tab 1 mg .....	6.86	100	Marevan
Tab 2 mg			
Tab 3 mg .....	9.70	100	Marevan
Tab 5 mg .....	11.75	100	Marevan

## Antiplatelets

<b>ASPIRIN</b>			
Tab 100 mg – <b>10% DV Dec-16 to 2019</b> .....	1.60	90	<b>Ethics Aspirin EC</b>
	12.50	990	<b>Ethics Aspirin EC</b>
Suppos 300 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>CLOPIDOGREL</b>			
Tab 75 mg – <b>1% DV Mar-17 to 2019</b> .....	5.44	84	<b>Arrow - Clopid</b>
<b>DIPYRIDAMOLE</b>			
Tab 25 mg			
Tab long-acting 150 mg – <b>1% DV Sep-16 to 2019</b> .....	11.52	60	<b>Pytazen SR</b>
Inj 5 mg per ml, 2 ml ampoule			
<b>EPTIFIBATIDE – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 2 mg per ml, 10 ml vial.....	111.00	1	Integrilin
⚡ Inj 750 mcg per ml, 100 ml vial.....	324.00	1	Integrilin
➡ <b>Restricted</b>			
<b>Initiation</b>			
Either:			
1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or			
2 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography.			
<b>PRASUGREL – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 5 mg .....	108.00	28	Effient
⚡ Tab 10 mg .....	120.00	28	Effient
➡ <b>Restricted</b>			
<b>Initiation – Bare metal stents</b>			
<i>Limited to 6 months treatment</i>			
Patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic.			
<b>Initiation – Drug-eluting stents</b>			
<i>Limited to 12 months treatment</i>			
Patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic.			
<b>Initiation – Stent thrombosis</b>			
Patient has experienced cardiac stent thrombosis whilst on clopidogrel.			
<b>Initiation – Myocardial infarction</b>			
<i>Limited to 1 week treatment</i>			
For short term use while in hospital following ST-elevated myocardial infarction.			
Note: Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment			
<b>TICAGRELOR – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 90 mg .....	90.00	56	Brilinta
➡ <b>Restricted</b>			
<b>Initiation</b>			
Restricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned.			
<b>TICLOPIDINE</b>			
Tab 250 mg			

## Fibrinolytic Agents

<b>ALTEPLASE</b>
Inj 2 mg vial
Inj 10 mg vial
Inj 50 mg vial
<b>TENECTEPLASE</b>
Inj 50 mg vial

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>UROKINASE</b>			
Inj 10,000 iu vial			
Inj 50,000 iu vial			
Inj 100,000 iu vial			
Inj 500,000 iu vial			

## Colony-Stimulating Factors

### Drugs Used to Mobilise Stem Cells

PLERIXAFOR – **Restricted** see terms [below](#)

↓ Inj 20 mg per ml, 1.2 ml vial.....8,740.00 1 Mozobil

→ **Restricted**

**Initiation – Autologous stem cell transplant**

Haematologist

*Limited to 3 days treatment*

All of the following:

- 1 Patient is to undergo stem cell transplantation; and
- 2 Patient has not had a previous unsuccessful mobilisation attempt with plerixafor; and
- 3 Any of the following:
  - 3.1 Both:
    - 3.1.1 Patient is undergoing G-CSF mobilisation; and
    - 3.1.2 Either:
      - 3.1.2.1 Has a suboptimal peripheral blood CD34 count of  $\leq 10 \times 10^6/L$  on day 5 after 4 days of G-CSF treatment; or
      - 3.1.2.2 Efforts to collect  $> 1 \times 10^6$  CD34 cells/kg have failed after one apheresis procedure; or
  - 3.2 Both:
    - 3.2.1 Patient is undergoing chemotherapy and G-CSF mobilisation; and
    - 3.2.2 Any of the following:
      - 3.2.2.1 Both:
        - 3.2.2.1.1 Has rising white blood cell counts of  $> 5 \times 10^9/L$ ; and
        - 3.2.2.1.2 Has a suboptimal peripheral blood CD34 count of  $\leq 10 \times 10^6/L$ ; or
      - 3.2.2.2 Efforts to collect  $> 1 \times 10^6$  CD34 cells/kg have failed after one apheresis procedure; or
      - 3.2.2.3 The peripheral blood CD34 cell counts are decreasing before the target has been received; or
  - 3.3 A previous mobilisation attempt with G-CSF or G-CSF plus chemotherapy has failed.

### Granulocyte Colony-Stimulating Factors

FILGRASTIM – **Restricted** see terms [below](#)

↓ Inj 300 mcg in 0.5 ml prefilled syringe .....270.00 5 Zarzio

↓ Inj 300 mcg in 1 ml vial .....520.00 4 Neupogen

↓ Inj 480 mcg in 0.5 ml prefilled syringe .....432.00 5 Zarzio

→ **Restricted**

Haematologist or oncologist

PEGFILGRASTIM – **Restricted** see terms [below](#)

↓ Inj 6 mg per 0.6 ml syringe .....1,080.00 1 Neulastim

→ **Restricted**

**Initiation**

For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk  $\geq 20\%$ ).

Note: \*Febrile neutropenia risk  $\geq 20\%$  after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Fluids and Electrolytes</b>			
<b>Intravenous Administration</b>			
CALCIUM CHLORIDE			
Inj 100 mg per ml, 10 ml vial			
CALCIUM GLUCONATE			
Inj 10%, 10 ml ampoule .....	34.24	10	Hospira
COMPOUND ELECTROLYTES			
Inj sodium 140 mmol/l with potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l and gluconate 23 mmol/l, bag .....	2.40	1,000 ml	Baxter
	5.00	500 ml	Baxter
COMPOUND ELECTROLYTES WITH GLUCOSE			
Inj glucose 50 g with 140 mmol/l sodium, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, bag .....	7.00	1,000 ml	Baxter
COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, bag .....	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
COMPOUND SODIUM LACTATE WITH GLUCOSE			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l and glucose 5%, bag .....	5.38	1,000 ml	Baxter
GLUCOSE [DEXTROSE]			
Inj 5%, bag .....	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
	2.84	100 ml	Baxter
	2.87	50 ml	Baxter
	3.87	250 ml	Baxter
Inj 10%, bag .....	6.11	500 ml	Baxter
	9.33	1,000 ml	Baxter
Inj 50%, bag .....	18.74	500 ml	Baxter
Inj 50%, 10 ml ampoule – 1% DV Oct-14 to 2017 .....	27.50	5	Biomed
Inj 50%, 90 ml bottle – 1% DV Oct-14 to 2017 .....	14.50	1	Biomed
Inj 70%, 1,000 ml bag			
Inj 70%, 500 ml bag			
GLUCOSE WITH POTASSIUM CHLORIDE			
Inj 5% glucose with 20 mmol/l potassium chloride, bag .....	12.09	1,000 ml	Baxter
Inj 5% glucose with 30 mmol/l potassium chloride, 1,000 ml bag			
Inj 10% glucose with 10 mmol/l potassium chloride, 500 ml bag			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE</b>			
Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 3,000 ml bag			
Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, bag .....	3.45	500 ml	Baxter
	8.31	1,000 ml	Baxter
Inj 4% glucose with potassium chloride 30 mmol/l and sodium chloride 0.18%, bag .....	10.74	1,000 ml	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, bag .....	8.29	1,000 ml	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.9%, bag .....	12.50	1,000 ml	Baxter
Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride 15 mmol/l, 500 ml bag			
<b>GLUCOSE WITH SODIUM CHLORIDE</b>			
Inj glucose 2.5% with sodium chloride 0.45%, bag .....	8.12	500 ml	Baxter
Inj glucose 5% with sodium chloride 0.45%, bag .....	5.80	1,000 ml	Baxter
Inj glucose 5% with sodium chloride 0.9%, bag .....	8.92	1,000 ml	Baxter
Inj glucose 5% with sodium chloride 0.2%, 500 ml bag			
<b>POTASSIUM CHLORIDE</b>			
Inj 75 mg (1 mmol) per ml, 10 ml ampoule			
Inj 225 mg (3 mmol) per ml, 20 ml ampoule			
<b>POTASSIUM CHLORIDE WITH SODIUM CHLORIDE</b>			
Inj 20 mmol/l potassium chloride with 0.9% sodium chloride, bag .....	7.66	1,000 ml	Baxter
Inj 30 mmol/l potassium chloride with 0.9% sodium chloride, bag .....	9.40	1,000 ml	Baxter
Inj 40 mmol/l potassium chloride with 0.9% sodium chloride, bag .....	12.26	1,000 ml	Baxter
Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag			
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag			
<b>POTASSIUM DIHYDROGEN PHOSPHATE</b>			
Inj 1 mmol per ml, 10 ml ampoule – <b>1% DV Oct-15 to 2018</b> .....	151.80	10	<b>Hospira</b>
<b>RINGER'S SOLUTION</b>			
Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, bag .....	8.69	1,000 ml	Baxter
<b>SODIUM ACETATE</b>			
Inj 4 mmol per ml, 20 ml ampoule			
<b>SODIUM BICARBONATE</b>			
Inj 8.4%, 10 ml vial			
Inj 8.4%, 50 ml vial .....	19.95	1	Biomed
Inj 8.4%, 100 ml vial .....	20.50	1	Biomed

## BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>SODIUM CHLORIDE</b>			
Inj 0.9%, 5 ml ampoule – <b>1% DV Mar-17 to 2019</b> .....	7.00	50	<b>InterPharma</b>
Inj 0.9%, 10 ml ampoule – <b>1% DV Mar-17 to 2019</b> .....	6.63	50	<b>Pfizer</b>
⚡ Inj 0.9%, 3 ml syringe, non-sterile pack – <b>1% DV Jun-15 to 2018</b> .....	10.65	30	<b>BD PosiFlush</b>
➡ <b>Restricted</b>			
<b>Initiation</b>			
For use in flushing of in-situ vascular access devices only.			
⚡ Inj 0.9%, 5 ml syringe, non-sterile pack – <b>1% DV Jun-15 to 2018</b> .....	10.80	30	<b>BD PosiFlush</b>
➡ <b>Restricted</b>			
<b>Initiation</b>			
For use in flushing of in-situ vascular access devices only.			
⚡ Inj 0.9%, 10 ml syringe, non-sterile pack – <b>1% DV Jun-15 to 2018</b> .....	11.25	30	<b>BD PosiFlush</b>
➡ <b>Restricted</b>			
<b>Initiation</b>			
For use in flushing of in-situ vascular access devices only.			
Inj 0.9%, 20 ml ampoule.....	7.50	30	<b>InterPharma</b>
	5.00	20	<b>Multichem</b>
Inj 23.4% (4 mmol/ml), 20 ml ampoule – <b>1% DV Oct-16 to 2019</b> .....	33.00	5	<b>Biomed</b>
Inj 0.45%, 500 ml bag – <b>1% DV Sep-16 to 2019</b> .....	71.28	18	<b>Baxter</b>
Inj 3%, 1,000 ml bag – <b>1% DV Sep-16 to 2019</b> .....	91.20	12	<b>Baxter</b>
Inj 0.9%, 50 ml bag – <b>1% DV Sep-16 to 2019</b> .....	109.80	60	<b>Baxter</b>
Inj 0.9%, 100 ml bag – <b>1% DV Sep-16 to 2019</b> .....	78.24	48	<b>Baxter</b>
Inj 0.9%, 250 ml bag – <b>1% DV Sep-16 to 2019</b> .....	44.64	24	<b>Baxter</b>
Inj 0.9%, 500 ml bag – <b>1% DV Sep-16 to 2019</b> .....	22.14	18	<b>Baxter</b>
Inj 0.9%, 1,000 ml bag – <b>1% DV Sep-16 to 2019</b> .....	15.12	12	<b>Baxter</b>
Inj 1.8%, 500 ml bottle			
<b>SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]</b>			
Inj 1 mmol per ml, 20 ml ampoule – <b>1% DV Oct-15 to 2018</b> .....	47.50	5	<b>Biomed</b>
<b>WATER</b>			
Inj 5 ml ampoule – <b>1% DV Mar-17 to 2019</b> .....	7.00	50	<b>InterPharma</b>
Inj 10 ml ampoule – <b>1% DV Mar-17 to 2019</b> .....	6.63	50	<b>Pfizer</b>
Inj 20 ml ampoule.....	7.50	30	<b>InterPharma</b>
	5.00	20	<b>Multichem</b>
Inj 250 ml bag			
Inj 500 ml bag			
Inj, 1,000 ml bag – <b>1% DV Sep-16 to 2019</b> .....	19.08	12	<b>Baxter</b>
<b>Oral Administration</b>			
<b>CALCIUM POLYSTYRENE SULPHONATE</b>			
Powder.....	169.85	300 g	<b>Calcium Resonium</b>
<b>COMPOUND ELECTROLYTES</b>			
Powder for oral soln – <b>1% DV Dec-16 to 2019</b> .....	2.30	10	<b>Enerlyte</b>
<b>COMPOUND ELECTROLYTES WITH GLUCOSE</b>			
Soln with electrolytes			
<b>PHOSPHORUS</b>			
Tab eff 500 mg (16 mmol)			
<b>POTASSIUM CHLORIDE</b>			
Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)			
Tab long-acting 600 mg (8 mmol).....	7.42	200	<b>Span-K</b>
Oral liq 2 mmol per ml			

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)  
e.g. *Brand* indicates brand example only. It is not a contracted product.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SODIUM BICARBONATE			
Cap 840 mg .....	8.52	100	Sodibic
SODIUM CHLORIDE			
Tab 600 mg			
Oral liq 2 mmol/ml			
SODIUM POLYSTYRENE SULPHONATE			
Powder – <b>1% DV Sep-15 to 2018</b> .....	84.65	454 g	<b>Resonium A</b>
<b>Plasma Volume Expanders</b>			
GELATINE, SUCCINYLATED			
Inj 4%, 500 ml bag .....	108.00	10	Gelofusine
HYDROXYETHYL STARCH 130/0.4 WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE AND SODIUM CHLORIDE			
Inj 6% with magnesium chloride 0.03%, potassium chloride 0.03%, sodium acetate 0.463% and sodium chloride 0.6%, 500 ml bag .....	198.00	20	Volulyte 6%
HYDROXYETHYL STARCH 130/0.4 WITH SODIUM CHLORIDE			
Inj 6% with sodium chloride 0.9%, 500 ml bag .....	198.00	20	Voluven

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Agents Affecting the Renin-Angiotensin System</b>			
<b>ACE Inhibitors</b>			
<b>CAPTOPRIL</b>			
↓ Oral liq 5 mg per ml .....	94.99	95 ml	Capoten
➡ <b>Restricted</b>			
<b>Initiation</b>			
Any of the following:			
1 For use in children under 12 years of age; or			
2 For use in tube-fed patients; or			
3 For management of rebound transient hypertension following cardiac surgery.			
<b>CILAZAPRIL</b>			
Tab 0.5 mg .....	2.00	90	Zapril
Tab 2.5 mg – 1% DV Dec-16 to 2019 .....	7.20	200	Apo-Cilazapril
Tab 5 mg – 1% DV Dec-16 to 2019 .....	12.00	200	Apo-Cilazapril
<b>ENALAPRIL MALEATE</b>			
Tab 5 mg – 1% DV Sep-15 to 2018 .....	0.96	100	Ethics Enalapril
Tab 10 mg – 1% DV Sep-15 to 2018 .....	1.24	100	Ethics Enalapril
Tab 20 mg – 1% DV Sep-15 to 2018 .....	1.78	100	Ethics Enalapril
<b>LISINOPRIL</b>			
Tab 5 mg – 1% DV Jan-16 to 2018 .....	1.80	90	Ethics Lisinopril
Tab 10 mg – 1% DV Jan-16 to 2018 .....	2.05	90	Ethics Lisinopril
Tab 20 mg – 1% DV Jan-16 to 2018 .....	2.76	90	Ethics Lisinopril
<b>PERINDOPRIL</b>			
Tab 2 mg – 1% DV Oct-14 to 2017 .....	3.75	30	Apo-Perindopril
Tab 4 mg – 1% DV Oct-14 to 2017 .....	4.80	30	Apo-Perindopril
<b>QUINAPRIL</b>			
Tab 5 mg – 1% DV Sep-15 to 2018 .....	4.31	90	Arrow-Quinapril 5
Tab 10 mg – 1% DV Sep-15 to 2018 .....	3.15	90	Arrow-Quinapril 10
Tab 20 mg – 1% DV Sep-15 to 2018 .....	5.97	90	Arrow-Quinapril 20
<b>TRANDOLAPRIL – Restricted:</b> For continuation only			
➡ Cap 1 mg			
➡ Cap 2 mg			
<b>ACE Inhibitors with Diuretics</b>			
<b>CILAZAPRIL WITH HYDROCHLOROTHIAZIDE</b>			
Tab 5 mg with hydrochlorothiazide 12.5 mg – 1% DV Sep-16 to 2019 .....	10.18	100	Apo-Cilazapril/ Hydrochlorothiazide
<b>ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE – Restricted:</b> For continuation only			
➡ Tab 20 mg with hydrochlorothiazide 12.5 mg			
<b>QUINAPRIL WITH HYDROCHLOROTHIAZIDE</b>			
Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Oct-15 to 2018 .....	3.65	30	Accuretic 10
Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Oct-15 to 2018 .....	4.78	30	Accuretic 20

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Angiotensin II Antagonists</b>			
CANDESARTAN CILEXETIL – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 4 mg – 1% DV Sep-15 to 2018 .....	2.50	90	<b>Candestar</b>
↓ Tab 8 mg – 1% DV Sep-15 to 2018 .....	3.68	90	<b>Candestar</b>
↓ Tab 16 mg – 1% DV Sep-15 to 2018 .....	6.12	90	<b>Candestar</b>
↓ Tab 32 mg – 1% DV Sep-15 to 2018 .....	10.66	90	<b>Candestar</b>
→ <b>Restricted</b>			
<b>Initiation – ACE inhibitor intolerance</b>			
Either:			
1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or			
2 Patient has a history of angioedema.			
<b>Initiation – Unsatisfactory response to ACE inhibitor</b>			
Patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.			
LOSARTAN POTASSIUM			
Tab 12.5 mg – 1% DV Jan-15 to 2017 .....	1.55	84	<b>Losartan Actavis</b>
Tab 25 mg – 1% DV Jan-15 to 2017 .....	1.90	84	<b>Losartan Actavis</b>
Tab 50 mg – 1% DV Jan-15 to 2017 .....	2.25	84	<b>Losartan Actavis</b>
Tab 100 mg – 1% DV Jan-15 to 2017 .....	2.60	84	<b>Losartan Actavis</b>
<b>Angiotensin II Antagonists with Diuretics</b>			
LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE			
Tab 50 mg with hydrochlorothiazide 12.5 mg – 1% DV Oct-14 to 2017 .....	2.18	30	<b>Arrow-Losartan &amp; Hydrochlorothiazide</b>
<b>Alpha-Adrenoceptor Blockers</b>			
DOXAZOSIN			
Tab 2 mg – 1% DV Sep-14 to 2017 .....	6.75	500	<b>Apo-Doxazosin</b>
Tab 4 mg – 1% DV Sep-14 to 2017 .....	9.67	500	<b>Apo-Doxazosin</b>
PHENOXYBENZAMINE HYDROCHLORIDE			
Cap 10 mg			
Inj 50 mg per ml, 2 ml ampoule			
PHENTOLAMINE MESYLATE			
Inj 5 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 1 ml ampoule			
PRAZOSIN			
Tab 1 mg .....	5.53	100	<b>Apo-Prazosin</b>
Tab 2 mg .....	7.00	100	<b>Apo-Prazosin</b>
Tab 5 mg .....	11.70	100	<b>Apo-Prazosin</b>
TERAZOSIN			
Tab 1 mg – 1% DV Sep-16 to 2019 .....	0.59	28	<b>Actavis</b>
Tab 2 mg – 1% DV Apr-17 to 2019 .....	7.50	500	<b>Apo-Terazosin</b>
Tab 5 mg – 1% DV Feb-17 to 2019 .....	10.90	500	<b>Apo-Terazosin</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Antiarrhythmics</b>			
<b>ADENOSINE</b>			
Inj 3 mg per ml, 2 ml vial			
↓ Inj 3 mg per ml, 10 ml vial			
➔ <b>Restricted</b>			
<b>Initiation</b>			
For use in cardiac catheterisation, electrophysiology and MRI.			
<b>AJMALINE – Restricted</b> see terms <a href="#">below</a>			
↓ Inj 5 mg per ml, 10 ml ampoule			
➔ <b>Restricted</b>			
Cardiologist			
<b>AMIODARONE HYDROCHLORIDE</b>			
Tab 100 mg – 1% DV Oct-16 to 2019 .....	4.66	30	<b>Cordarone-X</b>
Tab 200 mg – 1% DV Oct-16 to 2019 .....	7.63	30	<b>Cordarone-X</b>
Inj 50 mg per ml, 3 ml ampoule – 1% DV Jun-17 to 2019 .....	22.80	6	<b>Cordarone-X</b>
	9.98	5	<b>Lodi</b>
<i>(Cordarone-X Inj 50 mg per ml, 3 ml ampoule to be delisted 1 June 2017)</i>			
<b>ATROPINE SULPHATE</b>			
Inj 600 mcg per ml, 1 ml ampoule .....	71.00	50	AstraZeneca
<b>DIGOXIN</b>			
Tab 62.5 mcg – 1% DV Jun-16 to 2019 .....	6.67	240	<b>Lanoxin PG</b>
Tab 250 mcg – 1% DV Jun-16 to 2019 .....	14.52	240	<b>Lanoxin</b>
Oral liq 50 mcg per ml			
Inj 250 mcg per ml, 2 ml vial			
<b>DISOPYRAMIDE PHOSPHATE</b>			
Cap 100 mg			
<b>FLECAINIDE ACETATE</b>			
Tab 50 mg .....	38.95	60	Tambocor
Cap long-acting 100 mg .....	38.95	30	Tambocor CR
Cap long-acting 200 mg .....	68.78	30	Tambocor CR
Inj 10 mg per ml, 15 ml ampoule .....	52.45	5	Tambocor
<b>MEXILETINE HYDROCHLORIDE</b>			
Cap 150 mg .....	162.00	100	Mexiletine Hydrochloride USP
Cap 250 mg .....	202.00	100	Mexiletine Hydrochloride USP
<b>PROPAFENONE HYDROCHLORIDE</b>			
Tab 150 mg			

## Antihypertensives

**MIDODRINE – Restricted** see terms [below](#)

↓ Tab 2.5 mg

↓ Tab 5 mg

➔ **Restricted**

**Initiation**

Patient has disabling orthostatic hypotension not due to drugs.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Beta-Adrenoceptor Blockers</b>			
<b>ATENOLOL</b>			
Tab 50 mg – <b>1% DV Sep-15 to 2018</b> .....	4.61	500	<b>Mylan Atenolol</b>
Tab 100 mg – <b>1% DV Sep-15 to 2018</b> .....	7.67	500	<b>Mylan Atenolol</b>
Oral liq 5 mg per ml .....	21.25	300 ml	Atenolol-AFT
<b>BISOPROLOL FUMARATE</b>			
Tab 2.5 mg – <b>1% DV Mar-15 to 2017</b> .....	2.40	30	<b>Bosvate</b>
Tab 5 mg – <b>1% DV Mar-15 to 2017</b> .....	3.50	30	<b>Bosvate</b>
Tab 10 mg – <b>1% DV Mar-15 to 2017</b> .....	6.40	30	<b>Bosvate</b>
<b>CARVEDILOL</b>			
Tab 6.25 mg – <b>1% DV Jun-15 to 2017</b> .....	3.90	60	<b>Dicarz</b>
Tab 12.5 mg – <b>1% DV Jun-15 to 2017</b> .....	5.10	60	<b>Dicarz</b>
Tab 25 mg – <b>1% DV Jun-15 to 2017</b> .....	6.30	60	<b>Dicarz</b>
<b>CELIPROLOL</b>			
Tab 200 mg .....	21.40	180	Celol
<b>ESMOLOL HYDROCHLORIDE</b>			
Inj 10 mg per ml, 10 ml vial			
<b>LABETALOL</b>			
Tab 50 mg .....	8.99	100	Hybloc
Tab 100 mg .....	11.36	100	Hybloc
Tab 200 mg .....	29.74	100	Hybloc
Tab 400 mg			
Inj 5 mg per ml, 20 ml ampoule			
<b>METOPROLOL SUCCINATE</b>			
Tab long-acting 23.75 mg.....	2.39	90	Metoprolol - AFT CR
Tab long-acting 47.5 mg.....	3.48	90	Metoprolol - AFT CR
Tab long-acting 95 mg.....	5.73	90	Metoprolol - AFT CR
Tab long-acting 190 mg.....	11.54	90	Metoprolol - AFT CR
<b>METOPROLOL TARTRATE</b>			
Tab 50 mg – <b>1% DV Aug-16 to 2018</b> .....	4.64	100	<b>Apo-Metoprolol</b>
Tab 100 mg – <b>1% DV Aug-16 to 2018</b> .....	6.09	60	<b>Apo-Metoprolol</b>
Tab long-acting 200 mg.....	23.40	28	Slow-Lopresor
Inj 1 mg per ml, 5 ml vial.....	24.00	5	Lopresor
<b>NADOLOL</b>			
Tab 40 mg – <b>1% DV Oct-15 to 2018</b> .....	16.05	100	<b>Apo-Nadolol</b>
Tab 80 mg – <b>1% DV Oct-15 to 2018</b> .....	24.70	100	<b>Apo-Nadolol</b>
<b>PINDOLOL</b>			
Tab 5 mg .....	9.72	100	Apo-Pindolol
Tab 10 mg .....	15.62	100	Apo-Pindolol
Tab 15 mg .....	23.46	100	Apo-Pindolol
<b>PROPRANOLOL</b>			
Tab 10 mg .....	3.65	100	Apo-Propranolol
Tab 40 mg .....	4.65	100	Apo-Propranolol
Cap long-acting 160 mg .....	18.17	100	Cardinol LA
Oral liq 4 mg per ml			
Inj 1 mg per ml, 1 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>SOTALOL</b>			
Tab 80 mg – 1% DV Oct-16 to 2019.....	39.53	500	<b>Mylan</b>
Tab 160 mg – 1% DV Oct-16 to 2019.....	12.48	100	<b>Mylan</b>
Inj 10 mg per ml, 4 ml ampoule .....	65.39	5	<b>Sotacor</b>

## TIMOLOL MALEATE

Tab 10 mg

## Calcium Channel Blockers

### Dihydropyridine Calcium Channel Blockers

#### AMLODIPINE

Tab 2.5 mg – 1% DV Feb-15 to 2017 .....	2.21	100	<b>Apo-Amlodipine</b>
Tab 5 mg – 1% DV May-15 to 2017.....	5.04	250	<b>Apo-Amlodipine</b>
Tab 10 mg – 1% DV May-15 to 2017.....	7.21	250	<b>Apo-Amlodipine</b>

#### FELODIPINE

Tab long-acting 2.5 mg – 1% DV Sep-15 to 2018 .....	1.45	30	<b>Plendil ER</b>
Tab long-acting 5 mg – 1% DV Sep-15 to 2018 .....	1.55	30	<b>Plendil ER</b>
Tab long-acting 10 mg – 1% DV Sep-15 to 2018 .....	2.30	30	<b>Plendil ER</b>

#### ISRADIPINE

Tab 2.5 mg  
Cap 2.5 mg  
Cap long-acting 2.5 mg  
Cap long-acting 5 mg

#### NICARDIPINE HYDROCHLORIDE – Restricted see terms [below](#)

⚡ Inj 2.5 mg per ml, 10 ml vial

#### ➡ Restricted

#### Initiation

Anaesthetist, intensivist or paediatric cardiologist

Both:

- 1 Patient is a Paediatric Patient; and
- 2 Any of the following:
  - 2.1 Patient has hypertension requiring urgent treatment with an intravenous agent; or
  - 2.2 Patient has excessive ventricular afterload; or
  - 2.3 Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.

#### NIFEDIPINE

Tab long-acting 10 mg			
Tab long-acting 20 mg.....	9.59	100	<b>Nyefax Retard</b>
Tab long-acting 30 mg – 1% DV Sep-14 to 2017 .....	3.75	30	<b>Adefin XL</b>
Tab long-acting 60 mg – 1% DV Sep-14 to 2017 .....	5.75	30	<b>Adefin XL</b>
Cap 5 mg			

#### NIMODIPINE

Tab 30 mg  
Inj 200 mcg per ml, 50 ml vial

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Other Calcium Channel Blockers</b>			
<b>DILTIAZEM HYDROCHLORIDE</b>			
Tab 30 mg .....	4.60	100	Dilzem
Tab 60 mg .....	8.50	100	Dilzem
Cap long-acting 120 mg .....	31.83	500	Apo-Diltiazem CD
	1.91	30	Cardizem CD
Cap long-acting 180 mg .....	47.67	500	Apo-Diltiazem CD
	7.56	30	Cardizem CD
Cap long-acting 240 mg .....	63.58	500	Apo-Diltiazem CD
	10.22	30	Cardizem CD
Inj 5 mg per ml, 5 ml vial			
<b>PERHEXILINE MALEATE</b>			
Tab 100 mg – <b>1% DV Jun-16 to 2019</b> .....	62.90	100	<b>Pexsig</b>
<b>VERAPAMIL HYDROCHLORIDE</b>			
Tab 40 mg .....	7.01	100	Isoptin
Tab 80 mg – <b>1% DV Sep-14 to 2017</b> .....	11.74	100	<b>Isoptin</b>
Tab long-acting 120 mg .....	15.20	250	Verpamil SR
Tab long-acting 240 mg .....	25.00	250	Verpamil SR
Inj 2.5 mg per ml, 2 ml ampoule .....	25.00	5	Isoptin
<b>Centrally-Acting Agents</b>			
<b>CLONIDINE</b>			
Patch 2.5 mg, 100 mcg per day – <b>1% DV Jul-14 to 2017</b> .....	12.80	4	<b>Catapres-TTS-1</b>
Patch 5 mg, 200 mcg per day – <b>1% DV Jul-14 to 2017</b> .....	18.04	4	<b>Catapres-TTS-2</b>
Patch 7.5 mg, 300 mcg per day – <b>1% DV Jul-14 to 2017</b> .....	22.68	4	<b>Catapres-TTS-3</b>
<b>CLONIDINE HYDROCHLORIDE</b>			
Tab 25 mcg – <b>1% DV Sep-15 to 2018</b> .....	10.53	112	<b>Clonidine BNM</b>
Tab 150 mcg .....	34.32	100	Catapres
Inj 150 mcg per ml, 1 ml ampoule .....	16.07	5	Catapres
<b>METHYLDOPA</b>			
Tab 250 mg .....	15.10	100	Methyldopa Mylan
Tab 500 mg .....	23.15	100	Prodopa
<i>(Prodopa Tab 500 mg to be delisted 1 June 2017)</i>			
<b>Diuretics</b>			
<b>Loop Diuretics</b>			
<b>BUMETANIDE</b>			
Tab 1 mg .....	16.36	100	Burinex
Inj 500 mcg per ml, 4 ml vial			
<b>FUROSEMIDE [FRUSEMIDE]</b>			
Tab 40 mg – <b>1% DV Sep-15 to 2018</b> .....	8.00	1,000	<b>Diurin 40</b>
Tab 500 mg – <b>1% DV Sep-15 to 2018</b> .....	25.00	50	<b>Urex Forte</b>
Oral liq 10 mg per ml			
Inj 10 mg per ml, 2 ml ampoule – <b>1% DV Jun-16 to 2019</b> .....	1.20	5	<b>Frusemide-Claris</b>
Inj 10 mg per ml, 25 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Osmotic Diuretics

### MANNITOL

Inj 10%, 1,000 ml bag.....	24.85	1,000 ml	Baxter
Inj 20%, 500 ml bag.....	23.08	500 ml	Baxter

## Potassium Sparing Combination Diuretics

### AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE

Tab 5 mg with furosemide 40 mg

### AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE

Tab 5 mg with hydrochlorothiazide 50 mg

## Potassium Sparing Diuretics

### AMILORIDE HYDROCHLORIDE

Tab 5 mg .....	15.00	100	Apo-Amiloride
Oral liq 1 mg per ml .....	30.00	25 ml	Biomed

### SPIRONOLACTONE

Tab 25 mg – 1% DV Oct-16 to 2019.....	4.38	100	<b>Spiractin</b>
Tab 100 mg – 1% DV Oct-16 to 2019.....	11.80	100	<b>Spiractin</b>
Oral liq 5 mg per ml .....	30.00	25 ml	Biomed

## Thiazide and Related Diuretics

### BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]

Tab 2.5 mg – 1% DV Sep-14 to 2017 .....	5.48	500	<b>Arrow-Bendroflumethiazide</b>
Tab 5 mg – 1% DV Sep-14 to 2017 .....	8.95	500	<b>Arrow-Bendroflumethiazide</b>

### CHLOROTHIAZIDE

Oral liq 50 mg per ml .....	26.00	25 ml	Biomed
-----------------------------	-------	-------	--------

### CHLORTALIDONE [CHLORTHALIDONE]

Tab 25 mg .....	8.00	50	Hygroton
-----------------	------	----	----------

### INDAPAMIDE

Tab 2.5 mg – 1% DV Oct-16 to 2019.....	2.60	90	<b>Dapa-Tabs</b>
--	------	----	------------------

### METOLAZONE – **Restricted** see terms [below](#)

↓ Tab 5 mg

➔ **Restricted**

#### Initiation

Either:

- 1 Patient has refractory heart failure and is intolerant or has not responded to loop diuretics and/or loop-thiazide combination therapy; or
- 2 Patient has severe refractory nephrotic oedema unresponsive to high dose loop diuretics and concentrated albumin infusions.

## Lipid-Modifying Agents

### Fibrates

### BEZAFIBRATE

Tab 200 mg – 1% DV Oct-15 to 2018.....	9.05	90	<b>Bezalip</b>
Tab long-acting 400 mg – 1% DV Oct-15 to 2018.....	6.78	30	<b>Bezalip Retard</b>



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GEMFIBROZIL			
Tab 600 mg – 1% DV Jan-17 to 2019 .....	19.56	60	Lipazil

### HMG CoA Reductase Inhibitors (Statins)

#### ATORVASTATIN

Tab 10 mg – 1% DV Nov-16 to 2018 .....	9.29	500	Lorstat
Tab 20 mg – 1% DV Nov-16 to 2018 .....	13.32	500	Lorstat
Tab 40 mg – 1% DV Nov-16 to 2018 .....	21.23	500	Lorstat
Tab 80 mg – 1% DV Nov-16 to 2018 .....	36.26	500	Lorstat

#### PRAVASTATIN

Tab 10 mg			
Tab 20 mg – 1% DV Oct-14 to 2017 .....	3.45	30	Cholvastin
Tab 40 mg – 1% DV Oct-14 to 2017 .....	6.36	30	Cholvastin

#### SIMVASTATIN

Tab 10 mg – 1% DV Sep-14 to 2017 .....	0.95	90	Arrow-Simva
Tab 20 mg – 1% DV Sep-14 to 2017 .....	1.61	90	Arrow-Simva
Tab 40 mg – 1% DV Sep-14 to 2017 .....	2.83	90	Arrow-Simva
Tab 80 mg – 1% DV Sep-14 to 2017 .....	7.91	90	Arrow-Simva

### Resins

#### CHOLESTYRAMINE

Powder for oral liq 4 g

#### COLESTIPOL HYDROCHLORIDE

Grans for oral liq 5 g

### Selective Cholesterol Absorption Inhibitors

#### EZETIMIBE – **Restricted** see terms [below](#)

↓ Tab 10 mg – 1% DV Aug-15 to 2017 .....	3.35	30	Ezemibe
--	------	----	---------

#### → **Restricted**

#### Initiation

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
  - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 x normal) when treated with one statin; or
  - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
  - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

#### EZETIMIBE WITH SIMVASTATIN – **Restricted** see terms [below](#)

↓ Tab 10 mg with simvastatin 10 mg – 1% DV Aug-15 to 2017 .....	5.15	30	Zimybe
↓ Tab 10 mg with simvastatin 20 mg – 1% DV Aug-15 to 2017 .....	6.15	30	Zimybe
↓ Tab 10 mg with simvastatin 40 mg – 1% DV Aug-15 to 2017 .....	7.15	30	Zimybe
↓ Tab 10 mg with simvastatin 80 mg – 1% DV Aug-15 to 2017 .....	8.15	30	Zimybe

#### → **Restricted**

#### Initiation

All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

## Other Lipid-Modifying Agents

ACIPIMOX

Cap 250 mg

NICOTINIC ACID

Tab 50 mg – 1% DV Oct-14 to 2017.....	3.96	100	Apo-Nicotinic Acid
Tab 500 mg – 1% DV Oct-14 to 2017.....	17.37	100	Apo-Nicotinic Acid

## Nitrates

GLYCERYL TRINITRATE

Tab 600 mcg.....	8.00	100	Lycinate
Inj 1 mg per ml, 5 ml ampoule .....	22.70	10	Nitronal
Inj 1 mg per ml, 50 ml vial.....	86.60	10	Nitronal
Inj 5 mg per ml, 10 ml ampoule .....	100.00	5	Hospira
Oral pump spray, 400 mcg per dose .....	4.45	250 dose	Nitrolingual Pump Spray
Oral spray, 400 mcg per dose .....	4.45	250 dose	Glytrin
Patch 25 mg, 5 mg per day – 1% DV Sep-14 to 2017.....	15.73	30	Nitroderm TTS 5
Patch 50 mg, 10 mg per day – 1% DV Sep-14 to 2017 .....	18.62	30	Nitroderm TTS 10

(Nitronal Inj 1 mg per ml, 50 ml vial to be delisted 1 July 2017)

ISOSORBIDE MONONITRATE

Tab 20 mg – 1% DV Sep-14 to 2017.....	17.10	100	Ismo-20
Tab long-acting 40 mg – 1% DV Jun-16 to 2019.....	7.50	30	Ismo 40 Retard
Tab long-acting 60 mg.....	8.49	90	Duride

## Other Cardiac Agents

LEVOSIMENDAN – **Restricted** see terms [below](#)

⚡ Inj 2.5 mg per ml, 5 ml vial

⚡ Inj 2.5 mg per ml, 10 ml vial

➡ **Restricted**

**Initiation – Heart transplant**

Either:

- 1 For use as a bridge to heart transplant, in patients who have been accepted for transplant; or
- 2 For the treatment of heart failure following heart transplant.

**Initiation – Heart failure**

Cardiologist or intensivist

For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Sympathomimetics</b>			
<b>ADRENALINE</b>			
Inj 1 in 1,000, 1 ml ampoule .....	4.98	5	Aspen Adrenaline
	5.25		Hospira
Inj 1 in 1,000, 30 ml vial			
Inj 1 in 10,000, 10 ml ampoule .....	49.00	10	Aspen Adrenaline
	27.00	5	Hospira
Inj 1 in 10,000, 10 ml syringe			
<b>DOBUTAMINE HYDROCHLORIDE</b>			
Inj 12.5 mg per ml, 20 ml ampoule – <b>1% DV Jan-16 to 2018</b> .....	24.45	5	<b>Dobutamine-Claris</b>
<b>DOPAMINE HYDROCHLORIDE</b>			
Inj 40 mg per ml, 5 ml ampoule – <b>1% DV Sep-15 to 2018</b> .....	16.89	5	<b>DBL Sterile Dopamine Concentrate</b>
<b>EPHEDRINE</b>			
Inj 3 mg per ml, 10 ml syringe			
Inj 30 mg per ml, 1 ml ampoule – <b>1% DV Mar-15 to 2017</b> .....	51.48	10	<b>Max Health</b>
<b>ISOPRENALINE</b>			
Inj 200 mcg per ml, 1 ml ampoule			
Inj 200 mcg per ml, 5 ml ampoule			
<b>METARAMINOL</b>			
Inj 0.5 mg per ml, 20 ml syringe			
Inj 1 mg per ml, 1 ml ampoule			
Inj 1 mg per ml, 10 ml syringe			
Inj 10 mg per ml, 1 ml ampoule			
<b>NORADRENALINE</b>			
Inj 0.06 mg per ml, 100 ml bag			
Inj 0.06 mg per ml, 50 ml syringe			
Inj 0.1 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 50 ml syringe			
Inj 0.16 mg per ml, 50 ml syringe			
Inj 1 mg per ml, 100 ml bag			
Inj 1 mg per ml, 4 ml ampoule			
<b>PHENYLEPHRINE HYDROCHLORIDE</b>			
Inj 10 mg per ml, 1 ml ampoule .....	115.50	25	Neosynephrine HCL
<b>Vasodilators</b>			
<b>ALPROSTADIL HYDROCHLORIDE</b>			
Inj 500 mcg per ml, 1 ml ampoule – <b>1% DV Oct-15 to 2018</b> .....	1,650.00	5	<b>Prostin VR</b>
<b>AMYL NITRITE</b>			
Liq 98% in 3 ml capsule			
<b>DIAZOXIDE</b>			
Inj 15 mg per ml, 20 ml ampoule			
<b>HYDRALAZINE HYDROCHLORIDE</b>			
↓ Tab 25 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## ➔ Restricted

### Initiation

Either:

- 1 For the treatment of refractory hypertension; or
- 2 For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.

Inj 20 mg ampoule .....25.90 5 Apresoline

### MILRINONE

Inj 1 mg per ml, 10 ml ampoule – **1% DV Jul-16 to 2018** .....300.30 10 **Milrinone Generic Health**

### MINOXIDIL – Restricted see terms [below](#)

↓ Tab 10 mg .....70.00 100 Loniten

## ➔ Restricted

### Initiation

For patients with severe refractory hypertension who have failed to respond to extensive multiple therapies.

### NICORANDIL

Tab 10 mg .....27.95 60 Ikorel

Tab 20 mg .....33.28 60 Ikorel

### PAPAVERINE HYDROCHLORIDE

Inj 30 mg per ml, 1 ml vial

Inj 12 mg per ml, 10 ml ampoule .....217.90 5 Hospira

### PENTOXIFYLLINE [OXPENTIFYLLINE]

Tab 400 mg

### SODIUM NITROPRUSSIDE

Inj 50 mg vial

## Endothelin Receptor Antagonists

### AMBRISENTAN – Restricted see terms [below](#)

↓ Tab 5 mg .....4,585.00 30 Volibris

↓ Tab 10 mg .....4,585.00 30 Volibris

## ➔ Restricted

### Initiation

Either:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 In hospital stabilisations in emergency situations.

### BOSENTAN – Restricted see terms [below](#)

↓ Tab 62.5 mg – **1% DV Jan-16 to 2018** .....375.00 56 **Mylan-Bosentan**

↓ Tab 125 mg – **1% DV Jan-16 to 2018** .....375.00 56 **Mylan-Bosentan**

## ➔ Restricted

### Initiation

Either:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 In hospital stabilisation in emergency situations.

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

## Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – **Restricted** see terms [below](#)

↓ Tab 25 mg – 1% DV Sep-15 to 2018 .....	0.75	4	<b>Vedafil</b>
↓ Tab 50 mg – 1% DV Sep-15 to 2018 .....	0.75	4	<b>Vedafil</b>
↓ Tab 100 mg – 1% DV Sep-15 to 2018 .....	2.75	4	<b>Vedafil</b>

→ **Restricted**

### Initiation

Any of the following:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
- 3 For use in weaning patients from inhaled nitric oxide; or
- 4 For perioperative use in cardiac surgery patients; or
- 5 For use in intensive care as an alternative to nitric oxide; or
- 6 In-hospital stabilisation in emergency situations; or
- 7 All of the following:
  - 7.1 Patient has Raynaud's phenomenon; and
  - 7.2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
  - 7.3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
  - 7.4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

## Prostacyclin Analogues

EPOPROSTENOL – **Restricted** see terms [below](#)

↓ Inj 0.5 mg vial .....	36.61	1	<b>Veletri</b>
↓ Inj 1.5 mg vial .....	73.21	1	<b>Veletri</b>

→ **Restricted**

### Initiation

For use as a bridge to transplant for patients with Pulmonary Arterial Hypertension who are on the active waiting list for lung transplantation.

ILOPROST

Inj 50 mcg in 0.5 ml ampoule – 1% DV Jan-17 to 2019 .....	380.00	5	<b>Ilomedin</b>
↓ Nebuliser soln 10 mcg per ml, 2 ml .....	1,185.00	30	<b>Ventavis</b>

→ **Restricted**

### Initiation

Any of the following:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 For diagnostic use in catheter laboratories; or
- 3 For use following mitral or tricuspid valve surgery; or
- 4 In hospital stabilisation in emergency situations.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Anti-Infective Preparations</b>			
<b>Antibacterials</b>			
FUSIDIC ACID			
Crm 2%.....	2.52	15 g	DP Fusidic Acid Cream
Oint 2%.....	3.45	15 g	Foban
HYDROGEN PEROXIDE			
Crm 1%.....	8.56	15 g	Crystaderm
Soln 3% (10 vol) – 1% DV Nov-15 to 2018.....	1.40	100 ml	Pharmacy Health
MAFENIDE ACETATE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Powder 50 g sachet			
➔ <b>Restricted</b>			
<b>Initiation</b>			
For the treatment of burns patients.			
MUPIROCIN			
Oint 2%			
SULPHADIAZINE SILVER			
Crm 1%.....	12.30	50 g	Flamazine
<b>Antifungals</b>			
AMOROLFINE			
Nail soln 5% – 1% DV Jan-15 to 2017.....	19.95	5 ml	MycosNail
CICLOPIROX OLAMINE			
Nail soln 8% – 1% DV Sep-15 to 2018.....	6.50	7 ml	Apo-Ciclopirox
➔ Soln 1% – <b>Restricted:</b> For continuation only			
CLOTRIMAZOLE			
Crm 1% – 1% DV Sep-14 to 2017.....	0.52	20 g	Clomazol
➔ Soln 1% – <b>Restricted:</b> For continuation only			
ECONAZOLE NITRATE			
➔ Crm 1% – <b>Restricted:</b> For continuation only			
Foaming soln 1%			
KETOCONAZOLE			
Shampoo 2% – 1% DV Dec-14 to 2017.....	2.99	100 ml	Sebizole
METRONIDAZOLE			
Gel 0.75%			
MICONAZOLE NITRATE			
Crm 2% – 1% DV Mar-15 to 2017.....	0.55	15 g	Multichem
➔ Lotn 2% – <b>Restricted:</b> For continuation only			
Tinc 2%			
NYSTATIN			
Crm 100,000 u per g			
<b>Antiparasitics</b>			
MALATHION [MALDISON]			
Lotn 0.5%			
Shampoo 1%			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PERMETHRIN</b>			
Crm 5% – <b>1% DV Apr-15 to 2017</b> .....	4.20	30 g	<b>Lyderm</b>
Lotn 5% – <b>1% DV Sep-14 to 2017</b> .....	3.19	30 ml	<b>A-Scabies</b>
<b>PHENOTHHRIN</b>			
Shampoo 0.5%			

### Antiacne Preparations

<b>ADAPALENE</b>			
Crm 0.1%			
Gel 0.1%			
<b>BENZOYL PEROXIDE</b>			
Soln 5%			
<b>ISOTRETINOIN</b>			
Cap 10 mg .....	12.47	100	Isotane 10
	14.96	120	Oratane
Cap 20 mg .....	19.27	100	Isotane 20
	23.12	120	Oratane
<b>TRETINOIN</b>			
Crm 0.05%			

### Antipruritic Preparations

<b>CALAMINE</b>			
Crm, aqueous, BP – <b>1% DV Dec-15 to 2018</b> .....	1.49	100 g	<b>Pharmacy Health</b>
Lotn, BP – <b>1% DV Dec-15 to 2018</b> .....	12.94	2,000 ml	<b>PSM</b>
<b>CROTAMITON</b>			
Crm 10% – <b>1% DV Sep-15 to 2018</b> .....	3.37	20 g	<b>Itch-Soothe</b>

### Barrier Creams and Emollients

#### Barrier Creams

<b>DIMETHICONE</b>			
Crm 5% tube – <b>1% DV Sep-16 to 2019</b> .....	1.59	100 g	<b>healthE Dimethicone</b> <b>5%</b>
Lotn 4% – <b>1% DV Jul-17 to 2019</b> .....	4.98	200 ml	<b>healthE Dimethicone</b> <b>4% Lotion</b>
Crm 5% pump bottle – <b>1% DV Sep-16 to 2019</b> .....	4.59	500 ml	<b>healthE Dimethicone</b> <b>5%</b>
Crm 10% pump bottle – <b>1% DV Nov-15 to 2018</b> .....	4.90	500 ml	<b>healthE Dimethicone</b> <b>10%</b>
<b>ZINC</b>			
Crm			<i>e.g. Zinc Cream (Orion-)</i> <i>;Zinc Cream (PSM)</i>
Oint			<i>e.g. Zinc oxide (PSM)</i>
Paste			
<b>ZINC AND CASTOR OIL</b>			
Crm .....	1.63	20 g	<b>Orion</b>
Oint, BP – <b>1% DV Jul-15 to 2017</b> .....	1.39	20 g	<b>healthE</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ZINC WITH WOOL FAT</b>			
Crm zinc 15.25% with wool fat 4%			<i>e.g. Sudocrem</i>
<b>Emollients</b>			
<b>AQUEOUS CREAM</b>			
Crm 100 g – <b>1% DV Jan-16 to 2018</b> .....	1.00	100 g	<b>Pharmacy Health SLS-free</b>
Note: DV limit applies to the pack sizes of 100 g or less.			
Crm 500 g – <b>1% DV Mar-16 to 2018</b> .....	1.99	500 g	<b>AFT SLS-free</b>
Note: DV limit applies to the pack sizes of greater than 100 g.			
<b>CETOMACROGOL</b>			
Crm BP, 500 g – <b>1% DV Nov-15 to 2018</b> .....	2.74	500 g	<b>healthE</b>
Crm BP, 100 g – <b>1% DV Jan-16 to 2018</b> .....	1.47	1	<b>healthE</b>
<b>CETOMACROGOL WITH GLYCEROL</b>			
Crm 90% with glycerol 10%, .....	2.00	100 g	Pharmacy Health
	2.10		Pharmacy Health
	3.20		healthE
Crm 90% with glycerol 10% – <b>1% DV Aug-16 to 2019</b> .....	2.82	500 ml	<b>Pharmacy Health Sorbolene with Glycerin</b>
	3.87	1,000 ml	<b>Pharmacy Health Sorbolene with Glycerin</b>
<b>EMULSIFYING OINTMENT</b>			
Oint BP – <b>1% DV Apr-15 to 2017</b> .....	1.84	100 g	<b>Jaychem</b>
Note: DV limit applies to pack sizes of less than 200 g.			
Oint BP, 500 g – <b>1% DV Jul-15 to 2017</b> .....	2.73	500 g	<b>AFT</b>
Note: DV limit applies to pack sizes of greater than 200 g.			
<b>GLYCEROL WITH PARAFFIN</b>			
Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%			<i>e.g. QV cream</i>
<b>OIL IN WATER EMULSION</b>			
Crm .....	2.63	500 g	healthE Fatty Cream
Crm, 100 g .....	1.60	1	healthE Fatty Cream
<b>PARAFFIN</b>			
Oint liquid paraffin 50% with white soft paraffin 50% .....	3.10	100 g	healthE
White soft – <b>1% DV Sep-15 to 2018</b> .....	0.85	10 g	<b>healthE</b>
Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.			
Yellow soft			
<b>PARAFFIN WITH WOOL FAT</b>			
Lotn liquid paraffin 15.9% with wool fat 0.6%			<i>e.g. AlphaKeri;BK ;DP; Hydroderm Lotn</i>
Lotn liquid paraffin 91.7% with wool fat 3%			<i>e.g. Alpha Keri Bath Oil</i>
<b>UREA</b>			
Crm 10% – <b>1% DV Sep-16 to 2019</b> .....	1.37	100 g	<b>healthE Urea Cream</b>
<b>WOOL FAT</b>			
Crm			



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Corticosteroids</b>			
<b>BETAMETHASONE DIPROPIONATE</b>			
Crm 0.05%			
Oint 0.05%			
<b>BETAMETHASONE VALERATE</b>			
Crm 0.1% – <b>1% DV Jun-15 to 2018</b> .....	3.15	50 g	<b>Beta Cream</b>
Oint 0.1% – <b>1% DV Jun-15 to 2018</b> .....	3.15	50 g	<b>Beta Ointment</b>
Lotn 0.1%			
<b>CLOBETASOL PROPIONATE</b>			
Crm 0.05% – <b>1% DV Dec-16 to 2019</b> .....	2.20	30 g	<b>Dermol</b>
Oint 0.05% – <b>1% DV Dec-16 to 2019</b> .....	2.20	30 g	<b>Dermol</b>
<b>CLOBETASONE BUTYRATE</b>			
Crm 0.05%			
<b>DIFLUCORTOLONE VALERATE – Restricted:</b> For continuation only			
➔ Crm 0.1%			
➔ Fatty oint 0.1%			
<b>HYDROCORTISONE</b>			
Crm 1%, 30 g – <b>1% DV Feb-17 to 2019</b> .....	1.11	30 g	<b>DermAssist</b>
Note: DV limit applies to the pack sizes of less than or equal to 100 g.			
Crm 1%, 500 g – <b>1% DV Dec-16 to 2019</b> .....	16.25	500 g	<b>Pharmacy Health</b>
Note: DV limit applies to the pack sizes of greater than 100 g.			
<b>HYDROCORTISONE ACETATE</b>			
Crm 1%.....	2.48	14.2 g	AFT
<b>HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN</b>			
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – <b>1% DV Dec-14 to 2017</b> .....	10.57	250 ml	<b>DP Lotn HC</b>
<b>HYDROCORTISONE BUTYRATE</b>			
Crm 0.1%.....	2.30	30 g	Locoid Lipocream
	6.85	100 g	Locoid Lipocream
Oint 0.1%.....	6.85	100 g	Locoid
Milky emul 0.1% .....	6.85	100 ml	Locoid Crelo
<b>HYDROCORTISONE WITH PARAFFIN AND WOOL FAT</b>			
Lotn 1% with paraffin liquid 15.9% and wool fat 0.6%			
<b>METHYLPREDNISOLONE ACEPONATE</b>			
Crm 0.1%.....	4.95	15 g	Advantan
Oint 0.1%.....	4.95	15 g	Advantan
<b>MOMETASONE FUROATE</b>			
Crm 0.1% – <b>1% DV Nov-15 to 2018</b> .....	1.51	15 g	<b>Elocon Alcohol Free</b>
	2.90	50 g	<b>Elocon Alcohol Free</b>
Oint 0.1% – <b>1% DV Nov-15 to 2018</b> .....	1.51	15 g	<b>Elocon</b>
	2.90	50 g	<b>Elocon</b>
Lotn 0.1% – <b>1% DV Sep-15 to 2018</b>			
	7.35	30 ml	<b>Elocon</b>
<b>TRIAMCINOLONE ACETONIDE</b>			
Crm 0.02% – <b>1% DV Apr-15 to 2017</b> .....	6.30	100 g	<b>Aristocort</b>
Oint 0.02% – <b>1% DV Apr-15 to 2017</b> .....	6.35	100 g	<b>Aristocort</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Corticosteroids with Anti-Infective Agents

BETAMETHASONE VALERATE WITH CLIOQUINOL – **Restricted** see terms [below](#)

↓ Crm 0.1% with clioquinol 3%

➔ **Restricted**

**Initiation**

Either:

- 1 For the treatment of intertrigo; or
- 2 For continuation use.

BETAMETHASONE VALERATE WITH FUSIDIC ACID

Crm 0.1% with fusidic acid 2%

HYDROCORTISONE WITH MICONAZOLE

Crm 1% with miconazole nitrate 2% – **1% DV Sep-15 to 2018** ..... 2.00      15 g      **Micreme H**

HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN

Crm 1% with natamycin 1% and neomycin sulphate 0.5% ..... 2.79      15 g      Pimafucort

Oint 1% with natamycin 1% and neomycin sulphate 0.5% ..... 2.79      15 g      Pimafucort

TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRAMICIDIN AND NYSTATIN

Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and  
gramicidin 250 mcg per g

## Psoriasis and Eczema Preparations

ACITRETIN

Cap 10 mg – **1% DV Nov-14 to 2017** ..... 17.86      60      **Novatrelin**

Cap 25 mg – **1% DV Nov-14 to 2017** ..... 41.36      60      **Novatrelin**

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Gel 500 mcg with calcipotriol 50 mcg per g – **1% DV Sep-15 to 2018** ..... 26.12      30 g      **Daivobet**

Oint 500 mcg with calcipotriol 50 mcg per g – **1% DV Sep-15 to 2018** ..... 26.12      30 g      **Daivobet**

CALCIPOTRIOL

Oint 50 mcg per g – **1% DV Jul-17 to 2020** ..... 45.00      100 g      **Daivonex**

COAL TAR WITH SALICYLIC ACID AND SULPHUR

Oint 12% with salicylic acid 2% and sulphur 4%

METHOXSALEN [8-METHOXYPSORALEN]

Tab 10 mg

Lotn 1.2%

PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCIN

Soln 2.3% with trolamine laurilsulfate and fluorescein sodium ..... 3.36      500 ml      Pinetarsol

5.82      1,000 ml      Pinetarsol

POTASSIUM PERMANGANATE

Tab 400 mg

Crystals

## Scalp Preparations

BETAMETHASONE VALERATE

Scalp app 0.1% ..... 7.75      100 ml      Beta Scalp

CLOBETASOL PROPIONATE

Scalp app 0.05% ..... 6.96      30 ml      Dermol

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
HYDROCORTISONE BUTYRATE			
Scalp lotn 0.1%.....	3.65	100 ml	Locoid

### Wart Preparations

IMIQUIMOD			
Crm 5%, 250 mg sachet – <b>1% DV Feb-15 to 2017</b> .....	17.98	12	<b>Apo-Imiquimod Cream 5%</b>
PODOPHYLLOTOXIN			
Soln 0.5% .....	33.60	3.5 ml	Condyline
SILVER NITRATE			
Sticks with applicator			

### Other Skin Preparations

DIPHEMANIL METILSULFATE			
Powder 2%			
SUNSCREEN, PROPRIETARY			
Crm			
Lotn.....	3.30	100 g	Marine Blue Lotion SPF 50+
	5.10	200 g	Marine Blue Lotion SPF 50+

### Antineoplastics

FLUOROURACIL SODIUM			
Crm 5% – <b>1% DV Sep-15 to 2018</b> .....	8.95	20 g	<b>Efudix</b>
METHYL AMINOLEVULINATE HYDROCHLORIDE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Crm 16%			
➔ <b>Restricted</b>			
Dermatologist or plastic surgeon			

### Wound Management Products

CALCIUM GLUCONATE			
Gel 2.5%.....	21.00	1	healthE

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Anti-Infective Agents

### ACETIC ACID

Soln 3%

Soln 5%

### ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID

Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and  
ricinoleic acid 0.75% with applicator

### CHLORHEXIDINE GLUCONATE

Crm 1% – **1% DV Sep-15 to 2018** ..... 1.21

50 g

healthE

Lotn 1%, 200 ml – **1% DV Sep-15 to 2018** ..... 2.98

1

healthE

### CLOTRIMAZOLE

Vaginal crm 1% with applicator – **1% DV Nov-16 to 2019** ..... 1.60

35 g

Clomazol

Vaginal crm 2% with applicator – **1% DV Nov-16 to 2019** ..... 2.10

20 g

Clomazol

### MICONAZOLE NITRATE

Vaginal crm 2% with applicator – **1% DV Oct-14 to 2017** ..... 3.95

40 g

Micreme

### NYSTATIN

Vaginal crm 100,000 u per 5 g with applicator(s)

## Contraceptives

### Antiandrogen Oral Contraceptives

#### CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL

Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets – **1% DV**

**Dec-14 to 2017** ..... 5.36

168

Ginet

### Combined Oral Contraceptives

#### ETHINYLOESTRADIOL WITH DESOGESTREL

Tab 20 mcg with desogestrel 150 mcg

Tab 30 mcg with desogestrel 150 mcg

#### ETHINYLOESTRADIOL WITH LEVONORGESTREL

Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets ..... 2.65

84

Ava 20 ED

Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets ..... 2.30

84

Ava 30 ED

Tab 20 mcg with levonorgestrel 100 mcg

Tab 30 mcg with levonorgestrel 150 mcg

Tab 50 mcg with levonorgestrel 125 mcg ..... 9.45

84

Microgynon 50 ED

#### ETHINYLOESTRADIOL WITH NORETHISTERONE

Tab 35 mcg with norethisterone 1 mg

Tab 35 mcg with norethisterone 500 mcg

#### NORETHISTERONE WITH MESTRANOL

Tab 1 mg with mestranol 50 mcg

## Contraceptive Devices

#### INTRA-UTERINE DEVICE

IUD 29.1 mm length x 23.2 mm width ..... 31.60

1

Choice TT380 Short

IUD 33.6 mm length x 29.9 mm width ..... 31.60

1

Choice TT380 Standard

IUD 35.5 mm length x 19.6 mm width ..... 31.60

1

Choice Load 375

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Emergency Contraception

### LEVONORGESTREL

Tab 1.5 mg – 1% DV Jun-17 to 2019 ..... 4.95 1 **Postinor-1**

## Progestogen-Only Contraceptives

### LEVONORGESTREL

Tab 30 mcg

Subdermal implant (2 x 75 mg rods) – 5% DV Oct-14 to 31 Dec 2017 ..... 133.65 1 **Jadelle**

↓ Intra-uterine system, 20 mcg per day – 1% DV Aug-16 to 2019 ..... 269.50 1 **Mirena**

### → Restricted

#### Initiation – heavy menstrual bleeding

Obstetrician or gynaecologist

All of the following:

- 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and
- 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
- 3 Any of the following:
  - 3.1 Serum ferritin level < 16 mcg/l (within the last 12 months); or
  - 3.2 Haemoglobin level < 120 g/l; or
  - 3.3 The patient has had a uterine ultrasound and either a hysteroscopy or endometrial biopsy.

#### Continuation – heavy menstrual bleeding

Obstetrician or gynaecologist

Either:

- 1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or
- 2 Previous insertion was removed or expelled within 3 months of insertion.

#### Initiation – endometriosis

Obstetrician or gynaecologist

The patient has a clinical diagnosis of endometriosis confirmed by laparoscopy.

#### Continuation – endometriosis

Obstetrician or gynaecologist

Either:

- 1 Patient demonstrated satisfactory management of endometriosis; or
- 2 Previous insertion was removed or expelled within 3 months of insertion.

Note: endometriosis is an unregistered indication.

### MEDROXYPROGESTERONE ACETATE

Inj 150 mg per ml, 1 ml syringe – 1% DV Oct-16 to 2019 ..... 7.25 1 **Depo-Provera**

### NORETHISTERONE

Tab 350 mcg – 1% DV Oct-15 to 2018 ..... 6.25 84 **Noriday 28**

## Obstetric Preparations

### Antiprogestogens

#### MIFEPRISTONE

Tab 200 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Oxytocics</b>			
CARBOPROST TROMETAMOL			
Inj 250 mcg per ml, 1 ml ampoule			
DINOPROSTONE			
Pessaries 10 mg			
Vaginal gel 1 mg in 3 g.....	52.65	1	Prostin E2
Vaginal gel 2 mg in 3 g.....	64.60	1	Prostin E2
ERGOMETRINE MALEATE			
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017.....	94.70	5	DBL Ergometrine
OXYTOCIN			
Inj 5 iu per ml, 1 ml ampoule – 1% DV Nov-15 to 2018.....	4.03	5	Oxytocin BNM
Inj 10 iu per ml, 1 ml ampoule – 1% DV Nov-15 to 2018.....	5.03	5	Oxytocin BNM
OXYTOCIN WITH ERGOMETRINE MALEATE			
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1% DV Sep-15 to 2018 .....	11.13	5	Syntometrine
<b>Tocolytics</b>			
PROGESTERONE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Cap 100 mg – 1% DV Aug-16 to 2019.....	16.50	30	Utrogestan
➔ <b>Restricted</b>			
<b>Initiation</b>			
Gynaecologist or obstetrician			
<i>Re-assessment required after 12 months</i>			
Both:			
1 For the prevention of pre-term labour*; and			
2 Either:			
2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or			
2.2 The patient has a history of pre-term birth at less than 28 weeks.			
<b>Continuation</b>			
Gynaecologist or obstetrician			
<i>Re-assessment required after 12 months</i>			
All of the following:			
1 For the prevention of pre-term labour*; and			
2 Treatment is required for second or subsequent pregnancy; and			
3 Either:			
3.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or			
3.2 The patient has a history of pre-term birth at less than 28 weeks.			
Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 23.1)			
TERBUTALINE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 500 mcg ampoule			
➔ <b>Restricted</b>			
Obstetrician			
<b>Oestrogens</b>			
OESTRIOL			
Crm 1 mg per g with applicator			
Pessaries 500 mcg			

Price  
(ex man. excl. GST)  
\$ Per Brand or  
Generic  
Manufacturer

## Urologicals

### 5-Alpha Reductase Inhibitors

FINASTERIDE – **Restricted** see terms [below](#)

↓ Tab 5 mg – 1% DV Dec-14 to 2017 ..... 2.08 30 **Finpro**

→ **Restricted**

**Initiation**

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
  - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
  - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

### Alpha-1A Adrenoceptor Blockers

TAMSULOSIN – **Restricted** see terms [below](#)

↓ Cap 400 mcg ..... 13.51 100 **Tamsulosin-Rex**

→ **Restricted**

**Initiation**

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

### Urinary Alkalisers

POTASSIUM CITRATE – **Restricted** see terms [below](#)

↓ Oral liq 3 mmol per ml ..... 30.00 200 ml **Biomed**

→ **Restricted**

**Initiation**

Both:

- 1 The patient has recurrent calcium oxalate urolithiasis; and
- 2 The patient has had more than two renal calculi in the two years prior to the application.

SODIUM CITRO-TARTRATE

Grans eff 4 g sachets – 1% DV Feb-15 to 2017 ..... 2.93 28 **Ural**

### Urinary Antispasmodics

OXYBUTYNIN

Tab 5 mg – 1% DV Sep-16 to 2019 ..... 8.85 500 **Apo-Oxybutynin**

Oral liq 5 mg per 5 ml – 1% DV Sep-16 to 2019 ..... 60.40 473 ml **Apo-Oxybutynin**

SOLIFENACIN SUCCINATE – **Restricted** see terms [below](#)

↓ Tab 5 mg ..... 37.50 30 **Vesicare**

↓ Tab 10 mg ..... 37.50 30 **Vesicare**

→ **Restricted**

**Initiation**

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.

TOLTERODINE TARTRATE – **Restricted** see terms [on the next page](#)

↓ Tab 1 mg ..... 14.56 56 **Arrow-Tolterodine**

↓ Tab 2 mg ..... 14.56 56 **Arrow-Tolterodine**

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➡ Restricted

Initiation

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.



Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

## Anabolic Agents

### OXANDROLONE

↓ Tab 2.5 mg

→ **Restricted**

#### Initiation

For the treatment of burns patients.

## Androgen Agonists and Antagonists

### CYPROTERONE ACETATE

Tab 50 mg – <b>1% DV Oct-15 to 2018</b> .....	15.87	50	<b>Procur</b>
Tab 100 mg – <b>1% DV Oct-15 to 2018</b> .....	30.40	50	<b>Procur</b>

### TESTOSTERONE

Patch 2.5 mg per day .....	80.00	60	Androderm
----------------------------	-------	----	-----------

### TESTOSTERONE CYPIONATE

Inj 100 mg per ml, 10 ml vial – <b>1% DV Sep-14 to 2017</b> .....	76.50	1	<b>Depo-Testosterone</b>
---	-------	---	--------------------------

### TESTOSTERONE ESTERS

Inj testosterone decanoate 100 mg, testosterone isocarproate 60 mg,  
testosterone phenylpropionate 60 mg and testosterone propionate  
30 mg per ml, 1 ml ampoule

### TESTOSTERONE UNDECANOATE

Cap 40 mg – <b>1% DV Sep-15 to 2018</b> .....	16.80	60	<b>Andriol Testocaps</b>
Inj 250 mg per ml, 4 ml vial.....	86.00	1	Reandron 1000

## Calcium Homeostasis

### CALCITONIN

Inj 100 iu per ml, 1 ml ampoule – <b>1% DV Oct-14 to 2017</b> .....	121.00	5	<b>Miacalcic</b>
---	--------	---	------------------

### CINACALCET – **Restricted** see terms [below](#)

↓ Tab 30 mg .....	403.70	28	Sensipar
-------------------	--------	----	----------

→ **Restricted**

#### Initiation

Nephrologist or endocrinologist

*Re-assessment required after 6 months*

Either:

1 All of the following:

- 1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
- 1.2 The patient has persistent hypercalcaemia (serum calcium  $\geq 3$  mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
- 1.3 The patient is symptomatic; or

2 All of the following:

- 2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriopathy); and
- 2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium  $\geq 3$  mmol/L); and
- 2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation

Nephrologist or endocrinologist

Both:

- 1 The patient's serum calcium level has fallen to < 3mmol/L; and
- 2 The patient has experienced clinically significant symptom improvement.

Note: This does not include parathyroid adenomas unless these have become malignant.

## ZOLEDRONIC ACID

⚡ Inj 4 mg per 5 ml, vial .....	84.50	1	Zoledronic acid Mylan
	550.00		Zometa

## ➡ Restricted

### Initiation

Oncologist, haematologist or palliative care specialist

Any of the following:

- 1 Patient has hypercalcaemia of malignancy; or
- 2 Both:
  - 2.1 Patient has bone metastases or involvement; and
  - 2.2 Patient has severe bone pain resistant to standard first-line treatments; or
- 3 Both:
  - 3.1 Patient has bone metastases or involvement; and
  - 3.2 Patient is at risk of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone).

## Corticosteroids

### BETAMETHASONE

Tab 500 mcg

Inj 4 mg per ml, 1 ml ampoule

### BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE

Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

### DEXAMETHASONE

Tab 0.5 mg – 1% DV Jan-16 to 2018 .....	0.88	30	Dexamethsone
Tab 4 mg – 1% DV Jan-16 to 2018 .....	1.84	30	Dexamethsone
Oral liq 1 mg per ml .....	45.00	25 ml	Biomed

### DEXAMETHASONE PHOSPHATE

Inj 4 mg per ml, 1 ml ampoule – 1% DV Jul-16 to 2019 .....	14.19	10	Max Health
Inj 4 mg per ml, 2 ml ampoule – 1% DV Jul-16 to 2019 .....	12.59	5	Max Health
	25.18	10	Max Health

### FLUDROCORTISONE ACETATE

Tab 100 mcg.....	14.32	100	Florinef
------------------	-------	-----	----------

### HYDROCORTISONE

Tab 5 mg – 1% DV Sep-15 to 2018 .....	8.10	100	Douglas
Tab 20 mg – 1% DV Sep-15 to 2018 .....	20.32	100	Douglas
Inj 100 mg vial – 1% DV Oct-16 to 2019.....	5.30	1	Solu-Cortef

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>METHYLPREDNISOLONE (AS SODIUM SUCCINATE)</b>			
Tab 4 mg – <b>1% DV Oct-15 to 2018</b> .....	80.00	100	<b>Medrol</b>
Tab 100 mg – <b>1% DV Oct-15 to 2018</b> .....	180.00	20	<b>Medrol</b>
Inj 40 mg vial – <b>1% DV Oct-15 to 2018</b> .....	10.50	1	<b>Solu-Medrol</b>
Inj 125 mg vial – <b>1% DV Oct-15 to 2018</b> .....	22.25	1	<b>Solu-Medrol</b>
Inj 500 mg vial – <b>1% DV Oct-15 to 2018</b> .....	9.00	1	<b>Solu-Medrol</b>
Inj 1 g vial – <b>1% DV Oct-15 to 2018</b> .....	16.00	1	<b>Solu-Medrol</b>
<b>METHYLPREDNISOLONE ACETATE</b>			
Inj 40 mg per ml, 1 ml vial – <b>1% DV Oct-15 to 2018</b> .....	40.00	5	<b>Depo-Medrol</b>
<b>METHYLPREDNISOLONE ACETATE WITH LIDOCAINE [LIGNOCAINE]</b>			
Inj 40 mg with lidocaine [lignocaine], 1 ml vial – <b>1% DV Oct-15 to 2018</b> .....	9.25	1	<b>Depo-Medrol with Lidocaine</b>
<b>PREDNISOLONE</b>			
Oral liq 5 mg per ml.....	7.50	30 ml	<b>Redipred</b>
Enema 200 mcg per ml, 100 ml			
<b>PREDNISONE</b>			
Tab 1 mg – <b>1% DV Jun-17 to 2020</b> .....	10.68	500	<b>Apo-Prednisone</b>
Tab 2.5 mg – <b>1% DV Jun-17 to 2020</b> .....	12.09	500	<b>Apo-Prednisone</b>
Tab 5 mg – <b>1% DV Jun-17 to 2020</b> .....	11.09	500	<b>Apo-Prednisone</b>
Tab 20 mg – <b>1% DV Jun-17 to 2020</b> .....	29.03	500	<b>Apo-Prednisone</b>
<b>TRIAMCINOLONE ACETONIDE</b>			
Inj 10 mg per ml, 1 ml ampoule – <b>1% DV Apr-15 to 2017</b> .....	20.80	5	<b>Kenacort-A 10</b>
Inj 40 mg per ml, 1 ml ampoule – <b>1% DV Apr-15 to 2017</b> .....	51.70	5	<b>Kenacort-A 40</b>
<b>TRIAMCINOLONE HEXACETONIDE</b>			
Inj 20 mg per ml, 1 ml vial			

## Hormone Replacement Therapy

### Oestrogens

#### OESTRADIOL

Tab 1 mg			
Tab 2 mg			
Patch 25 mcg per day – <b>1% DV Oct-16 to 2019</b> .....	6.12	8	<b>Estradot</b>
Patch 50 mcg per day – <b>1% DV Oct-16 to 2019</b> .....	7.04	8	<b>Estradot</b>
Patch 75 mcg per day – <b>1% DV Mar-17 to 2019</b> .....	7.91	8	<b>Estradot</b>
Patch 100 mcg per day – <b>1% DV Oct-16 to 2019</b> .....	7.91	8	<b>Estradot</b>

#### OESTRADIOL VALERATE

Tab 1 mg – <b>1% DV Jun-15 to 2018</b> .....	12.36	84	<b>Progynova</b>
Tab 2 mg – <b>1% DV Jun-15 to 2018</b> .....	12.36	84	<b>Progynova</b>

#### OESTROGENS (CONJUGATED EQUINE)

Tab 300 mcg			
Tab 625 mcg			

## Progestogen and Oestrogen Combined Preparations

#### OESTRADIOL WITH NORETHISTERONE ACETATE

Tab 1 mg with 0.5 mg norethisterone acetate			
Tab 2 mg with 1 mg norethisterone acetate			
Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestradiol (12) and tab 1 mg oestradiol (6)			

## HORMONE PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### ESTROGENS WITH MEDROXYPROGESTERONE ACETATE

- Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate
- Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate

### Progestogens

#### MEDROXYPROGESTERONE ACETATE

Tab 2.5 mg – 1% DV Oct-16 to 2019.....	3.75	30	<b>Provera</b>
Tab 5 mg – 1% DV Oct-16 to 2019.....	14.00	100	<b>Provera</b>
Tab 10 mg – 1% DV Oct-16 to 2019.....	7.15	30	<b>Provera</b>

### Other Endocrine Agents

#### CABERGOLINE – Restricted see terms [below](#)

⚡ Tab 0.5 mg – 1% DV Sep-15 to 2018.....	4.75	2	<b>Dostinex</b>
	19.00	8	<b>Dostinex</b>

#### ➡ Restricted

##### Initiation

Any of the following:

- 1 Inhibition of lactation; or
- 2 Patient has pathological hyperprolactinemia; or
- 3 Patient has acromegaly.

#### CLOMIFENE CITRATE

Tab 50 mg .....	29.84	10	Mylan Clomiphen Serophene
-----------------	-------	----	------------------------------

#### DANAZOL

Cap 100 mg.....	68.33	100	Azol
Cap 200 mg.....	97.83	100	Azol

#### GESTRINONE

Cap 2.5 mg

#### METYRAPONE

Cap 250 mg

#### PENTAGASTRIN

Inj 250 mcg per ml, 2 ml ampoule

### Other Oestrogen Preparations

#### ETHINYLOESTRADIOL

Tab 10 mcg – 1% DV Sep-15 to 2018 .....	17.60	100	<b>NZ Medical &amp; Scientific</b>
---	-------	-----	------------------------------------

#### OESTRADIOL

Implant 50 mg

#### OESTRIOL

Tab 2 mg

### Other Progestogen Preparations

#### MEDROXYPROGESTERONE

Tab 100 mg – 1% DV Oct-16 to 2019.....	101.00	100	<b>Provera HD</b>
--	--------	-----	-------------------

#### NORETHISTERONE

Tab 5 mg – 1% DV Jun-15 to 2018 .....	18.29	100	<b>Primolut N</b>
---------------------------------------	-------	-----	-------------------

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

## Pituitary and Hypothalamic Hormones and Analogues

### CORTICOTRORELIN (OVINE)

Inj 100 mcg vial

### THYROTROPIN ALFA

Inj 900 mcg vial

## Adrenocorticotrophic Hormones

### TETRACOSACTIDE [TETRACOSACTRIN]

Inj 250 mcg per ml, 1 ml ampoule .....	75.00	1	Synacthen
Inj 1 mg per ml, 1 ml ampoule .....	690.00	1	Synacthen Depot

## GnRH Agonists and Antagonists

### BUSERELIN

Inj 1 mg per ml, 5.5 ml vial

### GONADORELIN

Inj 100 mcg vial

### GOSERELIN

Implant 3.6 mg, syringe – 1% DV Dec-16 to 2019 .....	66.48	1	<b>Zoladex</b>
Implant 10.8 mg, syringe – 1% DV Dec-16 to 2019 .....	177.50	1	<b>Zoladex</b>

### LEUPRORELIN ACETATE

Inj 3.75 mg prefilled dual chamber syringe .....	221.60	1	Lucrin Depot 1-month
Inj 7.5 mg syringe with diluent .....	166.20	1	Eligard 1 Month
Inj 11.25 mg prefilled dual chamber syringe .....	591.68	1	Lucrin Depot 3-month
Inj 22.5 mg syringe with diluent .....	443.76	1	Eligard 3 Month
Inj 30 mg prefilled dual chamber syringe .....	1,109.40	1	Lucrin Depot 6-month
Inj 45 mg syringe with diluent .....	832.05	1	Eligard 6 month

*(Eligard 1 Month Inj 7.5 mg syringe with diluent to be delisted 1 June 2017)*

*(Eligard 3 Month Inj 22.5 mg syringe with diluent to be delisted 1 June 2017)*

*(Lucrin Depot 6-month Inj 30 mg prefilled dual chamber syringe to be delisted 1 August 2017)*

*(Eligard 6 month Inj 45 mg syringe with diluent to be delisted 1 June 2017)*

## Gonadotrophins

### CHORIOGONADOTROPIN ALFA

Inj 250 mcg in 0.5 ml syringe

## Growth Hormone

### SOMATROPIN – **Restricted** see terms [below](#)

⚡ Inj 5 mg cartridge – 1% DV Jan-15 to 31 Dec 2017 .....	109.50	1	<b>Omnitrope</b>
⚡ Inj 10 mg cartridge – 1% DV Jan-15 to 31 Dec 2017 .....	219.00	1	<b>Omnitrope</b>
⚡ Inj 15 mg cartridge – 1% DV Jan-15 to 31 Dec 2017 .....	328.50	1	<b>Omnitrope</b>

### → **Restricted**

### Initiation – growth hormone deficiency in children

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

Either:

continued...

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
	Per	

continued...

- 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or
- 2 All of the following:
  - 2.1 Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
  - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
  - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
  - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
  - 2.5 Appropriate imaging of the pituitary gland has been obtained.

## Continuation – growth hormone deficiency in children

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 A current bone age is ≤ 14 years (female patients) or ≤ 16 years (male patients); and
- 2 Height velocity is ≥ 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is ≥ 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

## Initiation – Turner syndrome

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

## Continuation – Turner syndrome

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity ≥ 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is ≥ 2 cm per year, calculated over six months; and
- 3 A current bone age is ≤ 14 years; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

## Initiation – short stature without growth hormone deficiency

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

#### **Continuation – short stature without growth hormone deficiency**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity is  $\geq$  50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is  $\geq$  2 cm per year as calculated over six months; and
- 3 Current bone age is  $\leq$  14 years (female patients) or  $\leq$  16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

#### **Initiation – short stature due to chronic renal insufficiency**

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is  $\leq$  14 years (female patients) or  $\leq$  16 years (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
  - 6.1 The patient has a GFR  $\leq$  30 ml/min/1.73 m<sup>2</sup> as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l  $\times$  40 = corrected GFR (ml/min/1.73 m<sup>2</sup> ) in a child who may or may not be receiving dialysis; or
  - 6.2 The patient has received a renal transplant and has received < 5mg/ m<sup>2</sup> /day of prednisone or equivalent for at least 6 months.

#### **Continuation – short stature due to chronic renal insufficiency**

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity is  $\geq$  50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is  $\geq$  2 cm per year as calculated over six months; and
- 3 A current bone age is  $\leq$  14 years (female patients) or  $\leq$  16 years (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Initiation – Prader-Willi syndrome

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient is aged six months or older; and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 5 Either:
  - 5.1 Both:
    - 5.1.1 The patient is aged two years or older; and
    - 5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by  $\geq 0.5$  standard deviations in the preceding 12 months; or
  - 5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

## Continuation – Prader-Willi syndrome

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity is  $\geq 50$ th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is  $\geq 2$  cm per year as calculated over six months; and
- 3 A current bone age is  $\leq 14$  years (female patients) or  $\leq 16$  years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by  $\geq 0.5$  standard deviations in the preceding 12 months.

## Initiation – adults and adolescents

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of  $\leq 3$  mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test. Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of  $\leq 0.4$  mcg per litre.

continued...



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

**Continuation – adults and adolescents**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

Either:

- 1 All of the following:
  - 1.1 The patient has been treated with somatropin for < 12 months; and
  - 1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
  - 1.3 Serum IGF-I levels have increased to within ±1SD of the mean of the normal range for age and sex; and
  - 1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- 2 All of the following:
  - 2.1 The patient has been treated with somatropin for more than 12 months; and
  - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
  - 2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
  - 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

Thyroid and Antithyroid Preparations

CARBIMAZOLE  
Tab 5 mg

IODINE  
Soln BP 50 mg per ml

LEVOTHYROXINE  
Tab 25 mcg  
Tab 50 mcg  
Tab 100 mcg

LIOTHYRONINE SODIUM  
↓ Tab 20 mcg  
➔ **Restricted**

**Initiation**

For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy.

Inj 20 mcg vial

POTASSIUM IODATE  
Tab 170 mg

POTASSIUM PERCHLORATE  
Cap 200 mg

PROPYLTHIOURACIL – **Restricted** see terms [below](#)  
↓ Tab 50 mg .....35.00 100 PTU  
➔ **Restricted**

**Initiation**

Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

## PROTIRELIN

Inj 100 mcg per ml, 2 ml ampoule

## Vasopressin Agents

### ARGIPRESSIN [VASOPRESSIN]

Inj 20 u per ml, 1 ml ampoule

### DESMOPRESSIN ACETATE – Some items restricted see terms [below](#)

⚠ Tab 100 mcg – 1% DV Jun-16 to 2019 .....	25.00	30	<b>Minirin</b>
⚠ Tab 200 mcg – 1% DV Jun-16 to 2019 .....	54.45	30	<b>Minirin</b>
Nasal spray 10 mcg per dose – 1% DV Sep-14 to 2017 .....	22.95	6 ml	<b>Desmopressin-PH&amp;T</b>
Inj 4 mcg per ml, 1 ml ampoule			
Inj 15 mcg per ml, 1 ml ampoule			
Nasal drops 100 mcg per ml			

### ➡ Restricted

#### Initiation – Nocturnal enuresis

Either:

- 1 The nasal forms of desmopressin are contraindicated; or
- 2 An enuresis alarm is contraindicated.

Note: Cranial diabetes insipidus and the nasal forms of desmopressin are contraindicated.

### TERLIPRESSIN

Inj 0.1 mg per ml, 8.5 ml ampoule .....	450.00	5	<b>Glypressin</b>
Inj 1 mg per 8.5 ml ampoule – 1% DV Jun-15 to 2018 .....	215.00	5	<b>Glypressin</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Antibacterials</b>			
<b>Aminoglycosides</b>			
AMIKACIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 5 mg per ml, 10 ml syringe			
↓ Inj 5 mg per ml, 5 ml syringe .....	176.00	10	Biomed
↓ Inj 15 mg per ml, 5 ml syringe			
↓ Inj 250 mg per ml, 2 ml vial – <b>1% DV Oct-14 to 2017</b> .....	431.20	5	<b>DBL Amikacin</b>
➔ <b>Restricted</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
GENTAMICIN SULPHATE			
Inj 10 mg per ml, 1 ml ampoule .....	8.56	5	Hospira
Inj 10 mg per ml, 2 ml ampoule .....	175.10	25	APP Pharmaceuticals
Inj 40 mg per ml, 2 ml ampoule – <b>1% DV Sep-15 to 2018</b> .....	6.00	10	<b>Pfizer</b>
PAROMOMYCIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Cap 250 mg .....	126.00	16	Humatin
➔ <b>Restricted</b>			
Clinical microbiologist or infectious disease specialist			
STREPTOMYCIN SULPHATE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 400 mg per ml, 2.5 ml ampoule			
➔ <b>Restricted</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
TOBRAMYCIN			
↓ Powder			
➔ <b>Restricted</b>			
<b>Initiation</b>			
For addition to orthopaedic bone cement.			
↓ Inj 40 mg per ml, 2 ml vial – <b>1% DV Feb-17 to 2018</b> .....	15.00	5	<b>Tobramycin Mylan</b>
➔ <b>Restricted</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
↓ Inj 100 mg per ml, 5 ml vial			
➔ <b>Restricted</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
↓ Solution for inhalation 60 mg per ml, 5 ml .....	2,200.00	56 dose	TOBI
➔ <b>Restricted</b>			
<b>Initiation</b>			
Patient has cystic fibrosis.			
<b>Carbapenems</b>			
ERTAPENEM – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 1 g vial .....	73.50	1	Invanz
➔ <b>Restricted</b>			
Clinical microbiologist or infectious disease specialist			
IMIPENEM WITH CILASTATIN – <b>Restricted</b> see terms <a href="#">on the next page</a>			
↓ Inj 500 mg with 500 mg cilastatin vial – <b>1% DV Jun-15 to 2017</b> .....	13.79	1	<b>Imipenem+Cilastatin RBX</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**➔ Restricted**

Clinical microbiologist or infectious disease specialist

MEROPENEM – **Restricted** see terms [below](#)

‡ Inj 500 mg vial – 1% DV Oct-14 to 2017.....	35.22	10	DBL Meropenem
‡ Inj 1 g vial – 1% DV Oct-14 to 2017.....	65.21	10	DBL Meropenem

**➔ Restricted**

Clinical microbiologist or infectious disease specialist

**Cephalosporins and Cephamycins - 1st Generation**
**CEFALEXIN**

Cap 250 mg – 1% DV Dec-16 to 2019.....	3.50	20	Cephalexin ABM
Cap 500 mg – 1% DV Oct-16 to 2019.....	3.95	20	Cephalexin ABM
Grans for oral liq 25 mg per ml – 1% DV Sep-15 to 2018.....	8.00	100 ml	Cefalexin Sandoz
Grans for oral liq 50 mg per ml – 1% DV Sep-15 to 2018.....	11.00	100 ml	Cefalexin Sandoz

**CEFAZOLIN**

Inj 500 mg vial – 1% DV Sep-14 to 2017.....	3.99	5	AFT
Inj 1 g vial – 1% DV Sep-14 to 2017.....	3.38	5	AFT

**Cephalosporins and Cephamycins - 2nd Generation**
**CEFACLOR**

Cap 250 mg – 1% DV Sep-16 to 2019.....	24.70	100	Ranbaxy-Cefaclor
Grans for oral liq 25 mg per ml – 1% DV Sep-16 to 2019.....	3.53	100 ml	Ranbaxy-Cefaclor

**CEFOXITIN**

Inj 1 g vial – 1% DV Jan-16 to 2018.....	58.00	10	Cefoxitin Actavis
--	-------	----	-------------------

**CEFUROXIME**

Tab 250 mg.....	29.40	50	Zinnat
Inj 750 mg vial.....	3.70	5	Zinacef
Inj 1.5 g vial.....	1.30	1	Zinacef

**Cephalosporins and Cephamycins - 3rd Generation**
**CEFOTAXIME**

Inj 500 mg vial.....	1.90	1	Cefotaxime Sandoz
Inj 1 g vial – 1% DV Oct-14 to 2017.....	17.10	10	DBL Cefotaxime

CEFTAZIDIME – **Restricted** see terms [below](#)

‡ Inj 500 mg vial – 1% DV Jan-15 to 2017.....	5.30	1	Fortum
‡ Inj 1 g vial – 1% DV Jan-15 to 2017.....	1.55	1	Fortum
‡ Inj 2 g vial – 1% DV Jan-15 to 2017.....	3.34	1	Fortum

**➔ Restricted**

Clinical microbiologist, infectious disease specialist or respiratory specialist

**CEFTRIAXONE**

Inj 500 mg vial – 1% DV Nov-16 to 2019.....	1.20	1	DEVA
Inj 1 g vial – 1% DV Dec-16 to 2019.....	0.84	1	DEVA
Inj 2 g vial.....	2.75	1	Ceftriaxone-AFT

**Cephalosporins and Cephamycins - 4th Generation**

CEFEPIME – **Restricted** see terms [on the next page](#)

‡ Inj 1 g vial – 1% DV Oct-15 to 2018.....	3.95	1	Cefepime-AFT
‡ Inj 2 g vial – 1% DV Oct-15 to 2018.....	6.92	1	Cefepime-AFT

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

→ **Restricted**

Clinical microbiologist or infectious disease specialist

## Cephalosporins and Cephamycins - 5th Generation

CEFTAROLINE FOSAMIL – **Restricted** see terms [below](#)

↓ Inj 600 mg vial ..... 1,450.00 10 Zinforo

→ **Restricted**

**Initiation – multi-resistant organism salvage therapy**

Clinical microbiologist or infectious disease specialist

Either:

- 1 for patients where alternative therapies have failed; or
- 2 for patients who have a contraindication or hypersensitivity to standard current therapies.

## Macrolides

AZITHROMYCIN – **Restricted** see terms [below](#)

↓ Tab 250 mg – **1% DV Sep-15 to 2018** ..... 9.00 30 **Apo-Azithromycin**

↓ Tab 500 mg – **1% DV Sep-15 to 2018** ..... 1.05 2 **Apo-Azithromycin**

↓ Grans for oral liq 200 mg per 5 ml (40 mg per ml) – **1% DV Oct-15 to 2018** ..... 12.50 15 ml **Zithromax**

→ **Restricted**

**Initiation**

Any of the following:

- 1 Patient has received a lung transplant and requires treatment or prophylaxis for bronchiolitis obliterans syndrome; or
- 2 Patient has cystic fibrosis and has chronic infection with *Pseudomonas aeruginosa* or *Pseudomonas* related gram negative organisms; or
- 3 For any other condition for five days' treatment, with review after five days.

CLARITHROMYCIN – **Restricted** see terms [below](#)

↓ Tab 250 mg – **1% DV Sep-14 to 2017** ..... 3.98 14 **Apo-Clarithromycin**

↓ Tab 500 mg – **1% DV Sep-14 to 2017** ..... 10.40 14 **Apo-Clarithromycin**

↓ Grans for oral liq 50 mg per ml ..... 23.12 50 ml Klacid

↓ Inj 500 mg vial – **1% DV Mar-15 to 2017** ..... 20.40 1 **Martindale**

→ **Restricted**

**Initiation – Tab 250 mg and oral liquid**

Either:

- 1 Atypical mycobacterial infection; or
- 2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents.

**Initiation – Tab 500 mg**

*Helicobacter pylori* eradication.

**Initiation – Infusion**

Any of the following:

- 1 Atypical mycobacterial infection; or
- 2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or
- 3 Community-acquired pneumonia.

ERYTHROMYCIN (AS ETHYLSUCCINATE)

Tab 400 mg ..... 16.95 100 E-Mycin

Grans for oral liq 200 mg per 5 ml ..... 5.00 100 ml E-Mycin

Grans for oral liq 400 mg per 5 ml ..... 6.77 100 ml E-Mycin

ERYTHROMYCIN (AS LACTOBIONATE)

Inj 1 g vial ..... 16.00 1 Erythrocin IV

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ERYTHROMYCIN (AS STEARATE) – Restricted:</b> For continuation only			
➔ Tab 250 mg			
➔ Tab 500 mg			
<b>ROXITHROMYCIN</b>			
Tab 150 mg .....	7.48	50	Arrow-Roxithromycin
Tab 300 mg .....	14.40	50	Arrow-Roxithromycin
<b>Penicillins</b>			
<b>AMOXICILLIN</b>			
Cap 250 mg – 1% DV Sep-16 to 2019.....	14.97	500	<b>Apo-Amoxi</b>
Cap 500 mg – 1% DV Sep-16 to 2019.....	16.75	500	<b>Apo-Amoxi</b>
Grans for oral liq 125 mg per 5 ml .....	0.88	100 ml	Amoxicillin Actavis
	2.00		Ospamox
Grans for oral liq 250 mg per 5 ml .....	0.97	100 ml	Amoxicillin Actavis
	2.00		Ospamox
Inj 250 mg vial – 1% DV Oct-14 to 2017.....	10.67	10	<b>Ibiamox</b>
Inj 500 mg vial – 1% DV Oct-14 to 2017.....	12.41	10	<b>Ibiamox</b>
Inj 1 g vial – 1% DV Oct-14 to 2017.....	17.29	10	<b>Ibiamox</b>
<b>AMOXICILLIN WITH CLAVULANIC ACID</b>			
Tab 500 mg with clavulanic acid 125 mg – 1% DV Aug-16 to 2017 .....	1.95	20	<b>Augmentin</b>
Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml .....	3.83	100 ml	Augmentin
Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml .....	4.97	100 ml	Augmentin
Inj 500 mg with clavulanic acid 100 mg vial – 1% DV Sep-15 to 2018 .....	10.14	10	<b>m-Amoxiclav</b>
Inj 1,000 mg with clavulanic acid 200 mg vial – 1% DV Sep-15 to 2018 .....	12.80	10	<b>m-Amoxiclav</b>
<b>BENZATHINE BENZYL PENICILLIN</b>			
Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Sep-15 to 2018 .....	315.00	10	<b>Bicillin LA</b>
<b>BENZYL PENICILLIN SODIUM [PENICILLIN G]</b>			
Inj 600 mg (1 million units) vial – 1% DV Sep-14 to 2017 .....	10.35	10	<b>Sandoz</b>
<b>FLUCLOXACILLIN</b>			
Cap 250 mg – 1% DV Sep-15 to 2018.....	18.70	250	<b>Staphlex</b>
Cap 500 mg – 1% DV Sep-15 to 2018.....	62.90	500	<b>Staphlex</b>
Grans for oral liq 25 mg per ml – 1% DV Sep-15 to 2018.....	2.29	100 ml	<b>AFT</b>
Grans for oral liq 50 mg per ml – 1% DV Sep-15 to 2018.....	3.08	100 ml	<b>AFT</b>
Inj 250 mg vial – 1% DV Sep-14 to 2017.....	8.80	10	<b>Flucloxin</b>
Inj 500 mg vial – 1% DV Sep-14 to 2017.....	9.20	10	<b>Flucloxin</b>
Inj 1 g vial – 1% DV Jan-16 to 2017 .....	11.60	10	<b>Flucloxin</b>
<b>PHENOXYMETHYL PENICILLIN [PENICILLIN V]</b>			
Cap 250 mg – 1% DV Jun-15 to 2018.....	2.88	50	<b>Cilicaine VK</b>
Cap 500 mg – 1% DV Jun-15 to 2018.....	4.73	50	<b>Cilicaine VK</b>
Grans for oral liq 125 mg per 5 ml – 1% DV Sep-16 to 2019.....	1.48	100 ml	<b>AFT</b>
Grans for oral liq 250 mg per 5 ml – 1% DV Sep-16 to 2019.....	1.58	100 ml	<b>AFT</b>
<b>PIPERACILLIN WITH TAZOBACTAM – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 4 g with tazobactam 0.5 g vial .....	5.84	1	Hospira
	15.50		Tazocin EF
➔ <b>Restricted</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
<b>PROCAINE PENICILLIN</b>			
Inj 1.5 g in 3.4 ml syringe – 1% DV Sep-14 to 2017 .....	123.50	5	<b>Cilicaine</b>
<b>TICARCILLIN WITH CLAVULANIC ACID – Restricted</b> see terms <a href="#">on the next page</a>			
⚡ Inj 3 g with clavulanic acid 0.1 mg vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Clinical microbiologist, infectious disease specialist or respiratory specialist

## Quinolones

CIPROFLOXACIN – **Restricted** see terms [below](#)

↓ Tab 250 mg – 1% DV Sep-14 to 2017 .....	1.75	28	<b>Cipflox</b>
↓ Tab 500 mg – 1% DV Sep-14 to 2017 .....	2.00	28	<b>Cipflox</b>
↓ Tab 750 mg – 1% DV Sep-14 to 2017 .....	3.75	28	<b>Cipflox</b>
↓ Oral liq 50 mg per ml			
↓ Oral liq 100 mg per ml			
↓ Inj 2 mg per ml, 100 ml bag – 1% DV Mar-16 to 2018 .....	30.58	10	<b>Cipflox</b>

➔ **Restricted**

Clinical microbiologist or infectious disease specialist

MOXIFLOXACIN – **Restricted** see terms [below](#)

↓ Tab 400 mg .....	52.00	5	Avelox
↓ Inj 1.6 mg per ml, 250 ml bottle .....	70.00	1	Avelox IV 400

➔ **Restricted**

### Initiation – Mycobacterium infection

Infectious disease specialist, clinical microbiologist or respiratory specialist

Either:

1 Both:

1.1 Active tuberculosis; and

1.2 Any of the following:

1.2.1 Documented resistance to one or more first-line medications; or

1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or

1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or

1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or

1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or

2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.

### Initiation – Pneumonia

Infectious disease specialist or clinical microbiologist

Either:

1 Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or

2 Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.

### Initiation – Penetrating eye injury

Ophthalmologist

Five days treatment for patients requiring prophylaxis following a penetrating eye injury.

### Initiation – Mycoplasma genitalium

All of the following:

1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium; and

2 Has tried and failed to clear infection using azithromycin; and

3 Treatment is only for 7 days.

NORFLOXACIN

Tab 400 mg – 1% DV Sep-14 to 2017 .....	13.50	100	<b>Arrow-Norfloxacina</b>
---	-------	-----	---------------------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Tetracyclines</b>			
DEMECLOCYCLINE HYDROCHLORIDE			
Tab 150 mg			
Cap 150 mg			
Cap 300 mg			
DOXYCYCLINE			
➔ Tab 50 mg – <b>Restricted:</b> For continuation only			
Tab 100 mg – <b>1% DV Sep-14 to 2017</b> .....	6.75	250	<b>Doxine</b>
Inj 5 mg per ml, 20 ml vial			
MINOCYCLINE			
Tab 50 mg			
➔ Cap 100 mg – <b>Restricted:</b> For continuation only			
TETRACYCLINE			
Tab 250 mg			
Cap 500 mg.....	46.00	30	Tetracyclin Wolff
TIGECYCLINE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 50 mg vial			
➔ <b>Restricted</b>			
Clinical microbiologist or infectious disease specialist			
<b>Other Antibacterials</b>			
AZTREONAM – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 1 g vial .....	131.00	5	Azactam
➔ <b>Restricted</b>			
Clinical microbiologist or infectious disease specialist			
CHLORAMPHENICOL – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 1 g vial			
➔ <b>Restricted</b>			
Clinical microbiologist or infectious disease specialist			
CLINDAMYCIN – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Cap 150 mg – <b>1% DV Sep-16 to 2019</b> .....	4.10	16	<b>Clindamycin ABM</b>
⚡ Oral liq 15 mg per ml			
⚡ Inj 150 mg per ml, 4 ml ampoule – <b>1% DV Sep-16 to 2019</b> .....	65.00	10	<b>Dalacin C</b>
➔ <b>Restricted</b>			
Clinical microbiologist or infectious disease specialist			
COLISTIN SULPHOMETHATE [COLESTIMETHATE] – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 150 mg per ml, 1 ml vial.....	65.00	1	Colistin-Link
➔ <b>Restricted</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
DAPTOMYCIN – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 350 mg vial – <b>1% DV Sep-15 to 2018</b> .....	175.16	1	<b>Cubicin</b>
⚡ Inj 500 mg vial – <b>1% DV Sep-15 to 2018</b> .....	243.52	1	<b>Cubicin</b>
➔ <b>Restricted</b>			
Clinical microbiologist or infectious disease specialist			
FOSFOMYCIN – <b>Restricted</b> see terms <a href="#">on the next page</a>			
⚡ Powder for oral solution, 3 g sachet			



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted</b>			
Clinical microbiologist or infectious disease specialist			
FUSIDIC ACID – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 250 mg – <b>1% DV Jun-17 to 2020</b> .....	34.50	12	<b>Fucidin</b>
<b>➔ Restricted</b>			
Clinical microbiologist or infectious disease specialist			
HEXAMINE HIPPURATE			
Tab 1 g			
LINCOMYCIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 300 mg per ml, 2 ml vial			
<b>➔ Restricted</b>			
Clinical microbiologist or infectious disease specialist			
LINEZOLID – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 600 mg – <b>1% DV Sep-15 to 2018</b> .....	800.00	10	<b>Zyvox</b>
↓ Oral liq 20 mg per ml – <b>1% DV Sep-15 to 2018</b> .....	775.00	150 ml	<b>Zyvox</b>
↓ Inj 2 mg per ml, 300 ml bag – <b>1% DV Sep-15 to 2018</b> .....	1,650.00	10	<b>Zyvox</b>
<b>➔ Restricted</b>			
Clinical microbiologist or infectious disease specialist			
NITROFURANTOIN			
Tab 50 mg			
Tab 100 mg			
PIVMECILLINAM – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 200 mg			
<b>➔ Restricted</b>			
Clinical microbiologist or infectious disease specialist			
SULPHADIAZINE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 500 mg			
<b>➔ Restricted</b>			
Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist			
TEICOPLANIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 400 mg vial			
<b>➔ Restricted</b>			
Clinical microbiologist or infectious disease specialist			
TRIMETHOPRIM			
Tab 100 mg			
Tab 300 mg – <b>1% DV Oct-15 to 2018</b> .....	15.00	50	<b>TMP</b>
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]			
Tab 80 mg with sulphamethoxazole 400 mg			
Oral liq 8 mg with sulphamethoxazole 40 mg per ml .....	2.15	100 ml	Deprim
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule			
VANCOMYCIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 500 mg vial – <b>1% DV Oct-14 to 2017</b> .....	2.64	1	<b>Mylan</b>
<b>➔ Restricted</b>			
Clinical microbiologist or infectious disease specialist			

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Antifungals

### Imidazoles

#### KETOCONAZOLE

⚡ Tab 200 mg

➡ **Restricted**

Oncologist

### Polyene Antimycotics

#### AMPHOTERICIN B

⚡ Inj (liposomal) 50 mg vial – 1% DV Sep-15 to 2018 .....	3,450.00	10	<b>AmBisome</b>
---	----------	----	-----------------

➡ **Restricted**

#### Initiation

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

Either:

- 1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
- 2 Both:
  - 2.1 Possible invasive fungal infection; and
  - 2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

⚡ Inj 50 mg vial

➡ **Restricted**

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

#### NYSTATIN

Tab 500,000 u .....	17.09	50	Nilstat
Cap 500,000 u .....	15.47	50	Nilstat

### Triazoles

#### FLUCONAZOLE – **Restricted** see terms [below](#)

⚡ Cap 50 mg – 1% DV Nov-14 to 2017 .....	3.49	28	<b>Ozole</b>
⚡ Cap 150 mg – 1% DV Nov-14 to 2017 .....	0.71	1	<b>Ozole</b>
⚡ Cap 200 mg – 1% DV Nov-14 to 2017 .....	9.69	28	<b>Ozole</b>
⚡ Oral liquid 50 mg per 5 ml .....	98.50	35 ml	Diflucan
⚡ Inj 2 mg per ml, 50 ml vial – 1% DV Sep-16 to 2019 .....	4.95	1	<b>Fluconazole-Claris</b>
⚡ Inj 2 mg per ml, 100 ml vial – 1% DV Sep-16 to 2019 .....	6.47	1	<b>Fluconazole-Claris</b>

➡ **Restricted**

Consultant

#### ITRACONAZOLE – **Restricted** see terms [below](#)

⚡ Cap 100 mg – 1% DV Sep-16 to 2019 .....	2.79	15	<b>Itrazole</b>
⚡ Oral liquid 10 mg per ml			

➡ **Restricted**

Clinical immunologist, clinical microbiologist, dermatologist or infectious disease specialist

#### POSACONAZOLE – **Restricted** see terms [on the next page](#)

⚡ Tab modified-release 100 mg .....	869.86	24	Noxafil
⚡ Oral liq 40 mg per ml .....	761.13	105 ml	Noxafil

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**➔ Restricted****Initiation**

Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

Both:

- 1 Either:
  - 1.1 Patient has acute myeloid leukaemia; or
  - 1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
- 2 Patient is to be treated with high dose remission induction therapy or re-induction therapy.

**Continuation**

Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

Both:

- 1 Patient has previously received posaconazole prophylaxis during remission induction therapy; and
- 2 Any of the following:
  - 2.1 Patient is to be treated with high dose remission re-induction therapy; or
  - 2.2 Patient is to be treated with high dose consolidation therapy; or
  - 2.3 Patient is receiving a high risk stem cell transplant.

VORICONAZOLE – **Restricted** see terms [below](#)

↓ Tab 50 mg – 1% DV Jan-16 to 2018 .....	130.00	56	<b>Vttack</b>
↓ Tab 200 mg – 1% DV Jan-16 to 2018 .....	500.00	56	<b>Vttack</b>
↓ Powder for oral suspension 40 mg per ml .....	876.00	70 ml	Vfend
↓ Inj 200 mg vial .....	185.00	1	Vfend

**➔ Restricted****Initiation – Proven or probable aspergillus infection**

Clinical microbiologist, haematologist or infectious disease specialist

Both:

- 1 Patient is immunocompromised; and
- 2 Patient has proven or probable invasive aspergillus infection.

**Initiation – Possible aspergillus infection**

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient has possible invasive aspergillus infection; and
- 3 A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

**Initiation – Resistant candidiasis infections and other moulds**

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

- 1 Patient is immunocompromised; and
- 2 Either:
  - 2.1 Patient has fluconazole resistant candidiasis; or
  - 2.2 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp; and
- 3 A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.

**Other Antifungals**CASPOFUNGIN – **Restricted** see terms [on the next page](#)

↓ Inj 50 mg vial .....	667.50	1	Cancidas
↓ Inj 70 mg vial .....	862.50	1	Cancidas

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## ➔ Restricted

### Initiation

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist  
Either:

- 1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
- 2 Both:
  - 2.1 Possible invasive fungal infection; and
  - 2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

FLUCYTOSINE – **Restricted** see terms [below](#)

⚡ Cap 500 mg

## ➔ Restricted

Clinical microbiologist or infectious disease specialist

### TERBINAFINE

Tab 250 mg – 1% DV Sep-14 to 2017 .....	1.50	14	Dr Reddy's Terbinafine
---	------	----	------------------------

## Antimycobacterials

### Antileprotics

CLOFAZIMINE – **Restricted** see terms [below](#)

⚡ Cap 50 mg

## ➔ Restricted

Clinical microbiologist, dermatologist or infectious disease specialist

DAPSONE – **Restricted** see terms [below](#)

⚡ Tab 25 mg – 1% DV Sep-14 to 2017 .....	95.00	100	Dapsone
--	-------	-----	---------

⚡ Tab 100 mg – 1% DV Sep-14 to 2017 .....	110.00	100	Dapsone
---	--------	-----	---------

## ➔ Restricted

Clinical microbiologist, dermatologist or infectious disease specialist

### Antituberculotics

CYCLOSERINE – **Restricted** see terms [below](#)

⚡ Cap 250 mg

## ➔ Restricted

Clinical microbiologist, infectious disease specialist or respiratory specialist

ETHAMBUTOL HYDROCHLORIDE – **Restricted** see terms [below](#)

⚡ Tab 100 mg .....	48.01	56	Myambutol
--------------------	-------	----	-----------

⚡ Tab 400 mg .....	49.34	56	Myambutol
--------------------	-------	----	-----------

## ➔ Restricted

Clinical microbiologist, infectious disease specialist or respiratory specialist

ISONIAZID – **Restricted** see terms [below](#)

⚡ Tab 100 mg – 1% DV Sep-15 to 2018 .....	20.00	100	PSM
---	-------	-----	-----

## ➔ Restricted

Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician

ISONIAZID WITH RIFAMPICIN – **Restricted** see terms [on the next page](#)

⚡ Tab 100 mg with rifampicin 150 mg – 1% DV Sep-15 to 2018 .....	85.54	100	Rifinah
--	-------	-----	---------

⚡ Tab 150 mg with rifampicin 300 mg – 1% DV Sep-15 to 2018 .....	170.60	100	Rifinah
--	--------	-----	---------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted</b>			
Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician			
PARA-AMINOSALICYLIC ACID – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Grans for oral liq 4 g .....	280.00	30	Paser
<b>➔ Restricted</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
PROTIONAMIDE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 250 mg .....	305.00	100	Peteha
<b>➔ Restricted</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
PYRAZINAMIDE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 500 mg .....			
<b>➔ Restricted</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
RIFABUTIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Cap 150 mg – 1% DV Oct-16 to 2019 .....	275.00	30	Mycobutin
<b>➔ Restricted</b>			
Clinical microbiologist, gastroenterologist, infectious disease specialist or respiratory specialist			
RIFAMPICIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Cap 150 mg – 1% DV Nov-14 to 2017 .....	55.75	100	Rifadin
↓ Cap 300 mg – 1% DV Nov-14 to 2017 .....	116.25	100	Rifadin
↓ Oral liq 100 mg per 5 ml – 1% DV Nov-14 to 2017 .....	12.00	60 ml	Rifadin
↓ Inj 600 mg vial – 1% DV Nov-14 to 2017 .....	128.85	1	Rifadin
<b>➔ Restricted</b>			
Clinical microbiologist, dermatologist, internal medicine physician, paediatrician or public health physician			

## Antiparasitics

### Anthelmintics

ALBENDAZOLE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 200 mg			
↓ Tab 400 mg			
<b>➔ Restricted</b>			
Clinical microbiologist or infectious disease specialist			
IVERMECTIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 3 mg .....	17.20	4	Stromectol
<b>➔ Restricted</b>			
Clinical microbiologist, dermatologist or infectious disease specialist			
MEBENDAZOLE			
Tab 100 mg .....	24.19	24	De-Worm
Oral liq 100 mg per 5 ml			
PRAZIQUANTEL			
Tab 600 mg			

### Antiprotozoals

ARTEMETHER WITH LUMEFANTRINE – <b>Restricted</b> see terms <a href="#">on the next page</a>			
↓ Tab 20 mg with lumefantrine 120 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔ <b>Restricted</b> Clinical microbiologist or infectious disease specialist			
ARTESUNATE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 60 mg vial			
➔ <b>Restricted</b> Clinical microbiologist or infectious disease specialist			
ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 62.5 mg with proguanil hydrochloride 25 mg – <b>1% DV Nov-14 to 2017</b> .....	25.00	12	<b>Malarone Junior</b>
⚡ Tab 250 mg with proguanil hydrochloride 100 mg – <b>1% DV Nov-14 to 2017</b> .....	64.00	12	<b>Malarone</b>
➔ <b>Restricted</b> Clinical microbiologist or infectious disease specialist			
CHLOROQUINE PHOSPHATE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 250 mg			
➔ <b>Restricted</b> Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist			
MEFLOQUINE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 250 mg – <b>1% DV Dec-14 to 2017</b> .....	33.48	8	<b>Lariam</b>
➔ <b>Restricted</b> Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist			
METRONIDAZOLE			
Tab 200 mg .....	10.45	100	Trichozole
Tab 400 mg .....	18.15	100	Trichozole
Oral liq benzoate 200 mg per 5 ml .....	25.00	100 ml	Flagyl-S
Inj 5 mg per ml, 100 ml bottle .....	1.39	100 ml	AFT
Inj 5 mg per ml, 100 ml bag – <b>1% DV Apr-15 to 2017</b> .....	6.94	5	<b>AFT</b>
Suppos 500 mg .....	24.48	10	Flagyl
NITAZOXANIDE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 500 mg .....	1,680.00	30	Alinia
⚡ Oral liq 100 mg per 5 ml			
➔ <b>Restricted</b> Clinical microbiologist or infectious disease specialist			
ORNIDAZOLE			
Tab 500 mg – <b>1% DV Oct-16 to 2019</b> .....	23.00	10	<b>Arrow-Ornidazole</b>
PENTAMIDINE ISETHIONATE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 300 mg vial – <b>1% DV Mar-15 to 2017</b> .....	180.00	5	<b>Pentacarinat</b>
➔ <b>Restricted</b> Clinical microbiologist or infectious disease specialist			
PRIMAQUINE PHOSPHATE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 7.5 mg			
➔ <b>Restricted</b> Clinical microbiologist or infectious disease specialist			
PYRIMETHAMINE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 25 mg			
➔ <b>Restricted</b> Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>QUININE DIHYDROCHLORIDE – Restricted</b> see terms <a href="#">below</a>			
↓ Inj 60 mg per ml, 10 ml ampoule			
↓ Inj 300 mg per ml, 2 ml vial			
→ <b>Restricted</b>			
Clinical microbiologist or infectious disease specialist			
<b>QUININE SULPHATE</b>			
Tab 300 mg .....	61.91	500	Q 300
<b>SODIUM STIBOGLUCONATE – Restricted</b> see terms <a href="#">below</a>			
↓ Inj 100 mg per ml, 1 ml vial			
→ <b>Restricted</b>			
Clinical microbiologist or infectious disease specialist			
<b>SPIRAMYCIN – Restricted</b> see terms <a href="#">below</a>			
↓ Tab 500 mg			
→ <b>Restricted</b>			
Maternal-foetal medicine specialist			

## Antiretrovirals

### Non-Nucleoside Reverse Transcriptase Inhibitors

#### → **Restricted**

##### **Initiation – Confirmed HIV**

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
  - 2.1 Symptomatic patient; or
  - 2.2 Patient aged 12 months and under; or
  - 2.3 Both:
    - 2.3.1 Patient aged 1 to 5 years; and
    - 2.3.2 Any of the following:
      - 2.3.2.1 CD4 counts < 1000 cells/mm<sup>3</sup>; or
      - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
      - 2.3.2.3 Viral load counts > 100000 copies per ml; or
  - 2.4 Both:
    - 2.4.1 Patient aged 6 years and over; and
    - 2.4.2 CD4 counts < 500 cells/mm<sup>3</sup>.

##### **Initiation – Prevention of maternal transmission**

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

##### **Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
prophylaxis is required.			
<b>Initiation – Percutaneous exposure</b>			
Patient has percutaneous exposure to blood known to be HIV positive.			
<b>EFAVIRENZ – Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 50 mg – 1% DV Sep-15 to 2018 .....	63.38	30	<b>Stocrin</b>
† Tab 200 mg – 1% DV Sep-15 to 2018 .....	190.15	90	<b>Stocrin</b>
† Tab 600 mg – 1% DV Sep-15 to 2018 .....	63.38	30	<b>Stocrin</b>
† Oral liq 30 mg per ml			
<b>ETRAVIRINE – Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 200 mg .....	770.00	60	Intelence
<b>NEVIRAPINE – Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 200 mg – 1% DV Nov-15 to 2018 .....	65.00	60	<b>Nevirapine Alphapharm</b>
† Oral suspension 10 mg per ml .....	203.55	240 ml	Viramune Suspension

## Nucleoside Reverse Transcriptase Inhibitors

### ➡ Restricted

#### Initiation – Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
  - 2.1 Symptomatic patient; or
  - 2.2 Patient aged 12 months and under; or
  - 2.3 Both:
    - 2.3.1 Patient aged 1 to 5 years; and
    - 2.3.2 Any of the following:
      - 2.3.2.1 CD4 counts < 1000 cells/mm<sup>3</sup>; or
      - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
      - 2.3.2.3 Viral load counts > 100000 copies per ml; or
  - 2.4 Both:
    - 2.4.1 Patient aged 6 years and over; and
    - 2.4.2 CD4 counts < 500 cells/mm<sup>3</sup>.

#### Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

#### Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

#### Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ABACAVIR SULPHATE – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 300 mg – 1% DV Oct-14 to 2017.....	229.00	60	<b>Ziagen</b>
† Oral liq 20 mg per ml – 1% DV Oct-14 to 2017 .....	256.31	240 ml	<b>Ziagen</b>
ABACAVIR SULPHATE WITH LAMIVUDINE – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 600 mg with lamivudine 300 mg.....	427.29	30	<b>Kivexa</b>
DIDANOSINE [DDI] – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Cap 125 mg			
† Cap 200 mg			
† Cap 250 mg			
† Cap 400 mg			
<i>(Any Cap 125 mg to be delisted 1 July 2017)</i>			
<i>(Any Cap 200 mg to be delisted 1 July 2017)</i>			
<i>(Any Cap 250 mg to be delisted 1 July 2017)</i>			
<i>(Any Cap 400 mg to be delisted 1 July 2017)</i>			
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.....	1,313.19	30	<b>Atripla</b>
EMTRICITABINE – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Cap 200 mg.....	307.20	30	<b>Emtriva</b>
EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 200 mg with tenofovir disoproxil fumarate 300 mg.....	838.20	30	<b>Truvada</b>
LAMIVUDINE – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Oral liq 10 mg per ml			
STAVUDINE – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Cap 30 mg			
† Cap 40 mg			
† Powder for oral soln 1 mg per ml			
ZIDOVUDINE [AZT] – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Cap 100 mg – 1% DV Sep-16 to 2019.....	152.25	100	<b>Retrovir</b>
† Oral liq 10 mg per ml – 1% DV Sep-16 to 2019.....	30.45	200 ml	<b>Retrovir</b>
† Inj 10 mg per ml, 20 ml vial – 1% DV Oct-14 to 2017.....	750.00	5	<b>Retrovir IV</b>
ZIDOVUDINE [AZT] WITH LAMIVUDINE – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 300 mg with lamivudine 150 mg – 1% DV Sep-14 to 2017 .....	44.00	60	<b>Alphapharm</b>

## Protease Inhibitors

### ➔ **Restricted**

#### **Initiation – Confirmed HIV**

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
  - 2.1 Symptomatic patient; or
  - 2.2 Patient aged 12 months and under; or
  - 2.3 Both:
    - 2.3.1 Patient aged 1 to 5 years; and
    - 2.3.2 Any of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
2.3.2.1 CD4 counts < 1000 cells/mm <sup>3</sup> ; or			
2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or			
2.3.2.3 Viral load counts > 100000 copies per ml; or			
2.4 Both:			
2.4.1 Patient aged 6 years and over; and			
2.4.2 CD4 counts < 500 cells/mm <sup>3</sup> .			
<b>Initiation – Prevention of maternal transmission</b>			
Either:			
1 Prevention of maternal foetal transmission; or			
2 Treatment of the newborn for up to eight weeks.			
<b>Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV</b>			
Both:			
1 Treatment course to be initiated within 72 hours post exposure; and			
2 Any of the following:			
2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or			
2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or			
2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.			
<b>Initiation – Percutaneous exposure</b>			
Patient has percutaneous exposure to blood known to be HIV positive.			
ATAZANAVIR SULPHATE – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Cap 150 mg.....	568.34	60	Reyataz
† Cap 200 mg.....	757.79	60	Reyataz
DARUNAVIR – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 400 mg – 1% DV Jun-17 to 2020 .....	335.00	60	<b>Prezista</b>
† Tab 600 mg – 1% DV Jun-17 to 2020 .....	476.00	60	<b>Prezista</b>
INDINAVIR – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Cap 200 mg			
† Cap 400 mg			
LOPINAVIR WITH RITONAVIR – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 100 mg with ritonavir 25 mg .....	183.75	60	Kaletra
† Tab 200 mg with ritonavir 50 mg .....	735.00	120	Kaletra
† Oral liq 80 mg with ritonavir 20 mg per ml.....	735.00	300 ml	Kaletra
RITONAVIR – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 100 mg .....	43.31	30	Norvir
† Oral liq 80 mg per ml			

## Strand Transfer Inhibitors

### ➡ **Restricted**

#### **Initiation – Confirmed HIV**

Both:

- Confirmed HIV infection; and
- Any of the following:
  - Symptomatic patient; or
  - Patient aged 12 months and under; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## 2.3 Both:

2.3.1 Patient aged 1 to 5 years; and

2.3.2 Any of the following:

2.3.2.1 CD4 counts < 1000 cells/mm<sup>3</sup>; or

2.3.2.2 CD4 counts &lt; 0.25 × total lymphocyte count; or

2.3.2.3 Viral load counts &gt; 100000 copies per mL; or

## 2.4 Both:

2.4.1 Patient aged 6 years and over; and

2.4.2 CD4 counts < 500 cells/mm<sup>3</sup>.**Initiation – Prevention of maternal transmission**

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**

Patient has percutaneous exposure to blood known to be HIV positive.

DOLUTEGRAVIR – **Restricted** see terms [on the previous page](#)

⚡ Tab 50 mg .....	1,090.00	30	Tivicay
-------------------	----------	----	---------

RALTEGRAVIR POTASSIUM – **Restricted** see terms [on the previous page](#)

⚡ Tab 400 mg .....	1,090.00	60	Isentress
--------------------	----------	----	-----------

**Antivirals****Hepatitis B**ADEFOVIR DIPIVOXIL – **Restricted** see terms [below](#)

⚡ Tab 10 mg .....	670.00	30	Hepsera
-------------------	--------	----	---------

**→ Restricted****Initiation**

Gastroenterologist or infectious disease specialist

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine defined as:
- 2 Patient has raised serum ALT (> 1 × ULN); and
- 3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10-fold over nadir; and
- 4 Detection of M204I or M204V mutation; and
- 5 Either:

## 5.1 Both:

5.1.1 Patient is cirrhotic; and

5.1.2 Adefovir dipivoxil to be used in combination with lamivudine; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## 5.2 Both:

5.2.1 Patient is not cirrhotic; and

5.2.2 Adefovir dipivoxil to be used as monotherapy.

ENTECAVIR – **Restricted** see terms [below](#)

↓ Tab 0.5 mg .....400.00 30 Baraclude

→ **Restricted**

## Initiation

Gastroenterologist or infectious disease specialist

All of the following:

1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and

2 Patient is Hepatitis B nucleoside analogue treatment-naïve; and

3 Entecavir dose 0.5 mg/day; and

4 Either:

4.1 ALT greater than upper limit of normal; or

4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater or moderate fibrosis) on liver histology; and

5 Either:

5.1 HBeAg positive; or

5.2 Patient has ≥ 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and

6 No continuing alcohol abuse or intravenous drug use; and

7 Not co-infected with HCV, HIV or HDV; and

8 Neither ALT nor AST greater than 10 times upper limit of normal; and

9 No history of hypersensitivity to entecavir; and

10 No previous documented lamivudine resistance (either clinical or genotypic).

LAMIVUDINE – **Restricted** see terms [below](#)

↓ Tab 100 mg – 1% DV Nov-14 to 2017 .....6.00 28 **Zeffix**

↓ Oral liq 5 mg per ml – 1% DV Nov-14 to 2017 .....270.00 240 ml **Zeffix**

→ **Restricted**

## Initiation

Gastroenterologist, infectious disease specialist, paediatrician or general physician

Limited to 12 months treatment

Any of the following:

1 HBV DNA positive cirrhosis prior to liver transplantation; or

2 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or

3 Hepatitis B virus naïve patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or

4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; or

5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or

6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP).

**Continuation – patients who have maintained continuous treatment and response to lamivudine**

Gastroenterologist, infectious disease specialist, paediatrician or general physician

Re-assessment required after 2 years

All of the following:

1 Have maintained continuous treatment with lamivudine; and

2 Most recent test result shows continuing biochemical response (normal ALT); and

3 HBV DNA < 100,000 copies per ml by quantitative PCR at a reference laboratory.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

**Continuation – when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine**

Gastroenterologist, infectious disease specialist, paediatrician or general physician

*Re-assessment required after 2 years*

All of the following:

- 1 Lamivudine to be used in combination with adefovir dipivoxil; and
- 2 Patient is cirrhotic; and  
Documented resistance to lamivudine defined as:
- 3 All of the following:
  - 3.1 Patient has raised serum ALT ( $> 1 \times \text{ULN}$ ); and
  - 3.2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load  $\geq 10$ -fold over nadir; and
  - 3.3 Detection of M204I or M204V mutation.

**Continuation – when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil**

Gastroenterologist, infectious disease specialist, paediatrician or general physician

*Re-assessment required after 2 years*

Both:

- 1 Lamivudine to be used in combination with adefovir dipivoxil; and  
Documented resistance to lamivudine defined as:
- 2 All of the following:
  - 2.1 Patient has raised serum ALT ( $> 1 \times \text{ULN}$ ); and
  - 2.2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load  $\geq 10$ -fold over nadir; and
  - 2.3 Detection of N236T or A181T/V mutation.

**TENOFOVIR DISOPROXIL FUMARATE – Restricted** see terms [below](#)

↓ Tab 300 mg ..... 531.00      30      Viread

→ **Restricted**

**Initiation – Confirmed hepatitis B**

Any of the following:

- 1 All of the following:
  - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
  - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
  - 1.3 HBV DNA greater than 20,000 IU/mL or increased  $\leq 10$ -fold over nadir; and
  - 1.4 Any of the following:
    - 1.4.1 Lamivudine resistance - detection of M204I/V mutation; or
    - 1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or
    - 1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV; or
- 3 Patient has a decompensated cirrhosis with a Mayo score  $> 20$ .

**Initiation – Pregnant or Breastfeeding, Active hepatitis B**

*Limited to 12 months treatment*

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA  $> 20,000$  IU/mL and ALT  $> \text{ULN}$ .

**Initiation – Pregnant, prevention of vertical transmission**

*Limited to 6 months treatment*

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA  $> 20$  million IU/mL and ALT normal.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Initiation – Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
  - 2.1 Symptomatic patient; or
  - 2.2 Patient aged 12 months and under; or
  - 2.3 Both:
    - 2.3.1 Patient aged 1 to 5 years; and
    - 2.3.2 Any of the following:
      - 2.3.2.1 CD4 counts < 1000 cells/mm<sup>3</sup>; or
      - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
      - 2.3.2.3 Viral load counts > 100000 copies per ml; or
  - 2.4 Both:
    - 2.4.1 Patient aged 6 years and over; and
    - 2.4.2 CD4 counts < 500 cells/mm<sup>3</sup>.

## Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

## Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

## Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

## Hepatitis C

LEDIPASVIR WITH SOFOSBUVIR – **Restricted** see terms [below](#)

⚡ Tab 90 mg with sofosbuvir 400 mg.....24,363.46      28      Harvoni

### ➡ **Restricted**

#### Initiation

Note: Only for use in patients with approval by the Hepatitis C Treatment Panel (HepCTP). Applications will be considered by HepCTP at its regular meetings and approved subject to eligibility according to the Access Criteria (set out in Section B of the Pharmaceutical Schedule).

PARITAPREVIR, RITONAVIR AND OMBITASVIR WITH DASABUVIR

Note: Only for use in patients who have received supply of treatment via PHARMAC's approved direct distribution supply. Application details for accessing treatment may be obtained from PHARMAC's website <http://www.pharmac.govt.nz/hepatitis-c-treatments/>.

Tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg (56), with dasabuvir tab 250 mg (56).....16,500.00      1      Viekira Pak

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PARITAPREVIR, RITONAVIR AND OMBITASVIR WITH DASABUVIR AND RIBAVIRIN</b>			
Note: Only for use in patients who have received supply of treatment via PHARMAC's approved direct distribution supply. Application details for accessing treatment may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/hepatitis-c-treatments/">http://www.pharmac.govt.nz/hepatitis-c-treatments/</a> .			
Tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg (56) with dasabuvir tab 250 mg (56) and ribavirin tab 200 mg (168).....	16,500.00	1	Viekira Pak-RBV

## Herpesviridae

### ACICLOVIR

Tab dispersible 200 mg – 1% DV Sep-16 to 2019 .....	1.60	25	<b>Lovir</b>
Tab dispersible 400 mg – 1% DV Sep-16 to 2019 .....	5.38	56	<b>Lovir</b>
Tab dispersible 800 mg – 1% DV Sep-16 to 2019 .....	5.98	35	<b>Lovir</b>
Inj 250 mg vial – 1% DV Jan-16 to 2018 .....	10.10	5	<b>Aciclovir-Clarix</b>

CIDOFOVIR – **Restricted** see terms [below](#)

↓ Inj 75 mg per ml, 5 ml vial

→ **Restricted**

Clinical microbiologist, infectious disease specialist, otolaryngologist or oral surgeon

FOSCARNET SODIUM – **Restricted** see terms [below](#)

↓ Inj 24 mg per ml, 250 ml bottle

→ **Restricted**

Clinical microbiologist or infectious disease specialist

GANCICLOVIR – **Restricted** see terms [below](#)

↓ Inj 500 mg vial ..... 380.00 5 **Cymevene**

→ **Restricted**

Clinical microbiologist or infectious disease specialist

### VALACICLOVIR

Tab 500 mg – 1% DV Mar-16 to 2018 .....	6.42	30	<b>Vaclovir</b>
Tab 1,000 mg – 1% DV Mar-16 to 2018 .....	12.75	30	<b>Vaclovir</b>

VALGANCICLOVIR – **Restricted** see terms [below](#)

↓ Tab 450 mg – 1% DV Jun-15 to 2018 ..... 1,050.00 60 **Valcyte**

→ **Restricted**

**Initiation – Transplant cytomegalovirus prophylaxis**

*Limited to 3 months treatment*

Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

**Initiation – Lung transplant cytomegalovirus prophylaxis**

*Limited to 6 months treatment*

Both:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
  - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
  - 2.2 The recipient is cytomegalovirus positive.

**Initiation – Cytomegalovirus in immunocompromised patients**

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
  - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
  - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
  - 2.3 Patient has cytomegalovirus retinitis.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Influenza

OSELTAMIVIR – **Restricted** see terms [below](#)

⚡ Tab 75 mg

⚡ Powder for oral suspension 6 mg per ml

➔ **Restricted**

### Initiation

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

ZANAMIVIR

⚡ Powder for inhalation 5 mg.....37.38      20 dose      Relenza Rotadisk

➔ **Restricted**

### Initiation

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

## Immune Modulators

INTERFERON ALFA-2A

Inj 3 m iu prefilled syringe

Inj 6 m iu prefilled syringe

Inj 9 m iu prefilled syringe

INTERFERON ALFA-2B

Inj 18 m iu, 1.2 ml multidose pen

Inj 30 m iu, 1.2 ml multidose pen

Inj 60 m iu, 1.2 ml multidose pen

INTERFERON GAMMA – **Restricted** see terms [below](#)

⚡ Inj 100 mcg in 0.5 ml vial

➔ **Restricted**

### Initiation

Patient has chronic granulomatous disease and requires interferon gamma.

PEGYLATED INTERFERON ALFA-2A – **Restricted** see terms [below](#)

⚡ Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (168)

⚡ Inj 180 mcg prefilled syringe.....900.00      4      Pegasys

⚡ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) ..... 1,159.84      1      Pegasys RBV

⚡ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (168) ..... 1,290.00      1      Pegasys RBV

Combination Pack

Combination Pack

➔ **Restricted**

**Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant**

Limited to 48 weeks treatment

Any of the following:

- 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
- 2 Patient has chronic hepatitis C and is co-infected with HIV; or
- 3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.

continued...



	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

continued...

Notes: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

#### **Continuation – Chronic hepatitis C - genotype 1 infection**

Gastroenterologist, infectious disease specialist or general physician

*Re-assessment required after 48 weeks*

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
  - 3.1 Patient has responder relapsed; or
  - 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir.

#### **Initiation – Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior**

Gastroenterologist, infectious disease specialist or general physician

*Limited to 48 weeks treatment*

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
  - 3.1 Patient has responder relapsed; or
  - 3.2 Patient was a partial responder; or
  - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir.

#### **Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV**

*Limited to 6 months treatment*

Patient has chronic hepatitis C, genotype 2 or 3 infection.

#### **Initiation – Hepatitis B**

Gastroenterologist, infectious disease specialist or general physician

*Limited to 48 weeks treatment*

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naïve; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log<sub>10</sub> IU/ml; and
- 5 Either:
  - 5.1 HBeAg positive; or
  - 5.2 Serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon.

Notes: Approved dose is 180 mcg once weekly.

The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.

In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.

continued...

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

continued...

In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.

Pegylated Interferon alfa-2a is not approved for use in children.

	Price		Brand or
(ex man. excl. GST)	\$	Per	Generic
			Manufacturer

## Anticholinesterases

EDROPHONIUM CHLORIDE – **Restricted** see terms [below](#)

↓ Inj 10 mg per ml, 15 ml vial

↓ Inj 10 mg per ml, 1 ml ampoule

➔ **Restricted**

**Initiation**

For the diagnosis of myasthenia gravis.

NEOSTIGMINE METILSULFATE

Inj 2.5 mg per ml, 1 ml ampoule – **1% DV Sep-14 to 2017** ..... 98.00      50      **AstraZeneca**

NEOSTIGMINE METILSULFATE WITH GLYCOPYRROLONIUM BROMIDE

Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule –  
**1% DV Jul-16 to 2019** ..... 20.90      10      **Max Health**

PYRIDOSTIGMINE BROMIDE

Tab 60 mg – **1% DV Nov-16 to 2019** ..... 42.79      100      **Mestinon**

## Antirheumatoid Agents

AURANOFIN – **Restricted:** For continuation only

➔ Tab 3 mg

(Any Tab 3 mg to be delisted 1 September 2017)

HYDROXYCHLOROQUINE

Tab 200 mg – **1% DV Sep-15 to 2018** ..... 10.50      100      **Plaquenil**

LEFLUNOMIDE

Tab 10 mg – **1% DV Jun-17 to 2020** ..... 2.90      30      **Apo-Leflunomide**  
55.00      **Arava**

Tab 20 mg – **1% DV Jun-17 to 2020** ..... 2.90      30      **Apo-Leflunomide**  
76.00      **Arava**

(Arava Tab 10 mg to be delisted 1 June 2017)

(Arava Tab 20 mg to be delisted 1 June 2017)

PENICILLAMINE

Tab 125 mg ..... 67.23      100      D-Penamine

Tab 250 mg ..... 110.12      100      D-Penamine

SODIUM AUROTHIOMALATE

Inj 10 mg in 0.5 ml ampoule

Inj 20 mg in 0.5 ml ampoule

Inj 50 mg in 0.5 ml ampoule

## Drugs Affecting Bone Metabolism

### Bisphosphonates

ALENDRONATE SODIUM

↓ Tab 40 mg ..... 133.00      30      Fosamax

➔ **Restricted**

**Initiation – Paget's disease**

Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Paget's disease; and
- 2 Any of the following:
  - 2.1 Bone or articular pain; or
  - 2.2 Bone deformity; or
  - 2.3 Bone, articular or neurological complications; or
  - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
  - 2.5 Preparation for orthopaedic surgery.

↓ Tab 70 mg ..... 12.90      4      Fosamax

## ➔ Restricted

### Initiation – Osteoporosis

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq$  2.5 standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq$  -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score  $\leq$  -3.0 (see Note); or
- 5 A 10-year risk of hip fracture  $\geq$  3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (underlying cause – osteoporosis) or raloxifene.

### Initiation – glucocorticosteroid therapy

*Re-assessment required after 12 months*

Both:

- 1 The patient is receiving systemic glucocorticosteroid therapy ( $\geq$  5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
  - 2.1 The patient has documented BMD  $\geq$  1.5 standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq$  -1.5) (see Note); or
  - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
  - 2.3 The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene.

### Continuation – glucocorticosteroid therapy

*Re-assessment required after 12 months*

The patient is continuing systemic glucocorticosteroid therapy ( $\geq$  5 mg per day prednisone equivalents).

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score  $\leq$  -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ALENDRONATE SODIUM WITH COLECALCIFEROL – Restricted</b> see terms <a href="#">below</a>			
↓ Tab 70 mg with colecalciferol 5,600 iu .....	12.90	4	Fosamax Plus

➔ **Restricted**

**Initiation – Osteoporosis**

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq$  2.5 standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq$  -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score  $\leq$  -3.0 (see Note); or
- 5 A 10-year risk of hip fracture  $\geq$  3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (underlying cause – osteoporosis) or raloxifene.

**Initiation – glucocorticosteroid therapy**

*Re-assessment required after 12 months*

Both:

- 1 The patient is receiving systemic glucocorticosteroid therapy ( $\geq$  5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
  - 2.1 The patient has documented BMD  $\geq$  1.5 standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq$  -1.5) (see Note); or
  - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
  - 2.3 The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene.

**Continuation – glucocorticosteroid therapy**

*Re-assessment required after 12 months*

The patient is continuing systemic glucocorticosteroid therapy ( $\geq$  5 mg per day prednisone equivalents).

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score  $\geq$  -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

**ETIDRONATE DISODIUM**

Tab 200 mg – **1% DV Sep-15 to 2018** ..... 13.50 100 **Arrow-Etidronate**

**PAMIDRONATE DISODIUM**

Inj 3 mg per ml, 10 ml vial..... 6.80 1 Pamisol  
Inj 6 mg per ml, 10 ml vial..... 13.20 1 Pamisol  
Inj 9 mg per ml, 10 ml vial..... 19.20 1 Pamisol

**RISEDRONATE SODIUM**

Tab 35 mg – **1% DV Mar-17 to 2019** ..... 3.80 4 **Risedronate Sandoz**

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## ZOLEDRONIC ACID

⚡ Inj 5 mg per 100 ml, vial .....600.00 100 ml Aclasta

### ➡ Restricted

#### Initiation – Inherited bone fragility disorders

Any specialist

Patient has been diagnosed with an inherited bone fragility disorder (e.g. osteogenesis imperfecta).

#### Initiation – Osteoporosis

Any specialist

*Therapy limited to 3 doses*

Both:

- 1 Any of the following:
  - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq 2.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -2.5$ ) (see Note); or
  - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
  - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
  - 1.4 Documented T-Score  $\geq -3.0$  (see Note); or
  - 1.5 A 10-year risk of hip fracture  $\geq 3\%$ , calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
  - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

#### Initiation – glucocorticosteroid therapy

Any specialist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy ( $\geq 5$  mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
  - 2.1 The patient has documented BMD  $\geq 1.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -1.5$ ) (see Note); or
  - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
  - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) or raloxifene; and; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

#### Continuation – glucocorticosteroid therapy

Any specialist

*Re-assessment required after 12 months*

Both:

- 1 The patient is continuing systemic glucocorticosteroid therapy ( $\geq 5$  mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

#### Initiation – Paget's disease

Any specialist

*Re-assessment required after 12 months*

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
  - 2.1 Bone or articular pain; or
  - 2.2 Bone deformity; or
  - 2.3 Bone, articular or neurological complications; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.4 Asymptomatic disease, but risk of complications; or
- 2.5 Preparation for orthopaedic surgery; and

3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation – Paget’s disease

Any specialist

Re-assessment required after 12 months

Both:

- 1 Any of the following:
  - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
  - 1.2 The patient’s serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
  - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score  $\leq -2.5$  and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

RALOXIFENE – **Restricted** see terms [below](#)

↓ Tab 60 mg .....53.76 28 Evista

➔ **Restricted**

Initiation

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq 2.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -2.5$ ) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score  $\geq -3.0$  (see Notes); or
- 5 A 10-year risk of hip fracture  $\geq 3\%$ , calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or alendronate (Underlying cause - Osteoporosis).

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA).

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score  $\leq -2.5$  and, therefore, do not require BMD measurement for raloxifene funding.
  - Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
  - A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

TERIPARATIDE – **Restricted** see terms [below](#)

‡ Inj 250 mcg per ml, 2.4 ml cartridge .....490.00 1 Forteo

→ **Restricted**

## Initiation

Limited to 18 months treatment

All of the following:

- The patient has severe, established osteoporosis; and
- The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- The patient has had two or more fractures due to minimal trauma; and
- The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

## Enzymes

HYALURONIDASE

Inj 1,500 iu ampoule

## Hyperuricaemia and Antigout

ALLOPURINOL

Tab 100 mg – 1% DV Jan-17 to 2017 .....	15.11	1,000	<b>Allopurinol-Apotex</b> Apo-Allopurinol
Tab 300 mg – 1% DV Jan-17 to 2017 .....	15.91	500	<b>Allopurinol-Apotex</b> Apo-Allopurinol

(Apo-Allopurinol Tab 100 mg to be delisted 1 June 2017)

(Apo-Allopurinol Tab 300 mg to be delisted 1 June 2017)

BENZBROMARONE – **Restricted** see terms [on the next page](#)

‡ Tab 100 mg .....45.00 100 Benzbromaron AL 100

‡ Item restricted (see → above); ‡ Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.



Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

➔ **Restricted****Initiation**

Any specialist

All of the following:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
  - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
  - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
  - 2.3 Both:
    - 2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
    - 2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
  - 2.4 All of the following:
    - 2.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
    - 2.4.2 Allopurinol is contraindicated; and
    - 2.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
- 3 The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at [www.rheumatology.org.nz/home/resources-2/](http://www.rheumatology.org.nz/home/resources-2/)

**COLCHICINE**

Tab 500 mcg.....	10.08	100	Colgout
------------------	-------	-----	---------

**FEBUXOSTAT – Restricted** see terms [below](#)

↓ Tab 80 mg .....	39.50	28	Adenuric
↓ Tab 120 mg .....	39.50	28	Adenuric

➔ **Restricted****Initiation**

Any specialist

Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
  - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
  - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
  - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note).

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

## MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PROBENECID Tab 500 mg			
RASBURICASE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 1.5 mg vial			
➡ <b>Restricted</b>			
Haematologist			

### Muscle Relaxants and Related Agents

ATracurium BESylate			
Inj 10 mg per ml, 2.5 ml ampoule .....	10.00	5	Tracrium
Inj 10 mg per ml, 5 ml ampoule .....	12.50	5	Tracrium
BACLOFEN			
Tab 10 mg .....	3.85	100	Pacifen
Oral liq 1 mg per ml			
Inj 0.05 mg per ml, 1 ml ampoule – <b>1% DV Sep-15 to 2018</b> .....	11.55	1	<b>Lioresal Intrathecal</b>
Inj 2 mg per ml, 5 ml ampoule .....	209.29	1	Lioresal Intrathecal
CLOSTRIDIUM BOTULINUM TYPE A TOXIN			
Inj 100 u vial .....	467.50	1	Botox
Inj 300 u vial .....	388.50	1	Dysport
Inj 500 u vial .....	1,295.00	2	Dysport
DANTROLENE			
Cap 25 mg .....	65.00	100	Dantrium
Cap 50 mg .....	77.00	100	Dantrium
Inj 20 mg vial .....	800.00	6	Dantrium IV
MIVACURIUM CHLORIDE			
Inj 2 mg per ml, 5 ml ampoule .....	33.92	5	Mivacron
Inj 2 mg per ml, 10 ml ampoule .....	67.17	5	Mivacron
ORPHENADRINE CITRATE			
Tab 100 mg			
PANCURONIUM BROMIDE			
Inj 2 mg per ml, 2 ml ampoule .....	260.00	50	AstraZeneca
ROCURONIUM BROMIDE			
Inj 10 mg per ml, 5 ml vial – <b>1% DV Aug-16 to 2019</b> .....	25.95	10	<b>DBL Rocuronium Bromide</b>
SUXAMETHONIUM CHLORIDE			
Inj 50 mg per ml, 2 ml ampoule – <b>1% DV Jun-14 to 2017</b> .....	78.00	50	<b>AstraZeneca</b>
VECURONIUM BROMIDE			
Inj 10 mg vial			

### Reversers of Neuromuscular Blockade

SUGAMMADEX – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 100 mg per ml, 2 ml vial .....	1,200.00	10	Bridion
⚡ Inj 100 mg per ml, 5 ml vial .....	3,000.00	10	Bridion

➡ **Restricted**

**Initiation**

Any of the following:

continued...

Price	Brand or
(ex man. excl. GST)	Generic
\$ Per	Manufacturer

continued...

- 1 Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable); or
- 2 Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required; or
- 3 Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade; or
- 4 The duration of the patient's surgery is unexpectedly short; or
- 5 Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD); or
- 6 Patient has a partial residual block after conventional reversal.

## Non-Steroidal Anti-Inflammatory Drugs

CELECOXIB – **Restricted** see terms [below](#)

- ↓ Cap 100 mg
- ↓ Cap 200 mg
- ↓ Cap 400 mg

➔ **Restricted**

### Initiation

For preoperative and/or postoperative use for a total of up to 8 days' use.

#### DICLOFENAC SODIUM

Tab EC 25 mg – 1% DV Dec-15 to 2018 .....	1.30	50	<b>Diclofenac Sandoz</b>
Tab 50 mg dispersible .....	1.50	20	Voltaren D
Tab EC 50 mg – 1% DV Dec-15 to 2018 .....	1.00	50	<b>Diclofenac Sandoz</b>
Tab long-acting 75 mg – 1% DV Dec-15 to 2018 .....	15.20	500	<b>Apo-Diclo SR</b>
Tab long-acting 100 mg – 1% DV Dec-15 to 2018 .....	26.20	500	<b>Apo-Diclo SR</b>
Inj 25 mg per ml, 3 ml ampoule – 1% DV Oct-14 to 2017 .....	13.20	5	<b>Voltaren</b>
Suppos 12.5 mg – 1% DV Oct-14 to 2017 .....	2.04	10	<b>Voltaren</b>
Suppos 25 mg – 1% DV Oct-14 to 2017 .....	2.44	10	<b>Voltaren</b>
Suppos 50 mg – 1% DV Oct-14 to 2017 .....	4.22	10	<b>Voltaren</b>
Suppos 100 mg – 1% DV Oct-14 to 2017 .....	7.00	10	<b>Voltaren</b>

ETORICOXIB – **Restricted** see terms [below](#)

- ↓ Tab 30 mg
- ↓ Tab 60 mg
- ↓ Tab 90 mg
- ↓ Tab 120 mg

➔ **Restricted**

### Initiation

For preoperative and/or postoperative use for a total of up to 8 days' use.

#### IBUPROFEN

Tab 200 mg			
➔ Tab 400 mg – <b>Restricted:</b> For continuation only			
➔ Tab 600 mg – <b>Restricted:</b> For continuation only			
Tab long-acting 800 mg – 1% DV Jul-15 to 2018 .....	7.99	30	<b>Brufen SR</b>
Oral liq 20 mg per ml .....	1.89	200 ml	Fenpaed
Inj 5 mg per ml, 2 ml ampoule			
Inj 10 mg per ml, 2 ml vial			

# MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>INDOMETHACIN</b>			
Cap 25 mg			
Cap 50 mg			
Cap long-acting 75 mg			
Inj 1 mg vial			
Suppos 100 mg			
<b>KETOPROFEN</b>			
Cap long-acting 200 mg .....	12.07	28	Oruvail SR
<b>MEFENAMIC ACID</b> – <b>Restricted:</b> For continuation only			
➔ Cap 250 mg			
<b>MELOXICAM</b> – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 7.5 mg			
➔ <b>Restricted</b>			
<b>Initiation</b>			
Either:			
1 All of the following:			
1.1 Haemophilic arthropathy; and			
1.2 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and			
1.3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated; or			
2 For preoperative and/or postoperative use for a total of up to 8 days' use.			
<b>NAPROXEN</b>			
Tab 250 mg – 1% DV Sep-15 to 2018 .....	18.06	500	Noflam 250
Tab 500 mg – 1% DV Sep-15 to 2018 .....	18.91	250	Noflam 500
Tab long-acting 750 mg – 1% DV Jun-15 to 2018.....	5.60	28	Naprosyn SR 750
	18.00	90	Naprosyn SR 750
Tab long-acting 1 g – 1% DV Jun-15 to 2018.....	6.53	28	Naprosyn SR 1000
	21.00	90	Naprosyn SR 1000
<b>PARECOXIB</b>			
Inj 40 mg vial .....	100.00	10	Dynastat
<b>SULINDAC</b>			
Tab 100 mg			
Tab 200 mg			
<b>TENOXICAM</b>			
Tab 20 mg – 1% DV Sep-16 to 2019 .....	10.95	100	Tilcotil
Inj 20 mg vial .....	9.95	1	AFT

## Topical Products for Joint and Muscular Pain

**CAPSAICIN** – **Restricted** see terms [below](#)

⚡ Crm 0.025%.....9.95 45 g Zostrix

➔ **Restricted**

**Initiation**

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Agents for Parkinsonism and Related Disorders

### Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – **Restricted** see terms [below](#)

↓ Tab 50 mg ..... 400.00 56 Rilutek

→ **Restricted**

#### Initiation

Neurologist or respiratory specialist

*Re-assessment required after 6 months*

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
  - 5.1 The patient is ambulatory; or
  - 5.2 The patient is able to use upper limbs; or
  - 5.3 The patient is able to swallow.

#### Continuation

*Re-assessment required after 18 months*

All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
  - 3.1 The patient is ambulatory; or
  - 3.2 The patient is able to use upper limbs; or
  - 3.3 The patient is able to swallow.

#### TETRABENAZINE

Tab 25 mg – **1% DV Sep-16 to 2019** ..... 91.10 112 **Motetis**

### Anticholinergics

#### BENZATROPINE MESYLATE

Tab 2 mg ..... 7.99 60 Benztrop  
Inj 1 mg per ml, 2 ml ampoule ..... 95.00 5 Cogentin

#### PROCYCLIDINE HYDROCHLORIDE

Tab 5 mg

### Dopamine Agonists and Related Agents

#### AMANTADINE HYDROCHLORIDE

Cap 100 mg – **1% DV Oct-14 to 2017** ..... 38.24 60 **Symmetrel**

#### APOMORPHINE HYDROCHLORIDE

Inj 10 mg per ml, 1 ml ampoule .....  
Inj 10 mg per ml, 2 ml ampoule ..... 119.00 5 Movapro

#### BROMOCRIPTINE

Tab 2.5 mg  
Cap 5 mg

## NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ENTACAPONE</b>			
Tab 200 mg – 1% DV Sep-15 to 2018 .....	28.00	100	<b>Entapone</b>
<b>LEVODOPA WITH BENSERAZIDE</b>			
Tab dispersible 50 mg with benserazide 12.5 mg .....	10.00	100	Madopar Rapid
Cap 50 mg with benserazide 12.5 mg .....	8.00	100	Madopar 62.5
Cap 100 mg with benserazide 25 mg .....	12.50	100	Madopar 125
Cap long-acting 100 mg with benserazide 25 mg .....	17.00	100	Madopar HBS
Cap 200 mg with benserazide 50 mg .....	25.00	100	Madopar 250
<b>LEVODOPA WITH CARBIDOPA</b>			
Tab 100 mg with carbidopa 25 mg .....	20.00	100	Sinemet
		0	e.g. Kinson
Tab long-acting 200 mg with carbidopa 50 mg .....	47.50	100	Sinemet CR
Tab 250 mg with carbidopa 25 mg .....	40.00	100	Sinemet
		0	e.g. Sindopa
<b>PRAMIPEXOLE HYDROCHLORIDE</b>			
Tab 0.25 mg – 1% DV Sep-16 to 2019 .....	7.20	100	<b>Ramipex</b>
Tab 1 mg – 1% DV Sep-16 to 2019 .....	24.39	100	<b>Ramipex</b>
<b>ROPINIROLE HYDROCHLORIDE</b>			
Tab 0.25 mg – 1% DV Sep-16 to 2019 .....	2.78	100	<b>Apo-Ropinirole</b>
Tab 1 mg – 1% DV Sep-16 to 2019 .....	5.00	100	<b>Apo-Ropinirole</b>
Tab 2 mg – 1% DV Sep-16 to 2019 .....	7.72	100	<b>Apo-Ropinirole</b>
Tab 5 mg – 1% DV Sep-16 to 2019 .....	16.51	100	<b>Apo-Ropinirole</b>
<b>SELEGILINE HYDROCHLORIDE</b>			
Tab 5 mg			
<b>TOLCAPONE</b>			
Tab 100 mg – 1% DV Jan-17 to 2019 .....	132.50	100	<b>Tasmar</b>

## Anaesthetics

### General Anaesthetics

<b>DESFLURANE</b>			
Soln for inhalation 100%, 240 ml bottle – 1% DV Sep-16 to 2019 .....	1,350.00	6	<b>Suprane</b>
<b>DEXMEDETOMIDINE</b>			
Inj 100 mcg per ml, 2 ml vial – 1% DV Oct-14 to 2017 .....	479.85	5	<b>Precedex</b>
<b>ETOMIDATE</b>			
Inj 2 mg per ml, 10 ml ampoule			
<b>ISOFLURANE</b>			
Soln for inhalation 100%, 250 ml bottle – 1% DV Sep-16 to 2019 .....	1,020.00	6	<b>Aerrane</b>
<b>KETAMINE</b>			
Inj 1 mg per ml, 100 ml bag – 1% DV Sep-14 to 2017 .....	27.00	1	<b>Biomed</b>
Inj 4 mg per ml, 50 ml syringe – 1% DV Sep-14 to 2017 .....	25.00	1	<b>Biomed</b>
Inj 10 mg per ml, 10 ml syringe – 1% DV Sep-14 to 2017 .....	14.00	1	<b>Biomed</b>
Inj 100 mg per ml, 2 ml ampoule – 1% DV May-16 to 2018 .....	47.05	5	<b>Ketamine-Claris</b>
<b>METHOHEXITAL SODIUM</b>			
Inj 10 mg per ml, 50 ml vial			
<b>PROPOFOL</b>			
Inj 10 mg per ml, 20 ml vial – 10% DV Jun-16 to 2019 .....	5.27	5	<b>Proville MCT-LCT 1%</b>
Inj 10 mg per ml, 50 ml vial – 10% DV Jun-16 to 2019 .....	24.50	10	<b>Fresofol 1% MCT/LCT</b>
Inj 10 mg per ml, 100 ml vial – 10% DV Jun-16 to 2019 .....	49.00	10	<b>Fresofol 1% MCT/LCT</b>

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SEVOFLURANE Soln for inhalation 100%, 250 ml bottle – <b>1% DV Sep-16 to 2019</b> .....	840.00	6	<b>Baxter</b>
THIOPENTAL [THIOPENTONE] SODIUM Inj 500 mg ampoule			
<b>Local Anaesthetics</b>			
ARTICAINE HYDROCHLORIDE Inj 1%			
ARTICAINE HYDROCHLORIDE WITH ADRENALINE Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge			
BENZOCAINE Gel 20%			
BUPIVACAINE HYDROCHLORIDE Inj 5 mg per ml, 4 ml ampoule – <b>1% DV Jul-14 to 2017</b> ..... Inj 2.5 mg per ml, 20 ml ampoule Inj 2.5 mg per ml, 20 ml ampoule sterile pack – <b>1% DV Sep-15 to 2018</b> ..... Inj 5 mg per ml, 10 ml ampoule sterile pack – <b>1% DV Sep-15 to 2018</b> ..... Inj 5 mg per ml, 20 ml ampoule Inj 5 mg per ml, 20 ml ampoule sterile pack – <b>1% DV Sep-15 to 2018</b> ..... Inj 1.25 mg per ml, 100 ml bag Inj 1.25 mg per ml, 200 ml bag Inj 2.5 mg per ml, 100 ml bag – <b>1% DV Jul-14 to 2017</b> ..... Inj 2.5 mg per ml, 200 ml bag Inj 1.25 mg per ml, 500 ml bag	50.00  29.20 20.25 20.70  150.00  	5  5 5 5  5	<b>Marcaïn Isobaric</b>  <b>Marcaïn</b> <b>Marcaïn</b> <b>Marcaïn</b>  <b>Marcaïn</b>
BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – <b>1% DV Sep-14 to 2017</b> ..... Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – <b>1% DV Sep-14 to 2017</b> .....	135.00 115.00	5 5	<b>Marcaïn with Adrenaline</b> <b>Marcaïn with Adrenaline</b>
BUPIVACAINE HYDROCHLORIDE WITH FENTANYL Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag ..... Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag ..... Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe..... Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe.....	   210.00 210.00  72.00 92.00	10 10  10 10	<b>Bupafen</b> <b>Bupafen</b>  <b>Biomed</b> <b>Biomed</b>
BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE Inj 0.5% with glucose 8%, 4 ml ampoule .....	38.00	5	<b>Marcaïn Heavy</b>
COCAINE HYDROCHLORIDE Paste 5% Soln 15%, 2 ml syringe Soln 4%, 2 ml syringe.....	  25.46	  1	  <b>Biomed</b>

## NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>COCAINE HYDROCHLORIDE WITH ADRENALINE</b>			
Paste 15% with adrenaline 0.06%			
Paste 25% with adrenaline 0.06%			
<b>ETHYL CHLORIDE</b>			
Spray 100%			
<b>LIDOCAINE [LIGNOCAINE]</b>			
Crm 4%.....	27.00	30 g	LMX4
Crm 4% (5 g tubes) .....	27.00	5	LMX4
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE</b>			
Gel 2% – <b>1% DV Sep-15 to 2018</b> .....	3.40	20 ml	<b>Orion</b>
Soln 4%			
Spray 10% .....	75.00	50 ml	Xylocaine
Oral (viscous) soln 2% – <b>1% DV Sep-14 to 2017</b> .....	55.00	200 ml	<b>Xylocaine Viscous</b>
Inj 1%, 20 ml ampoule, sterile pack			
Inj 2%, 20 ml ampoule, sterile pack			
Inj 1%, 5 ml ampoule .....	8.75	25	Lidocaine-Claris
Inj 1%, 20 ml ampoule .....	2.40	1	Lidocaine-Claris
Inj 1%, 20 ml vial .....	12.00	5	Lidocaine-Claris
Inj 2%, 5 ml ampoule .....	6.90	25	Lidocaine-Claris
Inj 2%, 20 ml ampoule .....	2.40	1	Lidocaine-Claris
Inj 2%, 20 ml vial .....	12.00	5	Lidocaine-Claris
Gel 2%, 10 ml urethral syringe .....	43.26	10	Pfizer
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE</b>			
Inj 1% with adrenaline 1:100,000, 5 ml ampoule .....	27.00	10	Xylocaine
Inj 1% with adrenaline 1:200,000, 20 ml vial .....	50.00	5	Xylocaine
Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge			
Inj 2% with adrenaline 1:200,000, 20 ml vial .....	60.00	5	Xylocaine
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE</b>			
Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – <b>1% DV Oct-14 to 2017</b> .....	17.50	1	<b>Topicaïne</b>
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE</b>			
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe .....	43.26	10	Pfizer
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE</b>			
Nasal spray 5% with phenylephrine hydrochloride 0.5%			
<b>LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE</b>			
Crm 2.5% with prilocaine 2.5% .....	45.00	30 g	EMLA
Patch 25 mcg with prilocaine 25 mcg .....	115.00	20	EMLA
Crm 2.5% with prilocaine 2.5%, 5 g .....	45.00	5	EMLA
<b>MEPIVACAINE HYDROCHLORIDE</b>			
Inj 3%, 1.8 ml dental cartridge – <b>1% DV Oct-14 to 2017</b> .....	43.60	50	<b>Scandonest 3%</b>
Inj 3%, 2.2 ml dental cartridge – <b>1% DV Oct-14 to 2017</b> .....	43.60	50	<b>Scandonest 3%</b>
<b>PRILOCAINE HYDROCHLORIDE</b>			
Inj 0.5%, 50 ml vial .....	100.00	5	Citanest
Inj 2%, 5 ml ampoule .....	55.00	10	Citanest
<b>PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN</b>			
Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge			
Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ROPIVACAINE HYDROCHLORIDE</b>			
Inj 2 mg per ml, 10 ml ampoule – <b>1% DV Aug-15 to 2017</b> .....	9.05	5	<b>Ropivacaine Kabi</b>
Inj 2 mg per ml, 20 ml ampoule – <b>1% DV Aug-15 to 2017</b> .....	9.50	5	<b>Ropivacaine Kabi</b>
Inj 2 mg per ml, 100 ml bag – <b>1% DV Jul-15 to 2017</b> .....	60.00	5	<b>Naropin</b>
Inj 2 mg per ml, 200 ml bag – <b>1% DV Jul-15 to 2017</b> .....	79.50	5	<b>Naropin</b>
Inj 7.5 mg per ml, 10 ml ampoule – <b>1% DV Aug-15 to 2017</b> .....	10.20	5	<b>Ropivacaine Kabi</b>
Inj 7.5 mg per ml, 20 ml ampoule – <b>1% DV Aug-15 to 2017</b> .....	12.50	5	<b>Ropivacaine Kabi</b>
Inj 10 mg per ml, 10 ml ampoule – <b>1% DV Aug-15 to 2017</b> .....	10.90	5	<b>Ropivacaine Kabi</b>
Inj 10 mg per ml, 20 ml ampoule – <b>1% DV Aug-15 to 2017</b> .....	16.30	5	<b>Ropivacaine Kabi</b>
<b>ROPIVACAINE HYDROCHLORIDE WITH FENTANYL</b>			
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag .....	198.50	5	Naropin
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag .....	270.00	5	Naropin
<b>TETRACAINE [AMETHOCAINE] HYDROCHLORIDE</b>			
Gel 4%			

## Analgesics

### Non-Opioid Analgesics

#### ASPIRIN

Tab dispersible 300 mg – **1% DV Dec-16 to 2019** ..... 3.90 100 **Ethics Aspirin**

**CAPSAICIN** – **Restricted** see terms [below](#)

↓ Crm 0.075% ..... 12.50 45 g **Zostrix HP**

➔ **Restricted**

#### Initiation

For post-herpetic neuralgia or diabetic peripheral neuropathy.

**METHOXYFLURANE** – **Restricted** see terms [below](#)

↓ Soln for inhalation 99.9%, 3 ml bottle

➔ **Restricted**

#### Initiation

Both:

- 1 Patient is undergoing a painful procedure with an expected duration of less than one hour; and
- 2 Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane.

#### NEFOPAM HYDROCHLORIDE

Tab 30 mg

**PARACETAMOL** – **Some items restricted** see terms [on the next page](#)

Tab soluble 500 mg – **1% DV Oct-15 to 2017** ..... 1.60 20 **Paragesic Soluble**

Tab 500 mg

Oral liq 120 mg per 5 ml – **20% DV Oct-14 to 2017** ..... 4.15 1,000 ml **Paracare**

Oral liq 250 mg per 5 ml – **20% DV Sep-14 to 2017** ..... 4.35 1,000 ml **Paracare Double Strength**

↓ Inj 10 mg per ml, 50 ml vial – **1% DV Sep-14 to 2017** ..... 12.90 12 **Perfalgan**

↓ Inj 10 mg per ml, 100 ml vial – **1% DV Sep-14 to 2017** ..... 12.90 12 **Perfalgan**

Suppos 25 mg ..... 56.35 20 **Biomed**

Suppos 50 mg ..... 56.35 20 **Biomed**

Suppos 125 mg – **1% DV Dec-15 to 2018** ..... 3.69 10 **Gacet**

Suppos 250 mg – **1% DV Dec-15 to 2018** ..... 3.79 10 **Gacet**

Suppos 500 mg – **1% DV Nov-15 to 2018** ..... 12.60 50 **Paracare**

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted</b>			
<b>Initiation</b>			
Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours.			
<b>SUCROSE</b>			
Oral liq 25%			
<b>Opioid Analgesics</b>			
<b>ALFENTANIL</b>			
Inj 0.5 mg per ml, 2 ml ampoule – 1% DV Jan-15 to 2017 .....	39.07	10	<b>Hameln</b>
<b>CODEINE PHOSPHATE</b>			
Tab 15 mg – 1% DV Apr-17 to 2019 .....	5.75	100	<b>PSM</b>
Tab 30 mg – 1% DV Apr-17 to 2019 .....	6.80	100	<b>PSM</b>
Tab 60 mg – 1% DV Apr-17 to 2019 .....	13.50	100	<b>PSM</b>
<b>DIHYDROCODEINE TARTRATE</b>			
Tab long-acting 60 mg – 1% DV Sep-16 to 2019 .....	9.55	60	<b>DHC Continus</b>
<b>FENTANYL</b>			
Inj 10 mcg per ml, 10 ml syringe			
Inj 50 mcg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018 .....	3.95	10	<b>Boucher and Muir</b>
Inj 10 mcg per ml, 50 ml bag .....	210.00	10	<b>Biomed</b>
Inj 10 mcg per ml, 50 ml syringe .....	165.00	10	<b>Biomed</b>
Inj 50 mcg per ml, 10 ml ampoule – 1% DV Sep-15 to 2018 .....	10.45	10	<b>Boucher and Muir</b>
Inj 10 mcg per ml, 100 ml bag .....	210.00	10	<b>Biomed</b>
Inj 20 mcg per ml, 50 ml syringe .....	185.00	10	<b>Biomed</b>
Inj 20 mcg per ml, 100 ml bag			
Patch 12.5 mcg per hour .....	2.92	5	<b>Fentanyl Sandoz</b>
Patch 25 mcg per hour .....	3.66	5	<b>Fentanyl Sandoz</b>
Patch 50 mcg per hour .....	6.64	5	<b>Fentanyl Sandoz</b>
Patch 75 mcg per hour .....	9.18	5	<b>Fentanyl Sandoz</b>
Patch 100 mcg per hour .....	11.29	5	<b>Fentanyl Sandoz</b>
<b>METHADONE HYDROCHLORIDE</b>			
Tab 5 mg – 1% DV Sep-15 to 2018 .....	1.85	10	<b>Methatabs</b>
Oral liq 2 mg per ml – 1% DV Sep-15 to 2018 .....	5.55	200 ml	<b>Biodone</b>
Oral liq 5 mg per ml – 1% DV Sep-15 to 2018 .....	5.00	200 ml	<b>Biodone Forte</b>
Oral liq 10 mg per ml – 1% DV Sep-15 to 2018 .....	6.55	200 ml	<b>Biodone Extra Forte</b>
Inj 10 mg per ml, 1 ml vial .....	61.00	10	<b>AFT</b>
<b>MORPHINE HYDROCHLORIDE</b>			
Oral liq 1 mg per ml – 1% DV Oct-15 to 2018 .....	8.84	200 ml	<b>RA-Morph</b>
Oral liq 2 mg per ml – 1% DV Oct-15 to 2018 .....	14.00	200 ml	<b>RA-Morph</b>
Oral liq 5 mg per ml – 1% DV Oct-15 to 2018 .....	18.00	200 ml	<b>RA-Morph</b>
Oral liq 10 mg per ml – 1% DV Oct-15 to 2018 .....	26.00	200 ml	<b>RA-Morph</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MORPHINE SULPHATE</b>			
Tab long-acting 10 mg – <b>1% DV Sep-16 to 2019</b> .....	1.93	10	<b>Arrow-Morphine LA</b>
Tab immediate-release 10 mg – <b>1% DV Apr-15 to 2017</b> .....	2.80	10	<b>Sevredol</b>
Tab immediate-release 20 mg – <b>1% DV Apr-15 to 2017</b> .....	5.52	10	<b>Sevredol</b>
Tab long-acting 30 mg – <b>1% DV Sep-16 to 2019</b> .....	2.85	10	<b>Arrow-Morphine LA</b>
Tab long-acting 60 mg – <b>1% DV Sep-16 to 2019</b> .....	5.60	10	<b>Arrow-Morphine LA</b>
Tab long-acting 100 mg – <b>1% DV Sep-16 to 2019</b> .....	6.10	10	<b>Arrow-Morphine LA</b>
Cap long-acting 10 mg .....	1.70	10	m-Eslon
Cap long-acting 30 mg .....	2.50	10	m-Eslon
Cap long-acting 60 mg .....	5.40	10	m-Eslon
Cap long-acting 100 mg .....	6.38	10	m-Eslon
Inj 1 mg per ml, 100 ml bag – <b>1% DV Oct-14 to 2017</b> .....	185.00	10	<b>Biomed</b>
Inj 1 mg per ml, 10 ml syringe – <b>1% DV Oct-14 to 2017</b> .....	45.00	10	<b>Biomed</b>
Inj 1 mg per ml, 50 ml syringe – <b>1% DV Oct-14 to 2017</b> .....	87.50	10	<b>Biomed</b>
Inj 1 mg per ml, 2 ml syringe .....			
Inj 2 mg per ml, 30 ml syringe .....	135.00	10	Biomed
Inj 5 mg per ml, 1 ml ampoule – <b>1% DV Oct-14 to 2017</b> .....	12.48	5	<b>DBL Morphine Sulphate</b>
Inj 10 mg per ml, 1 ml ampoule – <b>1% DV Oct-14 to 2017</b> .....	9.09	5	<b>DBL Morphine Sulphate</b>
Inj 10 mg per ml, 100 mg cassette .....			
Inj 10 mg per ml, 100 ml bag .....			
Inj 15 mg per ml, 1 ml ampoule – <b>1% DV Oct-14 to 2017</b> .....	9.77	5	<b>DBL Morphine Sulphate</b>
Inj 30 mg per ml, 1 ml ampoule – <b>1% DV Oct-14 to 2017</b> .....	12.43	5	<b>DBL Morphine Sulphate</b>
Inj 200 mcg in 0.4 ml syringe .....			
Inj 300 mcg in 0.3 ml syringe .....			
<b>MORPHINE TARTRATE</b>			
Inj 80 mg per ml, 1.5 ml ampoule – <b>1% DV Oct-16 to 2019</b> .....	42.72	5	<b>DBL Morphine Tartrate</b>
Inj 80 mg per ml, 5 ml ampoule .....	107.67	5	Hospira
<b>OXYCODONE HYDROCHLORIDE</b>			
Tab controlled-release 5 mg – <b>1% DV Sep-16 to 2018</b> .....	2.63	20	<b>BNM</b>
Tab controlled-release 10 mg – <b>1% DV Sep-16 to 2018</b> .....	2.76	20	<b>BNM</b>
Tab controlled-release 20 mg – <b>1% DV Sep-16 to 2018</b> .....	4.72	20	<b>BNM</b>
Tab controlled-release 40 mg – <b>1% DV Sep-16 to 2018</b> .....	7.69	20	<b>BNM</b>
Tab controlled-release 80 mg – <b>1% DV Sep-16 to 2018</b> .....	14.11	20	<b>BNM</b>
Cap immediate-release 5 mg – <b>1% DV Oct-15 to 2018</b> .....	1.98	20	<b>OxyNorm</b>
Cap immediate-release 10 mg – <b>1% DV Oct-15 to 2018</b> .....	3.91	20	<b>OxyNorm</b>
Cap immediate-release 20 mg – <b>1% DV Oct-15 to 2018</b> .....	6.84	20	<b>OxyNorm</b>
Oral liq 5 mg per 5 ml .....	11.20	250 ml	OxyNorm
Inj 1 mg per ml, 100 ml bag .....			
Inj 10 mg per ml, 1 ml ampoule – <b>1% DV Feb-16 to 2018</b> .....	8.57	5	<b>OxyNorm</b>
Inj 10 mg per ml, 2 ml ampoule – <b>1% DV Feb-16 to 2018</b> .....	16.89	5	<b>OxyNorm</b>
Inj 50 mg per ml, 1 ml ampoule – <b>1% DV Dec-15 to 2018</b> .....	51.00	5	<b>OxyNorm</b>
<b>PARACETAMOL WITH CODEINE</b>			
Tab paracetamol 500 mg with codeine phosphate 8 mg .....	2.11	100	Paracetamol + Codeine (Relieve)

## NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PETHIDINE HYDROCHLORIDE</b>			
Tab 50 mg – 1% DV Nov-15 to 2018 .....	4.46	10	<b>PSM</b>
Tab 100 mg – 1% DV Nov-15 to 2018 .....	6.25	10	<b>PSM</b>
Inj 5 mg per ml, 10 ml syringe			
Inj 5 mg per ml, 100 ml bag			
Inj 10 mg per ml, 100 ml bag			
Inj 10 mg per ml, 50 ml syringe			
Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017 .....	5.51	5	<b>DBL Pethidine Hydrochloride</b>
Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017 .....	5.83	5	<b>DBL Pethidine Hydrochloride</b>
<b>REMIFENTANIL HYDROCHLORIDE</b>			
Inj 1 mg vial – 1% DV Nov-14 to 2017 .....	10.00	5	<b>Ultiva</b>
Inj 2 mg vial – 1% DV Nov-14 to 2017 .....	18.00	5	<b>Ultiva</b>
<b>TRAMADOL HYDROCHLORIDE</b>			
Tab sustained-release 100 mg – 1% DV Oct-14 to 2017 .....	2.00	20	<b>Tramal SR 100</b>
Tab sustained-release 150 mg – 1% DV Oct-14 to 2017 .....	3.00	20	<b>Tramal SR 150</b>
Tab sustained-release 200 mg – 1% DV Oct-14 to 2017 .....	4.00	20	<b>Tramal SR 200</b>
Cap 50 mg – 1% DV Oct-14 to 2017 .....	2.50	100	<b>Arrow-Tramadol</b>
Oral drops 100 mg per ml			
Oral soln 10 mg per ml			
Inj 10 mg per ml, 100 ml bag			
Inj 50 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017 .....	4.50	5	<b>Tramal 50</b>
Inj 50 mg per ml, 2 ml ampoule – 1% DV Oct-14 to 2017 .....	4.50	5	<b>Tramal 100</b>
<i>(Any Oral drops 100 mg per ml to be delisted 1 July 2017)</i>			

## Antidepressants

### Cyclic and Related Agents

<b>AMITRIPTYLINE</b>			
Tab 10 mg – 1% DV Sep-14 to 2017 .....	1.68	100	<b>Arrow-Amitriptyline</b>
Tab 25 mg – 1% DV Jan-15 to 2017 .....	1.68	100	<b>Arrow-Amitriptyline</b>
Tab 50 mg – 1% DV Jan-15 to 2017 .....	2.82	100	<b>Arrow-Amitriptyline</b>
<b>CLOMIPRAMINE HYDROCHLORIDE</b>			
Tab 10 mg – 1% DV Sep-15 to 2018 .....	12.60	100	<b>Apo-Clomipramine</b>
Tab 25 mg – 1% DV Sep-15 to 2018 .....	8.68	100	<b>Apo-Clomipramine</b>
<b>DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE</b>			
Tab 75 mg .....	11.19	100	<b>Dopress</b>
Cap 25 mg .....	6.45	100	<b>Dopress</b>
<b>DOXEPIN HYDROCHLORIDE</b>			
Cap 10 mg			
Cap 25 mg			
Cap 50 mg			
<b>IMIPRAMINE HYDROCHLORIDE</b>			
Tab 10 mg .....	5.48	50	<b>Tofranil</b>
	6.58	60	<b>Tofranil</b>
Tab 25 mg .....	8.80	50	<b>Tofranil</b>
<b>MAPROTILINE HYDROCHLORIDE</b>			
Tab 25 mg			
Tab 75 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MIANSERIN HYDROCHLORIDE – <b>Restricted:</b> For continuation only			
➔ Tab 30 mg			
NORTRIPTYLINE HYDROCHLORIDE			
Tab 10 mg – 1% DV Sep-16 to 2019	3.22	100	<b>Norpress</b>
Tab 25 mg – 1% DV Sep-16 to 2019	7.08	180	<b>Norpress</b>

### Monoamine-Oxidase Inhibitors - Non-Selective

PHENELZINE SULPHATE			
Tab 15 mg			
TRANLYCYPROMINE SULPHATE			
Tab 10 mg			

### Monoamine-Oxidase Type A Inhibitors

MOCLOBEMIDE			
Tab 150 mg – 1% DV Oct-15 to 2018	85.10	500	<b>Apo-Moclobemide</b>
Tab 300 mg – 1% DV Oct-15 to 2018	30.70	100	<b>Apo-Moclobemide</b>

### Other Antidepressants

MIRTAZAPINE			
Tab 30 mg – 1% DV Nov-15 to 2018	2.55	30	<b>Apo-Mirtazapine</b>
Tab 45 mg – 1% DV Nov-15 to 2018	3.25	30	<b>Apo-Mirtazapine</b>
VENLAFAXINE – Some items restricted see terms <a href="#">below</a>			
Tab modified release 37.5 mg	5.06	28	Arrow-Venlafaxine XR
Tab modified release 75 mg	6.44	28	Arrow-Venlafaxine XR
Tab modified release 150 mg	8.86	28	Arrow-Venlafaxine XR
Tab modified release 225 mg	14.34	28	Arrow-Venlafaxine XR
Cap 37.5 mg – 1% DV Jun-17 to 2020	6.38	84	<b>Enlafax XR</b>
↓ Cap modified release 37.5 mg	5.69	28	Efexor XR
Cap 75 mg – 1% DV Jun-17 to 2020	8.11	84	<b>Enlafax XR</b>
↓ Cap modified release 75 mg	11.40	28	Efexor XR
Cap 150 mg – 1% DV Jun-17 to 2020	11.16	84	<b>Enlafax XR</b>
↓ Cap modified release 150 mg	13.98	28	Efexor XR

(Arrow-Venlafaxine XR Tab modified release 37.5 mg to be delisted 1 June 2017)

(Arrow-Venlafaxine XR Tab modified release 75 mg to be delisted 1 June 2017)

(Arrow-Venlafaxine XR Tab modified release 150 mg to be delisted 1 June 2017)

(Arrow-Venlafaxine XR Tab modified release 225 mg to be delisted 1 June 2017)

(Efexor XR Cap modified release 37.5 mg to be delisted 1 June 2017)

(Efexor XR Cap modified release 75 mg to be delisted 1 June 2017)

(Efexor XR Cap modified release 150 mg to be delisted 1 June 2017)

#### ➔ **Restricted**

#### Initiation

Re-assessment required after 2 years

Both:

- 1 The patient has 'treatment-resistant' depression; and
- 2 Either:

- 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## 2.2 Both:

2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and

2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

## Continuation

*Re-assessment required after 2 years*

The patient has a high risk of relapse (prescriber determined).

## Selective Serotonin Reuptake Inhibitors

### CITALOPRAM HYDROBROMIDE

Tab 20 mg – 1% DV Jan-16 to 2018 .....	1.79	84	<b>PSM Citalopram</b>
--	------	----	-----------------------

### ESCITALOPRAM

Tab 10 mg .....	1.40	28	Air Flow Products
Tab 20 mg .....	2.40	28	Air Flow Products

### FLUOXETINE HYDROCHLORIDE

Tab dispersible 20 mg, scored – 1% DV Oct-16 to 2019.....	2.47	30	<b>Arrow-Fluoxetine</b>
Cap 20 mg – 1% DV Oct-16 to 2019 .....	1.99	90	<b>Arrow-Fluoxetine</b>

### PAROXETINE

Tab 20 mg – 1% DV Apr-17 to 2019 .....	4.02	90	<b>Apo-Paroxetine</b>
--	------	----	-----------------------

### SERTRALINE

Tab 50 mg – 1% DV Sep-16 to 2019 .....	3.05	90	<b>Arrow-Sertraline</b>
Tab 100 mg – 1% DV Sep-16 to 2019 .....	5.25	90	<b>Arrow-Sertraline</b>

## Antiepilepsy Drugs

### Agents for the Control of Status Epilepticus

#### CLONAZEPAM

Inj 1 mg per ml, 1 ml ampoule .....	19.00	5	Rivotril
-------------------------------------	-------	---	----------

#### DIAZEPAM

Inj 5 mg per ml, 2 ml ampoule .....	11.83	5	Hospira
Rectal tubes 5 mg.....	33.07	5	Stesolid
Rectal tubes 10 mg.....	40.87	5	Stesolid

#### LORAZEPAM

Inj 2 mg vial			
Inj 4 mg per ml, 1 ml vial			

#### PARALDEHYDE

Inj 5 ml ampoule			
------------------	--	--	--

#### PHENYTOIN SODIUM

Inj 50 mg per ml, 2 ml ampoule – 1% DV Oct-15 to 2018 .....	88.63	5	<b>Hospira</b>
Inj 50 mg per ml, 5 ml ampoule – 1% DV Oct-15 to 2018 .....	133.92	5	<b>Hospira</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Control of Epilepsy</b>			
<b>CARBAMAZEPINE</b>			
Tab 200 mg .....	14.53	100	Tegretol
Tab long-acting 200 mg.....	16.98	100	Tegretol CR
Tab 400 mg .....	34.58	100	Tegretol
Tab long-acting 400 mg.....	39.17	100	Tegretol CR
Oral liq 20 mg per ml .....	26.37	250 ml	Tegretol
<b>CLOBAZAM</b>			
Tab 10 mg			
<b>CLONAZEPAM</b>			
Oral drops 2.5 mg per ml			
<b>ETHOSUXIMIDE</b>			
Cap 250 mg			
Oral liq 50 mg per ml			
<b>GABAPENTIN – Restricted see terms <a href="#">below</a></b>			
↓ Cap 100 mg .....	7.16	100	Arrow-Gabapentin Neurontin Nupentin
↓ Cap 300 mg .....	11.00	100	Arrow-Gabapentin Neurontin Nupentin
↓ Cap 400 mg .....	13.75	100	Arrow-Gabapentin Neurontin Nupentin
<b>→ Restricted</b>			
<b>Initiation – preoperative and/or postoperative use</b>			
<i>Limited to 8 days treatment</i>			
<b>Initiation – pain management of burns patients</b>			
<i>Re-assessment required after 1 month</i>			
<b>Continuation – pain management of burns patients</b>			
<i>Re-assessment required after 1 month</i>			
The treatment remains appropriate and the patient is benefiting from treatment.			
<b>Initiation – epilepsy</b>			
<i>Re-assessment required after 15 months</i>			
Either:			
1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or			
2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.			
Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.			
<b>Continuation – epilepsy</b>			
Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.			
Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective			
<b>Initiation – Neuropathic pain or Chronic Kidney Disease-associated pruritus</b>			
<i>Re-assessment required after 3 months</i>			
Either:			

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 The patient has been diagnosed with neuropathic pain; or
- 2 Both:
  - 2.1 The patient has Chronic Kidney Disease Stage 5-associated pruritus\* where no other cause for pruritus can be identified (e.g. scabies, allergy); and
  - 2.2 The patient has persistent pruritus not relieved with a trial of emollient/moisturising creams alone.

## Continuation – Neuropathic pain or Chronic Kidney Disease-associated pruritus

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain or itch (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Note: Indications marked with \* are Unapproved Indications. Dosage adjustment of gabapentin is recommended for patients with renal impairment.

## LACOSAMIDE – Restricted see terms [below](#)

⚡ Tab 50 mg .....	25.04	14	Vimpat
⚡ Tab 100 mg .....	50.06	14	Vimpat
	200.24	56	Vimpat
⚡ Tab 150 mg .....	75.10	14	Vimpat
	300.40	56	Vimpat
⚡ Tab 200 mg .....	400.55	56	Vimpat
⚡ Inj 10 mg per ml, 20 ml vial			

## ➡ Restricted

### Initiation

*Re-assessment required after 15 months*

Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

### Continuation

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>LAMOTRIGINE</b>			
Tab dispersible 2 mg .....	6.74	30	Lamictal
Tab dispersible 5 mg .....	15.00	56	Arrow-Lamotrigine
	9.64	30	Lamictal
Tab dispersible 25 mg .....	20.40	56	Arrow-Lamotrigine
	29.09		Lamictal
	19.38		Logem
	14.74		Motrig
Tab dispersible 50 mg .....	34.70	56	Arrow-Lamotrigine
	47.89		Lamictal
	32.97		Logem
	24.73		Motrig
Tab dispersible 100 mg .....	59.90	56	Arrow-Lamotrigine
	79.16		Lamictal
	56.91		Logem
	42.34		Motrig
<b>LEVETIRACETAM</b>			
Tab 250 mg .....	24.03	60	Everet
Tab 500 mg .....	28.71	60	Everet
Tab 750 mg .....	45.23	60	Everet
Tab 1,000 mg .....	59.12	60	Everet
Inj 100 mg per ml, 5 ml vial			
<b>PHENOBARBITONE</b>			
Tab 15 mg – 1% DV Dec-15 to 2018 .....	30.00	500	<b>PSM</b>
Tab 30 mg – 1% DV Dec-15 to 2018 .....	31.00	500	<b>PSM</b>
<b>PHENYTOIN</b>			
Tab 50 mg			
<b>PHENYTOIN SODIUM</b>			
Cap 30 mg			
Cap 100 mg			
Oral liq 6 mg per ml			
<b>PRIMIDONE</b>			
Tab 250 mg			
<b>SODIUM VALPROATE</b>			
Tab 100 mg			
Tab EC 200 mg			
Tab EC 500 mg			
Oral liq 40 mg per ml			
Inj 100 mg per ml, 4 ml vial – 1% DV Sep-15 to 2018 .....	16.60	1	<b>Epilim IV</b>
<b>STIRIPENTOL – Restricted</b> see terms <a href="#">below</a>			
↓ Cap 250 mg .....	509.29	60	Diacomit
↓ Powder for oral liq 250 mg sachet .....	509.29	60	Diacomit
<b>→ Restricted</b>			
<b>Initiation</b>			
Paediatric neurologist			
Re-assessment required after 6 months			
Both:			
1 Patient has confirmed diagnosis of Dravet syndrome; and			

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

## Continuation

Paediatric neurologist

Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

## TOPIRAMATE

Tab 25 mg .....	11.07	60	Arrow-Topiramate
	26.04		Topamax
	11.07		Topiramate Actavis
Tab 50 mg .....	18.81	60	Arrow-Topiramate
	44.26		Topamax
	18.81		Topiramate Actavis
Tab 100 mg .....	31.99	60	Arrow-Topiramate
	75.25		Topamax
	31.99		Topiramate Actavis
Tab 200 mg .....	55.19	60	Arrow-Topiramate
	129.85		Topamax
	55.19		Topiramate Actavis
Cap sprinkle 15 mg.....	20.84	60	Topamax
Cap sprinkle 25 mg.....	26.04	60	Topamax

VIGABATRIN – **Restricted** see terms [below](#)

↓ Tab 500 mg

➡ **Restricted**

## Initiation

*Re-assessment required after 15 months*

Both:

1 Either:

1.1 Patient has infantile spasms; or

1.2 Both:

1.2.1 Patient has epilepsy; and

1.2.2 Either:

1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or

1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:

2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or

2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

## Continuation

Both:

1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and

2 Either:

2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

## Antimigraine Preparations

### Acute Migraine Treatment

DIHYDROERGOTAMINE MESYLATE

Inj 1 mg per ml, 1 ml ampoule

ERGOTAMINE TARTRATE WITH CAFFEINE

Tab 1 mg with caffeine 100 mg

METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL

Tab 5 mg with paracetamol 500 mg

RIZATRIPTAN

Tab orodispersible 10 mg – 1% DV Sep-14 to 2017 ..... 8.10 30 **Rizamelt**

SUMATRIPTAN

Tab 50 mg – 1% DV Jun-17 to 2019 ..... 24.44 100 **Apo-Sumatriptan**

102 **Apo-Sumatriptan**

29.80 100 Arrow-Sumatriptan

Tab 100 mg – 1% DV Jun-17 to 2019 ..... 46.23 100 **Apo-Sumatriptan**

102 **Apo-Sumatriptan**

54.80 100 Arrow-Sumatriptan

Inj 12 mg per ml, 0.5 ml cartridge ..... 13.80 2 Arrow-Sumatriptan

Inj 12 mg per ml, 0.5 ml prefilled pen ..... 42.67 2 Clustran

(Arrow-Sumatriptan Tab 50 mg to be delisted 1 June 2017)

(Arrow-Sumatriptan Tab 100 mg to be delisted 1 June 2017)

(Arrow-Sumatriptan Inj 12 mg per ml, 0.5 ml cartridge to be delisted 1 July 2017)

### Prophylaxis of Migraine

PIZOTIFEN

Tab 500 mcg – 1% DV Sep-15 to 2018 ..... 23.21 100 **Sandomigran**

### Antinausea and Vertigo Agents

APREPITANT – **Restricted** see terms [below](#)

↓ Cap 2 × 80 mg and 1 × 125 mg – 1% DV Sep-14 to 2017 ..... 100.00 3 **Emend Tri-Pack**

↓ Cap 40 mg ..... 71.43 5 **Emend**

→ **Restricted**

#### Initiation

Patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

BETAHISTINE DIHYDROCHLORIDE

Tab 16 mg – 1% DV Jun-14 to 2017 ..... 4.95 84 **Vergo 16**

CYCLIZINE HYDROCHLORIDE

Tab 50 mg – 1% DV Jan-16 to 2018 ..... 0.59 20 **Nauzene**

CYCLIZINE LACTATE

Inj 50 mg per ml, 1 ml ampoule ..... 14.95 5 **Nausicalm**

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DOMPERIDONE</b>			
Tab 10 mg – 1% DV Dec-15 to 2018 .....	3.20	100	<b>Prokinex</b>
<b>DROPERIDOL</b>			
Inj 2.5 mg per ml, 1 ml ampoule			
<b>GRANISETRON</b>			
Tab 1 mg – 1% DV Jan-15 to 2017 .....	5.98	50	<b>Granirex</b>
<i>(Granirex Tab 1 mg to be delisted 1 October 2017)</i>			
<b>HYOSCINE HYDROBROMIDE</b>			
Inj 400 mcg per ml, 1 ml ampoule .....	46.50	5	Hospira
↓ Patch 1.5 mg	11.95	2	Scopoderm TTS
<b>➡ Restricted</b>			
<b>Initiation</b>			
Any of the following:			
1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or			
2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective; or			
3 For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT3 antagonist have proven ineffective, are not tolerated or are contraindicated.			
<b>METOCLOPRAMIDE HYDROCHLORIDE</b>			
Tab 10 mg – 1% DV Sep-14 to 2017 .....	1.82	100	<b>Metamide</b>
Oral liq 5 mg per 5 ml			
Inj 5 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017 .....	4.50	10	<b>Pfizer</b>
<b>ONDANSETRON</b>			
Tab 4 mg – 1% DV May-17 to 2019 .....	3.36	50	<b>Apo-Ondansetron</b>
Tab dispersible 4 mg – 1% DV Oct-14 to 2017 .....	1.00	10	<b>Dr Reddy's</b>
			<b>Ondansetron</b>
Tab 8 mg – 1% DV May-17 to 2019 .....	4.77	50	<b>Apo-Ondansetron</b>
Tab dispersible 8 mg – 1% DV Oct-14 to 2017 .....	1.50	10	<b>Ondansetron</b>
			<b>ODT-DRLA</b>
Inj 2 mg per ml, 2 ml ampoule – 1% DV Sep-16 to 2019 .....	1.50	5	<b>Ondansetron-Claris</b>
Inj 2 mg per ml, 4 ml ampoule – 1% DV Nov-16 to 2019 .....	2.20	5	<b>Ondansetron Kabi</b>
<b>PROCHLORPERAZINE</b>			
Tab buccal 3 mg			
Tab 5 mg – 1% DV Jun-14 to 2017 .....	9.75	500	<b>Antinaus</b>
Inj 12.5 mg per ml, 1 ml ampoule			
Suppos 25 mg			
<b>PROMETHAZINE THEOCLATE – Restricted:</b> For continuation only			
➡ Tab 25 mg			
<b>TROPISETRON</b>			
Inj 1 mg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018 .....	8.95	1	<b>Tropisetron-AFT</b>
Inj 1 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018 .....	13.95	1	<b>Tropisetron-AFT</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Antipsychotic Agents

### General

#### AMISULPRIDE

Tab 100 mg – 1% DV Nov-16 to 2019 .....	4.56	30	<b>Sulprix</b>
Tab 200 mg – 1% DV Nov-16 to 2019 .....	14.75	60	<b>Sulprix</b>
Tab 400 mg – 1% DV Nov-16 to 2019 .....	27.70	60	<b>Sulprix</b>
Oral liq 100 mg per ml – 1% DV Oct-16 to 2019 .....	65.53	60 ml	<b>Solian</b>

#### ARIPIPRAZOLE – **Restricted** see terms [below](#)

↓ Tab 5 mg .....	123.54	30	Abilify
↓ Tab 10 mg .....	123.54	30	Abilify
↓ Tab 15 mg .....	175.28	30	Abilify
↓ Tab 20 mg .....	213.42	30	Abilify
↓ Tab 30 mg .....	260.07	30	Abilify

#### → **Restricted**

#### Initiation – schizophrenia or related psychoses

Any specialist

Both:

- 1 Patient is suffering from schizophrenia or related psychoses; and
- 2 Either:
  - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effect; or
  - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

#### Initiation – Autism spectrum disorder\*

Psychiatrist or paediatrician

All of the following:

- 1 The patient has been diagnosed with an autism spectrum disorder\* and has symptoms of severe irritability; and
- 2 An effective dose of risperidone has been trialled and has been discontinued because of unacceptable side effects or inadequate response; and
- 3 The patient is aged less than 18 years.

Note: Indications marked with \* are Unapproved Indications

#### CHLORPROMAZINE HYDROCHLORIDE

Tab 10 mg  
Tab 25 mg  
Tab 100 mg  
Oral liq 10 mg per ml  
Oral liq 20 mg per ml  
Inj 25 mg per ml, 2 ml ampoule

## NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>CLOZAPINE</b>			
Tab 25 mg .....	6.69	50	Clopine
	13.37	100	Clopine
	5.69	50	Clozaril
	11.36	100	Clozaril
Tab 50 mg .....	8.67	50	Clopine
	17.33	100	Clopine
Tab 100 mg .....	17.33	50	Clopine
	34.65	100	Clopine
	14.73	50	Clozaril
	29.45	100	Clozaril
Tab 200 mg .....	34.65	50	Clopine
	69.30	100	Clopine
Oral liq 50 mg per ml .....	17.33	100 ml	Clopine
<b>HALOPERIDOL</b>			
Tab 500 mcg – 1% DV Oct-16 to 2019 .....	6.23	100	<b>Serenace</b>
Tab 1.5 mg – 1% DV Oct-16 to 2019 .....	9.43	100	<b>Serenace</b>
Tab 5 mg – 1% DV Oct-16 to 2019 .....	29.72	100	<b>Serenace</b>
Oral liq 2 mg per ml – 1% DV Oct-16 to 2019 .....	23.84	100 ml	<b>Serenace</b>
Inj 5 mg per ml, 1ml ampoule – 1% DV Oct-16 to 2019 .....	21.55	10	<b>Serenace</b>
<b>LEVOMEPRMAZINE</b>			
Tab 25 mg			
Tab 100 mg			
<b>LEVOMEPRMAZINE HYDROCHLORIDE</b>			
Inj 25 mg per ml, 1 ml ampoule – 1% DV Sep-16 to 2019 .....	47.89	10	<b>Wockhardt</b>
<b>LITHIUM CARBONATE</b>			
Tab long-acting 400 mg			
Tab 250 mg – 1% DV Sep-15 to 2018 .....	34.30	500	<b>Lithicarb FC</b>
Tab 400 mg – 1% DV Sep-15 to 2018 .....	12.83	100	<b>Lithicarb FC</b>
Cap 250 mg – 1% DV Sep-14 to 2017 .....	9.42	100	<b>Douglas</b>
<b>OLANZAPINE</b>			
Tab 2.5 mg – 1% DV Sep-14 to 2017 .....	0.75	28	<b>Zypine</b>
Tab 5 mg – 1% DV Sep-14 to 2017 .....	1.65	28	<b>Zypine</b>
Tab orodispersible 5 mg – 1% DV Sep-14 to 2017 .....	1.75	28	<b>Zypine ODT</b>
Tab 10 mg – 1% DV Sep-14 to 2017 .....	2.55	28	<b>Zypine</b>
Tab orodispersible 10 mg – 1% DV Sep-14 to 2017 .....	3.05	28	<b>Zypine ODT</b>
Inj 10 mg vial			
<b>PERICYAZINE</b>			
Tab 2.5 mg			
Tab 10 mg			
<b>QUETIAPINE</b>			
Tab 25 mg – 1% DV Sep-14 to 2017 .....	2.10	90	<b>Quetapel</b>
Tab 100 mg – 1% DV Sep-14 to 2017 .....	4.20	90	<b>Quetapel</b>
Tab 200 mg – 1% DV Sep-14 to 2017 .....	7.20	90	<b>Quetapel</b>
Tab 300 mg – 1% DV Sep-14 to 2017 .....	12.00	90	<b>Quetapel</b>

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>RISPERIDONE – Some items restricted see terms below</b>			
Tab 0.5 mg – <b>1% DV Feb-15 to 2017</b> .....	1.90	60	<b>Actavis</b>
⚡ Tab orodispersible 0.5 mg .....	21.42	28	Risperdal Quicklet
Tab 1 mg – <b>1% DV Feb-15 to 30 Sep 2017</b> .....	2.10	60	<b>Actavis</b>
⚡ Tab orodispersible 1 mg .....	42.84	28	Risperdal Quicklet
Tab 2 mg – <b>1% DV Feb-15 to 2017</b> .....	2.34	60	<b>Actavis</b>
⚡ Tab orodispersible 2 mg .....	85.71	28	Risperdal Quicklet
Tab 3 mg – <b>1% DV Feb-15 to 2017</b> .....	2.55	60	<b>Actavis</b>
Tab 4 mg – <b>1% DV Feb-15 to 2017</b> .....	3.50	60	<b>Actavis</b>
Oral liq 1 mg per ml – <b>1% DV Sep-14 to 2017</b> .....	9.75	30 ml	<b>Risperon</b>

*(Risperdal Quicklet Tab orodispersible 0.5 mg to be delisted 1 June 2017)*

*(Risperdal Quicklet Tab orodispersible 1 mg to be delisted 1 June 2017)*

*(Risperdal Quicklet Tab orodispersible 2 mg to be delisted 1 June 2017)*

#### ➡ **Restricted**

#### **Initiation – Acute situations**

Both:

- 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

#### **Initiation – Chronic situations**

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilised refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

#### **TRIFLUOPERAZINE HYDROCHLORIDE – Restricted:** For continuation only

➡ Tab 1 mg

➡ Tab 2 mg

➡ Tab 5 mg

*(Any Tab 1 mg to be delisted 1 December 2017)*

*(Any Tab 2 mg to be delisted 1 December 2017)*

*(Any Tab 5 mg to be delisted 1 December 2017)*

#### **ZIPRASIDONE**

Cap 20 mg – <b>1% DV Jan-16 to 2018</b> .....	14.56	60	<b>Zusdone</b>
Cap 40 mg – <b>1% DV Jan-16 to 2018</b> .....	24.75	60	<b>Zusdone</b>
Cap 60 mg – <b>1% DV Jan-16 to 2018</b> .....	33.87	60	<b>Zusdone</b>
Cap 80 mg – <b>1% DV Jan-16 to 2018</b> .....	39.74	60	<b>Zusdone</b>

#### **ZUCLOPENTHIXOL ACETATE**

Inj 50 mg per ml, 1 ml ampoule

Inj 50 mg per ml, 2 ml ampoule

#### **ZUCLOPENTHIXOL HYDROCHLORIDE**

Tab 10 mg .....	31.45	100	Clopixol
-----------------	-------	-----	----------

### Depot Injections

#### **FLUPENTHIXOL DECANOATE**

Inj 20 mg per ml, 1 ml ampoule .....	13.14	5	Fluanxol
Inj 20 mg per ml, 2 ml ampoule .....	20.90	5	Fluanxol
Inj 100 mg per ml, 1 ml ampoule .....	40.87	5	Fluanxol

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FLUPHENAZINE DECANOATE – Restricted:</b> For continuation only			
➔ Inj 12.5 mg per 0.5 ml ampoule .....	17.60	5	Modecate
➔ Inj 25 mg per ml, 1 ml ampoule .....	27.90	5	Modecate
➔ Inj 25 mg per ml, 2 ml ampoule .....			e.g. Modecate
➔ Inj 100 mg per ml, 1 ml ampoule .....	154.50	5	Modecate
<i>(Modecate Inj 12.5 mg per 0.5 ml ampoule to be delisted 1 December 2017)</i>			
<i>(Modecate Inj 25 mg per ml, 1 ml ampoule to be delisted 1 December 2017)</i>			
<i>(e.g. Modecate Inj 25 mg per ml, 2 ml ampoule to be delisted 1 December 2017)</i>			
<i>(Modecate Inj 100 mg per ml, 1 ml ampoule to be delisted 1 December 2017)</i>			

## HALOPERIDOL DECANOATE

Inj 50 mg per ml, 1 ml ampoule .....	28.39	5	Haldol
Inj 100 mg per ml, 1 ml ampoule .....	55.90	5	Haldol Concentrate

## OLANZAPINE – Restricted see terms [below](#)

⚡ Inj 210 mg vial .....	280.00	1	Zyprexa Relprevv
⚡ Inj 300 mg vial .....	460.00	1	Zyprexa Relprevv
⚡ Inj 405 mg vial .....	560.00	1	Zyprexa Relprevv

### ➔ Restricted

#### Initiation

*Re-assessment required after 12 months*

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
- 2 All of the following:
  - 2.1 The patient has schizophrenia; and
  - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
  - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

#### Continuation

*Re-assessment required after 12 months*

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

## PALIPERIDONE – Restricted see terms [below](#)

⚡ Inj 25 mg syringe .....	194.25	1	Invega Sustenna
⚡ Inj 50 mg syringe .....	271.95	1	Invega Sustenna
⚡ Inj 75 mg syringe .....	357.42	1	Invega Sustenna
⚡ Inj 100 mg syringe .....	435.12	1	Invega Sustenna
⚡ Inj 150 mg syringe .....	435.12	1	Invega Sustenna

### ➔ Restricted

#### Initiation

*Re-assessment required after 12 months*

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
  - 2.1 The patient has schizophrenia or other psychotic disorder; and
  - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
  - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

#### Continuation

*Re-assessment required after 12 months*

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PIPOTHIAZINE PALMITATE – Restricted:</b> For continuation only			
➔ Inj 50 mg per ml, 1 ml ampoule			
➔ Inj 50 mg per ml, 2 ml ampoule			
<b>RISPERIDONE – Restricted</b> see terms <a href="#">below</a>			
↓ Inj 25 mg vial .....	135.98	1	Risperdal Consta
↓ Inj 37.5 mg vial .....	178.71	1	Risperdal Consta
↓ Inj 50 mg vial .....	217.56	1	Risperdal Consta
➔ <b>Restricted</b>			
<b>Initiation</b>			
<i>Re-assessment required after 12 months</i>			
Either:			
1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or			
2 All of the following:			
2.1 The patient has schizophrenia or other psychotic disorder; and			
2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and			
2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.			
<b>Continuation</b>			
<i>Re-assessment required after 12 months</i>			
The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.			
<b>ZUCLOPENTHIXOL DECANOATE</b>			
Inj 200 mg per ml, 1 ml ampoule .....	19.80	5	Clopixol
Inj 500 mg per ml, 1 ml ampoule .....			e.g. <i>Clopixol Conc</i>
<b>Anxiolytics</b>			
<b>ALPRAZOLAM – Restricted:</b> For continuation only			
➔ Tab 1 mg			
➔ Tab 250 mcg			
➔ Tab 500 mcg			
<i>(Any Tab 1 mg to be delisted 1 September 2017)</i>			
<i>(Any Tab 250 mcg to be delisted 1 September 2017)</i>			
<i>(Any Tab 500 mcg to be delisted 1 September 2017)</i>			
<b>BUSPIRONE HYDROCHLORIDE</b>			
Tab 5 mg – <b>1% DV Jul-16 to 2018</b> .....	23.80	100	<b>Orion</b>
Tab 10 mg – <b>1% DV Jul-16 to 2018</b> .....	14.96	100	<b>Orion</b>
<b>CLONAZEPAM</b>			
Tab 500 mcg .....	7.53	100	Paxam
Tab 2 mg .....	14.37	100	Paxam
<b>DIAZEPAM</b>			
Tab 2 mg .....	11.44	500	Arrow-Diazepam
Tab 5 mg .....	13.71	500	Arrow-Diazepam
<b>LORAZEPAM</b>			
Tab 1 mg – <b>1% DV Jun-15 to 2018</b> .....	10.79	250	<b>Ativan</b>
Tab 2.5 mg – <b>1% DV Jun-15 to 2018</b> .....	13.88	100	<b>Ativan</b>
<b>OXAZEPAM</b>			
Tab 10 mg – <b>1% DV Dec-14 to 2017</b> .....	6.17	100	<b>Ox-Pam</b>
Tab 15 mg – <b>1% DV Dec-14 to 2017</b> .....	8.53	100	<b>Ox-Pam</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Multiple Sclerosis Treatments

DIMETHYL FUMARATE – **Restricted** see terms [below](#)

⚡ Cap 120 mg.....	520.00	14	Tecfidera
⚡ Cap 240 mg.....	2,000.00	56	Tecfidera

➡ **Restricted**

### Initiation

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

FINGOLIMOD – **Restricted** see terms [below](#)

⚡ Cap 0.5 mg.....	2,650.00	28	Gilenya
-------------------	----------	----	---------

➡ **Restricted**

### Initiation

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

NATALIZUMAB – **Restricted** see terms [below](#)

⚡ Inj 20 mg per ml, 15 ml vial.....	1,750.00	1	Tysabri
-------------------------------------	----------	---	---------

➡ **Restricted**

### Initiation

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

TERIFLUNOMIDE – **Restricted** see terms [below](#)

⚡ Tab 14 mg .....	1,582.62	28	Aubagio
-------------------	----------	----	---------

➡ **Restricted**

### Initiation

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

## Other Multiple Sclerosis Treatments

➡ **Restricted**

### Initiation

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

GLATIRAMER ACETATE – **Restricted** see terms [above](#)

⚡ Inj 20 mg per ml, 1 ml syringe

INTERFERON BETA-1-ALPHA – **Restricted** see terms [above](#)

⚡ Inj 6 million iu in 0.5 ml pen injector.....	1,170.00	4	Avonex Pen
⚡ Inj 6 million iu in 0.5 ml syringe.....	1,170.00	4	Avonex
⚡ Inj 6 million iu vial .....	1,170.00	4	Avonex

(Avonex Inj 6 million iu vial to be delisted 1 June 2017)

INTERFERON BETA-1-BETA – **Restricted** see terms [above](#)

⚡ Inj 8 million iu per ml, 1 ml vial

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

## Sedatives and Hypnotics

### CHLORAL HYDRATE

Oral liq 100 mg per ml

Oral liq 200 mg per ml

LORMETAZEPAM – **Restricted:** For continuation only

➔ Tab 1 mg

MELATONIN – **Restricted** see terms [below](#)

↓ Tab modified-release 2 mg

*e.g. Circadin*

↓ Tab 1 mg

↓ Tab 2 mg

↓ Tab 3 mg

↓ Cap 2 mg

↓ Cap 3 mg

➔ **Restricted**

### Initiation

For in hospital use only. For the treatment of insomnia where benzodiazepines and zopiclone are contraindicated.

### MIDAZOLAM

Tab 7.5 mg ..... 40.00 100 Hypnovel

Oral liq 2 mg per ml

Inj 1 mg per ml, 5 ml ampoule – **5% DV Dec-16 to 2018** ..... 4.30 10 **Midazolam-Claris**

Inj 5 mg per ml, 3 ml ampoule – **5% DV Dec-16 to 2018** ..... 2.50 5 **Midazolam-Claris**

### NITRAZEPAM

Tab 5 mg – **1% DV Dec-14 to 2017** ..... 5.22 100 **Nitrados**

### PHENOBARBITONE

Inj 200 mg per ml, 1 ml ampoule

### TEMAZEPAM

Tab 10 mg – **1% DV Sep-14 to 2017** ..... 1.27 25 **Normison**

TRIAZOLAM – **Restricted:** For continuation only

➔ Tab 125 mcg

➔ Tab 250 mcg

### ZOPICLONE

Tab 7.5 mg – **1% DV Dec-15 to 2018** ..... 0.98 30 **Zopiclone Actavis**

8.99 500 **Zopiclone Actavis**

## Stimulants / ADHD Treatments

ATOMOXETINE – **Restricted** see terms [below](#)

↓ Cap 10 mg ..... 107.03 28 **Strattera**

↓ Cap 18 mg ..... 107.03 28 **Strattera**

↓ Cap 25 mg ..... 107.03 28 **Strattera**

↓ Cap 40 mg ..... 107.03 28 **Strattera**

↓ Cap 60 mg ..... 107.03 28 **Strattera**

↓ Cap 80 mg ..... 139.11 28 **Strattera**

↓ Cap 100 mg ..... 139.11 28 **Strattera**

➔ **Restricted**

### Initiation

All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
  - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
  - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
  - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
  - 3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Note: A "subsidised formulation of a stimulant" refers to currently listed methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

## CAFFEINE

Tab 100 mg

DEXAMFETAMINE SULFATE – **Restricted** see terms [below](#)

⚡ Tab 5 mg – 1% DV Dec-15 to 2018 ..... 17.00 100 **PSM**

## ➡ **Restricted**

### **Initiation – ADHD**

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

### **Initiation – Narcolepsy**

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

Patient suffers from narcolepsy.

### **Continuation – Narcolepsy**

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

The treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE – **Restricted** see terms [on the next page](#)

⚡ Tab extended-release 18 mg.....	58.96	30	Concerta
⚡ Tab extended-release 27 mg.....	65.44	30	Concerta
⚡ Tab extended-release 36 mg.....	71.93	30	Concerta
⚡ Tab extended-release 54 mg.....	86.24	30	Concerta
⚡ Tab immediate-release 5 mg.....	3.20	30	Rubifen
⚡ Tab immediate-release 10 mg.....	3.00	30	Ritalin
			Rubifen
⚡ Tab immediate-release 20 mg.....	7.85	30	Rubifen
⚡ Tab sustained-release 20 mg.....	50.00	100	Ritalin SR
	10.95	30	Rubifen SR
⚡ Cap modified-release 10 mg.....	15.60	30	Ritalin LA
⚡ Cap modified-release 20 mg.....	20.40	30	Ritalin LA
⚡ Cap modified-release 30 mg.....	25.52	30	Ritalin LA
⚡ Cap modified-release 40 mg.....	30.60	30	Ritalin LA

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

### ➔ Restricted

#### Initiation – ADHD (immediate-release and sustained-release formulations)

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

#### Initiation – Narcolepsy (immediate-release and sustained-release formulations)

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

Patient suffers from narcolepsy.

#### Continuation – Narcolepsy (immediate-release and sustained-release formulations)

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

The treatment remains appropriate and the patient is benefiting from treatment.

#### Initiation – Extended-release and modified-release formulations

Paediatrician or psychiatrist

Both:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Either:
  - 2.1 Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
  - 2.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

MODAFINIL – **Restricted** see terms [below](#)

↓ Tab 100 mg

### ➔ Restricted

#### Initiation – Narcolepsy

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

All of the following:

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:
  - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
  - 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
- 3 Either:
  - 3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
  - 3.2 Methylphenidate and dexamphetamine are contraindicated.

#### Continuation – Narcolepsy

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

The treatment remains appropriate and the patient is benefiting from treatment.

## Treatments for Dementia

### DONEPEZIL HYDROCHLORIDE

Tab 5 mg – 1% DV Feb-15 to 2017 .....	5.48	90	Donepezil-Rex
Tab 10 mg – 1% DV Feb-15 to 2017 .....	10.51	90	Donepezil-Rex

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

RIVASTIGMINE – **Restricted** see terms [below](#)

↓ Patch 4.6 mg per 24 hour .....	90.00	30	Exelon
↓ Patch 9.5 mg per 24 hour .....	90.00	30	Exelon

→ **Restricted**

## Initiation

*Re-assessment required after 6 months*

Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

## Continuation

*Re-assessment required after 12 months*

Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

## Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE – **Restricted** see terms [below](#)

↓ Tab 2 mg with naloxone 0.5 mg .....	57.40	28	Suboxone
↓ Tab 8 mg with naloxone 2 mg .....	166.00	28	Suboxone

→ **Restricted**

## Initiation – Detoxification

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Prescriber works in an opioid treatment service approved by the Ministry of Health.

## Initiation – Maintenance treatment

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Prescriber works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg – <b>1% DV Jun-17 to 2020</b> .....	11.00	30	<b>Zyban</b>
---	-------	----	--------------

DISULFIRAM

Tab 200 mg .....	44.30	100	Antabuse
------------------	-------	-----	----------

NALTREXONE HYDROCHLORIDE – **Restricted** see terms [below](#)

↓ Tab 50 mg .....	131.00	30	Naltraccord
-------------------	--------	----	-------------

→ **Restricted**

## Initiation – Alcohol dependence

Both:

- 1 Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.

## Initiation – Constipation

For the treatment of opioid-induced constipation.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>NICOTINE – Some items restricted</b> see terms <a href="#">below</a>			
Patch 7 mg per 24 hours – <b>1% DV Apr-14 to 2017</b> .....	10.57	28	<b>Habitrol</b>
Patch 14 mg per 24 hours – <b>1% DV Apr-14 to 2017</b> .....	11.31	28	<b>Habitrol</b>
Patch 21 mg per 24 hours – <b>1% DV Apr-14 to 2017</b> .....	11.95	28	<b>Habitrol</b>
↓ Oral spray 1 mg per dose .....			<i>e.g. Nicorette QuickMist Mouth Spray</i>
Lozenge 1 mg – <b>1% DV Apr-14 to 2017</b> .....	12.91	216	<b>Habitrol</b>
Lozenge 2 mg – <b>1% DV Apr-14 to 2017</b> .....	14.14	216	<b>Habitrol</b>
↓ Soln for inhalation 15 mg cartridge .....			<i>e.g. Nicorette Inhalator</i>
Gum 2 mg – <b>1% DV Apr-14 to 2017</b> .....	22.26	384	<b>Habitrol (Fruit)</b>
			<b>Habitrol (Mint)</b>
Gum 4 mg – <b>1% DV Apr-14 to 2017</b> .....	25.67	384	<b>Habitrol (Fruit)</b>
			<b>Habitrol (Mint)</b>

### ➔ Restricted

#### Initiation

Any of the following:

- 1 For perioperative use in patients who have a 'nil by mouth' instruction; or
- 2 For use within mental health inpatient units; or
- 3 For acute use in agitated patients who are unable to leave the hospital facilities.

**VARENICLINE – Restricted** see terms [below](#)

↓ Tab 0.5 mg x 11 and 1 mg x 14 .....	60.48	25	Champix
↓ Tab 1 mg .....	67.74	28	Champix
	135.48	56	Champix

### ➔ Restricted

#### Initiation

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
  - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
  - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period.

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Chemotherapeutic Agents</b>			
<b>Alkylating Agents</b>			
BUSULFAN			
Tab 2 mg .....	89.25	100	Myleran
Inj 6 mg per ml, 10 ml ampoule			
CARMUSTINE			
Inj 100 mg vial – 1% DV Sep-15 to 2018 .....	532.00	1	BiCNU
CHLORAMBUCIL			
Tab 2 mg			
CYCLOPHOSPHAMIDE			
Tab 50 mg .....	79.00	50	Endoxan
	158.00	100	Procytox
Inj 1 g vial – 1% DV Oct-15 to 2018 .....	35.03	1	Endoxan
Inj 2 g vial – 1% DV Oct-15 to 2018 .....	70.06	1	Endoxan
IFOSFAMIDE			
Inj 1 g vial .....	96.00	1	Holoxan
Inj 2 g vial .....	180.00	1	Holoxan
LOMUSTINE			
Cap 10 mg .....	132.59	20	Ceenu
Cap 40 mg .....	399.15	20	Ceenu
MELPHALAN			
Tab 2 mg			
Inj 50 mg vial			
THIOTEPA			
Inj 15 mg vial			
Inj 100 mg vial			
<b>Anthracyclines and Other Cytotoxic Antibiotics</b>			
BLEOMYCIN SULPHATE			
Inj 15,000 iu vial – 1% DV Oct-15 to 2018 .....	150.48	1	DBL Bleomycin Sulfate
DACTINOMYCIN [ACTINOMYCIN D]			
Inj 0.5 mg vial .....	145.00	1	Cosmegen
DAUNORUBICIN			
Inj 2 mg per ml, 10 ml vial .....	118.72	1	Pfizer
DOXORUBICIN HYDROCHLORIDE			
Inj 2 mg per ml, 5 ml vial			
Inj 2 mg per ml, 25 ml vial – 1% DV Feb-16 to 2018 .....	11.50	1	Doxorubicin Ebewe
Note: DV limit applies to all 50 mg presentations of doxorubicin hydrochloride.			
Inj 50 mg vial			
Inj 2 mg per ml, 50 ml vial – 1% DV Feb-16 to 2018 .....	23.00	1	Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial – 1% DV Feb-16 to 2018 .....	46.00	1	Doxorubicin Ebewe
EPIRUBICIN HYDROCHLORIDE			
Inj 2 mg per ml, 5 ml vial .....	25.00	1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial – 1% DV Nov-15 to 2018 .....	30.00	1	Epirubicin Ebewe
Inj 2 mg per ml, 50 ml vial – 1% DV Nov-15 to 2018 .....	32.50	1	Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial – 1% DV Nov-15 to 2018 .....	65.00	1	Epirubicin Ebewe

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>IDARUBICIN HYDROCHLORIDE</b>			
Inj 5 mg vial – <b>1% DV Nov-15 to 2018</b> .....	125.00	1	<b>Zavedos</b>
Inj 10 mg vial – <b>1% DV Nov-15 to 2018</b> .....	250.00	1	<b>Zavedos</b>
<b>MITOMYCIN C</b>			
Inj 5 mg vial – <b>1% DV Oct-16 to 2019</b> .....	204.08	1	<b>Arrow</b>
<b>MITOZANTRONE</b>			
Inj 2 mg per ml, 10 ml vial – <b>1% DV Sep-15 to 2018</b> .....	97.50	1	<b>Mitozantrone Ebewe</b>
<b>Antimetabolites</b>			
<b>AZACITIDINE – Restricted</b> see terms <a href="#">below</a>			
↓ Inj 100 mg vial .....	605.00	1	Vidaza
<b>→ Restricted</b>			
<b>Initiation</b>			
Haematologist			
<i>Re-assessment required after 12 months</i>			
All of the following:			
1 Any of the following:			
1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or			
1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or			
1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and			
2 The patient has performance status (WHO/ECOG) grade 0-2; and			
3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and			
4 The patient has an estimated life expectancy of at least 3 months.			
<b>Continuation</b>			
Haematologist			
<i>Re-assessment required after 12 months</i>			
Both:			
1 No evidence of disease progression, and; and			
2 The treatment remains appropriate and patient is benefitting from treatment.			
<b>CAPECITABINE</b>			
Tab 150 mg – <b>1% DV Jan-17 to 2019</b> .....	11.15	60	<b>Brinov</b>
Tab 500 mg – <b>1% DV Jan-17 to 2019</b> .....	62.28	120	<b>Brinov</b>
<b>CLADRIBINE</b>			
Inj 2 mg per ml, 5 ml vial			
Inj 1 mg per ml, 10 ml vial.....	5,249.72	7	Leustatin
<b>CYTARABINE</b>			
Inj 20 mg per ml, 5 ml vial.....	55.00	5	Pfizer
Inj 100 mg per ml, 10 ml vial.....	8.83	1	Pfizer
Inj 100 mg per ml, 20 ml vial.....	17.65	1	Pfizer
<b>FLUDARABINE PHOSPHATE</b>			
Tab 10 mg – <b>1% DV Sep-15 to 2018</b> .....	412.00	20	<b>Fludara Oral</b>
Inj 50 mg vial – <b>1% DV Dec-16 to 2019</b> .....	525.00	5	<b>Fludarabine Ebewe</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FLUOROURACIL</b>			
Inj 50 mg per ml, 20 ml vial – <b>1% DV Oct-15 to 2018</b> .....	10.00	1	<b>Fluorouracil Ebewe</b>
Inj 50 mg per ml, 50 ml vial – <b>1% DV Oct-15 to 2018</b> .....	17.00	1	<b>Fluorouracil Ebewe</b>
Inj 50 mg per ml, 100 ml vial – <b>1% DV Oct-15 to 2018</b> .....	30.00	1	<b>Fluorouracil Ebewe</b>
<b>GEMCITABINE</b>			
Inj 10 mg per ml, 20 ml vial – <b>1% DV Oct-14 to 2017</b> .....	8.36	1	<b>Gemcitabine Ebewe</b>
Inj 10 mg per ml, 100 ml vial – <b>1% DV Oct-14 to 2017</b> .....	15.89	1	<b>Gemcitabine Ebewe</b>
<b>MERCAPTOPURINE</b>			
Tab 50 mg .....	49.41	25	Puri-nethol
<b>METHOTREXATE</b>			
Tab 2.5 mg – <b>1% DV Sep-15 to 2018</b> .....	3.18	30	<b>Trexate</b>
Tab 10 mg – <b>1% DV Sep-15 to 2018</b> .....	21.00	50	<b>Trexate</b>
Inj 2.5 mg per ml, 2 ml vial.....			
Inj 7.5 mg prefilled syringe.....	14.61	1	Methotrexate Sandoz
Inj 10 mg prefilled syringe.....	14.66	1	Methotrexate Sandoz
Inj 15 mg prefilled syringe.....	14.77	1	Methotrexate Sandoz
Inj 20 mg prefilled syringe.....	14.88	1	Methotrexate Sandoz
Inj 25 mg prefilled syringe.....	14.99	1	Methotrexate Sandoz
Inj 30 mg prefilled syringe.....	15.09	1	Methotrexate Sandoz
Inj 25 mg per ml, 2 ml vial – <b>1% DV Oct-16 to 2019</b> .....	30.00	5	<b>DBL Methotrexate Onco-Vial</b>
Inj 25 mg per ml, 20 ml vial – <b>1% DV Oct-16 to 2019</b> .....	45.00	1	<b>DBL Methotrexate Onco-Vial</b>
Inj 100 mg per ml, 10 ml vial.....	25.00	1	Methotrexate Ebewe
Inj 100 mg per ml, 50 ml vial – <b>1% DV Oct-14 to 2017</b> .....	99.99	1	<b>Methotrexate Ebewe</b>
<b>THIOGUANINE</b>			
Tab 40 mg			

## Other Cytotoxic Agents

<b>AMSACRINE</b>			
Inj 50 mg per ml, 1.5 ml ampoule			
Inj 75 mg			
<b>ANAGRELIDE HYDROCHLORIDE</b>			
Cap 0.5 mg			
<b>ARSENIC TRIOXIDE</b>			
Inj 1 mg per ml, 10 ml vial.....	4,817.00	10	AFT
<b>BORTEZOMIB – Restricted</b> see terms <a href="#">below</a>			
↓ Inj 3.5 mg vial – <b>1% DV Jul-16 to 2019</b> .....	1,892.50	1	<b>Velcade</b>
➡ <b>Restricted</b>			

### Initiation – treatment naive multiple myeloma/amyloidosis

Limited to 15 months treatment

Both:

1 Either:

- 1.1 The patient has treatment-naive symptomatic multiple myeloma; or
- 1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis; and

2 Maximum of 9 treatment cycles.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

**Initiation – relapsed/refractory multiple myeloma/amyloidosis**

*Re-assessment required after 8 months*

All of the following:

- 1 Either:
  - 1.1 The patient has relapsed or refractory multiple myeloma; or
  - 1.2 The patient has relapsed or refractory systemic AL amyloidosis; and
- 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
- 3 The patient has not had prior publicly funded treatment with bortezomib; and
- 4 Maximum of 4 treatment cycles.

**Continuation – relapsed/refractory multiple myeloma/amyloidosis**

*Re-assessment required after 8 months*

Both:

- 1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and
- 2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

- 1 A known therapeutic chemotherapy regimen and supportive treatments; or
- 2 A transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

**COLASPASE [L-ASPARAGINASE]**

Inj 10,000 iu vial.....	102.32	1	Leunase
-------------------------	--------	---	---------

**DACARBAZINE**

Inj 200 mg vial – <b>1% DV Oct-16 to 2019</b> .....	58.06	1	<b>DBL Dacarbazine</b>
---	-------	---	------------------------

**ETOPOSIDE**

Cap 50 mg.....	340.73	20	Vepesid
Cap 100 mg.....	340.73	10	Vepesid
Inj 20 mg per ml, 5 ml vial – <b>1% DV Apr-16 to 2018</b> .....	7.90	1	<b>Rex Medical</b>

**ETOPOSIDE (AS PHOSPHATE)**

Inj 100 mg vial .....	40.00	1	Etopophos
-----------------------	-------	---	-----------

**HYDROXYUREA**

Cap 500 mg.....	31.76	100	Hydrea
-----------------	-------	-----	--------

**IRINOTECAN HYDROCHLORIDE**

Inj 20 mg per ml, 2 ml vial – <b>1% DV Sep-15 to 2018</b> .....	11.50	1	<b>Irinotecan Actavis 40</b>
Inj 20 mg per ml, 5 ml vial – <b>1% DV Sep-15 to 2018</b> .....	17.80	1	<b>Irinotecan Actavis 100</b>

**LENALIDOMIDE – Restricted see terms [below](#)**

⚠ Cap 10 mg.....	6,207.00	21	Revlimid
⚠ Cap 25 mg.....	7,627.00	21	Revlimid

➡ **Restricted**

**Initiation**

Haematologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
- 2 Either:
  - 2.1 Lenalidomide to be used as third line\* treatment for multiple myeloma; or
  - 2.2 Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and

2.2.2 The patient has experienced severe (grade  $\geq 3$ ), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and

3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

## Continuation

Haematologist

*Re-assessment required after 6 months*

Both:

1 No evidence of disease progression; and

2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with \* is an Unapproved Indication (refer to Interpretations and Definitions). A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

PEGASPARGASE – **Restricted** see terms [below](#)

⚡ Inj 750 iu per ml, 5 ml vial	3,005.00	1	Oncaspar
--------------------------------	----------	---	----------

➔ **Restricted**

## Initiation – Newly diagnosed ALL

*Limited to 12 months treatment*

All of the following:

1 The patient has newly diagnosed acute lymphoblastic leukaemia; and

2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and

3 Treatment is with curative intent.

## Initiation – Relapsed ALL

*Limited to 12 months treatment*

All of the following:

1 The patient has relapsed acute lymphoblastic leukaemia; and

2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and

3 Treatment is with curative intent.

## PENTOSTATIN [DEOXYCOFORMYCIN]

Inj 10 mg vial

## PROCARBAZINE HYDROCHLORIDE

Cap 50 mg	498.00	50	Natulan
-----------	--------	----	---------

TEMOZOLOMIDE – **Restricted** see terms [below](#)

⚡ Cap 5 mg – 1% DV Feb-17 to 2019	10.20	5	Orion Temozolomide
⚡ Cap 20 mg – 1% DV Feb-17 to 2019	18.30	5	Orion Temozolomide
⚡ Cap 100 mg – 1% DV Feb-17 to 2019	40.20	5	Orion Temozolomide
⚡ Cap 250 mg – 1% DV Feb-17 to 2019	96.80	5	Orion Temozolomide

➔ **Restricted**

## Initiation – High grade gliomas

*Re-assessment required after 12 months*

All of the following:

1 Either:

1.1 Patient has newly diagnosed glioblastoma multiforme; or

1.2 Patient has newly diagnosed anaplastic astrocytoma\*; and

2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 3 Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m<sup>2</sup> per day.

## Initiation – Neuroendocrine tumours

*Re-assessment required after 9 months*

All of the following:

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour\*; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m<sup>2</sup> per day; and
- 4 Temozolomide to be discontinued at disease progression.

## Continuation – High grade gliomas

*Re-assessment required after 12 months*

Either:

- 1 Both:
  - 1.1 Patient has glioblastoma multiforme; and
  - 1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
- 2 All of the following:
  - 2.1 Patient has anaplastic astrocytoma\*; and
  - 2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
  - 2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

## Continuation – Neuroendocrine tumours

*Re-assessment required after 6 months*

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a \* is an Unapproved Indication. Temozolomide is not funded for the treatment of relapsed glioblastoma multiforme.

THALIDOMIDE – **Restricted** see terms [below](#)

↓ Cap 50 mg .....	378.00	28	Thalomid
↓ Cap 100 mg .....	756.00	28	Thalomid

➔ **Restricted**

## Initiation

*Re-assessment required after 12 months*

Any of the following:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis\*; or
- 3 The patient has erythema nodosum leprosum.

## Continuation

Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen

Indication marked with \* is an Unapproved Indication

## TRETINOIN

Cap 10 mg .....	479.50	100	Vesanoid
-----------------	--------	-----	----------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Platinum Compounds</b>			
<b>CARBOPLATIN</b>			
Inj 10 mg per ml, 5 ml vial – 1% DV Sep-15 to 2018 .....	15.07	1	<b>DBL Carboplatin</b>
Inj 10 mg per ml, 15 ml vial – 1% DV Sep-15 to 2018 .....	14.05	1	<b>DBL Carboplatin</b>
Inj 10 mg per ml, 45 ml vial – 1% DV Sep-15 to 2018 .....	32.59	1	<b>DBL Carboplatin</b>
<b>CISPLATIN</b>			
Inj 1 mg per ml, 50 ml vial – 1% DV Nov-15 to 2018 .....	12.29	1	<b>DBL Cisplatin</b>
Inj 1 mg per ml, 100 ml vial – 1% DV Nov-15 to 2018 .....	22.46	1	<b>DBL Cisplatin</b>
<b>OXALIPLATIN</b>			
Inj 5 mg per ml, 10 ml vial – 1% DV Jun-16 to 2018 .....	13.32	1	<b>Oxaliccord</b>
Inj 5 mg per ml, 20 ml vial – 1% DV Jun-16 to 2018 .....	16.00	1	<b>Oxaliccord</b>
<b>Protein-Tyrosine Kinase Inhibitors</b>			
<b>DASATINIB – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 20 mg .....	3,774.06	60	Sprycel
⚡ Tab 50 mg .....	6,214.20	60	Sprycel
⚡ Tab 70 mg .....	7,692.58	60	Sprycel
⚡ Tab 100 mg .....	6,214.20	30	Sprycel
<b>➡ Restricted</b>			
<b>Initiation</b>			
For use in patients with approval from the CML/GIST Co-ordinator.			
<b>ERLOTINIB – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 100 mg .....	764.00	30	Tarceva
⚡ Tab 150 mg .....	1,146.00	30	Tarceva
<b>➡ Restricted</b>			
<b>Initiation</b>			
<i>Re-assessment required after 4 months</i>			
All of the following:			
1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and			
2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and			
3 Either:			
3.1 Patient is treatment naive; or			
3.2 Both:			
3.2.1 The patient has discontinued gefitinib within 12 weeks of starting treatment due to intolerance; and			
3.2.2 The cancer did not progress while on gefitinib; and			
4 Erlotinib is to be given for a maximum of 3 months.			
<b>Continuation</b>			
<i>Re-assessment required after 6 months</i>			
Both:			
1 Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and			
2 Erlotinib is to be given for a maximum of 3 months.			
<b>GEFITINIB – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 250 mg .....	1,700.00	30	Iressa
<b>➡ Restricted</b>			
<b>Initiation</b>			
<i>Re-assessment required after 4 months</i>			
All of the following:			

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Either:
  - 2.1 Patient is treatment naive; or
  - 2.2 Both:
    - 2.2.1 The patient has discontinued erlotinib within 12 weeks of starting treatment due to intolerance; and
    - 2.2.2 The cancer did not progress whilst on erlotinib; and
- 3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
- 4 Gefitinib is to be given for a maximum of 3 months.

## Continuation

*Re-assessment required after 6 months*

Both:

- 1 Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
- 2 Gefitinib is to be given for a maximum of 3 months.

## IMATINIB MESILATE

Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule

↓ Tab 100 mg .....	2,400.00	60	Glivec
--------------------	----------	----	--------

→ **Restricted**

## Initiation

*Re-assessment required after 12 months*

Both:

- 1 Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Maximum dose of 400 mg/day.

## Continuation

*Re-assessment required after 12 months*

Adequate clinical response to treatment with imatinib (prescriber determined).

Note: The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

Cap 100 mg – <b>1% DV Jul-14 to 2017</b> .....	298.90	60	<b>Imatinib-AFT</b>
Cap 400 mg .....	597.80	30	Imatinib-AFT

## LAPATINIB – **Restricted** see terms [below](#)

↓ Tab 250 mg .....	1,899.00	70	Tykerb
--------------------	----------	----	--------

→ **Restricted**

## Initiation

*Re-assessment required after 12 months*

Either:

- 1 All of the following:
  - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
  - 1.3 Lapatinib not to be given in combination with trastuzumab; and
  - 1.4 Lapatinib to be discontinued at disease progression; or
- 2 All of the following:
  - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
- 2.3 The cancer did not progress whilst on trastuzumab; and
- 2.4 Lapatinib not to be given in combination with trastuzumab; and
- 2.5 Lapatinib to be discontinued at disease progression.

## Continuation

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
- 3 Lapatinib not to be given in combination with trastuzumab; and
- 4 Lapatinib to be discontinued at disease progression.

NILOTINIB – **Restricted** see terms [below](#)

⚡ Cap 150 mg .....	4,680.00	120	Tasigna
⚡ Cap 200 mg .....	6,532.00	120	Tasigna

## ➡ Restricted

### Initiation

Haematologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
- 2 Either:
  - 2.1 Patient has documented CML treatment failure\* with imatinib; or
  - 2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: \*treatment failure as defined by Leukaemia Net Guidelines.

## Continuation

Haematologist

*Re-assessment required after 6 months*

All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

PAZOPANIB – **Restricted** see terms [below](#)

⚡ Tab 200 mg .....	1,334.70	30	Votrient
⚡ Tab 400 mg .....	2,669.40	30	Votrient

## ➡ Restricted

### Initiation

*Re-assessment required after 3 months*

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
  - 2.1 The patient is treatment naive; or
  - 2.2 The patient has only received prior cytokine treatment; or

continued...



Price	Brand or
(ex man. excl. GST)	Generic
\$	Manufacturer
Per	

continued...

2.3 Both:

- 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
- 2.3.2 The cancer did not progress whilst on sunitinib; and

3 The patient has good performance status (WHO/ECOG grade 0-2); and

4 The disease is of predominant clear cell histology; and

5 All of the following:

- 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
- 5.2 Haemoglobin level < lower limit of normal; and
- 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
- 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
- 5.5 Karnofsky performance score of ≤ 70; and
- 5.6 ≥ 2 sites of organ metastasis.

**Continuation**

*Re-assessment required after 3 months*

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

SUNITINIB – **Restricted** see terms [below](#)

↓ Cap 12.5 mg .....	2,315.38	28	Sutent
↓ Cap 25 mg .....	4,630.77	28	Sutent
↓ Cap 50 mg .....	9,261.54	28	Sutent

→ **Restricted**

**Initiation – RCC**

*Re-assessment required after 3 months*

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
  - 2.1 The patient is treatment naive; or
  - 2.2 The patient has only received prior cytokine treatment; or
  - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
- 2.4 Both:
  - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
  - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 All of the following:
  - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
  - 5.2 Haemoglobin level < lower limit of normal; and
  - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
  - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
  - 5.5 Karnofsky performance score of ≤ 70; and
  - 5.6 ≥ 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Notes: RCC - Sunitinib treatment should be stopped if disease progresses.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

## Continuation – RCC

*Re-assessment required after 3 months*

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

## Initiation – GIST

*Re-assessment required after 3 months*

Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
  - 2.1 The patient's disease has progressed following treatment with imatinib; or
  - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

## Continuation – GIST

*Re-assessment required after 6 months*

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
  - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
  - 1.2 The patient has had a partial response (a decrease in size of  $\geq 10\%$  or decrease in tumour density in Hounsfield Units (HU) of  $\geq 15\%$  on CT and no new lesions and no obvious progression of non-measurable disease); or
  - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of  $\geq 10\%$  and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

## Taxanes

### DOCETAXEL

Inj 10 mg per ml, 2 ml vial – 1% DV Dec-14 to 2017 .....	13.70	1	DBL Docetaxel
Inj 10 mg per ml, 8 ml vial – 1% DV Dec-14 to 2017 .....	29.99	1	DBL Docetaxel

### PACLITAXEL

Inj 6 mg per ml, 5 ml vial – 1% DV Sep-14 to 2017 .....	45.00	5	Paclitaxel Ebewe
Inj 6 mg per ml, 16.7 ml vial – 1% DV Sep-14 to 2017 .....	19.02	1	Paclitaxel Ebewe
Inj 6 mg per ml, 25 ml vial – 1% DV Sep-14 to 2017 .....	26.69	1	Paclitaxel Ebewe
Inj 6 mg per ml, 50 ml vial – 1% DV Sep-14 to 2017 .....	36.53	1	Paclitaxel Ebewe
Inj 6 mg per ml, 100 ml vial – 1% DV Sep-14 to 2017 .....	73.06	1	Paclitaxel Ebewe

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Treatment of Cytotoxic-Induced Side Effects</b>			
<b>CALCIUM FOLINATE</b>			
Tab 15 mg .....	104.26	10	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 5 ml ampoule – 1% DV Oct-14 to 2017 .....	18.25	5	<b>Calcium Folate Ebewe</b>
Inj 10 mg per ml, 10 ml vial – 1% DV Oct-14 to 2017 .....	7.33	1	<b>Calcium Folate Ebewe</b>
Inj 10 mg per ml, 30 ml vial – 1% DV Oct-14 to 2017 .....	22.51	1	<b>Calcium Folate Ebewe</b>
Inj 10 mg per ml, 100 ml vial – 1% DV Oct-14 to 2017 .....	67.51	1	<b>Calcium Folate Ebewe</b>
<b>MESNA</b>			
Tab 400 mg – 1% DV Oct-16 to 2019 .....	273.00	50	<b>Uromitexan</b>
Tab 600 mg – 1% DV Oct-16 to 2019 .....	407.50	50	<b>Uromitexan</b>
Inj 100 mg per ml, 4 ml ampoule – 1% DV Oct-16 to 2019 .....	161.25	15	<b>Uromitexan</b>
Inj 100 mg per ml, 10 ml ampoule – 1% DV Oct-16 to 2019 .....	370.35	15	<b>Uromitexan</b>

### Vinca Alkaloids

<b>VINBLASTINE SULPHATE</b>			
Inj 1 mg per ml, 10 ml vial .....	186.46	5	Hospira
<b>VINCRIStINE SULPHATE</b>			
Inj 1 mg per ml, 1 ml vial – 1% DV Oct-16 to 2019 .....	74.52	5	<b>DBL Vincristine Sulfate</b>
Inj 1 mg per ml, 2 ml vial – 1% DV Oct-16 to 2019 .....	85.61	5	<b>DBL Vincristine Sulfate</b>
<b>VINORELBINE</b>			
Inj 10 mg per ml, 1 ml vial – 1% DV Sep-15 to 2018 .....	8.00	1	<b>Navelbine</b>
Inj 10 mg per ml, 5 ml vial – 1% DV Sep-15 to 2018 .....	40.00	1	<b>Navelbine</b>

### Endocrine Therapy

**ABIRATERONE ACETATE – Restricted** see terms [below](#)

↓ Tab 250 mg ..... 4,276.19 120 Zytiga

→ **Restricted**

#### Initiation

Medical oncologist, radiation oncologist or urologist

*Re-assessment required after 5 months*

All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:
  - 4.1 All of the following:
    - 4.1.1 Patient is symptomatic; and
    - 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
    - 4.1.3 Patient has ECOG performance score of 0-1; and
    - 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
  - 4.2 All of the following:
    - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

4.2.2 Patient has ECOG performance score of 0-2; and

4.2.3 Patient has not had prior treatment with abiraterone.

## Continuation

Medical oncologist, radiation oncologist or urologist

*Re-assessment required after 5 months*

All of the following:

- 1 Significant decrease in serum PSA from baseline; and
- 2 No evidence of clinical disease progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The treatment remains appropriate and the patient is benefiting from treatment.

## BICALUTAMIDE

Tab 50 mg – 1% DV Sep-14 to 2017 .....	4.90	28	<b>Bicalaccord</b>
--	------	----	--------------------

## FLUTAMIDE

Tab 250 mg .....	55.00	100	Flutamin
------------------	-------	-----	----------

## MEGESTROL ACETATE

Tab 160 mg – 1% DV Oct-15 to 2018 .....	54.30	30	<b>Apo-Megestrol</b>
---	-------	----	----------------------

## OCTREOTIDE – Some items restricted see terms [below](#)

Inj 50 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017 .....	13.50	5	<b>DBL</b>
Inj 100 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017 .....	22.40	5	<b>DBL</b>
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017 .....	89.40	5	<b>DBL</b>
⚡ Inj 10 mg vial .....	1,772.50	1	Sandostatin LAR
⚡ Inj 20 mg vial .....	2,358.75	1	Sandostatin LAR
⚡ Inj 30 mg vial .....	2,951.25	1	Sandostatin LAR

## ➡ Restricted

### Initiation – Malignant bowel obstruction

All of the following:

- 1 The patient has nausea\* and vomiting\* due to malignant bowel obstruction\*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with \* are Unapproved Indications

### Initiation – acromegaly

*Re-assessment required after 3 months*

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
  - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
  - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
  - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

### Continuation – acromegaly

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

#### Initiation – Other indications

Any of the following:

- 1 VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
  - 2.1 Gastrinoma; and
  - 2.2 Either:
    - 2.2.1 Patient has failed surgery; or
    - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
  - 3.1 Insulinomas; and
  - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
  - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
  - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: restriction applies only to the long-acting formulations of octreotide

#### TAMOXIFEN CITRATE

Tab 10 mg .....	17.50	100	Genox
Tab 20 mg .....	2.63	30	Genox
	8.75	100	Genox

### Aromatase Inhibitors

#### ANASTROZOLE

Tab 1 mg .....	26.55	30	Aremed DP-Anastrozole
----------------	-------	----	--------------------------

#### EXEMESTANE

Tab 25 mg – <b>1% DV Jul-16 to 2017</b> .....	14.50	30	<b>Pfizer Exemestane</b>
---	-------	----	--------------------------

#### LETROZOLE

Tab 2.5 mg – <b>1% DV Jan-16 to 2018</b> .....	2.95	30	<b>Letrole</b>
--	------	----	----------------

### Immunosuppressants

#### Calcineurin Inhibitors

#### CICLOSPORIN

Cap 25 mg .....	44.63	50	Neoral
Cap 50 mg .....	88.91	50	Neoral
Cap 100 mg .....	177.81	50	Neoral
Oral liq 100 mg per ml .....	198.13	50 ml	Neoral
Inj 50 mg per ml, 5 ml ampoule – <b>1% DV Sep-15 to 2018</b> .....	276.30	10	<b>Sandimmun</b>

#### TACROLIMUS – **Restricted** see terms [on the next page](#)

⚡ Cap 0.5 mg – <b>1% DV Nov-14 to 31 Oct 2018</b> .....	85.60	100	<b>Tacrolimus Sandoz</b>
⚡ Cap 1 mg – <b>1% DV Nov-14 to 31 Oct 2018</b> .....	171.20	100	<b>Tacrolimus Sandoz</b>
⚡ Cap 5 mg – <b>1% DV Nov-14 to 31 Oct 2018</b> .....	428.00	50	<b>Tacrolimus Sandoz</b>
⚡ Inj 5 mg per ml, 1 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## ➔ Restricted

### Initiation – organ transplant recipients

Any specialist

For use in organ transplant recipients.

### Initiation – Steroid-resistant nephrotic syndrome\*

Any specialist

Either:

- 1 The patient is a child with steroid-resistant nephrotic syndrome\* (SRNS) where ciclosporin has been trialled in combination with prednisone and discontinued because of unacceptable side effects or inadequate clinical response; or
- 2 All of the following:
  - 2.1 The patient is an adult with SRNS; and
  - 2.2 Ciclosporin has been trialled in combination with prednisone and discontinued because of unacceptable side effects or inadequate clinical response; and
  - 2.3 Cyclophosphamide or mycophenolate have been trialled and discontinued because of unacceptable side effects or inadequate clinical response, or these treatments are contraindicated.

Note: Indications marked with \* are Unapproved Indications

## Fusion Proteins

ETANERCEPT – **Restricted** see terms [below](#)

⚡ Inj 25 mg vial .....	799.96	4	Enbrel
⚡ Inj 50 mg autoinjector .....	1,599.96	4	Enbrel
⚡ Inj 50 mg syringe .....	1,599.96	4	Enbrel

## ➔ Restricted

### Initiation – juvenile idiopathic arthritis

Rheumatologist or named specialist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
    - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
- 2 All of the following:
  - 2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
  - 2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
  - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m<sup>2</sup> weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
  - 2.5 Both:
    - 2.5.1 Either:
      - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
      - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

continued...

	Price		Brand or
(ex man. excl. GST)			Generic
\$	Per		Manufacturer

continued...

2.5.2 Physician's global assessment indicating severe disease.

**Continuation – juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 6 months*

- Both:
- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2 Either:
    - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
    - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

**Initiation – rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 6 months*

- Either:
- 1 Both:
    - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
    - 1.2 Either:
      - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
  - 2 All of the following:
    - 2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
    - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
    - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
    - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
    - 2.5 Any of the following:
      - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
      - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
      - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
  - 2.6 Either:
    - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
    - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
  - 2.7 Either:
    - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
    - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation – rheumatoid arthritis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

## Initiation – ankylosing spondylitis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
    - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
  - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
  - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
  - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
  - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
  - 2.5 Either:
    - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
    - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
- 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.  
Average normal chest expansion corrected for age and gender:

continued...



Price	Brand or
(ex man. excl. GST)	Generic
\$	Manufacturer
Per	

continued...

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

### Continuation – ankylosing spondylitis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- Etanercept to be administered at doses no greater than 50 mg every 7 days.

### Initiation – psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- Both:
  - The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
  - Either:
    - The patient has experienced intolerable side effects from adalimumab; or
    - The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- All of the following:
  - Patient has had severe active psoriatic arthritis for six months duration or longer; and
  - Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
  - Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
  - Either:
    - Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
    - Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- Any of the following:
  - Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
  - ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

## Continuation – psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

## Initiation – plaque psoriasis, prior TNF use

Dermatologist

*Limited to 4 months treatment*

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from adalimumab; or
  - 2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and
- 3 Patient must be reassessed for continuation after 3 doses.

## Initiation – plaque psoriasis, treatment-naïve

Dermatologist

*Limited to 4 months treatment*

All of the following:

- 1 Either:
  - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
  - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

## Continuation – plaque psoriasis

Dermatologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 Both:
    - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 1.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or
- 1.2 Both:
  - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
  - 1.2.2 Either:
    - 1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
    - 1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

#### **Initiation – pyoderma gangrenosum**

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum\*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Indications marked with \* are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part V (Miscellaneous Provisions) rule 5.5).

#### **Continuation – pyoderma gangrenosum**

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses.

#### **Initiation – adult-onset Still's disease**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 Either:
    - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
    - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
    - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
  - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
  - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
  - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation – adult-onset Still's disease

Rheumatologist

*Re-assessment required after 6 months*

The patient has a sustained improvement in inflammatory markers and functional status.

## Monoclonal Antibodies

ABCIXIMAB – **Restricted** see terms [below](#)

⚡ Inj 2 mg per ml, 5 ml vial.....579.53 1 ReoPro

➡ **Restricted**

### Initiation

Either:

- 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
- 2 For use in patients undergoing intra-cranial intervention.

ADALIMUMAB – **Restricted** see terms [below](#)

⚡ Inj 10 mg per 0.2 ml prefilled syringe..... 1,599.96 2 Humira  
 ⚡ Inj 20 mg per 0.4 ml syringe ..... 1,599.96 2 Humira  
 ⚡ Inj 40 mg per 0.8 ml pen..... 1,599.96 2 HumiraPen  
 ⚡ Inj 40 mg per 0.8 ml syringe ..... 1,599.96 2 Humira

(Humira Inj 10 mg per 0.2 ml prefilled syringe to be delisted 1 August 2017)

➡ **Restricted**

### Initiation – juvenile idiopathic arthritis

Rheumatologist or named specialist

*Re-assessment required after 6 months*

Either:

- 1 Either:
  - 1.1 Both:
    - 1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
    - 1.1.2 Either:
      - 1.1.2.1 The patient has experienced intolerable side effects from etanercept; or
      - 1.1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or
  - 2 All of the following:
    - 2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
    - 2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
    - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
    - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m<sup>2</sup> weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
  - 2.5 Both:
    - 2.5.1 Either:
      - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
      - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
    - 2.5.2 Physician's global assessment indicating severe disease.

continued...

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

continued...

**Continuation – juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 6 months*

- Both:
- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2 Either:
    - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
    - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

**Initiation – fistulising Crohn's disease**

Gastroenterologist

*Re-assessment required after 4 months*

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
  - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
  - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 A Baseline Fistula Assessment (a copy of which is available at [www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf](http://www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf)) has been completed and is no more than 1 month old at the time of application.

**Continuation – fistulising Crohn's disease**

Gastroenterologist

*Re-assessment required after 6 months*

- Either:
- 1 The number of open draining fistulae have decreased from baseline by at least 50%; or
  - 2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

**Initiation – Crohn's disease**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
  - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
  - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
  - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
  - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

**Continuation – Crohn's disease**

Gastroenterologist

*Re-assessment required after 3 months*

- Both:
- 1 Either:

continued...

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
	Per	

continued...

- 1.1 Either:
  - 1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
  - 1.1.2 CDAI score is 150 or less; or
- 1.2 Both:
  - 1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
  - 1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

## Initiation – rheumatoid arthritis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
    - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
  - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
  - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
  - 2.5 Any of the following:
    - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
    - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
    - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
  - 2.6 Either:
    - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
    - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
  - 2.7 Either:
    - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
    - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

## Continuation – rheumatoid arthritis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

## Initiation – ankylosing spondylitis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
    - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
  - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
  - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
  - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
  - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
  - 2.5 Either:
    - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
    - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
  - 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation – ankylosing spondylitis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Following 12 weeks' initial treatment and subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

## Initiation – psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
    - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
  - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
  - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
  - 2.4 Either:
    - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
    - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
  - 2.5 Any of the following:
    - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
    - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
    - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

## Continuation – psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

continued...



Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

**Initiation – plaque psoriasis, prior TNF use**

Dermatologist

*Limited to 4 months treatment*

Both:

- 1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from etanercept; or
  - 2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis.

**Initiation – plaque psoriasis, treatment-naïve**

Dermatologist

*Limited to 4 months treatment*

All of the following:

- 1 Either:
  - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
  - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation – plaque psoriasis**

Dermatologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 Both:
    - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
    - 1.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
  - 1.2 Both:
    - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
    - 1.2.2 Either:
      - 1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
      - 1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline

continued...

Price	Brand or
(ex man. excl. GST)	Generic
\$	Manufacturer
Per	

continued...

value; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – pyoderma gangrenosum**

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum\*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Indications marked with \* are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part V (Miscellaneous Provisions) rule 5.5).

**Continuation – pyoderma gangrenosum**

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses.

**Initiation – adult-onset Still's disease**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 Either:
    - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
    - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
    - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
  - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
  - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
  - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Continuation – adult-onset Still's disease**

Rheumatologist

*Re-assessment required after 6 months*

The patient has a sustained improvement in inflammatory markers and functional status.

**BASILIXIMAB – Restricted** see terms [below](#)

⚡ Inj 20 mg vial .....3,200.00 1 Simulect

➡ **Restricted**

**Initiation**

For use in solid organ transplants.

**BEVACIZUMAB – Restricted** see terms [on the next page](#)

⚡ Inj 25 mg per ml, 4 ml vial

⚡ Inj 25 mg per ml, 16 ml vial

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

**Initiation**

Either:

- 1 Ocular neovascularisation; or
- 2 Exudative ocular angiopathy.

INFLIXIMAB – **Restricted** see terms [below](#)

↓ Inj 100 mg – **10% DV Mar-15 to 29 Feb 2020** ..... 806.00      1      **Remicade**

➔ **Restricted**

**Initiation – Graft vs host disease**

Patient has steroid-refractory acute graft vs. host disease of the gut.

**Initiation – rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 4 months*

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
  - 2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
- 3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

**Continuation – rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

**Initiation – ankylosing spondylitis**

Rheumatologist

*Re-assessment required after 3 months*

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
  - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

**Continuation – ankylosing spondylitis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and

continued...

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
	Per	

continued...

- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

## Initiation – psoriatic arthritis

Rheumatologist

*Re-assessment required after 4 months*

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
  - 2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis. .

## Continuation – psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

## Initiation – severe ocular inflammation

*Therapy limited to 3 doses*

Both:

- 1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
- 2 Either:
  - 2.1 Patient has failed to achieve control of severe vision-threatening ocular inflammation following high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids; or
  - 2.2 Patient developed new inflammatory symptoms while receiving high dose steroids.

## Initiation – chronic ocular inflammation

*Therapy limited to 3 doses*

Both:

- 1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2 Patient has tried at least two other immunomodulatory agents.

## Continuation – ocular inflammation

Both:

- 1 Patient had a good clinical response to initial treatment; and
- 2 Either:
  - 2.1 A withdrawal of infliximab has been trialed and patient has relapsed after trial withdrawal; or
  - 2.2 Patient has Behcet's disease.

## Initiation – Pulmonary sarcoidosis

Both:

- 1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
- 2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

continued...

Price	Brand or
(ex man. excl. GST)	Generic
\$	Manufacturer
Per	

continued...

**Initiation – Crohn's disease (adults)**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
  - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
  - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
  - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
  - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

**Continuation – Crohn's disease (adults)**

Gastroenterologist

*Re-assessment required after 6 months*

Both:

- 1 Any of the following:
  - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
  - 1.2 CDAI score is 150 or less; or
  - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

**Initiation – Crohn's disease (children)**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:
  - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
  - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

**Continuation – Crohn's disease (children)**

Gastroenterologist

*Re-assessment required after 6 months*

Both:

- 1 Any of the following:
  - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
  - 1.2 PCDAI score is 15 or less; or
  - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be

continued...

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
	Per	

continued...

considered sixteen weeks after completing the last re-induction cycle.

## Initiation – fistulising Crohn's disease

Gastroenterologist

*Re-assessment required after 4 months*

Both:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
  - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
  - 2.2 Patient has one or more rectovaginal fistula(e).

## Continuation – fistulising Crohn's disease

Gastroenterologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
  - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

## Initiation – acute severe fulminant ulcerative colitis

Gastroenterologist

*Limited to 6 weeks treatment*

Both:

- 1 Patient has acute, severe fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

## Continuation – severe fulminant ulcerative colitis

Gastroenterologist

*Re-assessment required after 6 months*

Both:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

## Initiation – severe ulcerative colitis

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

- 1 Patient has histologically confirmed ulcerative colitis; and
- 2 Either:
  - 2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is  $\geq 4$ ; or
  - 2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is  $\geq 65$ ; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

continued...

(ex man. excl. GST) \$	Price Per	Brand or Generic Manufacturer

continued...

**Continuation – severe ulcerative colitis**

Gastroenterologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
- 2 Either:
  - 2.1 Patient is 18 years or older and the SCCAI score has reduced by  $\geq 2$  points from the SCCAI score when the patient was initiated on infliximab; or
  - 2.2 Patient is under 18 years and the PUCAI score has reduced by  $\geq 30$  points from the PUCAI score when the patient was initiated on infliximab; and
- 3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

**Initiation – plaque psoriasis**

Dermatologist

*Re-assessment required after 3 doses*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
    - 1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
  - 2.1 Either:
    - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
    - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
  - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
  - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
  - 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation – plaque psoriasis**

Dermatologist

*Re-assessment required after 3 doses*

Both:

- 1 Either:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## 1.1 Both:

- 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
- 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or

## 1.2 Both:

- 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
- 1.2.2 Either:
  - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
  - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and

2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

OBINUTUZUMAB – **Restricted** see terms [below](#)

⚡ Inj 25 mg per ml, 40 ml vial.....5,910.00 1 Gazyva

➡ **Restricted**

### Initiation

Haematologist

Limited to 6 months treatment

All of the following:

- 1 The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is obinutuzumab treatment naive; and
- 3 The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
- 4 Patient has adequate neutrophil and platelet counts\* unless the cytopenias are a consequence of marrow infiltration by CLL; and
- 5 Patient has good performance status; and
- 6 Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

\*  $\geq 1.5 \times 10^9/L$  and platelets  $\geq 75 \times 10^9/L$

OMALIZUMAB – **Restricted** see terms [below](#)

⚡ Inj 150 mg vial .....500.00 1 Xolair

➡ **Restricted**

### Initiation

Respiratory specialist

Re-assessment required after 6 months

All of the following:

- 1 Patient is over the age of 6; and
- 2 Patient has a diagnosis of severe, life threatening asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and

continued...



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 5 Proven compliance with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or eformoterol 12 micrograms bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; and
- 7 At least four admissions to hospital for a severe asthma exacerbation over the previous 24 months with at least one of those being in the previous 12 months; and
- 8 An Asthma Control Questionnaire (ACQ-5) score of at least 3.0 as assessed in the previous month.

#### Continuation

Respiratory specialist

*Re-assessment required after 6 months*

All of the following:

- 1 Hospital admissions have been reduced as a result of treatment; and
- 2 A reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 1.0 from baseline; and
- 3 A reduction in the maintenance oral corticosteroid dose of at least 50% from baseline.

**PERTUZUMAB – Restricted** see terms [below](#)

↓ Inj 30 mg per ml, 14 ml vial.....3,927.00 1 Perjeta

➔ **Restricted**

#### Initiation

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
  - 2.1 Patient is chemotherapy treatment naive; or
  - 2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
- 3 The patient has good performance status (ECOG grade 0-1); and
- 4 Pertuzumab to be administered in combination with trastuzumab; and
- 5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
- 6 Pertuzumab to be discontinued at disease progression.

#### Continuation

*Re-assessment required after 12 months*

Both:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

**RANIBIZUMAB – Restricted** see terms [below](#)

↓ Inj 10 mg per ml, 0.23 ml vial

↓ Inj 10 mg per ml, 0.3 ml vial

➔ **Restricted**

#### Initiation

*Re-assessment required after 3 doses*

Both:

- 1 Either:
  - 1.1 Age-related macular degeneration; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1.2 Choroidal neovascular membrane; and
- 2 Any of the following:
  - 2.1 The patient has had a severe ophthalmic inflammatory response following bevacizumab; or
  - 2.2 The patient has had a myocardial infarction or stroke within the last three months; or
  - 2.3 The patient has failed to respond to bevacizumab following three intraocular injections; or
  - 2.4 The patient is of child-bearing potential and has not completed a family.

## Continuation

Both:

- 1 Documented benefit after three doses must be demonstrated to continue; and
- 2 In the case of but previous non-response to bevacizumab, a retreat of bevacizumab is required to confirm non-response before continuing with ranibizumab.

RITUXIMAB – **Restricted** see terms [below](#)

⚡ Inj 10 mg per ml, 10 ml vial.....	1,075.50	2	Mabthera
⚡ Inj 10 mg per ml, 50 ml vial.....	2,688.30	1	Mabthera

## ➡ Restricted

### Initiation – haemophilia with inhibitors

Haematologist

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

### Continuation – haemophilia with inhibitors

Haematologist

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

### Initiation – post-transplant

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder\*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with \* are Unapproved Indications.

### Continuation – post-transplant

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder\*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with \* are Unapproved Indications.

### Initiation – indolent, low-grade lymphomas or hairy cell leukaemia\*

*Re-assessment required after 9 months*

Either:

- 1 Both:
  - 1.1 The patient has indolent low grade NHL or hairy cell leukaemia\* with relapsed disease following prior chemotherapy; and
  - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
  - 2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia\* requiring first-line systemic chemotherapy;

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

and

2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. \*Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

**Continuation – indolent, low-grade lymphomas or hairy cell leukaemia\***

*Re-assessment required after 9 months*

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia\* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. \*Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

**Initiation – aggressive CD20 positive NHL**

Either:

- 1 All of the following:
  - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
  - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
  - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
  - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
  - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Continuation – aggressive CD20 positive NHL**

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Initiation – Chronic lymphocytic leukaemia**

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
  - 3.1 The patient is chemotherapy treatment naive; or
  - 3.2 Both:
    - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
    - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance  $\geq 30$  ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. \*Good performance

continued...

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
	Per	

continued...

status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

## **Continuation – Chronic lymphocytic leukaemia**

*Re-assessment required after 12 months*

All of the following:

- 1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
- 2 The patient has had a rituximab treatment-free interval of 36 months or more; and
- 3 The patient does not have chromosome 17p deletion CLL; and
- 4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration); and
- 5 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

## **Initiation – rheumatoid arthritis - prior TNF inhibitor use**

Rheumatologist

*Limited to 4 months treatment*

All of the following:

- 1 Both:
  - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
    - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
  - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

## **Initiation – rheumatoid arthritis - TNF inhibitors contraindicated**

Rheumatologist

*Limited to 4 months treatment*

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
  - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
  - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
  - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
- 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
  - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 Either:
  - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

**Continuation – rheumatoid arthritis - re-treatment in 'partial responders' to rituximab**

Rheumatologist

*Re-assessment required after 4 months*

All of the following:

- 1 Any of the following:
  - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
  - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

**Continuation – rheumatoid arthritis - re-treatment in 'responders' to rituximab**

Rheumatologist

*Re-assessment required after 4 months*

All of the following:

- 1 Either:
  - 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
  - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

**Initiation – severe cold haemagglutinin disease (CHAD)**

Haematologist

*Re-assessment required after 4 weeks*

Both:

continued...

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
	Per	

continued...

- 1 Patient has cold haemagglutinin disease\*; and
- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms.

Note: Indications marked with \* are Unapproved Indications.

## **Continuation – severe cold haemagglutinin disease (CHAD)**

Haematologist

*Re-assessment required after 4 weeks*

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m<sup>2</sup> weekly for 4 weeks) is now planned; or
- 2 All of the following:
  - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease\*; and
  - 2.2 An initial response lasting at least 12 months was demonstrated; and
  - 2.3 Patient now requires repeat treatment.

Note: Indications marked with \* are Unapproved Indications.

## **Initiation – warm autoimmune haemolytic anaemia (warm AIHA)**

Haematologist

*Re-assessment required after 4 weeks*

Both:

- 1 Patient has warm autoimmune haemolytic anaemia\*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin.

Note: Indications marked with \* are Unapproved Indications.

## **Continuation – warm autoimmune haemolytic anaemia (warm AIHA)**

Haematologist

*Re-assessment required after 4 weeks*

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m<sup>2</sup> weekly for 4 weeks) is now planned; or
- 2 All of the following:
  - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia\*; and
  - 2.2 An initial response lasting at least 12 months was demonstrated; and
  - 2.3 Patient now requires repeat treatment.

Note: Indications marked with \* are Unapproved Indications.

## **Initiation – immune thrombocytopenic purpura (ITP)**

Haematologist

*Re-assessment required after 4 weeks*

Both:

- 1 Either:
  - 1.1 Patient has immune thrombocytopenic purpura\* with a platelet count of ≤ 20,000 platelets per microlitre; or
  - 1.2 Patient has immune thrombocytopenic purpura\* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
- 2 Any of the following:
  - 2.1 Treatment with steroids and splenectomy have been ineffective; or
  - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
  - 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy).

continued...

	Price	Brand or
(ex man. excl. GST)	\$	Generic
	Per	Manufacturer

continued...

Note: Indications marked with \* are Unapproved Indications.

**Continuation – immune thrombocytopenic purpura (ITP)**

Haematologist

*Re-assessment required after 4 weeks*

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m<sup>2</sup> weekly for 4 weeks) is now planned; or
- 2 All of the following:
  - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura\*; and
  - 2.2 An initial response lasting at least 12 months was demonstrated; and
  - 2.3 Patient now requires repeat treatment.

Note: Indications marked with \* are Unapproved Indications.

**Initiation – thrombotic thrombocytopenic purpura (TTP)**

Haematologist

*Re-assessment required after 4 weeks*

Either:

- 1 Patient has thrombotic thrombocytopenic purpura\* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
- 2 Patient has acute idiopathic thrombotic thrombocytopenic purpura\* with neurological or cardiovascular pathology.

Note: Indications marked with \* are Unapproved Indications.

**Continuation – thrombotic thrombocytopenic purpura (TTP)**

Haematologist

*Re-assessment required after 4 weeks*

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura\*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Note: Indications marked with \* are Unapproved Indications.

**Initiation – pure red cell aplasia (PRCA)**

Haematologist

*Re-assessment required after 6 weeks*

Patient has autoimmune pure red cell aplasia\* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with \* are Unapproved Indications.

**Continuation – pure red cell aplasia (PRCA)**

Haematologist

*Re-assessment required after 6 weeks*

Patient was previously treated with rituximab for pure red cell aplasia\* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with \* are Unapproved Indications.

**Initiation – ANCA associated vasculitis**

*Re-assessment required after 4 weeks*

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis\*; and
- 2 The total rituximab dose would not exceed the equivalent of 375 mg/m<sup>2</sup> of body-surface area per week for a total of 4 weeks; and
- 3 Any of the following:
  - 3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or

continued...

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
	Per	

continued...

- 3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
- 3.3 Cyclophosphamide and methotrexate are contraindicated; or
- 3.4 Patient is a female of child-bearing potential; or
- 3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with \* are Unapproved Indications.

## **Continuation – ANCA associated vasculitis**

*Re-assessment required after 4 weeks*

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis\*;
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m<sup>2</sup> of body-surface area per week for a total of 4 weeks.

Note: Indications marked with \* are Unapproved Indications.

## **Initiation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE\*;
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with \* are Unapproved Indications.

## **Continuation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

- 1 Patient's SLE\* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with \* are Unapproved Indications.

## **Initiation – Antibody-mediated renal transplant rejection**

Nephrologist

Patient has been diagnosed with antibody-mediated renal transplant rejection\*.

Note: Indications marked with \* are Unapproved Indications.

## **Initiation – ABO-incompatible renal transplant**

Nephrologist

Patient is to undergo an ABO-incompatible renal transplant\*.

Note: Indications marked with \* are Unapproved Indications.

## **Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

- 1 Patient is a child with SDNS\* or FRNS\*;
- 2 Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
- 3 Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
- 4 Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and

continued...



Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 5 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with a \* are Unapproved indications.

**Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome\*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with a \* are Unapproved indications.

**Initiation – Steroid resistant nephrotic syndrome (SRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

- 1 Patient is a child with SRNS\* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
- 2 Treatment with tacrolimus for at least 3 months has been ineffective; and
- 3 Genetic causes of nephrotic syndrome have been excluded; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with a \* are Unapproved indications.

**Continuation – Steroid resistant nephrotic syndrome (SRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome\*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with a \* are Unapproved indications.

**SILTUXIMAB – Restricted** see terms [below](#)

↓ Inj 100 mg vial – <b>1% DV Jun-16 to 2018</b> .....	770.57	1	<b>Sylvant</b>
↓ Inj 400 mg vial – <b>1% DV Jun-16 to 2018</b> .....	3,082.33	1	<b>Sylvant</b>

➔ **Restricted**

**Initiation**

Haematologist or rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

**Continuation**

Haematologist or rheumatologist

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>TOCILIZUMAB – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 20 mg per ml, 4 ml vial.....	220.00	1	Actemra
⚡ Inj 20 mg per ml, 10 ml vial.....	550.00	1	Actemra
⚡ Inj 20 mg per ml, 20 ml vial.....	1,100.00	1	Actemra

## ➔ Restricted

### Initiation – Rheumatoid Arthritis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 All of the following:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
    - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
  - 1.3 Either:
    - 1.3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
    - 1.3.2 Both:
      - 1.3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and
      - 1.3.2.2 Either:
        - 1.3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
        - 1.3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
  - 2.2 Tocilizumab is to be used as monotherapy; and
  - 2.3 Either:
    - 2.3.1 Treatment with methotrexate is contraindicated; or
    - 2.3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
  - 2.4 Either:
    - 2.4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or
    - 2.4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
  - 2.5 Either:
    - 2.5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
    - 2.5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
  - 2.6 Either:
    - 2.6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
    - 2.6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued...

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

continued...

**Continuation – Rheumatoid Arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

**Initiation – systemic juvenile idiopathic arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

**Continuation – systemic juvenile idiopathic arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

**Initiation – adult-onset Still's disease**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 Either:
    - 1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
    - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
    - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
  - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
  - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
  - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Continuation – adult-onset Still's disease**

Rheumatologist

*Re-assessment required after 6 months*

The patient has a sustained improvement in inflammatory markers and functional status.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## **Initiation – polyarticular juvenile idiopathic arthritis**

Rheumatologist

*Re-assessment required after 4 months*

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for juvenile idiopathic arthritis (JIA); and
- 1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or

2 All of the following:

- 2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
- 2.2 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m<sup>2</sup> weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 2.4 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.5 Both:

2.5.1 Either:

- 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
- 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

## **Continuation – polyarticular juvenile idiopathic arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
  - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

## **Initiation – idiopathic multicentric Castleman's disease**

Haematologist or rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

## **Continuation – idiopathic multicentric Castleman's disease**

Haematologist or rheumatologist

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

**Initiation – cytokine release syndrome**

Paediatric haematologist or paediatric oncologist

*Therapy limited to 3 doses*

All of the following:

- 1 The patient is enrolled in the Children's Oncology Group AALL1331 trial; and
- 2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
- 3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

TRASTUZUMAB – **Restricted** see terms [below](#)

↓ Inj 150 mg vial .....	1,350.00	1	Herceptin
↓ Inj 440 mg vial .....	3,875.00	1	Herceptin

→ **Restricted**

**Initiation – Early breast cancer**

*Limited to 12 months treatment*

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
  - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
  - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
  - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
  - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
  - 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

**Initiation – metastatic breast cancer (trastuzumab-naïve patients)**

*Limited to 12 months treatment*

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
  - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
  - 2.2 Both:
    - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
    - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
  - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
  - 3.2 All of the following:
    - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
    - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
    - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

**Initiation – metastatic breast cancer (patients previously treated with trastuzumab)**

*Limited to 12 months treatment*

All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
  - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
  - 2.2 Both:
    - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
    - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
  - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
  - 3.2 All of the following:
    - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
    - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
    - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

## Continuation – metastatic breast cancer

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

## Programmed Cell Death-1 (PD-1) Inhibitors

**NIVOLUMAB – Restricted** see terms [below](#)

⚡ Inj 10 mg per ml, 4 ml vial.....	1,051.98	1	Opdivo
⚡ Inj 10 mg per ml, 10 ml vial.....	2,629.96	1	Opdivo

➡ **Restricted**

### Initiation

Medical oncologist

*Re-assessment required after 4 months*

All of the following:

- 1 Patient has metastatic or unresectable melanoma stage III or IV; and
- 2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and
- 3 Either:
  - 3.1 Patient has not received funded pembrolizumab; or
  - 3.2 Both:
    - 3.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
    - 3.2.2 The cancer did not progress while the patient was on pembrolizumab; and
- 4 Nivolumab is to be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles); and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

nivolumab will not be continued beyond 12 weeks (6 cycles) if their disease progresses during this time.

### Continuation

Medical oncologist

*Re-assessment required after 4 months*

All of the following:

- 1 Any of the following:
  - 1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
  - 1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
  - 1.3 Patient has stable disease according to RECIST criteria (see Note); and
- 2 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and
- 3 No evidence of progressive disease according to RECIST criteria (see Note); and
- 4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and
- 5 Nivolumab will be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles).

Notes: Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.

Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB – **Restricted** see terms [below](#)

↓ Inj 50 mg vial .....2,340.00 1 Keytruda

➔ **Restricted**

### Initiation

Medical oncologist

*Re-assessment required after 4 months*

All of the following:

- 1 Patient has metastatic or unresectable melanoma stage III or IV; and
- 2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and
- 3 Either:
  - 3.1 Patient has not received funded nivolumab; or
  - 3.2 Both:
    - 3.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
    - 3.2.2 The cancer did not progress while the patient was on nivolumab; and
- 4 Pembrolizumab is to be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles); and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of Pembrolizumab will not be continued beyond 12 weeks (4 cycles) if their disease progresses during this time.

## Continuation

Medical oncologist

*Re-assessment required after 4 months*

All of the following:

- 1 Any of the following:
  - 1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
  - 1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
  - 1.3 Patient has stable disease according to RECIST criteria (see Note); and
- 2 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and
- 3 No evidence of progressive disease according to RECIST criteria (see Note); and
- 4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and
- 5 Pembrolizumab will be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles).

Notes: Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.

Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

## Other Immunosuppressants

### ANTITHYMOCYTE GLOBULIN (EQUINE)

Inj 50 mg per ml, 5 ml ampoule .....	2,351.25	5	ATGAM
--------------------------------------	----------	---	-------

### ANTITHYMOCYTE GLOBULIN (RABBIT)

Inj 25 mg vial

### AZATHIOPRINE

Tab 25 mg – 1% DV Jul-17 to 2019 .....	8.28	60	Azamun
	9.66	100	Imuran
Tab 50 mg – 1% DV Jul-17 to 2019 .....	13.22	100	Azamun
	10.58		Imuran
Inj 50 mg vial – 1% DV Jan-17 to 2019 .....	60.00	1	Imuran

(Azamun Tab 25 mg to be delisted 1 July 2017)

(Azamun Tab 50 mg to be delisted 1 July 2017)



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>BACILLUS CALMETTE-GUERIN (BCG) – Restricted</b> see terms <a href="#">below</a>			
↓ Inj 2-8 x 10 <sup>8</sup> CFU vial .....	149.37	1	OncoTICE
➔ <b>Restricted</b>			
<b>Initiation</b>			
For use in bladder cancer.			
<b>EVEROLIMUS – Restricted</b> see terms <a href="#">below</a>			
↓ Tab 5 mg .....	4,555.76	30	Afinitor
↓ Tab 10 mg .....	6,512.29	30	Afinitor
➔ <b>Restricted</b>			
<b>Initiation</b>			
Neurologist or oncologist			
<i>Re-assessment required after 3 months</i>			
Both:			
1 Patient has tuberous sclerosis; and			
2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.			
<b>Continuation</b>			
Neurologist or oncologist			
<i>Re-assessment required after 12 months</i>			
All of the following:			
1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and			
2 The treatment remains appropriate and the patient is benefiting from treatment; and			
3 Everolimus to be discontinued at progression of SEGAs.			
Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.			
<b>MYCOPHENOLATE MOFETIL</b>			
Tab 500 mg .....	25.00	50	CellCept
Cap 250 mg .....	25.00	100	CellCept
Powder for oral liq 1 g per 5 mL .....	187.25	165 mL	CellCept
Inj 500 mg vial .....	133.33	4	CellCept
<b>PICIBANIL</b>			
Inj 100 mg vial			
<b>SIROLIMUS – Restricted</b> see terms <a href="#">below</a>			
↓ Tab 1 mg .....	749.99	100	Rapamune
↓ Tab 2 mg .....	1,499.99	100	Rapamune
↓ Oral liq 1 mg per mL .....	449.99	60 mL	Rapamune
➔ <b>Restricted</b>			
<b>Initiation</b>			
For rescue therapy for an organ transplant recipient.			
Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:			
<ul style="list-style-type: none"> <li>• GFR &lt; 30 mL/min; or</li> <li>• Rapidly progressive transplant vasculopathy; or</li> <li>• Rapidly progressive obstructive bronchiolitis; or</li> <li>• HUS or TTP; or</li> <li>• Leukoencephalopathy; or</li> <li>• Significant malignant disease</li> </ul>			

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Antiallergy Preparations

Allergic Emergencies

ICATIBANT – **Restricted** see terms [below](#)

⚡ Inj 10 mg per ml, 3 ml prefilled syringe .....2,668.00 1 Firazyr

➡ **Restricted**

Initiation

Clinical immunologist or relevant specialist

*Re-assessment required after 12 months*

Both:

- 1 Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
- 2 The patient has undergone product training and has agreed upon an action plan for self-administration.

Continuation

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient is benefiting from treatment.

Allergy Desensitisation

BEE VENOM – **Restricted** see terms [below](#)

⚡ Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent

⚡ Inj 550 mcg vial with diluent

➡ **Restricted**

Initiation

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

PAPER WASP VENOM – **Restricted** see terms [below](#)

⚡ Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent

⚡ Inj 550 mcg vial with diluent

➡ **Restricted**

Initiation

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

YELLOW JACKET WASP VENOM – **Restricted** see terms [below](#)

⚡ Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent

⚡ Inj 550 mcg vial with diluent

➡ **Restricted**

Initiation

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

Allergy Prophylactics

BECLOMETHASONE DIPROPIONATE

Nasal spray 50 mcg per dose .....5.26 200 dose Alanase

Nasal spray 100 mcg per dose .....6.00 200 dose Alanase

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>BUDESONIDE</b>			
Nasal spray 50 mcg per dose .....	5.26	200 dose	Butacort Aqueous
Nasal spray 100 mcg per dose .....	6.00	200 dose	Butacort Aqueous
<b>FLUTICASONE PROPIONATE</b>			
Nasal spray 50 mcg per dose – <b>1% DV Sep-15 to 2018</b> .....	2.18	120 dose	<b>Flixonase Hayfever &amp; Allergy</b>
<b>IPRATROPIUM BROMIDE</b>			
Aqueous nasal spray 0.03% – <b>1% DV Jan-15 to 2017</b> .....	3.95	15 ml	<b>Univent</b>
<b>SODIUM CROMOGLYCATE</b>			
Nasal spray 4%			

### Antihistamines

<b>CETIRIZINE HYDROCHLORIDE</b>			
Tab 10 mg – <b>1% DV Mar-17 to 2019</b> .....	1.01	100	<b>Zista</b>
Oral liq 1 mg per ml – <b>1% DV Feb-15 to 2017</b> .....	2.99	200 ml	<b>Histaclear</b>
<b>CHLORPHENIRAMINE MALEATE</b>			
Oral liq 0.4 mg per ml			
Inj 10 mg per ml, 1 ml ampoule			
<b>CYPROHEPTADINE HYDROCHLORIDE</b>			
Tab 4 mg			
<b>FEXOFENADINE HYDROCHLORIDE</b>			
Tab 60 mg			
Tab 120 mg			
Tab 180 mg			
<b>LORATADINE</b>			
Tab 10 mg – <b>1% DV Sep-16 to 2019</b> .....	1.28	100	<b>Lorafix</b>
Oral liq 1 mg per ml – <b>1% DV Feb-17 to 2019</b> .....	2.15	120 ml	<b>Lorfast</b>
<b>PROMETHAZINE HYDROCHLORIDE</b>			
Tab 10 mg – <b>1% DV Sep-15 to 2018</b> .....	1.78	50	<b>Allersoothe</b>
Tab 25 mg – <b>1% DV Sep-15 to 2018</b> .....	1.99	50	<b>Allersoothe</b>
Oral liq 1 mg per ml – <b>1% DV Sep-15 to 2018</b> .....	2.59	100 ml	<b>Allersoothe</b>
Inj 25 mg per ml, 2 ml ampoule – <b>1% DV Oct-16 to 2019</b> .....	15.54	5	<b>Hospira</b>
<b>TRIMEPRAZINE TARTRATE</b>			
Oral liq 6 mg per ml			

### Anticholinergic Agents

<b>IPRATROPIUM BROMIDE</b>			
Aerosol inhaler 20 mcg per dose			
Nebuliser soln 250 mcg per ml, 1 ml ampoule – <b>1% DV Dec-16 to 2019</b> .....	3.35	20	<b>Univent</b>
Nebuliser soln 250 mcg per ml, 2 ml ampoule – <b>1% DV Dec-16 to 2019</b> .....	3.52	20	<b>Univent</b>

### Anticholinergic Agents with Beta-Adrenoceptor Agonists

<b>SALBUTAMOL WITH IPRATROPIUM BROMIDE</b>			
Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose			
Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – <b>1% DV Sep-15 to 2018</b> .....	3.59	20	<b>Duolin</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Long-Acting Muscarinic Agents

### GLYCOPYRRONIUM

Note: inhaled glycopyrronium treatment must not be used if the patient is also receiving treatment with subsidised tiotropium or umeclidinium.

Powder for inhalation 50 mcg per dose ..... 61.00      30 dose      Seebri Breezhaler

### TIOTROPIUM BROMIDE – **Restricted** see terms [below](#)

Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.

† Soln for inhalation 2.5 mcg per dose ..... 50.37      60 dose      Spiriva Respimat

† Powder for inhalation 18 mcg per dose ..... 50.37      30 dose      Spiriva

### ➔ **Restricted**

#### Initiation

All of the following:

- 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
- 2 In addition to standard treatment, the patient has trialed a short acting bronchodilator dose of at least 40 µg ipratropium q.i.d for one month; and
- 3 Either:
  - the patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:
    - 3.1 Grade 3 (stops for breath after walking about 100 meters or after a few minutes on the level); or
    - 3.2 Grade 4 (too breathless to leave the house, or breathless when dressing or undressing); and
- 4 Actual FEV<sub>1</sub> as a % of predicted, must be below 60%; and
- 5 Either:
  - 5.1 Patient is not a smoker (for reporting purposes only); or
  - 5.2 Patient is a smoker and has been offered smoking cessation counselling; and
- 6 The patient has been offered annual influenza immunization.

### UMECLIDINIUM

Note: Umeclidinium must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.

Powder for inhalation 62.5 mcg per dose ..... 61.50      30 dose      Incruse Ellipta

## Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

### ➔ **Restricted**

#### Initiation

*Re-assessment required after 2 years*

- Both:
- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
  - 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

#### Continuation

*Re-assessment required after 2 years*

- Both:
- 1 Patient is compliant with the medication; and
  - 2 Patient has experienced improved COPD symptom control (prescriber determined).

Note: Combination long acting muscarinic antagonist and long acting beta-2 agonist must not be used if the patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

### GLYCOPYRRONIUM WITH INDACATEROL – **Restricted** see terms [above](#)

† Powder for Inhalation 50 mcg with indacaterol 110 mcg ..... 81.00      30 dose      Ultibro Breezhaler

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>TIOTROPIUM BROMIDE WITH OLODATEROL – Restricted</b> see terms <a href="#">on the previous page</a>			
† Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg .....	81.00	60 dose	Spolto Respirat
<b>UMECLIDINIUM WITH VILANTEROL – Restricted</b> see terms <a href="#">on the previous page</a>			
† Powder for inhalation 62.5 mcg with vilanterol 25 mcg .....	77.00	30 dose	Anoro Ellipta

## Antifibrotics

**PIRFENIDONE – Restricted** see terms [below](#)

↓ Cap 267 mg ..... 3,645.00 270 Esbriet

### → Restricted

#### Initiation

Respiratory specialist

*Re-assessment required after 12 months*

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis as confirmed by histology, CT or biopsy; and
- 2 Forced vital capacity is between 50% and 80% predicted; and
- 3 Pirfenidone is to be discontinued at disease progression (See Notes).

#### Continuation

Respiratory specialist

*Re-assessment required after 12 months*

Both:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Pirfenidone is to be discontinued at disease progression (See Notes).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

## Beta-Adrenoceptor Agonists

### SALBUTAMOL

Oral liq 400 mcg per ml .....	2.06	150 ml	Ventolin
Inj 500 mcg per ml, 1 ml ampoule			
Inj 1 mg per ml, 5 ml ampoule			
Aerosol inhaler, 100 mcg per dose .....	3.80	200 dose	SalAir
	6.00		Ventolin
Nebuliser soln 1 mg per ml, 2.5 ml ampoule – <b>1% DV Sep-15 to 2018</b> .....	3.19	20	<b>Asthalin</b>
Nebuliser soln 2 mg per ml, 2.5 ml ampoule – <b>1% DV Sep-15 to 2018</b> .....	3.29	20	<b>Asthalin</b>

### TERBUTALINE SULPHATE

Powder for inhalation 250 mcg per dose  
Inj 0.5 mg per ml, 1 ml ampoule

## Cough Suppressants

### PHOLCODINE

Oral liq 1 mg per ml

## Decongestants

### OXYMETAZOLINE HYDROCHLORIDE

Aqueous nasal spray 0.25 mg per ml  
Aqueous nasal spray 0.5 mg per ml

### PSEUDOEPHEDRINE HYDROCHLORIDE

Tab 60 mg

## RESPIRATORY SYSTEM AND ALLERGIES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>SODIUM CHLORIDE</b>			
Aqueous nasal spray isotonic			
<b>SODIUM CHLORIDE WITH SODIUM BICARBONATE</b>			
Soln for nasal irrigation			
<b>XYLOMETAZOLINE HYDROCHLORIDE</b>			
Aqueous nasal spray 0.05%			
Aqueous nasal spray 0.1%			
Nasal drops 0.05%			
Nasal drops 0.1%			

### Inhaled Corticosteroids

<b>BECLOMETHASONE DIPROPIONATE</b>			
Aerosol inhaler 50 mcg per dose.....	8.54	200 dose	Beclazone 50
	9.30		Qvar
Aerosol inhaler 100 mcg per dose.....	12.50	200 dose	Beclazone 100
	15.50		Qvar
Aerosol inhaler 250 mcg per dose.....	22.67	200 dose	Beclazone 250
<b>BUDESONIDE</b>			
Nebuliser soln 250 mcg per ml, 2 ml ampoule			
Nebuliser soln 500 mcg per ml, 2 ml ampoule			
Powder for inhalation 100 mcg per dose			
Powder for inhalation 200 mcg per dose			
Powder for inhalation 400 mcg per dose			
<b>FLUTICASONE</b>			
Aerosol inhaler 50 mcg per dose.....	7.50	120 dose	Flixotide
			Floair
Powder for inhalation 50 mcg per dose.....	8.67	60 dose	Flixotide Accuhaler
Powder for inhalation 100 mcg per dose.....	13.87	60 dose	Flixotide Accuhaler
Aerosol inhaler 125 mcg per dose.....	13.60	120 dose	Flixotide
			Floair
Aerosol inhaler 250 mcg per dose.....	27.20	120 dose	Flixotide
			Floair
Powder for inhalation 250 mcg per dose.....	24.51	60 dose	Flixotide Accuhaler

### Leukotriene Receptor Antagonists

<b>MONTELUKAST – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 4 mg – 1% DV Jan-17 to 2019 .....	5.25	28	<b>Apo-Montelukast</b>
⚡ Tab 5 mg – 1% DV Jan-17 to 2019 .....	5.50	28	<b>Apo-Montelukast</b>
⚡ Tab 10 mg – 1% DV Jan-17 to 2019 .....	5.65	28	<b>Apo-Montelukast</b>

➡ **Restricted**

#### Initiation – Pre-school wheeze

Both:

- 1 To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and
- 2 The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.

#### Initiation – Exercise-induced asthma

All of the following:

continued...

	Price	Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

- 1 Patient has been trialed with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
- 2 Patient continues to receive optimal inhaled corticosteroid therapy; and
- 3 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

#### Initiation – Aspirin desensitisation

Clinical immunologist or allergist

All of the following:

- 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and
- 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and
- 3 Nasal polyposis, confirmed radiologically or surgically; and
- 4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

### Long-Acting Beta-Adrenoceptor Agonists

#### EFORMOTEROL FUMARATE

Powder for inhalation 6 mcg per dose

Powder for inhalation 12 mcg per dose

#### INDACATEROL

Powder for inhalation 150 mcg per dose .....61.00

30 dose

Onbrez Breezhaler

Powder for inhalation 300 mcg per dose .....61.00

30 dose

Onbrez Breezhaler

#### SALMETEROL

Aerosol inhaler 25 mcg per dose .....26.46

120 dose

Meterol

25.00

Serevent

Powder for inhalation 50 mcg per dose .....25.00

60 dose

Serevent Accuhaler

### Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

#### BUDESONIDE WITH EFORMOTEROL

Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg

Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg

Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg

Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg

Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg

#### FLUTICASONE FUROATE WITH VILANTEROL

Powder for inhalation 100 mcg with vilanterol 25 mcg .....44.08

30 dose

Breo Ellipta

#### FLUTICASONE WITH SALMETEROL

Aerosol inhaler 50 mcg with salmeterol 25 mcg .....37.48

120 dose

RexAir

33.74

Seretide

Powder for inhalation 100 mcg with salmeterol 50 mcg .....33.74

60 dose

Seretide Accuhaler

Aerosol inhaler 125 mcg with salmeterol 25 mcg .....49.69

120 dose

RexAir

44.08

Seretide

Powder for inhalation 250 mcg with salmeterol 50 mcg .....44.08

60 dose

Seretide Accuhaler

### Mast Cell Stabilisers

#### NEDOCROMIL

Aerosol inhaler 2 mg per dose

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## SODIUM CROMOGLYCATE

Powder for inhalation 20 mg per dose

Aerosol inhaler 5 mg per dose

(Any Powder for inhalation 20 mg per dose to be delisted 1 June 2017)

## Methylxanthines

### AMINOPHYLLINE

Inj 25 mg per ml, 10 ml ampoule – 1% DV Oct-14 to 2017 ..... 118.25      5      **DBL Aminophylline**

### CAFFEINE CITRATE

Oral liq 20 mg per ml (caffeine 10 mg per ml) ..... 14.85      25 ml      Biomed

Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule ..... 55.75      5      Biomed

### THEOPHYLLINE

Tab long-acting 250 mg

Oral liq 80 mg per 15 ml

## Mucolytics and Expectorants

### DORNASE ALFA – **Restricted** see terms [below](#)

↓ Nebuliser soln 2.5 mg per 2.5 ml ampoule ..... 250.00      6      Pulmozyme

#### → **Restricted**

#### **Initiation – cystic fibrosis**

The patient has cystic fibrosis and has been approved by the Cystic Fibrosis Panel.

#### **Initiation – significant mucus production**

Limited to 4 weeks treatment

Both:

- 1 Patient is an in-patient; and
- 2 The mucus production cannot be cleared by first line chest techniques.

#### **Initiation – pleural emphyema**

Limited to 3 days treatment

Both:

- 1 Patient is an in-patient; and
- 2 Patient diagnoses with pleural emphyema.

### SODIUM CHLORIDE

Nebuliser soln 7%, 90 ml bottle ..... 23.50      90 ml      Biomed

## Pulmonary Surfactants

### BERACTANT

Soln 200 mg per 8 ml vial ..... 550.00      1      Survanta

### PORACTANT ALFA

Soln 120 mg per 1.5 ml vial ..... 425.00      1      Curosurf

Soln 240 mg per 3 ml vial ..... 695.00      1      Curosurf

## Respiratory Stimulants

### DOXAPRAM

Inj 20 mg per ml, 5 ml vial



Price	Brand or
(ex man. excl. GST)	Generic
\$	Manufacturer
Per	

Sclerosing Agents

TALC  
Powder  
Soln (slurry) 100 mg per ml, 50 ml

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Anti-Infective Preparations</b>			
<b>Antibacterials</b>			
CHLORAMPHENICOL			
Eye oint 1% – 1% DV Jul-16 to 2019 .....	2.48	4 g	Chlorsig
Ear drops 0.5%			
Eye drops 0.5% – 1% DV Sep-15 to 2018 .....	0.98	10 ml	Chlorafast
Eye drops 0.5%, single dose			
CIPROFLOXACIN			
Eye drops 0.3%			
FRAMYCETIN SULPHATE			
Ear/eye drops 0.5%			
FUSIDIC ACID			
Eye drops 1% .....	4.50	5 g	Fucithalmic
GENTAMICIN SULPHATE			
Eye drops 0.3% .....	11.40	5 ml	Genoptic
PROPAMIDINE ISETHIONATE			
Eye drops 0.1%			
SULPHACETAMIDE SODIUM			
Eye drops 10%			
TOBRAMYCIN			
Eye oint 0.3% – 1% DV Sep-14 to 2017 .....	10.45	3.5 g	Tobrex
Eye drops 0.3% – 1% DV Sep-14 to 2017 .....	11.48	5 ml	Tobrex
<b>Antifungals</b>			
NATAMYCIN			
Eye drops 5%			
<b>Antivirals</b>			
ACICLOVIR			
Eye oint 3% – 1% DV Oct-16 to 2019 .....	14.92	4.5 g	ViruPOS
<b>Combination Preparations</b>			
CIPROFLOXACIN WITH HYDROCORTISONE			
Ear drops ciprofloxacin 0.2% with 1% hydrocortisone – 1% DV Mar-15 to 2017 .....	16.30	10 ml	Ciproxin HC Otic
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml			
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE			
Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g – 1% DV Sep-14 to 2017 .....	5.39	3.5 g	Maxitrol
Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml – 1% DV Sep-14 to 2017 .....	4.50	5 ml	Maxitrol
DEXAMETHASONE WITH TOBRAMYCIN			
Eye drops 0.1% with tobramycin 0.3% – 1% DV Mar-15 to 2017 .....	12.64	5 ml	Tobradex

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FLUMETASONE PIVALATE WITH CLIQUINOL</b> Ear drops 0.02% with cliquinol 1%			
<b>TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN</b> Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g .....	5.16	7.5 ml	Kenacomb

## Anti-Inflammatory Preparations

### Corticosteroids

<b>DEXAMETHASONE</b> Eye oint 0.1% – <b>1% DV Oct-14 to 2017</b> .....	5.86	3.5 g	<b>Maxidex</b>
Eye drops 0.1% – <b>1% DV Oct-14 to 2017</b> .....	4.50	5 ml	<b>Maxidex</b>
<b>FLUOROMETHOLONE</b> Eye drops 0.1% – <b>1% DV Sep-15 to 2018</b> .....	3.09	5 ml	<b>FML</b>
<b>PREDNISOLONE ACETATE</b> Eye drops 0.12% Eye drops 1% – <b>1% DV Jan-17 to 2019</b> .....	3.93	10 ml	<b>Prednisolone- AFT</b>
<b>PREDNISOLONE SODIUM PHOSPHATE</b> Eye drops 0.5%, single dose (preservative free) .....	38.50	20 dose	Minims Prednisolone

### Non-Steroidal Anti-Inflammatory Drugs

<b>DICLOFENAC SODIUM</b> Eye drops 0.1% – <b>1% DV Sep-14 to 2017</b> .....	13.80	5 ml	<b>Voltaren Ophtha</b>
<b>KETOROLAC TROMETAMOL</b> Eye drops 0.5%			

## Decongestants and Antiallergics

### Antiallergic Preparations

<b>LEVOCABASTINE</b> Eye drops 0.05%			
<b>LODOXAMIDE</b> Eye drops 0.1% – <b>1% DV Sep-14 to 2017</b> .....	8.71	10 ml	<b>Lomide</b>
<b>OLOPATADINE</b> Eye drops 0.1% .....	17.00	5 ml	Patanol
<b>SODIUM CROMOGLYCATE</b> Eye drops 2%			

### Decongestants

<b>NAPHAZOLINE HYDROCHLORIDE</b> Eye drops 0.1% – <b>1% DV Sep-14 to 2017</b> .....	4.15	15 ml	<b>Naphcon Forte</b>
--	------	-------	----------------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Diagnostic and Surgical Preparations</b>			
<b>Diagnostic Dyes</b>			
FLUORESCIEIN SODIUM			
Eye drops 2%, single dose			
Inj 10%, 5 ml vial .....	125.00	12	Fluorescite
Ophthalmic strips 1 mg			
FLUORESCIEIN SODIUM WITH LIGNOCAINE HYDROCHLORIDE			
Eye drops 0.25% with lignocaine hydrochloride 4%, single dose			
LISSAMINE GREEN			
Ophthalmic strips 1.5 mg			
ROSE BENGAL SODIUM			
Ophthalmic strips 1%			
<b>Irrigation Solutions</b>			
MIXED SALT SOLUTION FOR EYE IRRIGATION			
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml dropper bottle – <b>1% DV Jan-16 to 2018</b> .....	5.00	15 ml	<b>Balanced Salt Solution</b>
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml			<i>e.g. Balanced Salt Solution</i>
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml bottle – <b>1% DV Jan-16 to 2018</b> .....	10.50	500 ml	<b>Balanced Salt Solution</b>
<b>Ocular Anaesthetics</b>			
OXYBUPROCAINE HYDROCHLORIDE			
Eye drops 0.4%, single dose			
PROXYMETACAINE HYDROCHLORIDE			
Eye drops 0.5%			
TETRACAINE [AMETHOCAINE] HYDROCHLORIDE			
Eye drops 0.5%, single dose			
Eye drops 1%, single dose			
<b>Viscoelastic Substances</b>			
HYPROMELLOSE			
Inj 2%, 1 ml syringe			
Inj 2%, 2 ml syringe			
SODIUM HYALURONATE [HYALURONIC ACID]			
Inj 14 mg per ml, 0.85 ml syringe – <b>1% DV Sep-16 to 2019</b> .....	50.00	1	<b>Healon GV</b>
Inj 14 mg per ml, 0.55 ml syringe – <b>1% DV Sep-16 to 2019</b> .....	50.00	1	<b>Healon GV</b>
Inj 23 mg per ml, 0.6 ml syringe – <b>1% DV Sep-16 to 2019</b> .....	60.00	1	<b>Healon 5</b>
Inj 10 mg per ml, 0.85 ml syringe – <b>1% DV Sep-16 to 2019</b> .....	28.50	1	<b>Healon</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SULPHATE</b>			
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe .....	64.00	1	Duovisc
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe – <b>1% DV Sep-16 to 2019</b> .....	74.00	1	<b>Duovisc</b>
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml syringe – <b>1% DV Sep-16 to 2019</b> .....	67.00	1	<b>Viscoat</b>

## Other

### DISODIUM EDEATE

- Inj 150 mg per ml, 20 ml ampoule
- Inj 150 mg per ml, 20 ml vial
- Inj 150 mg per ml, 100 ml vial

### RIBOFLAVIN 5-PHOSPHATE

- Soln trans epithelial riboflavin
- Inj 0.1%
- Inj 0.1% plus 20% dextran T500

## Glaucoma Preparations

### Beta Blockers

#### BETAXOLOL

- Eye drops 0.25% – **1% DV Sep-14 to 2017** ..... 11.80 5 ml **Betoptic S**
- Eye drops 0.5% – **1% DV Sep-14 to 2017** ..... 7.50 5 ml **Betoptic**

#### LEVOBUNOLOL HYDROCHLORIDE

- Eye drops 0.5% ..... 7.00 5 ml Betagan

#### TIMOLOL

- Eye drops 0.25% – **1% DV Sep-14 to 2017** ..... 1.45 5 ml **Arrow-Timolol**
- Eye drops 0.25%, gel forming – **1% DV Sep-16 to 2019** ..... 3.30 2.5 ml **Timoptol XE**
- Eye drops 0.5% – **1% DV Sep-14 to 2017** ..... 1.45 5 ml **Arrow-Timolol**
- Eye drops 0.5%, gel forming – **1% DV Sep-16 to 2019** ..... 3.78 2.5 ml **Timoptol XE**

## Carbonic Anhydrase Inhibitors

#### ACETAZOLAMIDE

- Tab 250 mg – **1% DV Sep-14 to 2017** ..... 17.03 100 **Diamox**
- Inj 500 mg

#### BRINZOLAMIDE

- Eye drops 1%

#### DORZOLAMIDE

- Eye drops 2%

#### DORZOLAMIDE WITH TIMOLOL

- Eye drops 2% with timolol 0.5% – **1% DV Dec-15 to 2018** ..... 3.45 5 ml **Arrow-Dortim**

## Miotics

#### ACETYLCHOLINE CHLORIDE

- Inj 20 mg vial with diluent

## SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PILOCARPINE HYDROCHLORIDE</b>			
Eye drops 1% – 1% DV Sep-14 to 2017 .....	4.26	15 ml	<b>Isopto Carpine</b>
Eye drops 2% – 1% DV Sep-14 to 2017 .....	5.35	15 ml	<b>Isopto Carpine</b>
Eye drops 2%, single dose			
Eye drops 4% – 1% DV Sep-14 to 2017 .....	7.99	15 ml	<b>Isopto Carpine</b>

### Prostaglandin Analogues

<b>BIMATOPROST</b>			
Eye drops 0.03% – 1% DV Jul-16 to 2018 .....	3.65	3 ml	<b>Bimatoprost Actavis</b>
<b>LATANOPROST</b>			
Eye drops 0.005% – 1% DV Sep-15 to 2018 .....	1.50	2.5 ml	<b>Hysite</b>
<b>TRAVOPROST</b>			
Eye drops 0.004%			

### Sympathomimetics

<b>APRACLOINIDINE</b>			
Eye drops 0.5% – 1% DV Mar-15 to 2017 .....	19.77	5 ml	<b>Iopidine</b>
<b>BRIMONIDINE TARTRATE</b>			
Eye drops 0.2% – 1% DV Sep-14 to 2017 .....	4.32	5 ml	<b>Arrow-Brimonidine</b>
<b>BRIMONIDINE TARTRATE WITH TIMOLOL</b>			
Eye drops 0.2% with timolol 0.5%			

### Mydriatics and Cycloplegics

#### Anticholinergic Agents

<b>ATROPINE SULPHATE</b>			
Eye drops 0.5%			
Eye drops 1%, single dose			
Eye drops 1% – 1% DV Jul-14 to 2017 .....	17.36	15 ml	<b>Atropt</b>
<b>CYCLOPENTOLATE HYDROCHLORIDE</b>			
Eye drops 0.5%, single dose			
Eye drops 1% – 1% DV Sep-14 to 2017 .....	8.76	15 ml	<b>Cyclogyl</b>
Eye drops 1%, single dose			
<b>TROPICAMIDE</b>			
Eye drops 0.5% – 1% DV Oct-14 to 2017 .....	7.15	15 ml	<b>Mydriacyl</b>
Eye drops 0.5%, single dose			
Eye drops 1% – 1% DV Oct-14 to 2017 .....	8.66	15 ml	<b>Mydriacyl</b>
Eye drops 1%, single dose			

### Sympathomimetics

<b>PHENYLEPHRINE HYDROCHLORIDE</b>			
Eye drops 2.5%, single dose			
Eye drops 10%, single dose			

### Ocular Lubricants

<b>CARBOMER</b>			
Ophthalmic gel 0.3%, single dose .....	8.25	30	<b>Poly Gel</b>
Ophthalmic gel 0.2%			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>CARMELLOSE SODIUM WITH PECTIN AND GELATINE</b>			
Eye drops 0.5%			
Eye drops 0.5%, single dose			
Eye drops 1%			
Eye drops 1%, single dose			
<b>HYPROMELLOSE</b>			
Eye drops 0.5% .....	3.92	15 ml	Methopt
<b>HYPROMELLOSE WITH DEXTRAN</b>			
Eye drops 0.3% with dextran 0.1%.....	2.30	15 ml	Poly-Tears
Eye drops 0.3% with dextran 0.1%, single dose			
<b>MACROGOL 400 AND PROPYLENE GLYCOL</b>			
Eye drops 0.4% with propylene glycol 0.3% preservative free, single dose.....	4.30	24	Systane Unit Dose
<b>PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN</b>			
Eye oint 42.5% with soft white paraffin 57.3%			
<b>PARAFFIN LIQUID WITH WOOL FAT</b>			
Eye oint 3% with wool fat 3% – <b>1% DV Jul-14 to 2017</b> .....	3.63	3.5 g	<b>Poly-Visc</b>
<b>POLYVINYL ALCOHOL</b>			
Eye drops 1.4% – <b>1% DV Jun-16 to 2019</b> .....	2.62	15 ml	<b>Vistil</b>
Eye drops 3% – <b>1% DV Jun-16 to 2019</b> .....	3.68	15 ml	<b>Vistil Forte</b>
<b>POLYVINYL ALCOHOL WITH POVIDONE</b>			
Eye drops 1.4% with povidone 0.6%, single dose			
<b>RETINOL PALMITATE</b>			
Oint 138 mcg per g .....	3.80	5 g	VitA-POS
<b>SODIUM HYALURONATE [HYALURONIC ACID]</b>			
Eye drops 1 mg per ml .....	22.00	10 ml	Hylo-Fresh

### Other Otological Preparations

<b>ACETIC ACID WITH PROPYLENE GLYCOL</b>
Ear drops 2.3% with propylene glycol 2.8%
<b>DOCUSATE SODIUM</b>
Ear drops 0.5%

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Agents Used in the Treatment of Poisonings</b>			
<b>Antidotes</b>			
ACETYLCYSTEINE			
Tab eff 200 mg			
Inj 200 mg per ml, 10 ml ampoule – 1% DV Sep-15 to 2018.....	78.34	10	DBL Acetylcysteine
DIGOXIN IMMUNE FAB			
Inj 38 mg vial			
Inj 40 mg vial			
ETHANOL			
Liq 96%			
ETHANOL WITH GLUCOSE			
Inj 10% with glucose 5%, 500 ml bottle			
ETHANOL, DEHYDRATED			
Inj 100%, 5 ml ampoule			
Inj 96%			
FLUMAZENIL			
Inj 0.1 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018.....	85.05	5	Anexate
HYDROXOCOBALAMIN			
Inj 5 g vial			
Inj 2.5 g vial			
NALOXONE HYDROCHLORIDE			
Inj 400 mcg per ml, 1 ml ampoule .....	48.84	5	Hospira
PRALDOXIME IODIDE			
Inj 25 mg per ml, 20 ml ampoule			
SODIUM NITRITE			
Inj 30 mg per ml, 10 ml ampoule			
SODIUM THIOSULFATE			
Inj 250 mg per ml, 10 ml vial			
Inj 250 mg per ml. 50 ml vial			
Inj 500 mg per ml, 10 ml vial			
Inj 500 mg per ml, 20 ml ampoule			
SOYA OIL			
Inj 20%, 500 ml bag			
Inj 20%, 500 ml bottle			
<b>Antitoxins</b>			
BOTULISM ANTITOXIN			
Inj 250 ml vial			
DIPHThERIA ANTITOXIN			
Inj 10,000 iu vial			
<b>Antivenoms</b>			
RED BACK SPIDER ANTIVENOM			
Inj 500 u vial			



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>SNAKE ANTIVENOM</b>			
Inj 50 ml vial			

## Removal and Elimination

### CHARCOAL

Oral liq 200 mg per ml ..... 43.50      250 ml      Carbasorb-X

### DEFERASIROX – **Restricted** see terms [below](#)

↓ Tab 125 mg dispersible ..... 276.00      28      Exjade  
 ↓ Tab 250 mg dispersible ..... 552.00      28      Exjade  
 ↓ Tab 500 mg dispersible ..... 1,105.00      28      Exjade

### → **Restricted**

#### Initiation

Haematologist

*Re-assessment required after 2 years*

All of the following:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
- 2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
- 3 Any of the following:
  - 3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2\*; or
  - 3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
  - 3.3 Treatment with deferiprone has resulted in arthritis; or
  - 3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per  $\mu$ L) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per  $\mu$ L).

#### Continuation

Haematologist

*Re-assessment required after 2 years*

Either:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2\* and liver MRI T2\* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2\* and liver MRI T2\* levels. .

### DEFERIPRONE – **Restricted** see terms [below](#)

↓ Tab 500 mg ..... 533.17      100      Ferriprox  
 ↓ Oral liq 100 mg per ml ..... 266.59      250 ml      Ferriprox

### → **Restricted**

#### Initiation

Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia.

### DEFERRIOXAMINE MESILATE

Inj 500 mg vial – **1% DV Feb-16 to 2018** ..... 51.52      10      **Desferal**

### DICOBALT EDETATE

Inj 15 mg per ml, 20 ml ampoule

### DIMERCAPROL

Inj 50 mg per ml, 2 ml ampoule

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DIMERCAPTOSUCCINIC ACID</b>			
Cap 100 mg			e.g. PCNZ, Optimus Healthcare, Chemet
Cap 200 mg			e.g. PCNZ, Optimus Healthcare, Chemet
<b>SODIUM CALCIUM EDEATE</b>			
Inj 200 mg per ml, 2.5 ml ampoule			
Inj 200 mg per ml, 5 ml ampoule			

## Antiseptics and Disinfectants

<b>CHLORHEXIDINE</b>			
Soln 4% .....	1.86	50 ml	healthE
Soln 5% .....	15.50	500 ml	healthE
<b>CHLORHEXIDINE WITH CETRIMIDE</b>			
Crm 0.1% with cetrimide 0.5%			
Foaming soln 0.5% with cetrimide 0.5%			
<b>CHLORHEXIDINE WITH ETHANOL</b>			
Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml .....	2.65	1	healthE
Soln 2% with ethanol 70%, non-staining (pink) 100 ml .....	3.54	1	healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml .....	1.55	1	healthE
Soln 0.5% with ethanol 70%, staining (red) 100 ml .....	2.90	1	healthE
Soln 2% with ethanol 70%, staining (red) 100 ml .....	3.86	1	healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml .....	5.45	1	healthE
Soln 0.5% with ethanol 70%, staining (red) 500 ml .....	5.90	1	healthE
Soln 2% with ethanol 70%, staining (red) 500 ml .....	9.56	1	healthE
<b>IODINE WITH ETHANOL</b>			
Soln 1% with ethanol 70%, 100 ml .....	9.30	1	healthE
<b>ISOPROPYL ALCOHOL</b>			
Soln 70%, 500 ml .....	5.65	1	healthE
<b>POVIDONE-IODINE</b>			
‡ Vaginal tab 200 mg			
➔ <b>Restricted</b>			
<b>Initiation</b>			
Rectal administration pre-prostate biopsy.			
Oint 10% .....	3.27	25 g	Betadine
Soln 10% .....	6.20	500 ml	Betadine
	2.95	100 ml	Riodine
	6.20	500 ml	Riodine
Soln 5%			
Soln 7.5%			
Pad 10%			
Swab set 10%			
<b>POVIDONE-IODINE WITH ETHANOL</b>			
Soln 10% with ethanol 30% .....	10.00	500 ml	Betadine Skin Prep
Soln 10% with ethanol 70%			
<b>SODIUM HYPOCHLORITE</b>			
Soln			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Contrast Media</b>			
<b>Iodinated X-ray Contrast Media</b>			
DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE			
Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle.....	22.50	100 ml	Gastrografin
Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle.....	80.00	1	Urografin
DIATRIZOATE SODIUM			
Oral liq 370 mg per ml, 10 ml sachet.....	156.12	50	Ioscan
IODISED OIL			
Inj 38% w/w (480 mg per ml), 10 ml ampoule .....	230.00	1	Lipiodol Ultra Fluid
IODIXANOL			
Inj 270 mg per ml (iodine equivalent), 50 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	220.00	10	Visipaque
Inj 270 mg per ml (iodine equivalent), 100 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	430.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 50 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	220.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 100 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	430.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 200 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	850.00	10	Visipaque
IOHEXOL			
Inj 240 mg per ml (iodine equivalent), 50 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	75.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 20 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	57.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 50 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	75.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 100 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	150.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 20 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	59.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 50 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	75.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 75 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	114.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 100 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	150.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 200 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	290.00	10	Omnipaque

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Non-iodinated X-ray Contrast Media</b>			
<b>BARIUM SULPHATE</b>			
Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet.....	507.50	50	E-Z-Cat Dry
Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle.....	17.39	148 g	Varibar - Thin Liquid
Oral liq 600 mg per g (60% w/w), tube .....	36.51	454 g	E-Z-Paste
Oral liq 400 mg per ml (40% w/v), bottle .....	155.35	250 ml	Varibar - Honey
	38.40	240 ml	Varibar - Nectar
	145.04	230 ml	Varibar - Pudding
Enema 1,250 mg per ml (125% w/v), 500 ml bag .....	282.30	12	Liquibar
Oral liq 22 mg per g (2.2% w/w), 250 ml bottle.....	175.00	24	CT Plus+
Oral liq 22 mg per g (2.2% w/w), 450 ml bottle.....	220.00	24	CT Plus+
Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle .....	441.12	24	VoLumen
Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle .....	140.94	24	Readi-CAT 2
Powder for oral soln 97.65% w/w, 300 g bottle .....	237.76	24	X-Opaque-HD
Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle .....	52.35	3	Tagitol V
Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle.....	91.77	1	Liquibar
<b>BARIUM SULPHATE WITH SODIUM BICARBONATE</b>			
Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet.....	102.93	50	E-Z-Gas II
<b>CITRIC ACID WITH SODIUM BICARBONATE</b>			
Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet			<i>e.g. E-Z-GAS II</i>
<b>Paramagnetic Contrast Media</b>			
<b>GADOBENIC ACID</b>			
Inj 334 mg per ml, 10 ml vial.....	324.74	10	Multihance
Inj 334 mg per ml, 20 ml vial.....	636.28	10	Multihance
<b>GADOBUTROL</b>			
Inj 1 mmol per ml, 15 ml vial			
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe.....	180.00	5	Gadovist
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe.....	700.00	10	Gadovist
<b>GADODIAMIDE</b>			
Inj 287 mg per ml, 10 ml prefilled syringe.....	200.00	10	Omniscan
Inj 287 mg per ml, 10 ml vial.....	170.00	10	Omniscan
Inj 287 mg per ml, 5 ml vial.....	120.00	10	Omniscan
Inj 287 mg per ml, 15 ml prefilled syringe.....	320.00	10	Omniscan
<b>GADOTERIC ACID</b>			
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe.....	24.50	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle .....	34.50	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe.....	41.00	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe.....	55.00	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle .....	23.20	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle .....	46.30	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle .....	12.30	1	Dotarem
<b>GADOXETATE DISODIUM</b>			
Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe .....	300.00	1	Primovist

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MEGLUMINE GADOPENTETATE</b>			
Inj 469 mg per ml, 10 ml prefilled syringe.....	95.00	5	Magnevist
Inj 469 mg per ml, 10 ml vial.....	185.00	10	Magnevist
<b>MEGLUMINE IOTROXATE</b>			
Inj 105 mg per ml, 100 ml bottle .....	150.00	100 ml	Billiscopin

### Ultrasound Contrast Media

<b>PERFLUTREN</b>			
Inj 1.1 mg per ml, 1.5 ml vial – 5% DV Sep-14 to 2017 .....	180.00	1	<b>Definity</b>
	720.00	4	<b>Definity</b>

### Diagnostic Agents

<b>ARGININE</b>			
Inj 50 mg per ml, 500 ml bottle			
Inj 100 mg per ml, 300 ml bottle			
<b>HISTAMINE ACID PHOSPHATE</b>			
Nebuliser soln 0.6%, 10 ml vial			
Nebuliser soln 2.5%, 10 ml vial			
Nebuliser soln 5%, 10 ml vial			
<b>MANNITOL</b>			
Powder for inhalation			<i>e.g. Aridol</i>
<b>METHACHOLINE CHLORIDE</b>			
Powder 100 mg			
<b>SECRETIN PENTAHYDROCHLORIDE</b>			
Inj 100 u ampoule			
<b>SINCALIDE</b>			
Inj 5 mcg per vial			
<b>TUBERCULIN, PURIFIED PROTEIN DERIVATIVE</b>			
Inj 5 TU per 0.1 ml, 1 ml vial			

### Diagnostic Dyes

<b>BONNEY'S BLUE DYE</b>			
Soln			
<b>INDIGO CARMINE</b>			
Inj 4 mg per ml, 5 ml ampoule			
Inj 8 mg per ml, 5 ml ampoule			
<b>INDOCYANINE GREEN</b>			
Inj 25 mg vial			
<b>METHYLTHIONIUM CHLORIDE [METHYLENE BLUE]</b>			
Inj 10 mg per ml, 10 ml ampoule			
Inj 10 mg per ml, 5 ml ampoule			
<b>PATENT BLUE V</b>			
Inj 2.5%, 2 ml ampoule .....	440.00	5	Obex Medical

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Irrigation Solutions</b>			
<b>CHLORHEXIDINE</b>			
Irrigation soln 0.02%, bottle .....	6.20	100 ml	Baxter
Irrigation soln 0.05%, bottle .....	7.37	500 ml	Baxter
	7.83	100 ml	Baxter
Irrigation soln 0.1%, bottle .....	8.71	100 ml	Baxter
Irrigation soln 0.02%, 500 ml bottle			
Irrigation soln 0.1%, 30 ml ampoule			
<b>CHLORHEXIDINE WITH CETRIMIDE</b>			
Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule			
Irrigation soln 0.015% with cetrimide 0.15%, bottle .....	4.17	1,000 ml	Baxter
	6.04	100 ml	Baxter
	9.55	500 ml	Baxter
Irrigation soln 0.05% with cetrimide 0.5%, bottle .....	9.31	100 ml	Baxter
	12.14	500 ml	Baxter
Irrigation soln 0.1% with cetrimide 1%, bottle .....	10.00	100 ml	Baxter
<b>GLYCINE</b>			
Irrigation soln 1.5%, bottle .....	19.48	2,000 ml	Baxter
	22.70	3,000 ml	Baxter
<b>SODIUM CHLORIDE</b>			
Irrigation soln 0.9%, bottle .....	5.22	100 ml	Baxter
	6.19	500 ml	Baxter
	6.59	1,000 ml	Baxter
	15.11	2,000 ml	Baxter
	19.26	3,000 ml	Baxter
Irrigation soln 0.9%, 30 ml ampoule .....	19.50	30	Pfizer
<b>WATER</b>			
Irrigation soln, bottle .....	5.24	100 ml	Baxter
	5.94	500 ml	Baxter
	6.58	1,000 ml	Baxter
	16.47	2,000 ml	Baxter
	29.21	3,000 ml	Baxter

## Surgical Preparations

### BISMUTH SUBNITRATE AND IODOFORM PARAFFIN

Paste

### DIMETHYL SULFOXIDE

Soln 50%

Soln 99%

### PHENOL

Inj 6%, 10 ml ampoule

### PHENOL WITH IOXAGLIC ACID

Inj 12%, 10 ml ampoule

### TROMETAMOL

Inj 36 mg per ml, 500 ml bottle

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Cardioplegia Solutions

ELECTROLYTES

Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride, 1 mmol/l potassium hydrogen 2-ketoglutarate, 4 mmol/l magnesium chloride, 18 mmol/l histidine hydrochloride, 180 mmol/l histidine, 2 mmol/l tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium chloride, 1,000 ml bag

e.g. Custodiol-HTK

Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag

e.g. Cardioplegia Enriched Paed. Soln.

Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg per ml, 527 ml bag

e.g. Cardioplegia Enriched Solution

Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per ml, sodium chloride 1.788 mg ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag

e.g. Cardioplegia Base Solution

Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag

e.g. Cardioplegia Solution AHB7832

Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesium and 1.2 mmol/l calcium, 1,000 ml bag

e.g. Cardioplegia Electrolyte Solution

MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE

Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle

MONOSODIUM L-ASPARTATE

Inj 14 mmol per 10 ml, 10 ml

Cold Storage Solutions

SODIUM WITH POTASSIUM

Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag

## EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Extemporaneously Compounded Preparations</b>			
ACETIC ACID Liq			
ALUM Powder BP			
ARACHIS OIL [PEANUT OIL] Liq			
ASCORBIC ACID Powder			
BENZOIN Tincture compound BP			
BISMUTH SUBGALLATE Powder			
BORIC ACID Powder			
CARBOXYMETHYLCELLULOSE Soln 1.5%			
CETRIMIDE Soln 40%			
CHLORHEXIDINE GLUCONATE Soln 20 %			
CHLOROFORM Liq BP			
CITRIC ACID Powder BP			
CLOVE OIL Liq			
COAL TAR Soln BP – 1% DV Dec-16 to 2019 .....	32.95	200 ml	Midwest
CODEINE PHOSPHATE Powder			
COLLODION FLEXIBLE Liq			
COMPOUND HYDROXYBENZOATE Soln			
CYSTEAMINE HYDROCHLORIDE Powder			
DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule			
DITHRANOL Powder			
GLUCOSE [DEXTROSE] Powder			



# EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GLYCERIN WITH SODIUM SACCHARIN			
Suspension.....	32.50	473 ml	Ora-Sweet SF
GLYCERIN WITH SUCROSE			
Suspension.....	32.50	473 ml	Ora-Sweet
GLYCEROL			
Liq.....	19.80	2,000 ml	ABM
HYDROCORTISONE			
Powder – <b>1% DV Dec-14 to 2017</b> .....	59.50	25 g	<b>ABM</b>
LACTOSE			
Powder			
MAGNESIUM HYDROXIDE			
Paste			
MENTHOL			
Crystals			
METHADONE HYDROCHLORIDE			
Powder			
METHYL HYDROXYBENZOATE			
Powder			
METHYLCELLULOSE			
Powder			
Suspension.....	32.50	473 ml	Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN			
Suspension.....	32.50	473 ml	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE			
Suspension.....	32.50	473 ml	Ora-Blend
OLIVE OIL			
Liq			
PARAFFIN			
Liq			
PHENOBARBITONE SODIUM			
Powder			
PHENOL			
Liq			
PILOCARPINE NITRATE			
Powder			
POLYHEXAMETHYLENE BIGUANIDE			
Liq			
POVIDONE K30			
Powder			
PROPYLENE GLYCOL			
Liq.....	12.00	500 ml	ABM
SALICYLIC ACID			
Powder			
SILVER NITRATE			
Crystals			
SODIUM BICARBONATE			
Powder BP			

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

Price  
(ex man. excl. GST)  
\$ Per Brand or  
Generic  
Manufacturer

SODIUM CITRATE			
Powder			
SODIUM METABISULFITE			
Powder			
STARCH			
Powder			
SULPHUR			
Precipitated			
Sublimed			
SYRUP			
Liq (pharmaceutical grade).....	21.75	2,000 ml	Midwest
THEOBROMA OIL			
Oint			
TRI-SODIUM CITRATE			
Crystals			
TRICHLORACETIC ACID			
Grans			
UREA			
Powder BP			
WOOL FAT			
Oint, anhydrous			
XANTHAN			
Gum 1%			
ZINC OXIDE			
Powder			

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

## Food Modules

### Carbohydrate

#### ➔ Restricted

##### Initiation – Use as an additive

Any of the following:

- 1 Cystic fibrosis; or
- 2 Chronic kidney disease; or
- 3 Cancer in children; or
- 4 Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 5 Faltering growth in an infant/child; or
- 6 Bronchopulmonary dysplasia; or
- 7 Premature and post premature infant; or
- 8 Inborn errors of metabolism.

##### Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

CARBOHYDRATE SUPPLEMENT – **Restricted** see terms [above](#)

† Powder 95 g carbohydrate per 100 g, 368 g can

† Powder 96 g carbohydrate per 100 g, 400 g can

*e.g. Polycal*

### Fat

#### ➔ Restricted

##### Initiation – Use as an additive

Any of the following:

- 1 Patient has inborn errors of metabolism; or
- 2 Faltering growth in an infant/child; or
- 3 Bronchopulmonary dysplasia; or
- 4 Fat malabsorption; or
- 5 Lymphangiectasia; or
- 6 Short bowel syndrome; or
- 7 Infants with necrotising enterocolitis; or
- 8 Biliary atresia; or
- 9 For use in a ketogenic diet; or
- 10 Chyle leak; or
- 11 Ascites; or
- 12 Patient has increased energy requirements, and for whom dietary measures have not been successful.

##### Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

LONG-CHAIN TRIGLYCERIDE SUPPLEMENT – **Restricted** see terms [above](#)

† Liquid 50 g fat per 100 ml, 200 ml bottle

*e.g. Calogen*

† Liquid 50 g fat per 100 ml, 500 ml bottle

*e.g. Calogen*

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 50 g fat per 100 ml, 250 ml bottle			<i>e.g. Liquigen</i>
† Liquid 95 g fat per 100 ml, 500 ml bottle			<i>e.g. MCT Oil</i>
<b>WALNUT OIL – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liq			

## Protein

### ➔ Restricted

#### Initiation – Use as an additive

Either:

- 1 Protein losing enteropathy; or
- 2 High protein needs.

#### Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk. .

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

#### PROTEIN SUPPLEMENT – Restricted

 see terms [above](#)

† Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can			
† Powder 6 g protein per 7 g, can .....	8.95	227 g	Resource Beneprotein
† Powder 89 g protein, < 1.5 g carbohydrate and 2 g fat per 100 g, 225 g can			<i>e.g. Protifar</i>

## Other Supplements

#### BREAST MILK FORTIFIER

Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet	<i>e.g. FM 85</i>
Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet	<i>e.g. S26 Human Milk Fortifier</i>
Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet	<i>e.g. Nutricia Breast Milk Fortifier</i>

#### CARBOHYDRATE AND FAT SUPPLEMENT – Restricted

 see terms [below](#)

‡ Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can	<i>e.g. Super Soluble Duocal</i>
--	----------------------------------

### ➔ Restricted

#### Initiation

Both:

- 1 Infant or child aged four years or under; and
- 2 Any of the following:
  - 2.1 Cystic fibrosis; or
  - 2.2 Cancer in children; or
  - 2.3 Faltering growth; or
  - 2.4 Bronchopulmonary dysplasia; or
  - 2.5 Premature and post premature infants.

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

## Food/Fluid Thickeners

### NOTE:

While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:

- use was established prior to 1 July 2013; and
- the product has not been specifically considered and excluded by PHARMAC; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

#### CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN

Powder

*e.g. Feed Thickener  
Karicare Aptamil*

#### GUAR GUM

Powder

*e.g. Guarcol*

#### MAIZE STARCH

Powder

*e.g. Resource Thicken  
Up; Nutilis*

#### MALTODEXTRIN WITH XANTHAN GUM

Powder

*e.g. Instant Thick*

#### MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID

Powder

*e.g. Easy Thick*

## Metabolic Products

### ➔ Restricted

#### Initiation

Any of the following:

- 1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinemia or urea cycle disorders; or
- 2 Patient has adrenoleukodystrophy; or
- 3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

## Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN) – **Restricted** see terms [above](#)

† Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can

*e.g. GA1 Anamix Infant*

† Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can

*e.g. XLYS Low TRY  
Maxamaid*

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Homocystinuria Products

AMINO ACID FORMULA (WITHOUT METHIONINE) – **Restricted** see terms [on the previous page](#)

† Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. HCU Anamix Infant
† Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			e.g. XMET Maxamaid
† Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			e.g. XMET Maxamum
† Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle			e.g. HCU Anamix Junior LQ

### Isovaleric Acidaemia Products

AMINO ACID FORMULA (WITHOUT LEUCINE) – **Restricted** see terms [on the previous page](#)

† Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. IVA Anamix Infant
† Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			e.g. XLEU Maxamaid
† Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			e.g. XLEU Maxamum

### Maple Syrup Urine Disease Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – **Restricted** see terms [on the previous page](#)

† Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. MSUD Anamix Infant
† Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			e.g. MSUD Maxamum
† Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle			e.g. MSUD Anamix Junior LQ

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Phenylketonuria Products			
AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – <b>Restricted</b> see terms <a href="#">on page 213</a>			
† Tab 8.33 mg			e.g. Phlexy-10
† Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet			e.g. PKU Anamix Junior
† Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. PKU Anamix Infant
† Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			e.g. XP Maxamaid
† Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			e.g. XP Maxamum
† Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet			e.g. Phlexy-10
† Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle			e.g. PKU Lophlex LQ 10
† Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle			e.g. PKU Lophlex LQ 20
† Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle.....	13.10	125 ml	PKU Anamix Junior LQ (Berry) PKU Anamix Junior LQ (Orange) PKU Anamix Junior LQ (Unflavoured)
† Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle			e.g. PKU Lophlex LQ 20
† Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle			e.g. PKU Lophlex LQ 10
† Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle			e.g. PKU Lophlex LQ 20
† Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle			e.g. PKU Lophlex LQ 10
† Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton			e.g. Easiphen

Propionic Acidaemia and Methylmalonic Acidaemia Products

AMINO ACID FORMULA (WITHOUT Isoleucine, Methionine, Threonine and Valine) – <b>Restricted</b> see terms <a href="#">on page 213</a>			
† Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. MMA/PA Anamix Infant
† Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			e.g. XMTVI Maxamaid
† Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			e.g. XMTVI Maxamum

Protein Free Supplements

Protein Free Supplement – <b>Restricted</b> see terms <a href="#">on page 213</a>			
† Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can			e.g. Energivit

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Tyrosinaemia Products

AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) – **Restricted** see terms [on page 213](#)

† Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet			e.g. TYR Anamix Junior
† Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. TYR Anamix Infant
† Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can			e.g. XPHEN, TYR Maxamaid
† Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle			e.g. TYR Anamix Junior LQ

## Urea Cycle Disorders Products

AMINO ACID SUPPLEMENT – **Restricted** see terms [on page 213](#)

† Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can			e.g. Dialamine
† Powder 79 g protein per 100 g, 200 g can			e.g. Essential Amino Acid Mix

## X-Linked Adrenoleukodystrophy Products

GLYCEROL TRIERUCATE – **Restricted** see terms [on page 213](#)

† Liquid, 1,000 ml bottle			
---------------------------	--	--	--

GLYCEROL TRIOLEATE – **Restricted** see terms [on page 213](#)

† Liquid, 500 ml bottle			
-------------------------	--	--	--

## Specialised Formulas

### Diabetic Products

#### ➡ Restricted

##### Initiation

Any of the following:

- 1 For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
- 2 For patients with pancreatic insufficiency; or
- 3 For patients who have, or are expected to, eat little or nothing for 5 days; or
- 4 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- 5 For use pre- and post-surgery; or
- 6 For patients being tube-fed; or
- 7 For tube-feeding as a transition from intravenous nutrition.

LOW-GI ENTERAL FEED 1 KCAL/ML – **Restricted** see terms [above](#)

† Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml bottle.....	7.50	1,000 ml	Glucerna Select RTH (Vanilla)
† Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag			e.g. Nutrison Advanced Diason



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>LOW-GI ORAL FEED 1 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per 100 ml, can.....	2.10	237 ml	Sustagen Diabetic (Vanilla)
† Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 250 ml bottle.....	1.88	250 ml	Glucerna Select (Vanilla)
† Liquid 6 g protein, 9.5 g carbohydrate, 4.7 g fat and 2.6 g fibre per 100 ml, can.....	2.10	237 ml	Resource Diabetic (Vanilla)
† Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle			<i>e.g. Diasip</i>

## Elemental and Semi-Elemental Products

### ➔ Restricted

#### Initiation

Any of the following:

- 1 Malabsorption; or
- 2 Short bowel syndrome; or
- 3 Enterocutaneous fistulas; or
- 4 Eosinophilic enteritis (including oesophagitis); or
- 5 Inflammatory bowel disease; or
- 6 Acute pancreatitis where standard feeds are not tolerated; or
- 7 Patients with multiple food allergies requiring enteral feeding.

**AMINO ACID ORAL FEED – Restricted** see terms [above](#)

† Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet..... 4.50 80 g Vivonex TEN

**AMINO ACID ORAL FEED 0.8 KCAL/ML – Restricted** see terms [above](#)

† Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton *e.g. Elemental 028 Extra*

**PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML – Restricted** see terms [above](#)

† Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag *e.g. Nutrison Advanced Peptisorb*

**PEPTIDE-BASED ORAL FEED – Restricted** see terms [above](#)

† Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can *e.g. Peptamen Junior*

† Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can *e.g. MCT Peptide; MCT Peptide 1+*

† Powder 15.8 g protein, 49.5 g carbohydrate and 4.65 g fat per 76 g sachet..... 7.50 76 g Alitraq

† Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle.... 18.06 1,000 ml Vital  
(Alitraq Powder 15.8 g protein, 49.5 g carbohydrate and 4.65 g fat per 76 g sachet to be delisted 1 September 2017)

**PEPTIDE-BASED ORAL FEED 1 KCAL/ML – Restricted** see terms [above](#)

† Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, carton..... 4.95 237 ml Peptamen OS 1.0 (Vanilla)

## Fat Modified Products

**FAT-MODIFIED FEED – Restricted** see terms [on the next page](#)

† Powder 12.9 g protein, 69.1 g carbohydrate and 12.9 g fat per 100 g, 400 g can *e.g. Monogen*

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➡ **Restricted**

**Initiation**

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**Hepatic Products**

➡ **Restricted**

**Initiation**

For children (up to 18 years) who require a liver transplant.

HEPATIC ORAL FEED – **Restricted** see terms [above](#)

† Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can .....	78.97	400 g	Heparon Junior
--	-------	-------	----------------

**High Calorie Products**

➡ **Restricted**

**Initiation**

Any of the following:

- 1 Patient is fluid volume or rate restricted; or
- 2 Patient requires low electrolyte; or
- 3 Both:
  - 3.1 Any of the following:
    - 3.1.1 Cystic fibrosis; or
    - 3.1.2 Any condition causing malabsorption; or
    - 3.1.3 Faltering growth in an infant/child; or
    - 3.1.4 Increased nutritional requirements; and
  - 3.2 Patient has substantially increased metabolic requirements.

ENTERAL FEED 2 KCAL/ML – **Restricted** see terms [above](#)

† Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle .....	5.50	500 ml	Nutrison Concentrated
† Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle .....	11.00	1,000 ml	TwoCal HN RTH (Vanilla)

ORAL FEED 2 KCAL/ML – **Restricted** see terms [above](#)

† Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle .....	1.90	200 ml	Two Cal HN
---	------	--------	------------

**High Protein Products**

HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – **Restricted** see terms [below](#)

‡ Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Protein Plus</i>
--	--	--	-----------------------------------

➡ **Restricted**

**Initiation**

Both:

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
  - 2.1 Patient has liver disease; or
  - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
  - 2.3 Patient is fluid restricted; or
  - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – **Restricted** see terms [below](#)

- ↓ Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag

e.g. *Nutrison Protein Plus Multi Fibre***→ Restricted****Initiation**

Both:

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
  - 2.1 Patient has liver disease; or
  - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
  - 2.3 Patient is fluid restricted; or
  - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

**Infant Formulas**AMINO ACID FORMULA – **Restricted** see terms [below](#)

↓ Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can		e.g. <i>Neocate</i>
↓ Powder 13 g protein, 52.5 g carbohydrate and 24.5 g fat per 100 g, 400 g can		e.g. <i>Neocate LCP</i>
↓ Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can .....53.00	400 g	Neocate Gold (Unflavoured)
↓ Powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can		e.g. <i>Neocate Advance</i>
↓ Powder 15 g protein, 56 g carbohydrate and 20 g fat per 100 g, can .....43.60	400 g	Alfamino Junior
↓ Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can .....53.00	400 g	Neocate Advance (Vanilla)
↓ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can.....53.00	400 g	Elecare LCP (Unflavoured)
↓ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can.....53.00	400 g	Elecare (Unflavoured) Elecare (Vanilla)

**→ Restricted****Initiation**

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows' milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

Note: A reasonable trial is defined as a 2-4 week trial.

**Continuation**

Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula.

## EXTENSIVELY HYDROLYSED FORMULA – **Restricted** see terms [below](#)

- ⚡ Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g,  
450 g can

*e.g. Aptamil Gold+ Pepti Junior*

### ➡ **Restricted**

#### **Initiation**

Any of the following:

- 1 Both:
  - 1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
  - 1.2 Either:
    - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
    - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure; or
- 11 For step down from Amino Acid Formula.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

#### **Continuation**

Both:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.

## FRUCTOSE-BASED FORMULA

- Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g,  
400 g can

*e.g. Galactomin 19*

## LACTOSE-FREE FORMULA

- Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml, 900 g  
can

*e.g. Karicare Aptamil Gold De-Lact*

- Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g  
can

*e.g. S26 Lactose Free*

## LOW-CALCIUM FORMULA

- Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g,  
400 g can

*e.g. Locasol*

## PAEDIATRIC ORAL FEED 1 KCAL/ML – **Restricted** see terms [on the next page](#)

- ⚡ Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per  
100 ml, 100 ml bottle

*e.g. Infatrini*

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted****Initiation**

Both:

- 1 Either:
  - 1.1 The patient is fluid restricted; or
  - 1.2 The patient has increased nutritional requirements due to faltering growth; and
- 2 Patient is under 18 months old and weighs less than 8kg.

PRETERM FORMULA – **Restricted** see terms [below](#)

↓ Powder 1.9 g protein, 7.5 g carbohydrate and 3.9 g fat per 14 g, can .....	15.25	400 g	S-26 Gold Premgro
↓ Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, bottle .....	0.75	100 ml	S26 LBW Gold RTF
↓ Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle			<i>e.g. Pre Nan Gold RTF</i>
↓ Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 70 ml bottle			<i>e.g. Karicare Aptamil Gold+Preterm</i>

➔ **Restricted****Initiation**

For infants born before 33 weeks' gestation or weighing less than 1.5 kg at birth.

## THICKENED FORMULA

Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can			<i>e.g. Karicare Aptamil Thickened AR</i>
--	--	--	---

**Ketogenic Diet Products**HIGH FAT FORMULA – **Restricted** see terms [below](#)

↓ Powder 14.4 g protein, 2.9 g carbohydrate and 69.2 g fat per 100 g, can .....	35.50	300 g	Ketocal 4:1 (Unflavoured)
↓ Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can .....	35.50	300 g	Ketocal 4:1 (Vanilla)
			Ketocal 3:1 (Unflavoured)

➔ **Restricted****Initiation**

For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

**Paediatric Products**➔ **Restricted****Initiation**

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
  - 2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
  - 2.2 Any condition causing malabsorption; or
  - 2.3 Faltering growth in an infant/child; or
  - 2.4 Increased nutritional requirements; or
  - 2.5 The child is being transitioned from TPN or tube feeding to oral feeding; or
  - 2.6 The child has eaten, or is expected to eat, little or nothing for 3 days.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PAEDIATRIC ORAL FEED – Restricted</b> see terms <a href="#">on the previous page</a>			
† Powder 14.9 g protein, 54.3 g carbohydrate and 24.7 g fat per 100 g, can ....	28.00	850 g	Pediasure (Vanilla)
<b>PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag.....	4.00	500 ml	Nutrini Low Energy Multifibre RTH
<b>PAEDIATRIC ENTERAL FEED 1 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag.....	2.68	500 ml	Pediasure RTH
† Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag			<i>e.g. Nutrini RTH</i>
<b>PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag.....	6.00	500 ml	Nutrini Energy Multi Fibre
† Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag			<i>e.g. Nutrini Energy RTH</i>
<b>PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle .....	1.07	200 ml	Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla) Pediasure (Vanilla)
† Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, can .....	1.34	250 ml	
<b>PAEDIATRIC ORAL FEED 1.5 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortini</i>
† Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle			<i>e.g. Fortini Multifibre</i>

## Renal Products

**LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – Restricted** see terms [below](#)

‡ Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle..... 6.08 500 ml Nepro HP RTH

### ➔ Restricted

#### Initiation

For patients with acute or chronic kidney disease.

**LOW ELECTROLYTE ORAL FEED – Restricted** see terms [below](#)

‡ Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can ..... *e.g. Kindergen*

### ➔ Restricted

#### Initiation

For children (up to 18 years) with acute or chronic kidney disease.

**LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML**

‡ Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton..... 2.67 220 ml Nepro HP (Strawberry)  
Nepro HP (Vanilla)

### ➔ Restricted

#### Initiation

For patients with acute or chronic kidney disease.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – <b>Restricted</b> see terms <a href="#">below</a></b>			
↓ Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton .....	3.31	237 ml	Novasource Renal (Vanilla)
↓ Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml bottle			
↓ Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton			<i>e.g. Renilon 7.5</i>
<b>→ Restricted</b>			
<b>Initiation</b>			
For patients with acute or chronic kidney disease.			

## Respiratory Products

<b>LOW CARBOHYDRATE ORAL FEED 1.5 KCAL/ML – <b>Restricted</b> see terms <a href="#">below</a></b>			
↓ Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, bottle .....	1.66	237 ml	Pulmocare (Vanilla)
<b>→ Restricted</b>			
<b>Initiation</b>			
For patients with CORD and hypercapnia, defined as a CO <sub>2</sub> value exceeding 55 mmHg.			

## Surgical Products

<b>HIGH ARGININE ORAL FEED 1.4 KCAL/ML – <b>Restricted</b> see terms <a href="#">below</a></b>			
↓ Liquid 10.1 g protein, 15 g carbohydrate, 4.5 g fat and 0 g fibre per 100 ml, carton.....	4.00	178 ml	Impact Advanced Recovery
<b>→ Restricted</b>			
<b>Initiation</b>			
Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery.			
<b>PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML – <b>Restricted</b> see terms <a href="#">below</a></b>			
↓ Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle.....	6.80	4	preOp
<b>→ Restricted</b>			
<b>Initiation</b>			
Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.			

## Standard Feeds

### → Restricted

#### Initiation

Any of the following:

For patients with malnutrition, defined as any of the following:

- Any of the following:
  - BMI < 18.5; or
  - Greater than 10% weight loss in the last 3-6 months; or
  - BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
- For patients who have, or are expected to, eat little or nothing for 5 days; or
- For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
4 For use pre- and post-surgery; or			
5 For patients being tube-fed; or			
6 For tube-feeding as a transition from intravenous nutrition; or			
7 For any other condition that meets the community Special Authority criteria.			
<b>ENTERAL FEED 1.5 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 5.4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 1,000 ml bottle			<i>e.g. Isosource Standard RTH</i>
† Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bag.....	7.00	1,000 ml	Nutrison Energy
† Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Energy Multi Fibre</i>
† Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can .....	1.75	250 ml	Ensure Plus HN
† Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag .....	7.00	1,000 ml	Ensure Plus HN RTH
† Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag.....	7.00	1,000 ml	Jevity HiCal RTH
<b>ENTERAL FEED 1 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle .....	5.29	1,000 ml	Osmolite RTH
† Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle .....	5.29	1,000 ml	Jevity RTH
† Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, can .....	1.32	237 ml	Jevity
† Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bag			<i>e.g. NutrisonStdRTH; NutrisonLowSodium</i>
† Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag			<i>e.g. Nutrison Multi Fibre</i>
<i>(Jevity Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, can to be delisted 1 June 2017)</i>			
<b>ENTERAL FEED 1.2 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag			<i>e.g. Jevity Plus RTH</i>
<b>ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per 100 ml, bag.....	5.29	1,000 ml	Nutrison 800 Complete Multi Fibre



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ORAL FEED – Restricted</b> see terms <a href="#">on page 223</a>			
† Powder 15.9 g protein, 57.4 g carbohydrate and 14 g fat per 100 g, can .....26.00		850 g	Ensure (Chocolate)
			Ensure (Vanilla)
† Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can .....26.00		850 g	Ensure (Chocolate)
			Ensure (Vanilla)
† Powder 21.9 g protein, 53.5 g carbohydrate and 14.5 g fat per 100 g, can .....3.67		350 g	Fortisip (Vanilla)
† Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can .....14.90		840 g	Sustagen Hospital Formula (Chocolate)
			Sustagen Hospital Formula (Vanilla)
Note: Community subsidy of Sustagen Hospital Formula is subject to both Special Authority criteria and a manufacturer's surcharge. Higher subsidy by endorsement is available for patients meeting the following endorsement criteria; fat malabsorption, fat intolerance or chyle leak.			
<i>(Ensure (Chocolate) Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can to be delisted 1 August 2017)</i>			
<i>(Ensure (Vanilla) Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can to be delisted 1 August 2017)</i>			
<b>ORAL FEED 1 KCAL/ML – Restricted</b> see terms <a href="#">on page 223</a>			
† Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml, 237 ml carton			<i>e.g. Resource Fruit Beverage</i>
<b>ORAL FEED 1.5 KCAL/ML – Restricted</b> see terms <a href="#">on page 223</a>			
† Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can .....1.33		237 ml	Ensure Plus (Vanilla)
† Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, carton.....1.26		200 ml	Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest) Ensure Plus (Vanilla)
† Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle			<i>e.g. Fortijuice</i>
† Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortisip</i>
† Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle			<i>e.g. Fortisip Multi Fibre</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Bacterial and Viral Vaccines

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – **Restricted** see terms [below](#)

<b>↓</b> Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe – 1% DV Jul-14 to 2017.....	0.00	10	<b>Infanrix IPV</b>
--	------	----	---------------------

→ **Restricted**

### Initiation

Any of the following:

- 1 A single dose for children up to the age of 7 who have completed primary immunisation; or
- 2 A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
- 3 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 4 Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE –

**Restricted** see terms [below](#)

<b>↓</b> Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial – 1% DV Jul-14 to 2017 .....	0.00	10	<b>Infanrix-hexa</b>
--	------	----	----------------------

→ **Restricted**

### Initiation

Any of the following:

- 1 Up to four doses for children up to and under the age of 10 for primary immunisation; or
- 2 An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 3 Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

## Bacterial Vaccines

ADULT DIPHTHERIA AND TETANUS VACCINE

<b>↓</b> Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe – 1% DV Jul-14 to 2017.....	0.00	5	<b>ADT Booster</b>
--	------	---	--------------------

→ **Restricted**

### Initiation

Any of the following:

- 1 For vaccination of patients aged 45 and 65 years old; or
- 2 For vaccination of previously unimmunised or partially immunised patients; or
- 3 For revaccination following immunosuppression; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 4 For boosting of patients with tetanus-prone wounds; or
- 5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**BACILLUS CALMETTE-GUERIN VACCINE – Restricted** see terms [below](#)

<p>↓ Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial Danish strain 1331, live attenuated, vial with diluent – <b>1% DV Oct-14 to 2017</b>.....</p>	0.00	10	<b>BCG Vaccine</b>
--	------	----	--------------------

→ **Restricted**

**Initiation**

All of the following:

For infants at increased risk of tuberculosis defined as:

- 1 Living in a house or family with a person with current or past history of TB; and
- 2 Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; and
- 3 During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.

Note: A list of countries with high rates of TB are available at <http://www.health.govt.nz/tuberculosis> (Search for Downloads) or [www.bcgatlas.org/index.php](http://www.bcgatlas.org/index.php)

**DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Restricted** see terms [below](#)

<p>↓ Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe – <b>1% DV Jul-14 to 2017</b>.....</p>	0.00	1 10	<b>Boostrix Boostrix</b>
--	------	---------	------------------------------

→ **Restricted**

**Initiation**

Any of the following:

- 1 A single vaccine for pregnant woman between gestational weeks 28 and 38; or
- 2 A course of up to four vaccines is funded for children from age 7 up to the age of 18 years inclusive to complete full primary immunisation; or
- 3 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens.

Note: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Restricted** see terms [below](#)

<p>↓ Inj 10 mcg vial with diluent syringe – <b>1% DV Jul-14 to 2017</b>.....</p>	0.00	1	<b>Act-HIB</b>
--	------	---	----------------

→ **Restricted**

**Initiation**

*Therapy limited to 1 dose*

Any of the following:

- 1 For primary vaccination in children; or
- 2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or
- 3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE – Restricted</b> see terms <a href="#">below</a>			
<b>†</b> Inj 4 mcg or each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial – <b>1% DV Jul-14 to 2017</b> .....	0.00	1	<b>Menactra</b>
<b>⇒ Restricted</b>			
<b>Initiation</b>			
Any of the following:			
1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or			
2 One dose for close contacts of meningococcal cases; or			
3 A maximum of two doses for bone marrow transplant patients; or			
4 A maximum of two doses for patients following immunosuppression*.			
Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.			
*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.			
<b>MENINGOCOCCAL C CONJUGATE VACCINE – Restricted</b> see terms <a href="#">below</a>			
<b>†</b> Inj 10 mcg in 0.5 ml syringe – <b>1% DV Jul-14 to 2017</b> .....	0.00	1 10	<b>Neisvac-C</b> <b>Neisvac-C</b>
<b>⇒ Restricted</b>			
<b>Initiation</b>			
Any of the following:			
1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or			
2 One dose for close contacts of meningococcal cases; or			
3 A maximum of two doses for bone marrow transplant patients; or			
4 A maximum of two doses for patients following immunosuppression*.			
Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.			
*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.			
<b>PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – Restricted</b> see terms <a href="#">below</a>			
<b>†</b> Inj 30.8 mcg in 0.5 ml syringe – <b>1% DV Oct-14 to 2017</b> .....	0.00	1 10	<b>Prevenar 13</b> <b>Prevenar 13</b>
<b>⇒ Restricted</b>			
<b>Initiation</b>			
Any of the following:			
1 A primary course of up to four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or			
2 Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV10; or			
3 One dose is funded for high risk children (over the age of 17 months and up to the age of 18) who have previously received four doses of PCV10; or			
4 Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients with HIV, for patients post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, primary immunodeficiency; or			
5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.			
Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes			
<b>PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – Restricted</b> see terms <a href="#">on the next page</a>			
<b>†</b> Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) – <b>1% DV Jun-15 to 2017</b> .....	0.00	1	<b>Pneumovax 23</b>

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

➔ **Restricted****Initiation**

Any of the following:

- 1 Up to three doses (as appropriate) for patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy; functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or
- 2 Up to two doses are funded for high risk children to the age of 18; or
- 3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

SALMONELLA TYPHI VACCINE – **Restricted** see terms [below](#)

↓ Inj 25 mcg in 0.5 ml syringe

➔ **Restricted****Initiation**

For use during typhoid fever outbreaks.

**Viral Vaccines**HEPATITIS A VACCINE – **Restricted** see terms [below](#)↓ Inj 720 ELISA units in 0.5 ml syringe – **1% DV Jul-14 to 2017** ..... 0.00

1

**Havrix Junior**↓ Inj 1440 ELISA units in 1 ml syringe – **1% DV Jul-14 to 2017** ..... 0.00

1

**Havrix**➔ **Restricted****Initiation**

All of the following:

- 1 Two vaccinations for use in transplant patients; and
- 2 Two vaccinations for use in children with chronic liver disease; and
- 3 One dose of vaccine for close contacts of known hepatitis A cases.

HEPATITIS B RECOMBINANT VACCINE

↓ Inj 5 mcg in 0.5 ml vial – **1% DV Jul-14 to 2017**

0.00

1

**HBvaxPRO**➔ **Restricted****Initiation**

Any of the following:

- 1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
- 2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
- 3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or
- 4 For HIV positive patients; or
- 5 For hepatitis C positive patients; or
- 6 For patients following non-consensual sexual intercourse; or
- 7 For patients following immunosuppression; or
- 8 For transplant patients; or
- 9 following needle stick injury.

↓ Inj 10 mcg in 1 ml vial – **1% DV Jul-14 to 2017** ..... 0.00

1

**HBvaxPRO**➔ **Restricted****Initiation**

Any of the following:

- 1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
- 2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or
- 4 For HIV positive patients; or
- 5 For hepatitis C positive patients; or
- 6 for patients following non-consensual sexual intercourse; or
- 7 For patients following immunosuppression; or
- 8 For transplant patients; or
- 9 following needle stick injury.

↓ Inj 40 mcg per 1 ml vial – **1% DV Jul-14 to 2017**

0.00 1 **HBvaxPRO**

➔ **Restricted**

**Initiation**

Both:

- 1 For dialysis patients; and
- 2 For liver or kidney transplant patient.

HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] – **Restricted** see terms [below](#)

↓ Inj 120 mcg in 0.5 ml syringe – **1% DV Jul-14 to 2017** ..... 0.00 10 **Gardasil**  
(Gardasil Inj 120 mcg in 0.5 ml syringe to be delisted 1 October 2017)

➔ **Restricted**

**Initiation – people aged 9 to 26 years**

*Therapy limited to 3 doses*

Up to three doses for people aged 9 to 26 years inclusive.

**Initiation – post chemotherapy**

*Therapy limited to 4 doses*

Up to 4 doses for people aged 9 to 26 years inclusive, post chemotherapy.

HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] – **Restricted** see terms [below](#)

↓ Inj 270 mcg in 0.5 ml syringe – **0% DV Jul-17 to 2020** ..... 0.00 10 **Gardasil 9**

➔ **Restricted**

**Initiation – Children aged 14 years and under**

*Therapy limited to 2 doses*

Children aged 14 years and under.

**Initiation – other conditions**

Either:

- 1 Up to 3 doses for people aged 15 to 26 years inclusive; or
- 2 Both:
  - 2.1 People aged 9 to 26 years inclusive; and
  - 2.2 Any of the following:
    - 2.2.1 Up to 3 doses for confirmed HIV infection; or
    - 2.2.2 Up to 3 doses for transplant (including stem cell) patients; or
    - 2.2.3 Up to 4 doses for Post chemotherapy.

INFLUENZA VACCINE – **Restricted** see terms [below](#)

↓ Inj 45 mcg in 0.5 ml syringe – **0% DV Feb-17 to 31 Dec 2019** ..... 90.00 10 **Influvac**

➔ **Restricted**

**Initiation – People over 65**

The patient is 65 years of age or over.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

### Initiation – cardiovascular disease

Any of the following:

- 1 Ischaemic heart disease; or
- 2 Congestive heart failure; or
- 3 Rheumatic heart disease; or
- 4 Longenital heart disease; or
- 5 Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

### Initiation – chronic respiratory disease

Either:

- 1 Asthma, if on a regular preventative therapy; or
- 2 Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

### Initiation – Other conditions

Any of the following:

- 1 Any of the following:
  - 1.1 Diabetes; or
  - 1.2 chronic renal disease; or
  - 1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
  - 1.4 Autoimmune disease; or
  - 1.5 Immune suppression or immune deficiency; or
  - 1.6 HIV; or
  - 1.7 Transplant recipient; or
  - 1.8 Neuromuscular and CNS diseases/ disorders; or
  - 1.9 Haemoglobinopathies; or
  - 1.10 Is a child on long term aspirin; or
  - 1.11 Has a cochlear implant; or
  - 1.12 Errors of metabolism at risk of major metabolic decompensation; or
  - 1.13 Pre and post splenectomy; or
  - 1.14 Down syndrome; or
  - 1.15 Is pregnant; or
  - 1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or
- 2 Patients who are compulsorily detained long-term in a forensic unit within a DHB hospital; or
- 3 People under 18 years of age living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board).

MEASLES, MUMPS AND RUBELLA VACCINE – **Restricted** see terms [below](#)

↓ Inj 1000 TCID50 measles, 12500 TCID50 mumps and  
1000 TCID50 rubella vial with diluent – **1% DV Jul-14 to 2017** ..... 0.00 10 **M-M-R-II**

### ➔ Restricted

### Initiation – first dose prior to 12 months

*Therapy limited to 3 doses*

Any of the following:

- 1 For primary vaccination in children; or
- 2 For revaccination following immunosuppression; or
- 3 For any individual susceptible to measles, mumps or rubella.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
<b>Initiation – first dose after 12 months</b>			
<i>Therapy limited to 2 doses</i>			
Any of the following:			
1 For primary vaccination in children; or			
2 For revaccination following immunosuppression; or			
3 For any individual susceptible to measles, mumps or rubella.			
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.			
<b>POLIOMYELITIS VACCINE – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 80 D-antigen units in 0.5 ml syringe – <b>1% DV Jul-14 to 2017</b>	0.00	1	<b>IPOL</b>
➡ <b>Restricted</b>			
<b>Initiation</b>			
<i>Therapy limited to 3 doses</i>			
Either:			
1 For partially vaccinated or previously unvaccinated individuals; or			
2 For revaccination following immunosuppression.			
Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.			
<b>RABIES VACCINE</b>			
Inj 2.5 IU vial with diluent			
<b>ROTAVIRUS LIVE REASSORTANT ORAL VACCINE – Restricted</b> see terms <a href="#">below</a>			
⚡ Oral susp G1, G2, G3, G4, P1(8) 11.5 million CCID50 units per 2 ml, tube – <b>1% DV Jul-14 to 2017</b>	0.00	10	<b>RotaTeg</b>
➡ <b>Restricted</b>			
<b>Initiation</b>			
<i>Therapy limited to 3 doses</i>			
Both:			
1 First dose to be administered in infants aged under 15 weeks of age; and			
2 No vaccination being administered to children aged 8 months or over.			
<b>VARICELLA VACCINE [CHICKEN POX VACCINE] – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 2,000 PFU vial with diluent – <b>1% DV Jul-14 to 2017</b>	0.00	1	<b>Varilrix</b>
➡ <b>Restricted</b>			
<b>Initiation</b>			
<i>Therapy limited to 2 doses</i>			
Any of the following:			
1 Any of the following:			
for non-immune patients			
1.1 With chronic liver disease who may in future be candidates for transplantation; or			
1.2 With deteriorating renal function before transplantation; or			
1.3 Prior to solid organ transplant; or			
1.4 Prior to any elective immunosuppression*; or			
1.5 For post exposure prophylaxis who are immune competent inpatients.; or			
2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or			
3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or			
4 For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or			
5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of			
continued...			



	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

continued...

- varicella; or
- 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
- 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: \* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

## PART III: OPTIONAL PHARMACEUTICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Optional Pharmaceuticals</b>			
<b>NOTE:</b>			
In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a number of additional Optional Pharmaceuticals, including some wound care products and disposable laparoscopic equipment, are listed in an addendum to Part III which is available at <a href="http://www.pharmac.govt.nz">www.pharmac.govt.nz</a> . The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.			
<b>BLOOD GLUCOSE DIAGNOSTIC TEST METER</b>			
1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips .....	20.00	1	Caresens II Caresens N Caresens N POP
Meter .....	19.00	1	Accu-Chek Performa FreeStyle Lite On Call Advanced
	9.00		
<b>BLOOD GLUCOSE DIAGNOSTIC TEST STRIP</b>			
Blood glucose test strips .....	28.75	50 test	Accu-Chek Performa CareSens CareSens N FreeStyle Lite Freestyle Optium
	10.56		
	21.65		
	28.75		
Blood glucose test strips x 50 and lancets x 5 .....	19.10	50 test	On Call Advanced
<b>BLOOD KETONE DIAGNOSTIC TEST METER</b>			
Meter .....	40.00	1	Freestyle Optium Neo
<b>INSULIN PEN NEEDLES</b>			
29 g x 12.7 mm .....	10.50	100	B-D Micro-Fine
31 g x 5 mm .....	11.75	100	B-D Micro-Fine
31 g x 6 mm .....	10.50	100	ABM
31 g x 8 mm .....	10.50	100	B-D Micro-Fine
32 g x 4 mm .....	10.50	100	B-D Micro-Fine
<b>INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE</b>			
Syringe 0.3 ml with 29 g x 12.7 mm needle .....	13.00	100	B-D Ultra Fine
Syringe 0.3 ml with 31 g x 8 mm needle .....	13.00	100	B-D Ultra Fine II
Syringe 0.5 ml with 29 g x 12.7 mm needle .....	13.00	100	B-D Ultra Fine
Syringe 0.5 ml with 31 g x 8 mm needle .....	13.00	100	B-D Ultra Fine II
Syringe 1 ml with 29 g x 12.7 mm needle .....	13.00	100	B-D Ultra Fine
Syringe 1 ml with 31 g x 8 mm needle .....	13.00	100	B-D Ultra Fine II
<b>KETONE BLOOD BETA-KETONE ELECTRODES</b>			
Test strips .....	15.50	10 strip	Freestyle Optium Ketone
<b>MASK FOR SPACER DEVICE</b>			
Small .....	2.20	1	e-chamber Mask
<b>PEAK FLOW METER</b>			
Low Range .....	9.54	1	Mini-Wright AFS Low Range
Normal Range .....	9.54	1	Mini-Wright Standard
<b>PREGNANCY TEST - HCG URINE</b>			
Cassette – 1% DV Sep-15 to 2017 .....	17.60	40 test	<b>EasyCheck</b>
<b>SODIUM NITROPRUSSIDE</b>			
Test strip .....	6.00	50 strip	Accu-Chek Ketur-Test

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SPACER DEVICE			
220 ml (single patient) .....	2.95	1	e-chamber Turbo
510 ml (single patient) .....	5.12	1	e-chamber La Grande
800 ml.....	6.50	1	Volumatic

<b>- Symbols -</b>		Renin-Angiotensin System.....	42	Infections.....	82
8-methoxypsoralen.....	58	Agents for Parkinsonism and Related Disorders.....	109	Amsacrine.....	138
<b>- A -</b>		Agents Used in the Treatment of Poisonings.....	200	Amyl nitrite.....	51
A-Scabies.....	55	Ajmaline.....	44	Anabolic Agents.....	65
Abacavir sulphate.....	89	Alanase.....	186	Anaesthetics.....	110
Abacavir sulphate with lamivudine.....	89	Albendazole.....	85	Anagrelide hydrochloride.....	138
Abciximab.....	156	Alendronate sodium.....	99	Analgesics.....	113
Abilify.....	125	Alendronate sodium with colecalciferol.....	101	Anastrozole.....	149
Abiraterone acetate.....	147	Alfacalcidol.....	27	Andriol Testocaps.....	65
Acarbose.....	16	Alfamino Junior.....	219	Androderm.....	65
Accu-Chek Ketur-Test.....	234	Alfentanil.....	114	Androgen Agonists and Antagonists.....	65
Accu-Chek Performa.....	234	Alglucosidase alfa.....	21	Anexate.....	200
Accuretic 10.....	42	Alinia.....	86	Anoro Ellipta.....	189
Accuretic 20.....	42	Alitraq.....	217	Antabuse.....	134
Acetazolamide.....	197	Allersoothe.....	187	Antacids and Antiflatulents.....	13
Acetic acid		Allopurinol.....	104	Anti-Infective Agents.....	60
Extemporaneously Compounded Preparations.....	208	Allopurinol-Apotex.....	104	Anti-Infective Preparations	
Genito-Urinary.....	60	Alpha tocopheryl acetate.....	27	Dermatological.....	54
Acetic acid with hydroxyquinoline, glycerol and ricinoleic acid.....	60	Alpha-Adrenoceptor Blockers.....	43	Sensory.....	194
Acetic acid with propylene glycol.....	199	Alprazolam.....	129	Anti-Inflammatory Preparations.....	195
Acetylcholine chloride.....	197	Alprostadiol hydrochloride.....	51	Antiacne Preparations.....	55
Acetylcysteine.....	200	Alteplase.....	36	Antiallergy Preparations.....	186
Aciclovir		Alum.....	208	Antianaemics.....	29
Infections.....	95	Aluminium chloride.....	31	Antiarhythmics.....	44
Sensory.....	194	Aluminium hydroxide.....	13	Antibacterials.....	75
Aciclovir-Claris.....	95	Aluminium hydroxide with magnesium hydroxide and simethicone.....	13	Anticholinergic Agents.....	187
Acid Citrate Dextrose A.....	34	Amantadine hydrochloride.....	109	Anticholinesterases.....	99
Acidex.....	13	AmBisome.....	82	Antidepressants.....	116
Acipimox.....	50	Ambrisentan.....	52	Antidiarrhoeals and Intestinal Anti-Inflammatory Agents.....	13
Acitretin.....	58	Amethocaine		Antiepilepsy Drugs.....	118
Aclasta.....	102	Nervous.....	113	Antifibrinolytics, Haemostatics and Local Sclerosants.....	31
Act-HIB.....	227	Sensory.....	196	Antifibrotics.....	189
Actemra.....	178	Amikacin.....	75	Antifungals.....	82
Actinomycin D.....	136	Amiloride hydrochloride.....	48	Antihypotensives.....	44
Adalimumab.....	156	Amiloride hydrochloride with furosemide.....	48	Antimigraine Preparations.....	123
Adapalene.....	55	Amiloride hydrochloride with hydrochlorothiazide.....	48	Antimycobacterials.....	84
Adefin XL.....	46	Aminophylline.....	192	Antinausea.....	124
Adefovir dipivoxil.....	91	Amiodarone hydrochloride.....	44	Antinausea and Vertigo Agents.....	123
Adenosine.....	44	Amisulpride.....	125	Antiparasitics.....	85
Adenuric.....	105	Amitriptyline.....	116	Antipruritic Preparations.....	55
Adrenaline.....	51	Amlodipine.....	46	Antipsychotic Agents.....	125
ADT Booster.....	226	Amorolfine.....	54	Antiretrovirals.....	87
Adult diphtheria and tetanus vaccine.....	226	Amoxicillin.....	78	Antirheumatoid Agents.....	99
Advantan.....	57	Amoxicillin Actavis.....	78	Antiseptics and Disinfectants.....	202
Advate.....	33	Amoxicillin with clavulanic acid.....	78	Antispasmodics and Other Agents	
Aerrane.....	110	Amphotericin B		Altering Gut Motility.....	15
Afinitor.....	185	Alimentary.....	25	Antithrombotics.....	34
AFT SLS-free.....	56			Antithymocyte globulin (equine).....	184
Agents Affecting the				Antithymocyte globulin (rabbit).....	184
				Antitumorcerants.....	15

69

Barium sulphate with sodium bicarbonate.....	204	Bezalip.....	48	fenatanyl.....	111
Barrier Creams and Emollients.....	55	Bezalip Retard.....	48	Bupivacaine hydrochloride with glucose.....	111
Basiliximab.....	162	Bicalaccord.....	148	Buprenorphine with naloxone.....	134
BCG Vaccine.....	227	Bicalutamide.....	148	Bupropion hydrochloride.....	134
BD PosiFlush.....	40	Bicillin LA.....	78	Burinex.....	47
Beclazone 100.....	190	BiCNU.....	136	Buscopan.....	15
Beclazone 250.....	190	Bile and Liver Therapy.....	16	Buserelin.....	69
Beclazone 50.....	190	Biliscopin.....	205	Bupirone hydrochloride.....	129
Beclomethasone dipropionate.....	186, 190	Bimatoprost.....	198	Busulfan.....	136
Bee venom.....	186	Bimatoprost Actavis.....	198	Butacort Aqueous.....	187
Bendrofluazide.....	48	Biodone.....	114	<b>- C -</b>	
Bendroflumethiazide [Bendrofluazide].....	48	Biodone Extra Forte.....	114		
BeneFIX.....	32	Biotin.....	21	Cabergoline.....	68
Benzathine benzylpenicillin.....	78	Bisacodyl.....	20	Caffeine.....	132
Benzatropine mesylate.....	109	Bismuth subgallate.....	208	Caffeine citrate.....	192
Benzbromaron AL 100.....	104	Bismuth subnitrate and iodoform paraffin.....	206	Calamine.....	55
Benzbromarone.....	104	Bisoprolol fumarate.....	45	Calcipotriol.....	58
Benzocaine.....	111	Bivalirudin.....	34	Calcitonin.....	65
Benzoin.....	208	Bleomycin sulphate.....	136	Calcitriol.....	27
Benzoyl peroxide.....	55	Blood glucose diagnostic test meter.....	234	Calcitriol-AFT.....	27
Benzotrop.....	109	Blood glucose diagnostic test strip.....	234	Calcium carbonate.....	13, 23
Benzylamine hydrochloride.....	25	Blood ketone diagnostic test meter.....	234	Calcium Channel Blockers.....	46
Benzylamine hydrochloride with cetylpyridinium chloride.....	25	Bonney's blue dye.....	205	Calcium chloride.....	38
Benzylpenicillin sodium [Penicillin G].....	78	Boostrix.....	227	Calcium folinate.....	147
Beractant.....	192	Boric acid.....	208	Calcium Folate Ebewe.....	147
Beta Cream.....	57	Bortezomib.....	138	Calcium gluconate.....	
Beta Ointment.....	57	Bosentan.....	52	Blood.....	38
Beta Scalp.....	58	Bosvate.....	45	Dermatological.....	59
Beta-Adrenoceptor Agonists.....	189	Botox.....	106	Calcium Homeostasis.....	65
Beta-Adrenoceptor Blockers.....	45	Botulism antitoxin.....	200	Calcium polystyrene sulphonate.....	40
Betadine.....	202	Bplex.....	27	Calcium Resonium.....	40
Betadine Skin Prep.....	202	Breo Ellipta.....	191	Calsource.....	23
Betagan.....	197	Bridion.....	106	Candacis.....	83
Betahistine dihydrochloride.....	123	Brilinta.....	36	Candesartan cilexetil.....	43
Betaine.....	21	Brimonidine tartrate.....	198	Candestar.....	43
Betamethasone.....	66	Brimonidine tartrate with timolol.....	198	Capecitabine.....	137
Betamethasone dipropionate.....	57	Brinov.....	137	Capoten.....	42
Betamethasone dipropionate with calcipotriol.....	58	Brinzolamide.....	197	Capsaicin.....	
Betamethasone sodium phosphate with betamethasone acetate.....	66	Bromocriptine.....	109	Musculoskeletal.....	108
Betamethasone valerate.....	57-58	Brufen SR.....	107	Nervous.....	113
Betamethasone valerate with clioquinol.....	58	Budesonide.....		Captopril.....	42
Betamethasone valerate with fusidic acid.....	58	Alimentary.....	13	Carbamazepine.....	119
Betaxolol.....	197	Respiratory.....	187, 190	Carbasorb-X.....	201
Betoptic.....	197	Budesonide with eformoterol.....	191	Carbimazole.....	73
Betoptic S.....	197	Bumetanide.....	47	Carbomer.....	198
Bevacizumab.....	162	Bupafen.....	111	Carboplatin.....	142
Bezafibrate.....	48	Bupivacaine hydrochloride.....	111	Carboprost trometamol.....	62
		Bupivacaine hydrochloride with adrenaline.....	111	Carboxymethylcellulose.....	
		Bupivacaine hydrochloride with		Alimentary.....	25
				Extemporaneously Compounded Preparations.....	208
				Cardinol LA.....	45
				Cardizem CD.....	47
				CareSens.....	234
				Caresens II.....	234
				Caresens N.....	234

Caresens N POP .....	234	Chlorhexidine with ethanol .....	202	Clomazol .....	
Carmellose sodium with pectin and gelatine .....		Chloroform .....	208	Dermatological .....	54
Alimentary .....	25	Chloroquine phosphate .....	86	Genito-Urinary .....	60
Sensory .....	199	Chlorothiazide .....	48	Clomifene citrate .....	68
Carmustine .....	136	Chlorpheniramine maleate .....	187	Clomipramine hydrochloride .....	116
Carvedilol .....	45	Chlorpromazine hydrochloride .....	125	Clonazepam .....	118-119, 129
Caspofungin .....	83	Chlorsig .....	194	Clonidine .....	47
Catapres .....	47	Chlortalidone [Chlorthalidone] .....	48	Clonidine BNM .....	47
Catapres-TTS-1 .....	47	Chlorthalidone .....	48	Clonidine hydrochloride .....	47
Catapres-TTS-2 .....	47	Choice Load 375 .....	60	Clopidogrel .....	36
Catapres-TTS-3 .....	47	Choice TT380 Short .....	60	Clopine .....	126
Ceenu .....	136	Choice TT380 Standard .....	60	Clopixol .....	127, 129
Cefaclor .....	76	Cholestyramine .....	49	Clostridium botulinum type A toxin .....	106
Cefalexin .....	76	Choline salicylate with cetalkonium chloride .....	25	Clotrimazole .....	
Cefalexin Sandoz .....	76	Cholvastin .....	49	Dermatological .....	54
Cefazolin .....	76	Choriogonadotropin alfa .....	69	Genito-Urinary .....	60
Cefepime .....	76	Ciclopirox olamine .....	54	Clove oil .....	208
Cefepime-AFT .....	76	Ciclosporin .....	149	Clozapine .....	126
Cefotaxime .....	76	Cidofovir .....	95	Clozaril .....	126
Cefotaxime Sandoz .....	76	Cilazapril .....	42	Clustran .....	123
Cefoxitin .....	76	Cilazapril with hydrochlorothiazide .....	42	Co-trimoxazole .....	81
Cefoxitin Actavis .....	76	Cilicaine .....	78	Coal tar .....	208
Ceftaroline fosamil .....	77	Cilicaine VK .....	78	Coal tar with salicylic acid and sulphur .....	58
Ceftazidime .....	76	Cimetidine .....	15	Cocaine hydrochloride .....	111
Ceftriaxone .....	76	Cinacalcet .....	65	Cocaine hydrochloride with adrenaline .....	112
Ceftriaxone-AFT .....	76	Cinchocaine hydrochloride with hydrocortisone .....	14	Codeine phosphate .....	
Cefuroxime .....	76	Cipflox .....	79	Extemporaneously Compounded Preparations .....	208
Celecoxib .....	107	Ciprofloxacin .....		Nervous .....	114
Celiprolol .....	45	Infections .....	79	Cogentin .....	109
CellCept .....	185	Sensory .....	194	Colaspase [L-asparaginase] .....	139
Celol .....	45	Ciprofloxacin with hydrocortisone .....	194	Colchicine .....	105
Centrally-Acting Agents .....	47	Ciproxin HC Otic .....	194	Colecalciferol .....	27
Cephalexin ABM .....	76	Cisplatin .....	142	Colestimethate .....	80
Cetirizine hydrochloride .....	187	Citalopram hydrobromide .....	118	Colestipol hydrochloride .....	49
Cetomacrogol .....	56	Citanest .....	112	Colgout .....	105
Cetomacrogol with glycerol .....	56	Citric acid .....	208	Colifoam .....	14
Cetrimide .....	208	Citric acid with magnesium oxide and sodium picosulfate .....	19	Colistin sulphomethate [Colestimethate] .....	80
Champix .....	135	Citric acid with sodium bicarbonate .....	204	Colistin-Link .....	80
Charcoal .....	201	Cladribine .....	137	Collodion flexible .....	208
Chemotherapeutic Agents .....	136	Clarithromycin .....	77	Colloidal bismuth subcitrate .....	16
Chicken pox vaccine .....	232	Clexane .....	34	Colofac .....	15
Chlorafast .....	194	Clindamycin .....	80	Colony-Stimulating Factors .....	37
Chloral hydrate .....	131	Clindamycin ABM .....	80	Coloxyl .....	20
Chlorambucil .....	136	Clinicians Multivit & Mineral Boost .....	25	Compound electrolytes .....	38, 40
Chloramphenicol .....		Clinicians Renal Vit .....	26	Compound electrolytes with glucose .....	38, 40
Infections .....	80	Clobazam .....	119	Compound hydroxybenzoate .....	208
Sensory .....	194	Clobetasol propionate .....	57-58	Compound sodium lactate [Hartmann's solution] .....	38
Chlorhexidine .....	202, 206	Clobetasone butyrate .....	57	Compound sodium lactate with glucose .....	38
Chlorhexidine gluconate .....		Clofazimine .....	84		
Alimentary .....	25				
Extemporaneously Compounded Preparations .....	208				
Genito-Urinary .....	60				
Chlorhexidine with cetrimide .....	202, 206				

Concerta.....	132	DBL Aminophylline.....	192	Dextrose	
Condylone.....	59	DBL Bleomycin Sulfate.....	136	Alimentary.....	17
Contraceptives.....	60	DBL Carboplatin.....	142	Blood.....	38
Contrast Media.....	203	DBL Cefotaxime.....	76	Extemporaneously Compounded	
Cordarone-X.....	44	DBL Cisplatin.....	142	Preparations.....	208
Corticosteroids		DBL Dacarbazine.....	139	Dextrose with sodium citrate and	
Dermatological.....	57	DBL Docetaxel.....	146	citric acid [Acid Citrate Dextrose	
Hormone Preparations.....	66	DBL Ergometrine.....	62	A].....	34
Corticotrorelin (ovine).....	69	DBL Leucovorin Calcium.....	147	DHC Continus.....	114
Cosmegen.....	136	DBL Meropenem.....	76	Diabetes.....	16
Cough Suppressants.....	189	DBL Methotrexate Onco-Vial.....	138	Diacomit.....	121
Creon 10000.....	18	DBL Morphine Sulphate.....	115	Diagnostic Agents.....	205
Creon 25000.....	18	DBL Morphine Tartrate.....	115	Diagnostic and Surgical	
Crotamiton.....	55	DBL Pethidine Hydrochloride.....	116	Preparations.....	196
Crystaderm.....	54	DBL Rocuronium Bromide.....	106	Diamide Relief.....	13
CT Plus+.....	204	DBL Sterile Dopamine		Diamox.....	197
Cubicin.....	80	Concentrate.....	51	Diatrizoate meglumine with sodium	
Curosurf.....	192	DBL Vincristine Sulfate.....	147	amidotrizoate.....	203
Cvite.....	27	DDI.....	89	Diatrizoate sodium.....	203
Cyclizine hydrochloride.....	123	De-Worm.....	85	Diazepam.....	118, 129
Cyclizine lactate.....	123	Decongestants.....	189	Diazoxide	
Cyclogyl.....	198	Decongestants and		Alimentary.....	16
Cyclopentolate hydrochloride.....	198	Antiallergics.....	195	Cardiovascular.....	51
Cyclophosphamide.....	136	Decozol.....	25	Dicarz.....	45
Cycloserine.....	84	Deferasirox.....	201	Dichlorobenzyl alcohol with	
Cyklokapron.....	32	Deferiprone.....	201	amylmetacresol.....	25
Cymevene.....	95	Defibrotide.....	34	Diclofenac Sandoz.....	107
Cyproheptadine hydrochloride.....	187	Definity.....	205	Diclofenac sodium	
Cyproterone acetate.....	65	Demeclocycline hydrochloride.....	80	Musculoskeletal.....	107
Cyproterone acetate with		Deoxycoformycin.....	140	Sensory.....	195
ethinyloestradiol.....	60	Depo-Medrol.....	67	Dicobalt edetate.....	201
Cysteamine hydrochloride.....	208	Depo-Medrol with Lidocaine.....	67	Didanosine [DDI].....	89
Cytarabine.....	137	Depo-Provera.....	61	Diflucan.....	82
Cytotec.....	15	Depo-Testosterone.....	65	Diflucortolone valerate.....	57
<b>- D -</b>				Digestives Including Enzymes.....	18
D-Penamine.....	99	Deprim.....	81	Digoxin.....	44
Dabigatran.....	34	DermAssist.....	57	Digoxin immune Fab.....	200
Dacarbazine.....	139	Dermol.....	57-58	Dihydrocodeine tartrate.....	114
Dactinomycin [Actinomycin D].....	136	Desferal.....	201	Dihydroergotamine mesylate.....	123
Daivobet.....	58	Desferrioxamine mesilate.....	201	Diltiazem hydrochloride.....	47
Daivonex.....	58	Desflurane.....	110	Dilzem.....	47
Dalacin C.....	80	Desmopressin acetate.....	74	Dimercaprol.....	201
Dalteparin.....	34	Desmopressin-PH&T.....	74	Dimercaptosuccinic acid.....	202
Danaparoid.....	34	Dexamethasone		Dimethicone.....	55
Danazol.....	68	Hormone Preparations.....	66	Dimethyl fumarate.....	130
Dantrium.....	106	Sensory.....	195	Dimethyl sulfoxide.....	206
Dantrium IV.....	106	Dexamethasone phosphate.....	66	Dinoprostone.....	62
Dantrolene.....	106	Dexamethasone with framycetin and		Diphemanyl metilsulfate.....	59
Dapa-Tabs.....	48	gramicidin.....	194	Diphenoxylate hydrochloride with	
Dapsone.....	84	Dexamethasone with neomycin		atropine sulphate.....	13
Daptomycin.....	80	sulphate and polymyxin B		Diphtheria antitoxin.....	200
Darunavir.....	90	sulphate.....	194	Diphtheria, tetanus and pertussis	
Dasatinib.....	142	Dexamethasone with		vaccine.....	227
Daunorubicin.....	136	tobramycin.....	194	Diphtheria, tetanus, pertussis and	
DBL Acetylcysteine.....	200	Dexamfetamine sulfate.....	132	polio vaccine.....	226
DBL Amikacin.....	75	Dexmedetomidine.....	110	Diphtheria, tetanus, pertussis, polio,	
		Dexmethsone.....	66		



hepatitis B and haemophilus influenzae type B vaccine.....	226	e-chamber La Grande .....	235	e.g. IVA Anamix Infant.....	214
Dipyridamole.....	36	e-chamber Mask.....	234	e.g. Jevity Plus RTH.....	224
Disodium edetate.....	197	e-chamber Turbo.....	235	e.g. Karicare Aptamil Gold De-Lact.....	220
Disodium hydrogen phosphate with sodium dihydrogen phosphate.....	208	E-Mycin.....	77	e.g. Karicare Aptamil Gold+ Preterm.....	221
Disopyramide phosphate.....	44	E-Z-Cat Dry .....	204	e.g. Karicare Aptamil Thickened AR.....	221
Disulfiram.....	134	E-Z-Gas II .....	204	e.g. Kindergen.....	222
Dithranol.....	208	E-Z-Paste .....	204	e.g. Kinson.....	110
Diuretics.....	47	e.g. Alpha Keri Bath Oil.....	56	e.g. Liquigen.....	212
Diurin 40 .....	47	e.g. AlphaKeri;BK ;DP; Hydroderm Lotn.....	56	e.g. Locasol.....	220
Dobutamine hydrochloride.....	51	e.g. Aptamil Gold+ Pepti Junior.....	220	e.g. MCT Oil.....	212
Dobutamine-Claris.....	51	e.g. Aridol.....	205	e.g. MCT Peptide; MCT Peptide 1+.....	217
Docetaxel.....	146	e.g. Balanced Salt Solution .....	196	e.g. MMA/PA Anamix Infant.....	215
Docusate sodium Alimentary.....	20	e.g. Benerva.....	27	e.g. Modecate.....	128
Sensory.....	199	e.g. Calogen.....	211	e.g. Monogen.....	217
Docusate sodium with sennosides .....	20	e.g. Cardioplegia Base Solution.....	207	e.g. MSUD Anamix Infant.....	214
Dolutegravir.....	91	e.g. Cardioplegia Electrolyte Solution.....	207	e.g. MSUD Anamix Junior LQ .....	214
Domperidone.....	124	e.g. Cardioplegia Enriched Paed. Soln.....	207	e.g. MSUD Maxamum.....	214
Donepezil hydrochloride.....	133	e.g. Cardioplegia Enriched Solution.....	207	e.g. Mylanta.....	13
Donepezil-Rex.....	133	e.g. Cardioplegia Solution AHB7832 .....	207	e.g. Mylanta Double Strength.....	13
Dopamine hydrochloride.....	51	e.g. Circadin.....	131	e.g. Neocate.....	219
Dopress.....	116	e.g. Clopixol Conc.....	129	e.g. Neocate Advance .....	219
Dornase alfa.....	192	e.g. Custodiol-HTK.....	207	e.g. Neocate LCP .....	219
Dorzolamide .....	197	e.g. Dialamine.....	216	e.g. Nicorette Inhalator.....	135
Dorzolamide with timolol.....	197	e.g. Diasip .....	217	e.g. Nicorette QuickMist Mouth Spray.....	135
Dostinex.....	68	e.g. Driclor.....	31	e.g. Nutricia Breast Milk Fortifer.....	212
Dosulepin [Dothiepin] hydrochloride.....	116	e.g. E-Z-GAS II.....	204	e.g. Nutrini Energy RTH .....	222
Dotarem.....	204	e.g. Easiphen.....	215	e.g. Nutrini RTH.....	222
Dothiepin.....	116	e.g. Easy Thick.....	213	e.g. Nutrison Advanced Diason.....	216
Doxapram.....	192	e.g. Elemental 028 Extra.....	217	e.g. Nutrison Advanced Peptisorb.....	217
Doxazosin.....	43	e.g. Essential Amino Acid Mix.....	216	e.g. Nutrison Energy Multi Fibre.....	224
Doxepin hydrochloride.....	116	e.g. Feed Thickener Karicare Aptamil.....	213	e.g. Nutrison Multi Fibre.....	224
Doxine.....	80	e.g. FM 85 .....	212	e.g. Nutrison Protein Plus.....	218
Doxorubicin Ebewe.....	136	e.g. Fortijuice.....	225	e.g. Nutrison Protein Plus Multi Fibre.....	219
Doxorubicin hydrochloride.....	136	e.g. Fortini.....	222	e.g. NutrisonStdRTH; NutrisonLowSodium .....	224
Doxycycline.....	80	e.g. Fortini Multifibre.....	222	e.g. Pabrinex IM.....	26
DP Fusidic Acid Cream .....	54	e.g. Fortisip.....	225	e.g. Pabrinex IV.....	26
DP Lotn HC .....	57	e.g. Fortisip Multi Fibre.....	225	e.g. Paediatric Seravit.....	26
DP-Anastrozole .....	149	e.g. GA1 Anamix Infant.....	213	e.g. PCNZ, Optimus Healthcare, Chemet.....	202
Dr Reddy's Omeprazole .....	16	e.g. Galactomin 19 .....	220	e.g. Peptamen Junior.....	217
Dr Reddy's Ondansetron.....	124	e.g. Gaviscon Double Strength .....	13	e.g. Phlexy-10 .....	215
Dr Reddy's Terbinafine.....	84	e.g. Gaviscon Infant.....	13	e.g. PicoPrep.....	19
Droperidol.....	124	e.g. Glycoprep-C.....	19	e.g. PKU Anamix Infant.....	215
Drugs Affecting Bone Metabolism.....	99	e.g. Guarcol.....	213	e.g. PKU Anamix Junior.....	215
Duolin.....	187	e.g. HCU Anamix Infant.....	214	e.g. PKU Lophlex LQ 10.....	215
Duovisc.....	197	e.g. HCU Anamix Junior LQ .....	214		
Duride.....	50	e.g. Infatrin.....	220		
Dynastat.....	108	e.g. Instant Thick.....	213		
Dysport.....	106	e.g. Isosource Standard RTH.....	224		

e.g. PKU Lophlex LQ 20.....	215	Emend Tri-Pack.....	123	Estradot.....	67
e.g. Polycal.....	211	EMLA.....	112	Etanercept.....	150
e.g. Pre Nan Gold RTF.....	221	Emtricitabine.....	89	Ethambutol hydrochloride.....	84
e.g. Protifar.....	212	Emtricitabine with tenofovir disoproxil fumarate.....	89	Ethanol.....	200
e.g. QV cream.....	56	Emtriva.....	89	Ethanol with glucose.....	200
e.g. Renilon 7.5.....	223	Emulsifying ointment.....	56	Ethanol, dehydrated.....	200
e.g. Resource Fruit Beverage.....	225	Enalapril maleate.....	42	Ethics Aspirin.....	113
e.g. Resource Thicken Up; Nutilis.....	213	Enalapril maleate with hydrochlorothiazide.....	42	Ethics Aspirin EC.....	35
e.g. S26 Human Milk Fortifier.....	212	Enbrel.....	150	Ethics Enalapril.....	42
e.g. S26 Lactose Free.....	220	Endocrine Therapy.....	147	Ethics Lisinopril.....	42
e.g. Sindopa.....	110	Endoxan.....	136	Ethinylestradiol.....	68
e.g. Sudocrem.....	56	Enerlyte.....	40	Ethinylestradiol with desogestrel.....	60
e.g. Super Soluble Duocal.....	212	Enlaxaf XR.....	117	Ethinylestradiol with levonorgestrel.....	60
e.g. TYR Anamix Infant.....	216	Enoxaparin sodium.....	34	Ethinylestradiol with norethisterone.....	60
e.g. TYR Anamix Junior.....	216	Ensure (Chocolate).....	225	Ethosuximide.....	119
e.g. TYR Anamix Junior LQ.....	216	Ensure (Vanilla).....	225	Ethyl chloride.....	112
e.g. Vitabdeck.....	26	Ensure Plus (Banana).....	225	Etidronate disodium.....	101
e.g. Vitadol C.....	26	Ensure Plus (Chocolate).....	225	Etomidate.....	110
e.g. XLEU Maxamaid.....	214	Ensure Plus (Fruit of the Forest).....	225	Etopophos.....	139
e.g. XLEU Maxamum.....	214	Ensure Plus (Vanilla).....	225	Etoposide.....	139
e.g. XLYS Low TRY Maxamaid.....	213	Ensure Plus HN.....	224	Etoposide (as phosphate).....	139
e.g. XMET Maxamaid.....	214	Ensure Plus HN RTH.....	224	Etoricoxib.....	107
e.g. XMET Maxamum.....	214	Entacapone.....	110	Etravirine.....	88
e.g. XMTVI Maxamaid.....	215	Entapone.....	110	Everet.....	121
e.g. XMTVI Maxamum.....	215	Entecavir.....	92	Everolimus.....	185
e.g. XP Maxamaid.....	215	Enzymes.....	104	Evista.....	103
e.g. XP Maxamum.....	215	Ephedrine.....	51	Exelon.....	134
e.g. XPHEN, TYR Maxamaid.....	216	Epilim IV.....	121	Exemestane.....	149
e.g. Zinc Cream (Orion); Zinc Cream (PSM).....	55	Epirubicin Ebewe.....	136	Exjade.....	201
e.g. Zinc oxide (PSM).....	55	Epirubicin hydrochloride.....	136	Extemporaneously Compounded Preparations.....	208
e.g. Energivit.....	215	Epoetin alfa [Erythropoietin alfa].....	29	Ezemibe.....	49
EasyCheck.....	234	Epoetin beta [Erythropoietin beta].....	30	Ezetimibe.....	49
Econazole nitrate.....	54	Epoprostenol.....	53	Ezetimibe with simvastatin.....	49
Edrophonium chloride.....	99	Eprex.....	29		
Efavirenz.....	88	Eptacog alfa [Recombinant factor VIIa].....	32	<b>- F -</b>	
Efavirenz with emtricitabine and tenofovir disoproxil fumarate.....	89	Eptifibatide.....	36	Factor eight inhibitor bypassing fraction.....	32
Efexor XR.....	117	Ergometrine maleate.....	62	Febuxostat.....	105
Effient.....	36	Ergotamine tartrate with caffeine.....	123	FEIBA NF.....	32
Eformoterol fumarate.....	191	Erlotinib.....	142	Felodipine.....	46
Efudix.....	59	Ertapenem.....	75	Fenpaed.....	107
Elaprase.....	22	Erythrocin IV.....	77	Fentanyl.....	114
Elecare (Unflavoured).....	219	Erythromycin (as ethylsuccinate).....	77	Fentanyl Sandoz.....	114
Elecare (Vanilla).....	219	Erythromycin (as lactobionate).....	77	Ferinject.....	24
Elecare LCP (Unflavoured).....	219	Erythromycin (as stearate).....	78	Ferodan.....	24
Electrolytes.....	207	Erythropoietin alfa.....	29	Ferric carboxymaltose.....	24
Eligard 1 Month.....	69	Erythropoietin beta.....	30	Ferric subsulfate.....	31
Eligard 3 Month.....	69	Esbriet.....	189	Ferriprox.....	201
Eligard 6 month.....	69	Escitalopram.....	118	Ferro-F-Tabs.....	24
Elocon.....	57	Esmolol hydrochloride.....	45	Ferro-tab.....	24
Elocon Alcohol Free.....	57			Ferrograd.....	24
Eltrombopag.....	31			Ferrous fumarate.....	24
Emend.....	123			Ferrous fumarate with folic acid.....	24

Ferrous gluconate with ascorbic acid.....	24	Fluticasone propionate.....	187	Genox.....	149
Ferrous sulphate.....	24	Fluticasone with salmeterol.....	191	Gentamicin sulphate	
Ferrous sulphate with ascorbic acid.....	24	FML.....	195	Infections.....	75
Ferrous sulphate with folic acid.....	24	Foban.....	54	Sensory.....	194
Ferrum H.....	24	Folic acid.....	30	Gestrinone.....	68
Fexofenadine hydrochloride.....	187	Fondaparinux sodium.....	34	Gilenya.....	130
Filgrastim.....	37	Food Modules.....	211	Ginet.....	60
Finasteride.....	63	Food/Fluid Thickeners.....	213	Glatiramer acetate.....	130
Fingolimod.....	130	Forteo.....	104	Glaucoma Preparations.....	197
Finpro.....	63	Fortisip (Vanilla).....	225	Glibenclamide.....	18
Firazyr.....	186	Fortum.....	76	Gliclazide.....	18
Flagyl.....	86	Fosamax.....	99-100	Glipizide.....	18
Flagyl-S.....	86	Fosamax Plus.....	101	Glivec.....	143
Flamazine.....	54	Foscarnet sodium.....	95	Glizide.....	18
Flecainide acetate.....	44	Fosfomycin.....	80	Glucagen Hypokit.....	17
Fleet Phosphate Enema.....	20	Fragmin.....	34	Glucagon hydrochloride.....	17
Flixonase Hayfever & Allergy.....	187	Framycetin sulphate.....	194	Glucerna Select (Vanilla).....	217
Flixotide.....	190	FreeStyle Lite.....	234	Glucerna Select RTH (Vanilla).....	216
Fliotide Accuhaler.....	190	Freestyle Optium.....	234	Glucobay.....	16
Floair.....	190	Freestyle Optium Ketone.....	234	Glucose [Dextrose]	
Florinef.....	66	Freestyle Optium Neo.....	234	Alimentary.....	17
Fluanxol.....	127	Fresofol 1% MCT/LCT.....	110	Blood.....	38
Flucloxacillin.....	78	Frusemide.....	47	Extemporaneously Compounded	
Flucloxin.....	78	Frusemide-Claris.....	47	Preparations.....	208
Fluconazole.....	82	Fucidin.....	81	Glucose with potassium chloride.....	38
Fluconazole-Claris.....	82	Fucithalmic.....	194	Glucose with potassium chloride and	
Flucytosine.....	84	Fungilin.....	25	sodium chloride.....	39
Fludara Oral.....	137	Furosemide [Frusemide].....	47	Glucose with sodium chloride.....	39
Fludarabine Ebewe.....	137	Fusidic acid		Glucose with sucrose and	
Fludarabine phosphate.....	137	Dermatological.....	54	fructose.....	17
Fludrocortisone acetate.....	66	Infections.....	81	Glycerin with sodium saccharin.....	209
Fluids and Electrolytes.....	38	Sensory.....	194	Glycerin with sucrose.....	209
Flumazenil.....	200	- G -		Glycerol	
Flumetasone pivalate with		Gabapentin.....	119	Alimentary.....	20
clioquinol.....	195	Gacet.....	113	Extemporaneously Compounded	
Fluocortolone caproate with		Gadobenic acid.....	204	Preparations.....	209
fluocortolone pivalate and		Gadobutrol.....	204	Glycerol with paraffin.....	56
cinchocaine.....	14	Gadodiamide.....	204	Glyceryl trinitrate	
Fluorescein sodium.....	196	Gadoteric acid.....	204	Alimentary.....	15
Fluorescein sodium with lignocaine		Gadovist.....	204	Cardiovascular.....	50
hydrochloride.....	196	Gadoxetate disodium.....	204	Glycine.....	206
Fluorescein.....	196	Galsulfase.....	22	Glycopyrronium.....	188
Fluorometholone.....	195	Ganciclovir.....	95	Glycopyrronium bromide.....	15
Fluorouracil.....	138	Gardasil.....	230	Glycopyrronium with	
Fluorouracil Ebewe.....	138	Gardasil 9.....	230	indacaterol.....	188
Fluorouracil sodium.....	59	Gastrodenol.....	16	Glypressin.....	74
Fluoxetine hydrochloride.....	118	Gastrografin.....	203	Glytrin.....	50
Flupenthixol decanoate.....	127	Gastrosoothe.....	15	Gonadorelin.....	69
Fluphenazine decanoate.....	128	Gazyva.....	168	Goserelin.....	69
Flutamide.....	148	Gefitinib.....	142	Granirex.....	124
Flutamin.....	148	Gelatin, succinylated.....	41	Granisetron.....	124
Fluticasone.....	190	Gelofusine.....	41	- H -	
Fluticasone furoate with		Gemcitabine.....	138	Habitrol.....	135
vilanterol.....	191	Gemcitabine Ebewe.....	138	Habitrol (Fruit).....	135
		Gemfibrozil.....	49	Habitrol (Mint).....	135
		Genoptic.....	194	Haem arginate.....	22

Haemophilus influenzae type B vaccine .....	227	Hydrocortisone acetate	191
Haldol .....	128	Alimentary .....	14
Haldol Concentrate .....	128	Dermatological .....	57
Haloperidol .....	126	Hydrocortisone and paraffin liquid and lanolin .....	57
Haloperidol decanoate .....	128	Hydrocortisone butyrate .....	57, 59
Hartmann's solution .....	38	Hydrocortisone with miconazole .....	58
Harvoni .....	94	Hydrocortisone with natamycin and neomycin .....	58
Havrix .....	229	Hydrocortisone with paraffin and wool fat .....	57
Havrix Junior .....	229	Hydrogen peroxide .....	54
HBvaxPRO .....	229-230	Hydroxocobalamin	
Healon .....	196	Alimentary .....	27
Healon 5 .....	196	Various .....	200
Healon GV .....	196	Hydroxychloroquine .....	99
healthE Dimethicone 10% .....	55	Hydroxyethyl starch 130/0.4 with magnesium chloride, potassium chloride, sodium acetate and sodium chloride .....	41
healthE Dimethicone 4% Lotion .....	55	Hydroxyethyl starch 130/0.4 with sodium chloride .....	41
healthE Dimethicone 5% .....	55	Hydroxyurea .....	139
healthE Fatty Cream .....	56	Hygroton .....	48
healthE Urea Cream .....	56	Hylo-Fresh .....	199
Heparin sodium .....	35	Hyoscine butylbromide .....	15
Heparinised saline .....	35	Hyoscine hydrobromide .....	124
Heparon Junior .....	218	Hyperuricaemia and Antigout .....	104
Hepatitis A vaccine .....	229	Hypnovel .....	131
Hepatitis B recombinant vaccine .....	229	Hypromellose .....	196, 199
Hepsera .....	91	Hypromellose with dextran .....	199
Herceptin .....	181	Hysite .....	198
Hexamine hippurate .....	81	- I -	
Histaclear .....	187	Ibiamox .....	78
Histamine acid phosphate .....	205	Ibuprofen .....	107
Holoxan .....	136	Icatibant .....	186
Hormone Replacement Therapy .....	67	Idarubicin hydrochloride .....	137
HPV .....	230	Idarucizumab .....	32
Humalog Mix 25 .....	17	Idursulfase .....	22
Humalog Mix 50 .....	17	Ifosfamide .....	136
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] .....	230	Ikorel .....	52
Human papillomavirus (6, 11, 16 and 18) vaccine [HPV] .....	230	Ilomedin .....	53
Humatin .....	75	Iloprost .....	53
Humira .....	156	Imatinib mesilate .....	143
HumiraPen .....	156	Imatinib-AFT .....	143
Hyaluronic acid		Imiglucerase .....	22
Alimentary .....	25	Imipenem with cilastatin .....	75
Sensory .....	196-197, 199	Imipenem+Cilastatin RBX .....	75
Hyaluronidase .....	104	Imipramine hydrochloride .....	116
Hybloc .....	45	Imiquimod .....	59
Hydralazine hydrochloride .....	51	Immune Modulators .....	96
Hydrea .....	139	Immunosuppressants .....	149
Hydrocortisone		Impact Advanced Recovery .....	223
Dermatological .....	57	Imuran .....	184
Extemporaneously Compounded Preparations .....	209	Incruse Ellipta .....	188
Hormone Preparations .....	66		
		Indacaterol .....	191
		Indapamide .....	48
		Indigo carmine .....	205
		Indinavir .....	90
		Indocyanine green .....	205
		Indomethacin .....	108
		Infanrix IPV .....	226
		Infanrix-hexa .....	226
		Infliximab .....	163
		Influenza vaccine .....	230
		Influvac .....	230
		Inhaled Corticosteroids .....	190
		Insulin aspart .....	17
		Insulin aspart with insulin aspart protamine .....	17
		Insulin glargine .....	17
		Insulin glulisine .....	18
		Insulin isophane .....	17
		Insulin lispro .....	18
		Insulin lispro with insulin lispro protamine .....	17
		Insulin neutral .....	18
		Insulin neutral with insulin isophane .....	17
		Insulin pen needles .....	234
		Insulin syringes, disposable with attached needle .....	234
		Integrilin .....	36
		Intelence .....	88
		Interferon alfa-2a .....	96
		Interferon alfa-2b .....	96
		Interferon beta-1-alpha .....	130
		Interferon beta-1-beta .....	130
		Interferon gamma .....	96
		Intra-uterine device .....	60
		Invanz .....	75
		Invega Sustenna .....	128
		Iodine .....	73
		Iodine with ethanol .....	202
		Iodised oil .....	203
		Iodixanol .....	203
		Iohexol .....	203
		Iopidine .....	198
		Ioscan .....	203
		IPOL .....	232
		Ipratropium bromide .....	187
		Iressa .....	142
		Irinotecan Actavis 100 .....	139
		Irinotecan Actavis 40 .....	139
		Irinotecan hydrochloride .....	139
		Iron polymaltose .....	24
		Iron sucrose .....	24
		Irrigation Solutions .....	206
		Isentress .....	91
		Ismo 40 Retard .....	50
		Ismo-20 .....	50

Isoflurane.....	110	Lamictal.....	121	Lignocaine	
Isoniazid.....	84	Lamivudine.....	89, 92	Hormone Preparations.....	67
Isoniazid with rifampicin.....	84	Lamotrigine.....	121	Nervous.....	112
Isoprenaline.....	51	Lanoxin.....	44	Lincomycin.....	81
Isopropyl alcohol.....	202	Lanoxin PG.....	44	Linezolid.....	81
Isoptin.....	47	Lansoprazole.....	15	Lioresal Intrathecal.....	106
Isopto Carpine.....	198	Lantus.....	17	Liothyronine sodium.....	73
Isosorbide mononitrate.....	50	Lantus SoloStar.....	17	Lipazil.....	49
Isotane 10.....	55	Lanzol Relief.....	15	Lipid-Modifying Agents.....	48
Isotane 20.....	55	Lapatinib.....	143	Lipiodol Ultra Fluid.....	203
Isotretinoin.....	55	Lariam.....	86	Liquibar.....	204
Ispaghula (psyllium) husk.....	19	Latanoprost.....	198	Lisinopril.....	42
Isradipine.....	46	Lax-Sachets.....	20	Lissamine green.....	196
Itch-Soothe.....	55	Lax-Suppositories.....	20	Lithicarb FC.....	126
Itraconazole.....	82	Lax-Tabs.....	20	Lithium carbonate.....	126
Itrazole.....	82	Laxatives.....	19	LMX4.....	112
Ivermectin.....	85	Laxsol.....	20	Local Preparations for Anal and	
<b>- J -</b>		Ledipasvir with sofosbuvir.....	94	Rectal Disorders.....	14
Jadelle.....	61	Leflunomide.....	99	Locoid.....	57, 59
Jaychem.....	56	Lenalidomide.....	139	Locoid Crelo.....	57
Jevity.....	224	Letrole.....	149	Locoid Lipocream.....	57
Jevity HiCal RTH.....	224	Letrozole.....	149	Lodi.....	44
Jevity RTH.....	224	Leukotriene Receptor		Lodoxamide.....	195
<b>- K -</b>		Antagonists.....	190	Logem.....	121
Kaletra.....	90	Leunase.....	139	Lomide.....	195
Kenacomb.....	195	Leuporelin acetate.....	69	Lomustine.....	136
Kenacort-A 10.....	67	Leustatin.....	137	Long-Acting Beta-Adrenoceptor	
Kenacort-A 40.....	67	Levetiracetam.....	121	Agonists.....	191
Kenalog in Orabase.....	25	Levobunolol hydrochloride.....	197	Loniten.....	52
Ketamine.....	110	Levocabastine.....	195	Loperamide hydrochloride.....	13
Ketamine-Claris.....	110	Levocarnitine.....	23	Lopinavir with ritonavir.....	90
Ketocal 3:1 (Unflavoured).....	221	Levodopa with benserazide.....	110	Lopresor.....	45
Ketocal 4:1 (Unflavoured).....	221	Levodopa with carbidopa.....	110	Lorafix.....	187
Ketocal 4:1 (Vanilla).....	221	Levomepromazine.....	126	Loratadine.....	187
Ketoconazole		Levomepromazine		Lorazepam.....	118, 129
Dermatological.....	54	hydrochloride.....	126	Lorfast.....	187
Infections.....	82	Levonorgestrel.....	61	Lormetazepam.....	131
Ketone blood beta-ketone		Levosimendan.....	50	Lorstat.....	49
electrodes.....	234	Levothyroxine.....	73	Losartan Actavis.....	43
Ketoprofen.....	108	Lidocaine [Lignocaine].....	112	Losartan potassium.....	43
Ketorolac trometamol.....	195	Lidocaine [Lignocaine]		Losartan potassium with	
Keytruda.....	183	hydrochloride.....	112	hydrochlorothiazide.....	43
Kivexa.....	89	Lidocaine [Lignocaine] hydrochloride		Lovir.....	95
Klacid.....	77	with adrenaline.....	112	Lucrin Depot 1-month.....	69
Klean Prep.....	19	Lidocaine [Lignocaine] hydrochloride		Lucrin Depot 3-month.....	69
Kogenate FS.....	33	with adrenaline and tetracaine		Lucrin Depot 6-month.....	69
Konakion MM.....	33	hydrochloride.....	112	Lycinate.....	50
Konsyl-D.....	19	Lidocaine [Lignocaine] hydrochloride		Lyderm.....	55
<b>- L -</b>		with chlorhexidine.....	112	<b>- M -</b>	
L-asparaginase.....	139	Lidocaine [Lignocaine] hydrochloride		m-Amoxiclav.....	78
L-ornithine L-aspartate.....	16	with phenylephrine		m-Eslon.....	115
Labetalol.....	45	hydrochloride.....	112	M-M-R-II.....	231
Lacosamide.....	120	Lidocaine [Lignocaine] with		m-Nystatin.....	25
Lactose.....	209	prilocaine.....	112	Mabthera.....	170
Lactulose.....	20	Lidocaine-Claris.....	112	Macrogol 3350 with ascorbic acid,	
Laevolac.....	20				

potassium chloride and sodium chloride.....	19	Melatonin.....	131	blue].....	205
Macroglol 3350 with potassium chloride, sodium bicarbonate and sodium chloride.....	20	Meloxicam.....	108	Methylxanthines.....	192
Macroglol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate.....	19	Melphalan.....	136	Metoclopramide hydrochloride.....	124
Macroglol 400 and propylene glycol.....	199	Menactra.....	228	Metoclopramide hydrochloride with paracetamol.....	123
Madopar 125.....	110	Meningococcal (A, C, Y and W-135) conjugate vaccine.....	228	Metolazone.....	48
Madopar 250.....	110	Meningococcal C conjugate vaccine.....	228	Metoprolol - AFT CR.....	45
Madopar 62.5.....	110	Menthhol.....	209	Metoprolol succinate.....	45
Madopar HBS.....	110	Mepivacaine hydrochloride.....	112	Metoprolol tartrate.....	45
Madopar Rapid.....	110	Mercaptopurine.....	138	Metronidazole.....	
Mafenide acetate.....	54	Meropenem.....	76	Dermatological.....	54
Magnesium hydroxide.....		Mesalazine.....	14	Infections.....	86
Alimentary.....	24	Mesna.....	147	Metyrapone.....	68
Extemporaneously Compounded Preparations.....	209	Mestinon.....	99	Mexiletine hydrochloride.....	44
Magnesium oxide.....	24	Metabolic Disorder Agents.....	21	Mexiletine Hydrochloride USP.....	44
Magnesium sulphate.....	24	Metabolic Products.....	213	Miacalcic.....	65
Magnevist.....	205	Metamide.....	124	Mianserin hydrochloride.....	117
Malarone.....	86	Metaraminol.....	51	Micolette.....	20
Malarone Junior.....	86	Metchek.....	18	Miconazole.....	25
Malathion [Maldison].....	54	Meterol.....	191	Miconazole nitrate.....	
Maldison.....	54	Metformin hydrochloride.....	18	Dermatological.....	54
Mannitol.....		Metformin Mylan.....	18	Genito-Urinary.....	60
Cardiovascular.....	48	Methacholine chloride.....	205	Micreme.....	60
Various.....	205	Methadone hydrochloride.....		Micreme H.....	58
Maprotiline hydrochloride.....	116	Extemporaneously Compounded Preparations.....	209	Microgynon 50 ED.....	60
Marcaïn.....	111	Nervous.....	114	Midazolam.....	131
Marcaïn Heavy.....	111	Methatabs.....	114	Midazolam-Claris.....	131
Marcaïn Isobaric.....	111	Methohexital sodium.....	110	Midodrine.....	44
Marcaïn with Adrenaline.....	111	Methopt.....	199	Mifepristone.....	61
Marevan.....	35	Methotrexate.....	138	Milrinone.....	52
Marine Blue Lotion SPF 50+.....	59	Methotrexate Ebewe.....	138	Milrinone Generic Health.....	52
Mask for spacer device.....	234	Methotrexate Sandoz.....	138	Minerals.....	23
Mast Cell Stabilisers.....	191	Methoxsalen.....		Mini-Wright AFS Low Range.....	234
Maxidex.....	195	[8-methoxypsoralen].....	58	Mini-Wright Standard.....	234
Maxitrol.....	194	Methoxyflurane.....	113	Minidiab.....	18
Measles, mumps and rubella vaccine.....	231	Methyl aminolevulinate hydrochloride.....	59	Minims Prednisolone.....	195
Mebendazole.....	85	Methyl hydroxybenzoate.....	209	Minirin.....	74
Mebeverine hydrochloride.....	15	Methylcellulose.....	209	Minocycline.....	80
Medrol.....	67	Methylcellulose with glycerin and sodium saccharin.....	209	Minoxidil.....	52
Medroxyprogesterone.....	68	Methylcellulose with glycerin and sucrose.....	209	Mirena.....	61
Medroxyprogesterone acetate.....		Methyldopa.....	47	Mirtazapine.....	117
Genito-Urinary.....	61	Methyldopa Mylan.....	47	Misoprostol.....	15
Hormone Preparations.....	68	Methylene blue.....	205	Mitomycin C.....	137
Mefenamic acid.....	108	Methylphenidate hydrochloride.....	132	Mitozantrone.....	137
Mefloquine.....	86	Methylprednisolone (as sodium succinate).....	67	Mitozantrone Ebewe.....	137
Megestrol acetate.....	148	Methylprednisolone aceponate.....	57	Mivacron.....	106
Meglumine gadopentetate.....	205	Methylprednisolone acetate.....	67	Mivacurium chloride.....	106
Meglumine iotroxate.....	205	Methylprednisolone acetate with lidocaine [Lignocaine].....	67	Mixed salt solution for eye irrigation.....	196
		Methylthioninium chloride [Methylene		Moclobemide.....	117

247



Oncaspar.....	140	Papaverine hydrochloride.....	52	Perfalgan.....	113
OncoTICE.....	185	Paper wasp venom.....	186	Perflutren.....	205
Ondansetron.....	124	Para-aminosalicylic Acid.....	85	Perhexiline maleate.....	47
Ondansetron Kabi.....	124	Paracare.....	113	Pericyazine.....	126
Ondansetron ODT-DRLA.....	124	Paracare Double Strength.....	113	Perindopril.....	42
Ondansetron-Claris.....	124	Paracetamol.....	113	Perjeta.....	169
One-Alpha.....	27	Paracetamol + Codeine (Relieve).....	115	Permethrin.....	55
Opdivo.....	182	Paracetamol with codeine.....	115	Pertuzumab.....	169
Optional Pharmaceuticals.....	234	Paraffin.....		Peteha.....	85
Ora-Blend.....	209	Alimentary.....	20	Pethidine hydrochloride.....	116
Ora-Blend SF.....	209	Dermatological.....	56	Pexsig.....	47
Ora-Plus.....	209	Extemporaneously Compounded Preparations.....	209	Pfizer Exemestane.....	149
Ora-Sweet.....	209	Paraffin liquid with soft white paraffin.....	199	Pharmacy Health SLS-free.....	56
Ora-Sweet SF.....	209	Paraffin liquid with wool fat.....	199	Pharmacy Health Sorbolene with Glycerin.....	56
Oratane.....	55	Paraffin with wool fat.....	56	Pheburane.....	23
Orion Temozolomide.....	140	Paragesic Soluble.....	113	Phenelzine sulphate.....	117
Ornidazole.....	86	Paraldehyde.....	118	Phenindione.....	35
Orphenadrine citrate.....	106	Parecoxib.....	108	Phenobarbitone.....	121, 131
Oruvail SR.....	108	Paritaprevir, ritonavir and oimbitasvir with dasabuvir.....	94	Phenobarbitone sodium.....	209
Oseltamivir.....	96	Paritaprevir, ritonavir and ombitasvir with dasabuvir and ribavirin.....	95	Phenol.....	
Osmolite RTH.....	224	Paromomycin.....	75	Extemporaneously Compounded Preparations.....	209
Ospamox.....	78	Paroxetine.....	118	Various.....	206
Other Cardiac Agents.....	50	Paser.....	85	Phenol oily.....	15
Other Endocrine Agents.....	68	Patanol.....	195	Phenol with ioxaglic acid.....	206
Other Oestrogen Preparations.....	68	Patent blue V.....	205	Phenothrin.....	55
Other Otological Preparations.....	199	Paxam.....	129	Phenoxybenzamine hydrochloride.....	43
Other Progestogen Preparations.....	68	Pazopanib.....	144	Phenoxymethylpenicillin [Penicillin V].....	78
Other Skin Preparations.....	59	Peak flow meter.....	234	Phentolamine mesylate.....	43
Ox-Pam.....	129	Peanut oil.....	208	Phenylephrine hydrochloride Cardiovascular.....	51
Oxalliccord.....	142	Pediasure (Chocolate).....	222	Sensory.....	198
Oxaliplatin.....	142	Pediasure (Strawberry).....	222	Phenytoin.....	121
Oxandrolone.....	65	Pediasure (Vanilla).....	222	Phenytoin sodium.....	118, 121
Oxazepam.....	129	Pediasure RTH.....	222	Pholcodine.....	189
Oxpentifylline.....	52	Pegaspargase.....	140	Phosphorus.....	40
Oxybuprocaine hydrochloride.....	196	Pegasys.....	96	Phytomenadione.....	33
Oxybutynin.....	63	Pegasys RBV Combination Pack.....	96	Picibanil.....	185
Oxycodone hydrochloride.....	115	Pegfilgrastim.....	37	Pilocarpine hydrochloride.....	198
Oxymetazoline hydrochloride.....	189	Pegylated interferon alfa-2a.....	96	Pilocarpine nitrate.....	209
OxyNorm.....	115	Pembrolizumab.....	183	Pimafucort.....	58
Oxytocin.....	62	Penicillamine.....	99	Pindolol.....	45
Oxytocin BNM.....	62	Penicillin G.....	78	Pine tar with tolamine laurilsulfate and fluorescein.....	58
Oxytocin with ergometrine maleate.....	62	Penicillin V.....	78	Pinetarsol.....	58
Ozole.....	82	Pentacarinat.....	86	Pioglitazone.....	18
<b>- P -</b>		Pentagastrin.....	68	Piperacillin with tazobactam.....	78
Pacifen.....	106	Pentamidine isethionate.....	86	Pipothiazine palmitate.....	129
Paclitaxel.....	146	Pentasa.....	14	Pirfenidone.....	189
Paclitaxel Ebewe.....	146	Pentostatin [Deoxycoformycin].....	140	Pituitary and Hypothalamic Hormones and Analogues.....	69
Paliperidone.....	128	Pentoxifylline [Oxpentifylline].....	52	Pivmecillinam.....	81
Pamidronate disodium.....	101	Peptamen OS 1.0 (Vanilla).....	217	Pizotifen.....	123
Pamisol.....	101	Peptisoothie.....	15		
Pancreatic enzyme.....	18				
Pancuronium bromide.....	106				
Pantoprazole.....	16				
Panzop Relief.....	16				



PKU Anamix Junior LQ (Berry).....	215	Pregnancy test - hCG urine.....	234	Pyrimethamine.....	86
PKU Anamix Junior LQ (Orange).....	215	preOp.....	223	Pytazen SR.....	36
PKU Anamix Junior LQ (Unflavoured).....	215	Prevenar 13.....	228	<b>- Q -</b>	
Plaquenil.....	99	Prezista.....	90	Q 300.....	87
Plendil ER.....	46	Prilocaine hydrochloride.....	112	Quetapel.....	126
Plerixafor.....	37	Prilocaine hydrochloride with felypressin.....	112	Quetiapine.....	126
Pneumococcal (PCV13) conjugate vaccine.....	228	Primaquine phosphate.....	86	Quinapril.....	42
Pneumococcal (PPV23) polysaccharide vaccine.....	228	Primidone.....	121	Quinapril with hydrochlorothiazide.....	42
Pneumovax 23.....	228	Primolut N.....	68	Quinine dihydrochloride.....	87
Podophyllotoxin.....	59	Primovist.....	204	Quinine sulphate.....	87
Polidocanol.....	31	Probenecid.....	106	Qvar.....	190
Poliomyelitis vaccine.....	232	Procaine penicillin.....	78	<b>- R -</b>	
Poloxamer.....	20	Procaine penicillin.....	78	RA-Morph.....	114
Poly Gel.....	198	Procarbazine hydrochloride.....	140	Rabies vaccine.....	232
Poly-Tears.....	199	Prochlorperazine.....	124	Raloxifene.....	103
Poly-Visc.....	199	Proctosedyl.....	14	Raltegravir potassium.....	91
Polyhexamethylene biguanide.....	209	Procur.....	65	Ramipex.....	110
Polyvinyl alcohol.....	199	Procyclidine hydrochloride.....	109	Ranbaxy-Cefaclor.....	76
Polyvinyl alcohol with povidone.....	199	Procytox.....	136	Ranibizumab.....	169
Poractant alfa.....	192	Prodopa.....	47	Ranitidine.....	15
Posaconazole.....	82	Progesterone.....	62	Ranitidine Relief.....	15
Postinor-1.....	61	Proglucem.....	16	Rapamune.....	185
Potassium chloride.....	39-40	Proglycem.....	16	Rasburicase.....	106
Potassium chloride with sodium chloride.....	39	Prokinex.....	124	Readi-CAT 2.....	204
Potassium citrate.....	63	Promethazine hydrochloride.....	187	Reandron 1000.....	65
Potassium dihydrogen phosphate.....	39	Promethazine theoclate.....	124	Recombinant factor IX.....	32-33
Potassium iodate.....		Propafenone hydrochloride.....	44	Recombinant factor VIIa.....	32
Alimentary.....	24	Propamide isethionate.....	194	Recombinant factor VIII.....	32-33
Hormone Preparations.....	73	Propofol.....	110	Rectogesic.....	15
Potassium iodate with iodine.....	24	Propranolol.....	45	Red back spider antivenom.....	200
Potassium perchlorate.....	73	Propylene glycol.....	209	Redipred.....	67
Potassium permanganate.....	58	Propylthiouracil.....	73	Relenza Rotadisk.....	96
Povidone K30.....	209	Prostin E2.....	62	Remicade.....	163
Povidone-iodine.....	202	Prostin VR.....	51	Remifentanyl hydrochloride.....	116
Povidone-iodine with ethanol.....	202	Protamine sulphate.....	35	ReoPro.....	156
Pradaxa.....	34	Protionamide.....	85	Resonium A.....	41
Pralidoxime iodide.....	200	Protirelin.....	74	Resource Beneprotein.....	212
Pramipexole hydrochloride.....	110	Provera.....	68	Resource Diabetic (Vanilla).....	217
Prasugrel.....	36	Provera HD.....	68	Respiratory Stimulants.....	192
Pravastatin.....	49	Provide MCT-LCT 1%.....	110	Retinol.....	27
Praxbind.....	32	Proxymetacaine hydrochloride.....	196	Retinol Palmitate.....	199
Praziquantel.....	85	Pseudoephedrine hydrochloride.....	189	Retrovir.....	89
Prazosin.....	43	PSM Citalopram.....	118	Retrovir IV.....	89
Precedex.....	110	Psoriasis and Eczema Preparations.....	58	Revlimid.....	139
Prednisolone.....	67	PTU.....	73	Revolade.....	31
Prednisolone acetate.....	195	Pulmocare (Vanilla).....	223	RexAir.....	191
Prednisolone sodium phosphate.....	195	Pulmonary Surfactants.....	192	Reyataz.....	90
Prednisolone- AFT.....	195	Pulmozyme.....	192	Riboflavin 5-phosphate.....	197
Prednisone.....	67	Puri-nethol.....	138	Rifabutin.....	85
		Pyrainamide.....	85	Rifadin.....	85
		Pyridostigmine bromide.....	99	Rifampicin.....	85
		Pyridoxal-5-phosphate.....	23	Rifaximin.....	16
		Pyridoxine hydrochloride.....	27	Rifinah.....	84
				Rilutek.....	109
				Riluzole.....	109

Ringer's solution.....	39	Selegiline hydrochloride .....	110	Sodium citro-tartrate.....	63
Riodine .....	202	Sennosides.....	20	Sodium cromoglycate	
Risedronate Sandoz.....	101	Sensipar.....	65	Alimentary.....	14
Risedronate sodium.....	101	Serenace .....	126	Respiratory.....	187, 192
Risperdal Consta.....	129	Seretide .....	191	Sensory.....	195
Risperdal Quicklet.....	127	Seretide Accuhaler.....	191	Sodium dihydrogen phosphate	
Risperidone .....	127, 129	Serevent.....	191	[Sodium acid phosphate].....	40
Risperon .....	127	Serevent Accuhaler.....	191	Sodium fluoride.....	23
Ritalin.....	132	Serophene.....	68	Sodium hyaluronate [Hyaluronic acid]	
Ritalin LA.....	132	Sertraline.....	118	Alimentary.....	25
Ritalin SR.....	132	Sevoflurane .....	111	Sensory.....	196, 199
Ritonavir.....	90	Sevredol.....	115	Sodium hyaluronate [Hyaluronic acid]	
Rituximab.....	170	Sildenafil.....	53	with chondroitin sulphate.....	197
Rivaroxaban.....	35	Siltuximab.....	177	Sodium hypochlorite.....	202
Rivastigmine.....	134	Silver nitrate		Sodium metabisulfite.....	210
Rivotril.....	118	Dermatological.....	59	Sodium nitrite.....	200
RIXUBIS.....	33	Extemporaneously Compounded		Sodium nitroprusside	
Rizamelt.....	123	Preparations.....	209	Cardiovascular.....	52
Rizatriptan.....	123	Simethicone.....	13	Optional Pharmaceuticals.....	234
Rocuronium bromide.....	106	Simulect.....	162	Sodium phenylbutyrate.....	23
Ropinirole hydrochloride.....	110	Simvastatin.....	49	Sodium phosphate with phosphoric	
Ropivacaine hydrochloride.....	113	Sinacalide.....	205	acid.....	20
Ropivacaine hydrochloride with		Sinemet.....	110	Sodium polystyrene sulphonate .....	41
fentanyl.....	113	Sinemet CR.....	110	Sodium stibogluconate .....	87
Ropivacaine Kabi.....	113	Sirolimus.....	185	Sodium tetradecyl sulphate .....	31
Rose bengal sodium.....	196	Slow-Lopresor.....	45	Sodium thiosulfate.....	200
RotaTeq.....	232	Snake antivenom.....	201	Sodium valproate.....	121
Rotavirus live reassortant oral		Sodibic.....	41	Sodium with potassium.....	207
vaccine .....	232	Sodium acetate.....	39	Solian.....	125
Roxane .....	13	Sodium acid phosphate.....	40	Solifenacin succinate.....	63
Roxithromycin.....	78	Sodium alginate with magnesium		Solu-Cortef .....	66
Rubifen.....	132	alginate.....	13	Solu-Medrol .....	67
Rubifen SR.....	132	Sodium alginate with sodium		Somatropin.....	69
<b>- S -</b>					
S-26 Gold Premgro.....	221	bicarbonate and calcium		Sotacor.....	46
S26 LBW Gold RTF.....	221	carbonate.....	13	Sotalol.....	46
SalAir.....	189	Sodium aurothiomalate.....	99	Soya oil.....	200
Salazopyrin.....	14	Sodium benzoate.....	23	Spacer device.....	235
Salazopyrin EN.....	14	Sodium bicarbonate		Span-K.....	40
Salbutamol.....	189	Blood.....	39, 41	Specialised Formulas.....	216
Salbutamol with ipratropium		Extemporaneously Compounded		Spioflo Respimat .....	189
bromide.....	187	Preparations.....	209	Spiractin.....	48
Salicylic acid.....	209	Sodium calcium edetate.....	202	Spiramycin.....	87
Salmeterol.....	191	Sodium chloride		Spiriva.....	188
Salmonella typhi vaccine.....	229	Blood.....	40-41	Spiriva Respimat .....	188
Sandimmun .....	149	Respiratory.....	190, 192	Spiroonactone.....	48
Sandomigran.....	123	Various.....	206	Sprycel.....	142
Sandostatin LAR.....	148	Sodium chloride with sodium		Standard Feeds.....	223
Scalp Preparations.....	58	bicarbonate.....	190	Staphlex.....	78
Scandonest 3%.....	112	Sodium citrate		Starch.....	210
Sclerosing Agents.....	193	Alimentary.....	13	Stavudine.....	89
Scopoderm TTS.....	124	Extemporaneously Compounded		Sterculia with frangula .....	19
Sebizole.....	54	Preparations.....	210	Stesolid.....	118
Secretin pentahydrochloride.....	205	Sodium citrate with sodium chloride		Stimulants / ADHD Treatments .....	131
Sedatives and Hypnotics.....	131	and potassium chloride.....	35	Stiripentol.....	121
Seebri Breezhaler.....	188	Sodium citrate with sodium lauryl		Stocrin.....	88
		sulphoacetate.....	20	Strattera.....	131

Streptomycin sulphate.....	75	Tenoxicam.....	108	Tofranil.....	116
Stromectol.....	85	Terazosin.....	43	Tolcapone.....	110
Suboxone.....	134	Terbinafine.....	84	Tolterodine tartrate.....	63
Sucralfate.....	16	Terbutaline.....	62	Topamax.....	122
Sucrose.....	114	Terbutaline sulphate.....	189	Topical Products for Joint and Muscular Pain.....	108
Sugammadex.....	106	Teriflunomide.....	130	Topiramate.....	122
Sulindac.....	108	Teriparatide.....	104	Topiramate Actavis.....	122
Sulphacetamide sodium.....	194	Terlipressin.....	74	Tracrium.....	106
Sulphadiazine.....	81	Testosterone.....	65	Tramadol hydrochloride.....	116
Sulphadiazine silver.....	54	Testosterone cypionate.....	65	Tramal 100.....	116
Sulphasalazine.....	14	Testosterone esters.....	65	Tramal 50.....	116
Sulphur.....	210	Testosterone undecanoate.....	65	Tramal SR 100.....	116
Sulprix.....	125	Tetrabenazine.....	109	Tramal SR 150.....	116
Sumatriptan.....	123	Tetracaine [Amethocaine] hydrochloride Nervous.....	113	Tramal SR 200.....	116
Sunitinib.....	145	Sensory.....	196	Trandolapril.....	42
Sunscreen, proprietary.....	59	Tetracosactide [Tetracosactrin].....	69	Tranexamic acid.....	32
Suprane.....	110	Tetracosactrin.....	69	Tranylcypromine sulphate.....	117
Surgical Preparations.....	206	Tetracyclin Wolff.....	80	Trastuzumab.....	181
Survanta.....	192	Tetracycline.....	80	Travoprost.....	198
Sustagen Diabetic (Vanilla).....	217	Thalidomide.....	141	Treatments for Dementia.....	133
Sustagen Hospital Formula (Chocolate).....	225	Thalomid.....	210	Treatments for Substance Dependence.....	134
Sustagen Hospital Formula (Vanilla).....	225	Theobroma oil.....	141	Tretinoin.....	
Sutent.....	145	Theophylline.....	192	Dermatological.....	55
Suxamethonium chloride.....	106	Thiamine hydrochloride.....	27	Oncology.....	141
Sylvant.....	177	Thioguanine.....	138	Trexate.....	138
Symmetrel.....	109	Thiopental [Thiopentone] sodium.....	111	Tri-sodium citrate.....	210
Sympathomimetics.....	51	Thiopentone.....	111	Triamcinolone acetoneide Alimentary.....	25
Synacthen.....	69	Thiotepa.....	136	Dermatological.....	57
Synacthen Depot.....	69	Thrombin.....	32	Hormone Preparations.....	67
Syntometrine.....	62	Thymol glycerin.....	25	Triamcinolone acetoneide with gramicidin, neomycin and nystatin.....	195
Syrup.....	210	Thyroid and Antithyroid Preparations.....	73	Triamcinolone acetoneide with neomycin sulphate, gramicidin and nystatin.....	58
Systane Unit Dose.....	199	Thyrotropin alfa.....	69	Triamcinolone hexacetoneide.....	67
<b>- T -</b>		Ticagrelor.....	36	Triazolam.....	131
Tacrolimus.....	149	Ticarcillin with clavulanic acid.....	78	Trichloroacetic acid.....	210
Tacrolimus Sandoz.....	149	Ticlopidine.....	36	Trichozole.....	86
Tagitol V.....	204	Tigecycline.....	80	Trientine dihydrochloride.....	23
Talc.....	193	Tilcotil.....	108	Trifluoperazine hydrochloride.....	127
Tambocor.....	44	Timolol.....	197	Trimeprazine tartrate.....	187
Tambocor CR.....	44	Timolol maleate.....	46	Trimethoprim.....	81
Tamoxifen citrate.....	149	Timoptol XE.....	197	Trimethoprim with sulphamethoxazole [Co-trimoxazole].....	81
Tamsulosin.....	63	Tiotropium bromide.....	188	Trisodium citrate.....	35
Tamsulosin-Rex.....	63	Tiotropium bromide with olodaterol.....	189	Trometamol.....	206
Tarceva.....	142	Tivicay.....	91	Tropicamide.....	198
Tasigna.....	144	TMP.....	81	Tropisetron.....	124
Tasmar.....	110	TOBI.....	75	Tropisetron-AFT.....	124
Tazocin EF.....	78	Tobradex.....	194	Truvada.....	89
Tecfidera.....	130	Tobramycin.....			
Tegretol.....	119	Infections.....	75		
Tegretol CR.....	119	Sensory.....	194		
Teicoplanin.....	81	Tobramycin Mylan.....	75		
Temazepam.....	131	Tobrex.....	194		
Temozolomide.....	140	Tocilizumab.....	178		
Tenecteplase.....	36				
Tenofovir disoproxil fumarate.....	93				

Tuberculin, purified protein derivative.....	205	Vesicare.....	63	Xylometazoline hydrochloride.....	190
Two Cal HN.....	218	Vexazone.....	18	Xyntha.....	32
TwoCal HN RTH (Vanilla).....	218	Vfend.....	83	- Y -	
Tykerb.....	143	Vidaza.....	137	Yellow jacket wasp venom.....	186
Tysabri.....	130	Viekira Pak.....	94	- Z -	
- U -		Viekira Pak-RBV.....	95	Zanamivir.....	96
Ultibro Breezhaler.....	188	Vigabatrin.....	122	Zantac.....	15
Ultiva.....	116	Vimpat.....	120	Zapril.....	42
Ultraproct.....	14	Vinblastine sulphate.....	147	Zarzio.....	37
Umeclidinium.....	188	Vincristine sulphate.....	147	Zavedos.....	137
Umeclidinium with vilanterol.....	189	Vinorelbine.....	147	Zeffix.....	92
Univent.....	187	Viral Vaccines.....	229	Ziagen.....	89
Ural.....	63	Viramune Suspension.....	88	Zidovudine [AZT].....	89
Urea.....		Viread.....	93	Zidovudine [AZT] with lamivudine.....	89
Dermatological.....	56	ViruPOS.....	194	Zimybe.....	49
Extemporaneously Compounded Preparations.....	210	Viscoat.....	197	Zinacef.....	76
Urex Forte.....	47	Visipaque.....	203	Zinc	
Urografin.....	203	Vistil.....	199	Alimentary.....	24
Urokinase.....	37	Vistil Forte.....	199	Dermatological.....	55
Urologicals.....	63	Vit.D3.....	27	Zinc and castor oil.....	55
Uromitexan.....	147	VitA-POS.....	199	Zinc chloride.....	24
Ursodeoxycholic acid.....	18	Vital.....	217	Zinc oxide.....	210
Ursosan.....	18	Vitamin A with vitamins D and C.....	26	Zinc sulphate.....	25
Utrogestan.....	62	Vitamin B complex.....	27	Zinc with wool fat.....	56
- V -		Vitamin B6 25.....	27	Zincaps.....	25
Vaclovir.....	95	Vitamins.....	25	Zinforo.....	77
Valaciclovir.....	95	Vivonex TEN.....	217	Zinnat.....	76
Valcyte.....	95	Volibris.....	52	Ziprasidone.....	127
Valganciclovir.....	95	Voltaren.....	107	Zista.....	187
Vancomycin.....	81	Voltaren D.....	107	Zithromax.....	77
Varenicline.....	135	Voltaren Ophtha.....	195	Zoladex.....	69
Varibar - Honey.....	204	Volulyte 6%.....	41	Zoledronic acid	
Varibar - Nectar.....	204	Volumatic.....	235	Hormone Preparations.....	66
Varibar - Pudding.....	204	Volumen.....	204	Musculoskeletal.....	102
Varibar - Thin Liquid.....	204	Voluven.....	41	Zoledronic acid Mylan.....	66
Varicella vaccine [Chicken pox vaccine].....	232	Voriconazole.....	83	Zometa.....	66
Varilrix.....	232	Votrient.....	144	Zopiclone.....	131
Vasodilators.....	51	Vttack.....	83	Zopiclone Actavis.....	131
Vasopressin.....	74	- W -		Zostrix.....	108
Vasopressin Agents.....	74	Warfarin sodium.....	35	Zostrix HP.....	113
Vecuronium bromide.....	106	Wart Preparations.....	59	Zuclopenthixol acetate.....	127
Vedafil.....	53	Water		Zuclopenthixol decanoate.....	129
Velcade.....	138	Blood.....	40	Zuclopenthixol hydrochloride.....	127
Veletri.....	53	Various.....	206	Zusdone.....	127
Venlafaxine.....	117	Wool fat		Zyban.....	134
Venofer.....	24	Dermatological.....	56	Zypine.....	126
Ventavis.....	53	Extemporaneously Compounded Preparations.....	210	Zypine ODT.....	126
Ventolin.....	189	- X -		Zyprexa Relprevv.....	128
Vepesid.....	139	X-Opaque-HD.....	204	Zytiga.....	147
Verapamil hydrochloride.....	47	Xanthan.....	210	Zyvox.....	81
Vergo 16.....	123	Xarelto.....	35		
Verpamil SR.....	47	Xifaxan.....	16		
Vesanoid.....	141	Xolair.....	168		
		Xylocaine.....	112		
		Xylocaine Viscous.....	112		







